

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT
COOPERATION TREATY (PCT)**

(43) International Publication Date
11 September 1998 (11.09.1998)

(10) International Publication Number
PCT WO 98/39446 A2

(51) International Patent Classification⁶:

C12N 15/12, 5/10, 1/21, C07K 14/47, 16/18,
C12Q 1/68, G01N 33/50, 33/53, 33/68,
A61K 38/17

(21) International Application Number:

PCT/US98/04482

(22) International Filing Date:

06 March 1998 (06.03.1998)

(25) Filing Language:

English

(26) Publication Language:

(30) Priority Data

60/040,162	07 March 1997	US
	(07.03.1997)	
60/040,333	07 March 1997	US
	(07.03.1997)	
60/038,621	07 March 1997	US
	(07.03.1997)	
60/040,161	07 March 1997	US
	(07.03.1997)	
60/040,626	07 March 1997	US
	(07.03.1997)	
60/040,334	07 March 1997	US
	(07.03.1997)	
60/040,336	07 March 1997	US
	(07.03.1997)	
60/040,163	07 March 1997	US
	(07.03.1997)	
60/043,580	11 April 1997	US
	(11.04.1997)	
60/043,568	11 April 1997	US
	(11.04.1997)	
60/043,314	11 April 1997	US
	(11.04.1997)	
60/043,569	11 April 1997	US
	(11.04.1997)	
60/043,311	11 April 1997	US
	(11.04.1997)	
60/043,671	11 April 1997	US
	(11.04.1997)	

(74) Agents: BROOKES, Anders, A., et al;

Human Genome Sciences, Inc., 9410 Key
West Avenue, Rockville, MD 10850 (US).

(81) Designated States (national): AL, AM, AT,

AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU,
ZW

(84) Designated States (regional): ARIPO patent

(GH, GM, KE, LS, MW, SD, SZ, UG, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European patent (AT, BE, CH,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, ML, MR, NE, SN,
TD, TG)

60/043,674	11 April 1997 (11.04.1997)	US
60/043,669	11 April 1997 (11.04.1997)	US
60/043,312	11 April 1997 (11.04.1997)	US
60/043,313	11 April 1997 (11.04.1997)	US
60/043,672	11 April 1997 (11.04.1997)	US
60/043,315	11 April 1997 (11.04.1997)	US
60/043,578	11 April 1997 (11.04.1997)	US
60/043,576	11 April 1997 (11.04.1997)	US
60/043,670	11 April 1997 (11.04.1997)	US
60/047,598	23 May 1997 (23.05.1997)	US
60/047,632	23 May 1997 (23.05.1997)	US
60/047,503	23 May 1997 (23.05.1997)	US
60/047,613	23 May 1997 (23.05.1997)	US
60/047,600	23 May 1997 (23.05.1997)	US
60/047,615	23 May 1997 (23.05.1997)	US
60/047,583	23 May 1997 (23.05.1997)	US
60/047,617	23 May 1997 (23.05.1997)	US
60/047,502	23 May 1997 (23.05.1997)	US
60/047,592	23 May 1997 (23.05.1997)	US
60/047,581	23 May 1997 (23.05.1997)	US
60/047,584	23 May 1997 (23.05.1997)	US
60/047,500	23 May 1997 (23.05.1997)	US
60/047,587	23 May 1997 (23.05.1997)	US

60/047,492	23 May 1997 (23.05.1997)	US
60/047,597	23 May 1997 (23.05.1997)	US
60/047,618	23 May 1997 (23.05.1997)	US
60/047,582	23 May 1997 (23.05.1997)	US
60/047,596	23 May 1997 (23.05.1997)	US
60/047,612	23 May 1997 (23.05.1997)	US
60/047,633	23 May 1997 (23.05.1997)	US
60/047,601	23 May 1997 (23.05.1997)	US
60/047,595	23 May 1997 (23.05.1997)	US
60/047,599	23 May 1997 (23.05.1997)	US
60/047,588	23 May 1997 (23.05.1997)	US
60/047,585	23 May 1997 (23.05.1997)	US
60/047,586	23 May 1997 (23.05.1997)	US
60/047,590	23 May 1997 (23.05.1997)	US
60/047,594	23 May 1997 (23.05.1997)	US
60/047,589	23 May 1997 (23.05.1997)	US
60/047,593	23 May 1997 (23.05.1997)	US
60/047,614	23 May 1997 (23.05.1997)	US
60/047,501	23 May 1997 (23.05.1997)	US
60/048,964	06 June 1997 (06.06.1997)	US
60/048,974	06 June 1997 (06.06.1997)	US
60/056,886	22 August 1997 (22.08.1997)	US
60/056,877	22 August 1997 (22.08.1997)	US

60/056,889	22 August 1997 (22.08.1997)	US
60/056,893	22 August 1997 (22.08.1997)	US
60/056,630	22 August 1997 (22.08.1997)	US
60/056,878	22 August 1997 (22.08.1997)	US
60/056,662	22 August 1997 (22.08.1997)	US
60/056,872	22 August 1997 (22.08.1997)	US
60/056,882	22 August 1997 (22.08.1997)	US
60/056,637	22 August 1997 (22.08.1997)	US
60/056,903	22 August 1997 (22.08.1997)	US
60/056,888	22 August 1997 (22.08.1997)	US
60/056,879	22 August 1997 (22.08.1997)	US
60/056,880	22 August 1997 (22.08.1997)	US
60/056,894	22 August 1997 (22.08.1997)	US
60/056,911	22 August 1997 (22.08.1997)	US
60/056,636	22 August 1997 (22.08.1997)	US
60/056,874	22 August 1997 (22.08.1997)	US
60/056,910	22 August 1997 (22.08.1997)	US
60/056,864	22 August 1997 (22.08.1997)	US
60/056,631	22 August 1997 (22.08.1997)	US
60/056,845	22 August 1997 (22.08.1997)	US
60/056,892	22 August 1997 (22.08.1997)	US
60/056,632	22 August 1997 (22.08.1997)	US
60/056,664	22 August 1997 (22.08.1997)	US

60/056,876	22 August 1997 (22.08.1997)	US
60/056,881	22 August 1997 (22.08.1997)	US
60/056,909	22 August 1997 (22.08.1997)	US
60/056,875	22 August 1997 (22.08.1997)	US
60/056,862	22 August 1997 (22.08.1997)	US
60/056,887	22 August 1997 (22.08.1997)	US
60/056,908	22 August 1997 (22.08.1997)	US
60/056,884	22 August 1997 (22.08.1997)	US
60/057,761	05 September 1997 (05.09.1997)	US
60/057,650	05 September 1997 (05.09.1997)	US

(71) Applicant *(for all designated States except US):* **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only):*
RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). **FISCHER, Carrie, L.** [US/US]; 5810 Hall Street, Burke, VA 22015 (US). **SOPPET, Daniel, R.** [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). **CARTER, Kenneth, C.** [US/US]; 11601 Brandy Hall Lane, North Potomac, MD 20878 (US). **BEDNARIK, Daniel, P.** [US/US]; 8822 Blue Sea Drive, Columbia, MD 21046 (US). **ENDRESS, Gregory, A.** [US/US]; 9729 Claggett Farm Drive, Potomac, MD 20854 (US). **YU, Guo-Liang** [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). **NI, Jian** [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). **FENG, Ping** [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). **YOUNG, Paul, E.** [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US).

GREENE, John, M. [US/US]; 872
 Diamond Drive, Gaithersburg, MD 20878
 (US). **FERRIE, Ann, M.** [US/US]; 13203 L
 Astoria Hill Court, Germantown, MD 20874
 (US). **DUAN, Roxanne** [US/US]; 4541
 Fairfield Drive, Bethesda, MD 20814 (US).
HU, Jing-Shan [CN/US]; 1247 Lakeside
 Drive #3034, Sunnyvale, CA 94086 (US).
FLORENCE, Kimberley, A. [US/US];
 12805 Atlantic Avenue, Rockville, MD
 20851 (US). **OLSEN, Henrik, S.** [DK/US];
 182 Kendrick Place #24, Gaithersburg, MD
 20878 (US). **EBNER, Reinhard** [DE/US];
 9906 Shelburne Terrace #316, Gaithersburg,
 MD 20878 (US). **BREWER, Laurie, A.**
 [US/US]; 14920 Mt. Nebo Road, Poolesville,
 MD 20837 (US). **MOORE, Paul, A.**
 [GB/US]; Apartment #104, 1908 Holly
 Ridge Drive, McLean, VA 22102 (US). **SHI,**
Yanggu [CN/US]; 437 West Side Drive,
 Gaithersburg, MD 20878 (US). **LAFLEUR,**
David, W. [US/US]; 1615 Q Street, N.W.
 #807, Washington, DC 20009 (US). **LI, Yi**
 [CN/US]; 1247 Lakeside Drive #3034,
 Sunnyvale, CA 94086 (US). **ZENG,**
Zhizhen [CN/US]; 13950 Saddlevue Drive,
 Gaithersburg, MD 20878 (US). **KYAW, Hla**
 [MM/US]; 520 Sugarbush Circle, Frederick,
 MD 21703 (US).

Published

--

-- *without international search report and to be republished upon receipt of that report*

(54) Title: 70 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to 70 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

70 Human Secreted Proteins of the Invention This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins

essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space—a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

of the Invention The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description Definitions The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e. g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO : X or the cDNA contained within the clone deposited with the ATCC. For example, the

polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.

Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO : X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO : X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 12301 Park Lawn Drive, Rockville, Maryland 20852, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO : X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and denatured, sheared salmon sperm DNA, followed by washing the filters in 1x SSC at about

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.

Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency) ; salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at in a solution comprising 6X SSPE (20X SSPE = 3M ; 0.2M ; 0.02M EDTA, pH 7.4), 0. SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA ; followed by washes at with 0. SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e. g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to sequences (such as any 3' terminal tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e. g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For

example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA ; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i. e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art.

Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from natural processes or may be made by synthetic methods.

Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS- STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W.

H. Freeman and Company, New York (1993) ; POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983) ; Seifter et al., Meth Enzymol 182 : 626-646 (1990) ; Rattan et al., Ann NY Acad Sci 663 : 48-62 (1992).) "SEQ ID NO : X" refers to a polynucleotide sequence while "SEQ ID NO : Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i. e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.) Polynucleotides and Polypeptides of the Invention FEATURES OF PROTEIN ENCODED BY GENE NO : 1 The translation product of Gene NO : shares sequence homology with alpha-L- fucosidase which is thought to be important as a

lysosomal enzyme that hydrolyzes fucose from fucoglycoconjugates. (See Accession No. gi/178409.) Lysosome fructosidase is involved in certain lysosome storage diseases. (See Biochem. Biophys.

Res. Commun., 164 : 439-445 (1989).) Fucosidosis, an autosomal recessive lysosomal storage disorder characterized by progressive neurological deterioration and mental retardation. The disease results from deficient activity of alpha-L-fucosidase, a lysosomal enzyme that hydrolyzes fucose from fucoglycoconjugates. This gene likely encodes a novel fucosidase isoenzyme. Based on homology, it is likely that the translated product of this gene is also involved in lysosome catabolism of molecules and that aberrations in the concentration and/or composition of this product may be causative in lysosome storage disorders. Preferred polypeptide fragments comprise the amino acid sequence PGHLLPHKWENC (SEQ ID NO : 257).

Gene NO : 1 is expressed primarily in stromal cells, and to a lesser extent in human fetal kidney and human tonsils.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fucosidosis and other lysosome storage disorders. Similarly, polypeptides and antibodies directed to the polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues of cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., stromal cells, kidney, tonsils, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology of Gene NO : 1 to alpha-L-fucosidase indicates that polypeptides and polynucleotides corresponding to Gene NO : are useful for the treatment of fucosidosis and general lysosomal disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 134 as residues : to Leu-6, Thr-32 to Glu-39, Lys-80 to Lys-85, and Met-90 to Pro-96.

FEATURES OF PROTEIN ENCODED BY GENE NO : 2 The translation product of Gene No. 2 shares sequence homology with stromal cell-derived factor-2 (SDF-2) which is a novel secreted factor. See, for example, Gene, 176 (1-2) : 211-214, (1996, Oct. 17.) The amino acid sequence of SDF-2 shows similarity to yeast dolichyl phosphate-D-mannose : protein mannosyltransferases, Pmt1p [Strahl-Bolsinger et al. Proc. Natl. Acad. Sci. USA 90, 8164-8168 (1993)] and Pmt2p [Lussier et al. J. Biol. Chem. 270, 2770-2775 (1995)], whose activities have not been detected in higher eukaryotes. Based on the sequence similarity, the translation product of this gene is expected to share certain biological activities with SDF-2, Pmt1p and Pmt2p.

Gene NO : 2 is expressed primarily in immune system tissue and cancerous tissues, such as liver hepatoma, human B-cell lymphoma, spleen in a patient suffering from chronic lymphocytic leukemia, hemangiopericytoma, pharynx carcinoma, breast cancer, thyroid, bone marrow, osteoblasts and to a lesser extent in a few other tissues such as kidney pyramids.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of the

diseases and conditions which include, but are not limited to, disorders in kidney, liver, and immune organs, particularly cancers.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the kidney, liver, thyroid, and bone marrow expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., liver, spleen, B-cells, pharynx, thyroid, mammary tissue, bone marrow, osteoblasts and kidneys, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology of Gene NO : 2 to stromal cell-derived factor-2 indicates that polypeptides and polynucleotides corresponding to Gene NO : 2 are useful for diagnosis and therapeutic treatment of disorders in kidney, liver, and immune organs since stromal cells play important role in organ function. Stroma carries the blood supply and provides support for the growth of parenchymal cells and is therefore crucial to the growth of a neoplasm. Nucleic acids of the present invention comprise, but preferably do not consist of, and more preferably do not comprise, SEQ ID NO : 3 from US Patent No. 5, 576, 423, incorporated herein by reference, and shown herein as SEQ ID NO : 258).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 135 as residues : His-56 to Gly-65, Ala-74 to Ser-80, to Pro-97, Leu-124 to Glu- 129, Glu-135 to Asp-143, to Ser-180, and Ala-194 to Thr-199.

FEATURES OF PROTEIN ENCODED BY GENE NO : 3 The translation product of Gene NO : 3 shares sequence homology with LZIP-2 and other leucine zipper proteins, which are thought to be important in nucleic acid binding. This gene has been reported in Mol. Cell. Biol. 17 (9), 5117-5126 (1997) as "Luman". Luman is a cyclic AMP response element (CRE)-binding protein/activating transcription factor 1 protein of the basic leucine zipper superfamily. It binds CREs in vitro and activates CRE-containing promoters when transfected into COS7 cells. The complete amino acid sequence of Luman reported in Mol. Cell. Biol. 17 (9) : 5117-5126 (1997) is :

MELELDAGDQDLLAFLLEESGDLGTAPDEAVRAPLDWALPLSEVPSDWEVDDLL
CSLLSPASLNILSSSNPCLVHHHTYSLPRETVSMDLESESCRKEGTQMTPQH
QESRRKKKVYVGGLESRLKYTAQNLMELQNKVQLLEEQNLSLLDQLRKLQAM
DPYQLELPALQSEVPKSTHQWLDGSDCVLQAPGNTSCLLHYMPQAPSAEPPL EWPFPDLSS
EPLCRGPILPLQANLTRKGGWLPTGSPSVILQDRYSG (SEQ ID N : 259).

Gene NO : 3 is expressed primarily in apoptotic T-cells and Soares senescent cells and to a lesser extent in multiple tissues and cell types, including, multiple sclerosis tissue, and hippocampus.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, mediated disorders, transplantation, immunodeficiency, and tumor necrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system and transplantation, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., multiple sclerosis tissue, hippocampus, bone marrow and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology of Gene NO : 3 to leucine zipper nucleic acid binding proteins indicates that polypeptides and polynucleotides corresponding to Gene NO : 3 are useful for diagnosis and treatment of immunologically mediated disorders, transplantation, immunodeficiency, and tumor necrosis. The secreted nucleic acid binding protein in the apoptotic tissues may be involved in the disposal of the DNA released by apoptotic cells. Furthermore, the studies conducted in support of Luman suggest that the translation product of this gene may be used to identify transcriptional regulation elements which in turn are useful in modulation of immune function.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 136 as residues : Asn-7 to Ser-12, Tyr-32 to Gly-38, Pro-55 to Tyr-60, Glu-70 to Thr- 76, and Pro-104 to Leu-110.

FEATURES OF PROTEIN ENCODED BY GENE NO : 4 The translation product of Gene NO : 4 shares sequence homology with a number of tetraspan transmembrane surface molecules such as human metastasis tumor suppressor gene, tumor associated antigen protein, CD53 hematopoietic antigen, human membrane antigen TM4 superfamily protein, metastasis controlling peptide, and human CD9 sequence, which are thought to be important in development of cancer, immune system development and functions.

Gnee NO : 4 is expressed primarily in cancers of several different tissues and to a lesser extent in normal tissue like prostate, skin and kidney.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers and disorders of the immune system, prostate and kidney.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the kidney, skin, prostate and immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., kidney, skin and prostate, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology of Gene NO : 4 to tetraspan transmembrane surface molecules such as human metastasis tumor suppressor gene, tumor associated antigen protein, CD53 hematopoietic antigen, human membrane antigen TM4 superfamily protein, metastasis controlling peptide, and human CD9 sequence, indicates that polypeptides and polynucleotides corresponding to Gene NO : 4 are involved with the cellular control of growth and differentiation. Therefore, the translation product of this gene is believed to be useful for diagnosis and treatment of neoplasia and disorders of the kidney, skin and prostate. For example, recombinant protein can be produced in transformed host cells for diagnostic and prognostic applications. Alterations in the protein sequence are indicative of the presence of malignant cancer, or of a predisposition to malignancy, in a subject. Gene therapy can be used to restore the wild-type gene product to a subject. Additionally, the antibodies are a useful tool for the identification of hematopoietic neoplasms, and may prove helpful for identifying morphologically poorly defined cells. Moreover, this protein can be used to isolate cognate receptors and ligands and

identify potential agonists and antagonists using techniques known in the art. The protein also has activity, regulates hematopoiesis and stimulates growth and regeneration as a male/female contraceptive, increases fertility depending on activin and inhibin like activities. Other uses are as a chemotactic agent for lymphocytes, treatment of coagulation disorders, an anti-inflammatory agent, an antimicrobial or analgesic and as a modulator of behavior and metabolism. The DNA can be used in genetic diagnosis or gene therapy, and for the production of recombinant protein. It can also be used to identify protein expressing cells, isolate related sequences, prepare primers for genetic fingerprinting and generate anti-protein or anti-DNA antibodies. In addition, residues in the translation product for this gene are believed to be the extracellular domain.

Thus, polypeptide comprising residues 1-71 or derivatives (including fragments) or analogs thereof, are useful as a soluble polypeptide which may be routinely used therapeutically to antagonize the activities of the receptor.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 137 as residues : Lys-118 to Phe-127, Asn-145 to Ala-160, and Thr-177 to Val-188.

FEATURES OF PROTEIN ENCODED BY GENE NO : 5 Gene NO : 5 is expressed primarily in human testes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the testes including cancer and reproductive disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., testes and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of Gene NO : 5 indicates that the protein product of this gene is useful for treatment/diagnosis of diseases of the testes, particularly testicular cancer since expression is observed primarily in the testes.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 138 as residue : Gly-22 to Gln-30.

FEATURES OF PROTEIN ENCODED BY GENE NO : 6 The translation product of Gene NO : 6 shares sequence homology with GALNS (N-acetylgalactosamine 6-sulphatase) which is thought to be important in the storage of the glycosaminoglycans, keratan sulfate and chondroitin 6-sulfate. See Genbank accession no. Based on the sequence similarity, the translation product of this gene is expected to share biological activities with GALNS.

Gene NO : 6 is expressed primarily in human bone marrow.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential

identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, storage disorders of glycosaminoglycans, keratan sulfate and chondroitin 6-sulfate, e. g., Morquio A syndrome. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly involving cell storage disorder, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., bone marrow and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology of Gene NO : 6 to 6-sulphatase indicates that polypeptides and polynucleotides corresponding to Gene NO : 6 are useful for the treatment and diagnosis of storage disorders of glycosaminoglycans, keratan sulfate and chondroitin 6-sulfate. Such disorders are known in the art and include, e. g., Morquio A syndrome which is caused by an error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine. Morquio A syndrome is characterized by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait ; autosomal recessive inheritance.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 139 as residues : Gly-29 to Pro-36 and Glu-57 to Leu-64.

FEATURES OF PROTEIN ENCODED BY GENE NO : 7 The translation product of Gene NO : 7 shares sequence homology with carboxy peptidase E and H (carboxypeptidase E is thought to be important in the biosynthesis of numerous peptide hormones and neurotransmitters). The translation product of this gene also shares sequence homology with bone-related carboxypeptidase"OSF-5"from the mouse. See European patent application EP-588118-A. Based on the sequence similarity to OSF-5, the translation product of this gene will hereinafter sometimes be referred to as"human-OSF-5"or"hOSF-5".

Gene NO : 7 is expressed primarily in tumor cell lines derived from connective tissues including chondrosarcoma, synovial sarcoma, Wilm's tumor and rhabdomyosarcoma and to a lesser extent in a myeloid progenitor cell line, bone marrow, and placenta.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, various cancers involving the skeletal system and connective tissues in general, in particular at cartilage interfaces. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the skeletal system and various other tumor tissues, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., connective tissues and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The restricted tissue distribution and homology of Gene NO : 7 to carboxypeptidase E and mouse OSF-5 indicates that polypeptides and polynucleotides corresponding to Gene NO : 7 are for processing of peptides to their mature form that may have various activities similar to the activities of neuropeptides

but in the periphery. In addition the abundance of expression in cancer tissues indicates that aberrant expression and subsequent processing may play a role in the progression of malignancies, e. g., growth factor and/or adhesion factor activities. In particular, the expression of this gene is restricted to connective tissues and embryonic tissues.

Furthermore, it is overexpressed in cancers of these same tissues (i. e., in sarcomas).

Moreover, hOSF-5 shares very strong sequence similarity with mOSF-5 which is a known bone growth factor and is thought to be useful in obtaining products for the diagnosis and treatment of bone metabolic diseases, e. g., osteoporosis and Paget's disease. Like OSF-5, the translation product of this gene is believed to be a bone- specific carboxypeptidase which acts as an adhesion molecule/growth factor and takes part in osteogenesis at the site of bone induction. hOSF-5 can, therefore, be used to treat bone metabolic diseases, osteoporosis, Paget's disease, osteomalacia, hyperostosis or osteopetrosis. Furthermore, hOSF-5 can be used to stimulate the regeneration of bone at the site of mechanical damage, e. g., accidentally or surgically caused fractures.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 140 as residues : Leu-24 to Val-30, Ala-89 to Lys-94, Phe-150 to Trp-157, Leu-162 to Asp-167, Asp-187 to Ser-199, His-241 to Asp-254, and Pro-362 to Asp-376.

FEATURES OF PROTEIN ENCODED BY GENE NO : 8 Gene NO : 8 is expressed primarily in bone marrow, and to a lesser extent in an cell line.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematological disorders including cancer and anemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune and hematologic systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., bone marrow, kidney, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 8 are useful as a growth factor for hematopoietic stem cells or progenitor cells, e. g., in the treatment of bone marrow stem cell loss in chemotherapy patients and in the treatment of kidney disease.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 141 as residues : Gly-30 to Lys-35.

FEATURES OF PROTEIN ENCODED BY GENE NO : 9 Gene NO : 9 is expressed primarily in neutrophils.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the cell type present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the cell type indicated. For a number of disorders of the above tissues or cells,

particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues or cell types (e. g., neutrophils, bone marrow, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 9 are useful for immune modulation or as a growth factor to stimulate neutrophil differentiation or proliferation that may be useful in the treatment of neutropenia.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 142 as residues : Thr-22 to Pro-37.

FEATURES OF PROTEIN ENCODED BY GENE NO : 10 Gene NO : 10 is expressed primarily in the epidermis.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the epidermis such as psoriasis or eczema or may be involved in the normal proliferation or differentiation of the epithelial cells or fibroblasts constituting the skin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., epidermis and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 10 are useful for diagnosis and treatment of skin conditions and as an aid in the healing of various epidermal injuries including wounds, and diabetic ulcers.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 143 as residues : Ser-3 to Ser-9 and Trp-27 to Glu-32.

FEATURES OF PROTEIN ENCODED BY GENE NO : 11 The translation product of Gene NO : 11 shares sequence homology with phosphatidylcholine 2-acylhydrolase (PLA2). See, for example, Genbank accession no. PLA2 is involved in inflammation, where it is responsible for the conversion of cell membrane phospholipids into arachidonic acid. Arachidonic acid in turn feeds into both the lipoxygenase and cyclooxygenase pathways to produce leukotrienes (involved in chemotaxis, vasoconstriction, bronchoconstriction, and increased vascular permeability) and prostaglandins (responsible for vasodilation, potentiate edema, and increased pain). Diseases in which PLA2 is implicated as a major factor include rheumatoid arthritis, sepsis, ischemia, and thrombosis. The inventors refer to the translation product of this gene as PLA2-like protein based on the sequence similarity. Furthermore, owing to the sequence similarity PLA2 and PLA2-like protein are expected to share certain biological activities.

Gene NO : is expressed primarily in human cerebellum and in T-cells.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cerebellum disorders, rheumatoid arthritis, sepsis, ischemia, and thrombosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the cerebellum and Purkinje cells, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., brain, bone marrow, T-cells, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : are useful for diagnosis and treatment of cerebellum disorders, rheumatoid arthritis, sepsis, ischemia, and thrombosis. This gene is also useful as a chromosome marker. It is believed to map to Chr. 15,

FEATURES OF PROTEIN ENCODED BY GENE NO : 12 Gene NO : 12 is expressed primarily in highly vascularized tissues such as placenta, uterus, tumors, fetal liver, fetal spleen and also in the C7MCF7 cell line treated with estrogen.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometriosis, endometritis, endometrial carcinoma, primary hepatocellular carcinoma, and spleen-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the endometrium, liver and spleen, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., endometrium, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 12 are useful for diagnosis and treatment of diseases of the endometrium (such as endometrial carcinoma, endometriosis, and endometritis), liver diseases (such as primary hepatocellular carcinoma), and spleen-related diseases.

SEQ ID NO : 145 as residues : Ala-29 to Leu-35, Leu-50 to Ser-57, Glu-96 to Glu-105, Asp-140 to Asp-148, and to Ser-197.

FEATURES OF PROTEIN ENCODED BY GENE NO : 13 Gene NO : 13 is expressed primarily in B cell lymphoma and to a lesser extent in other tissues.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, B cell lymphoma ; hematopoietic disorders ; immune dysfunction.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., bone marrow and B-cells and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Enhanced expression of this gene product in B cell lymphoma indicates that it may play a role in the proliferation of hematopoietic cells. It is also believed to be involved in the survival and/or differentiation of various hematopoietic lineages.

Expression in lymphoma also indicates that it may be involved in other cancers and abnormal cellular proliferation. The tissue distribution, therefore, indicates that polypeptides and polynucleotides corresponding to Gene NO : 13 are useful for the diagnosis and/or therapeutic treatment of hematopoietic disorders, particularly B cell lymphoma. Furthermore, since overexpression of this gene is associated with the development of B cell lymphoma, antagonists of this protein are useful to interfere with the progression of the disease. This protein is useful in assays for identifying such antagonists. Assays for identifying antagonists are known in the art and are described briefly elsewhere herein. Preferred antagonists include antibodies and antisense nucleic acid molecules. Preferred are antagonists which inhibit B-cell proliferation.

FEATURES OF PROTEIN ENCODED BY GENE NO : 14 The translation product of Gene NO : 14 shares sequence homology with very low density lipoprotein receptor which is thought to be important in transport of lipoproteins. Owing to the sequence similarity the translation product of this gene is believed to share certain biological activities with VLDL receptors. Assaying such activity may be achieved by assays known in the art and set forth elsewhere herein.

This gene is expressed primarily in human synovium, umbilical vein endothelial cells, CD34+ cells, Jurkat cells, and HL60 cells, and to a lesser extent in thymus, meningioma, hypothalamus, adult testis, and fetal liver and spleen.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, atherosclerosis, ataxia malabsortion, vascular damage, hyperlipidemia, and other cardiovascular diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and hematological systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., endothelium, thymus meningioma, hypothalamus, testes, liver, and spleen and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the vascular endothelial cells and homology to VLDL receptors indicates that polypeptides and polynucleotides corresponding to Gene NO : 14 are useful for diagnosis and treatment of atherosclerosis, ataxia malabsortion, and hyperlipidemia. These and other factors often result in other cardiovascular diseases.

Additionally, the presence of the gene product in cells of blood lineages indicates that it may be useful in hematopoietic regulation and hemostasis.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 147 as residues : Pro-39 to Ser-52, Trp-71 to Thr-76, and Pro-94 to His-100.

FEATURES OF PROTEIN ENCODED BY GENE NO : 15 The translation product of Gene NO : 15 shares sequence homology with kallikrein which is thought to be important in blood pressure and renal secretion.

Furthermore, this gene has now been characterized as a novel hepatitis B virus X binding protein that inhibits viral replication. See, for example, J. Virol. 72 (3), 1737- 1743 (1998).

This gene is expressed primarily in kidney, placenta, lung, aorta and other endothelial cells, caudate nucleus and to a lesser extent in melanocytes, liver, adipose tissue.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renovascular hypertension, renal secretion, electrolyte metabolism, toxemia of pregnancy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the renovascular or respiratory vascular systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., kidney, placenta, lung, endothelial cells, melanocytes, liver, and adipose tissue, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to kallikrein indicates that polypeptides and polynucleotides corresponding to Gene NO : 15 are useful for treating renovascular hypertension, renal secretion, electrolyte metabolism, toxemia of pregnancy and hydronephrosis. The protein expression in the organs like kidney, lung and vascular endothelial cells indicates the gene involvement in hemodynamic regulatory functions.

The translation product of this gene is also useful in the treatment of viral infection, particularly liver infection, and particularly hepatitis B virus (es).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 148 as residues : Leu-9 to Asn-15 and Thr-56 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 16 The translation product of Gene NO : 16 shares sequence homology with secretory component protein, immunoglobulins and their receptors which are thought to be important in immunological functions. The amino acid sequence of secretory component protein can be accessed as accession no. incorporated herein by reference.

Gene NO : 16 is expressed primarily in macrophages, monocytes and dendritic cells and to a lesser extent in placenta and brain.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential

identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues or cells (e. g., macrophages, monocytes, dendritic cells, placenta and brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to immunoglobulins and secretory component protein indicates that polypeptides and polynucleotides corresponding to Gene NO : 16 are useful for diagnosis and treatment of inflammation and bacterial infection, and other diseases where immunomodulation would be beneficial.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 149 as residues : Pro-37 to Cys-51, Gln-53 to Cys-60, Asn-99 to Gly-106, Gly-145 to and to Ser-164.

FEATURES OF PROTEIN ENCODED BY GENE NO : 17 The translation product of Gene NO : 17 is evolutionarily conserved and shares sequence homology with proteins from yeast and *C. elegans*. See, for example, Genbank accession no. As is known in the art, strong sequence similarity to a secreted protein from *C. elegans* is predictive of cellular location of human proteins.

Gene NO : 17 is expressed primarily in colon carcinoma cell lines, mesangial cells, many tumors like T cell lymphoma, osteoclastoma, Wilm's tumor, adrenal gland tumor, testes tumor, synovial sarcoma, and to a lesser extent in placenta, lung and brain.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, rapidly growing/dividing cells such as cancerous tissue, including, colon carcinoma, lymphomas, and sarcomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal, hematological and immune systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., placenta, lung, brain, colon, mesangial cells, adrenal gland, T-cells, testes, and lymph tissue, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in colon cancer and many other tumors indicates that the polynucleotides and polypeptides of Gene NO : 17 are useful for cancer diagnosis and therapeutic targeting. The extracellular nature may contribute to solid tumor angiogenesis and cell growth stimulation. The tissue distribution of this gene in cells of the immune system indicates that polypeptides and polynucleotides corresponding to Gene NO : 17 are useful for treatment, prophylaxis and diagnosis of immune and autoimmune diseases, such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS.

Its expression predominantly in hematopoietic cells also indicates that the gene could be important for the treatment and/or detection of hematopoietic disorders such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The protein can also be used to enhance or protect proliferation, differentiation and functional activation of hematopoietic progenitor cells such as bone marrow cells, which could be useful for cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The protein may also be useful to increase the proliferation of peripheral blood leukocytes, which could be useful in the combat of a range of hematopoietic disorders including immunodeficiency diseases, leukemia, and septicemia.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 150 as residues : Val-131 to Asn-136.

FEATURES OF PROTEIN ENCODED BY GENE NO : 18 The translation product of Gene NO : 18 shares sequence homology with immunoglobulin, which is thought to be important in immunoreactions.

Gene NO : 18 is expressed primarily in macrophage.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., macrophage and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in macrophages and the weak homology to immunoglobulin indicates that polypeptides and polynucleotides corresponding to Gene NO : 18 are useful for diagnosing and treating immune response disorders, including inflammation, antigen presentation and immunosurveillance.

FEATURES OF PROTEIN ENCODED BY GENE NO : 19 The translation product of Gene NO : 19 shares sequence homology with proline rich proteins which are thought to be important in protein-protein interaction.

This gene has a wide range of tissue distribution, but is expressed primarily in normal prostate, synovial fibroblasts, brain amygdala depression, fetal bone and fetal cochlea, and to a lesser extent in adult retina, umbilical vein endothelial cells, atrophic endometrium, osteoclastoma, melanocytes, pancreatic carcinoma and smooth muscle.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer metastasis, wound healing, tissue repair. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the skeletal, connective tissues, reproductive and central nervous system, expression of this gene at significantly higher or lower levels may routinely be

detected in certain tissues and cell types (e. g., brain, prostate, fibroblasts, bone, cochlea, retina, endothelial cells, endometrium, pancreas and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to proline-rich proteins indicates that the protein is a extracellular matrix protein or an ingredient of bodily fluid. Polypeptides and polynucleotides corresponding to Gene NO : 19 are useful for cancer metastasis intervention, tissue culture additive, bone modeling, wound healing and tissue repair.

FEATURES OF PROTEIN ENCODED BY GENE NO : 20 Gene NO : 20 is expressed primarily in prostate cancer, leukocytes, meningioma, adult liver, pancreas, brain, and to a lesser extent in lung.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the prostate and brain, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., prostate, leukocytes, meningioma, liver, brain, pancreas and lung, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Prostate cancer cell lines are known to be responsive to estrogen and androgen.

The protein expression of Gene NO : 20 appears to be influenced by both estrogen and androgen levels. The prostate cancer tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 20 are useful in the intervention and detection of prostate hyperplasia and prostate cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO : 21 The translation product of Gene NO : 21 is identical to the human wnt-7a gene.

Wnt-7a is a secreted signaling molecule, thought to be important in signaling and the regulation of cell fate and pattern formation during embryogenesis. Specifically, knock out studies in mice have demonstrated that wnt7a plays a critical role in the development of the dorsal-ventral patterning in the developing limb, and to a lesser extent plays a role in the development of anterior-posterior patterning. Overexpression of wnt7a can induce transformation of cultured mammary cells, suggesting that it is an oncogene.

Expression of Gene NO : 21 has only been observed in testes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, testicular cancer ; abnormal limb development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the testes or developing embryo. For a number of disorders of the above tissues or cells, particularly of the developing embryo, expression of this gene at

significantly higher or lower levels may routinely be detected in the developing embryo or amniotic fluid taken from a pregnant individual and compared relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Also, expression of this gene at significantly higher or lower levels may routinely be detected in the testes of patient suffering from testicular cancer and compared relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to mouse wnt7a indicates that polypeptides and polynucleotides corresponding to Gene NO : 21 are useful to restore abnormal limb development in an affected individual. Furthermore, its oncogenic potential and tissue distribution indicates that it could serve as a diagnostic for testicular cancer.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 154 as residues : Gly-22 to Arg-28.

FEATURES OF PROTEIN ENCODED BY GENE NO : 22 Gene NO : 22 is expressed primarily in fetal liver/spleen, breast, testes and placenta and to a lesser extent in brain, and a series of cancer tissues.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, brain diseases, male infertility, and disposition to pregnant miscarriages. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, hematopoietic system, and sexual organs, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., liver, spleen, testes, placenta, and brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene indicates that polypeptides and polynucleotides corresponding to Gene NO : 22 are useful as a marker for non- differentiated, dividing cells and hence could serve as an oncogenic marker. Its high expression in fetal liver, suggests an involvement in hematopoiesis and/or the immune system. Hence it is useful as a factor to enhance an individuals immune system, e. g., in individuals with immune disorders. It is also thought to affect the survival, proliferation, and differentiation of a number of hematopoietic cell lineages, including hematopoietic stem cells. Its disruption, e. g., mutation or altered expression, may also be a marker of immune disorder. Its expression in the testes, suggests it may be important in controlling male fertility. Expression of this gene in breast further reflects a role in immune function and immune surveillance (breast lymph node). This gene is believed to be useful as a marker for breast cancer.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 155 as residues : Gln-57 to Lys-70 and Ala-91 to Pro-100.

FEATURES OF PROTEIN ENCODED BY GENE NO : 23 Gene NO : 23 is expressed primarily in bone marrow and brain (whole and fetal).

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases

and conditions which include, but are not limited to, neurological, immune and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the central nervous and hematopoietic systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., bone marrow, brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 23 are useful in the diagnosis and treatment of disorders related to the central nervous system (e. g. neuro-degenerative conditions, trauma, and behavior abnormalities) and hematopoiesis. In addition, the expression in fetal brain indicates a role for this gene product in diagnosis of predisposition to developmental defects of the brain.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 156 as residues : Thr-23 to Tyr-29.

FEATURES OF PROTEIN ENCODED BY GENE NO : 24 Gene NO : 24 is expressed primarily in smooth muscle, placenta, prostate, and osteoblasts.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular pathologies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, reproductive and skeletal systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., placenta, smooth muscle, prostate, and osteoblasts, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 24 are useful for detection and treatment of neoplasias and developmental abnormalities associated with these tissues.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 157 as residues : Asn-21 to Thr-26.

FEATURES OF PROTEIN ENCODED BY GENE NO : 25 The translation product of Gene NO : 25 shares sequence homology with Pregnancy Associated Mouse Protein (See, FEBS Lett 1993 May 17 ; 322 (3) : 219-222). Based on the sequence similarity the translation product of this gene is expected to share certain biological activities with PAMP-1.

Gene NO : 25 is expressed primarily in 12-week-old human embryos and prostate.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases

and conditions which include, but are not limited to, prostate disorders (cancer). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., embryonic tissue, and prostate, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 25 are useful for the diagnosis and treatment of prostate disorders (such as cancer) and developmental abnormalities and fetal deficiencies. The homology to indicates that this gene and gene product are useful in detecting pregnancy.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 158 as residues : Pro-23 to Glu-28 and Ser-44 to Gly-55.

FEATURES OF PROTEIN ENCODED BY GENE NO : 26 Gene NO : 26 is expressed primarily in testes and to a lesser extent in epididymis.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and endocrine disorders, as well as testicular cancer.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the male reproductive and endocrine systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., testes, and epididymis, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 26 are useful for the treatment and diagnosis of conditions concerning proper testicular function (e. g., endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 159 as residues : Pro-24 to Gly-33 and Arg-70 to Gly-76.

FEATURES OF PROTEIN ENCODED BY GENE NO : 27 The translation product of Gene NO : 27 shares sequence homology with salivary protein precursors which are thought to be important in immune response and production of secreted proteins.

Gene NO : 27 is expressed primarily in salivary gland tissue.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, diseases of the salivary gland. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, digestive system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., salivary gland, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to salivary secreted protein indicates that polypeptides and polynucleotides corresponding to Gene NO : 27 are useful for treatment of immune disorders and diagnostic uses related to secretion of protein in disease states. For example, the gene product can be used as an anti-microbial agent, an ingredient for oral or dental hygiene, treatment of xerostomia, sialorrhea, intervention for inflammation including parotitis, and an indication for tumors in the salivary gland (adenomas, carcinomas).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 160 as residues : Asp-21 to Gly-28, Asp-30 to Glu-43, Glu-49 to Glu-62, and Thr-75 to Pro-83.

FEATURES OF PROTEIN ENCODED BY GENE NO : 28 Gene NO : 28 is expressed primarily in human fetal heart tissue and to a lesser extent in olfactory tissue.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, olfactory and cardiovascular disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune, olfactory and vascular systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., olfactory tissue, and heart, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 28 are useful for diagnosis and treatment of immune, olfactory and vascular disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 161 as residues : Cys-33 to Gly-44, to Ser-130 to Gly-142, Lys-150 to Gly-157, and Thr-159 to Asp-177.

FEATURES OF PROTEIN ENCODED BY GENE NO : 29 Gene NO : 29 is expressed primarily in

brain and to a lesser degree in activated macrophages, endothelial and smooth muscle cells, and some bone cancers.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of brain and endothelial present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegeneration, inflammation and other immune disorders, fibrotic conditions.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification brain, smooth muscle, and endothelium. For a number of disorders of the above tissues or cells, particularly of the brain and endothelium, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues or cell types (e. g., brain, endothelial cells, macrophages, smooth muscle, and bone, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Tissue distribution suggests polypeptides and polynucleotides corresponding to Gene NO : 29 are useful in study and treatment of neurodegenerative and immune disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 162 as residues : Asn-18 to Glu-20, Ser-33 to Gln-48, Cys-55 to Ser-56, Pro-67 to Cys-69.

FEATURES OF PROTEIN ENCODED BY GENE NO : 30 Gene NO : 30 is expressed primarily in early stage human brain and to a lesser extent in cord blood, heart, and some tumors.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of developing CNS tissue present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., brain and heart, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that that polypeptides and polynucleotides corresponding to Gene NO : 30 are useful for the treatment of cancer and of neurodegenerative and cognitive disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO : 31 Gene NO : 31 is expressed primarily in brain and thymus and to a lesser extent in several other organs and tissues including the hematopoietic system, liver skin and bone Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, CNS disorders, hematopoietic system disorders, disorders of the endocrine system, bone, and skin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above

tissues or cells, particularly CNS disorders, hematopoietic system disorders, disorders of the endocrine system, bone, and skin, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., hematopoietic cells, brain, thymus, liver, bone, and epidermis, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 31 are useful for treatment and diagnosis of CNS disorders, hematopoietic system disorders, disorders of the endocrine system, and of bone and skin.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 164 as residues : Thr-35 to Arg-40, Pro-55 to His-75, Pro-93 to Ala-98, to Pro-119, and Pro-132 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 32 Gene NO : 32 is expressed primarily in organs and tissue of the nervous system and to a lesser extent in various developing tissues and organs.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system and disorders of developing and growing tissues and organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly disorders of the CNS, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 32 are useful for diagnosis and treatment of disorders of the central nervous system, general neurological diseases and neoplasias.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 165 as residues : Ser-33 to Lys-41 and Glu-86 to Glu-91.

FEATURES OF PROTEIN ENCODED BY GENE NO : 33 Residues 141-156 in the translation product for Gene NO : 33 as shown in the sequence listing matches phosphopantetheine binding site motifs. (or pantetheine 4'phosphate) is the prosthetic group of acyl carrier proteins (ACP) in some multienzyme complexes where it serves as a 'swinging arm' for the attachment of activated fatty acid and amino-acid groups. Phosphopantetheine is attached to a serine residue in these proteins. ACP proteins or domains have been found in various enzyme systems which are listed below. Fatty acid synthetase (FAS), which catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH.

Bacterial and plant chloroplast FAS are composed of eight separate subunits which correspond to the different enzymatic activities ; ACP is one of these polypeptides.

Fungal FAS consists of two multifunctional proteins, FAS 1 and FAS2 ; the ACP domain is located in the N-terminal section of FAS2. Vertebrate FAS consists of a single multifunctional enzyme ; the ACP

domain is located between the beta-ketoacyl reductase domain and the C-terminal thioesterase domain. Based on the presence of a phosphopantetheine binding site in the translation product of this gene, it is believed to share activities fatty acid synthetase polypeptides. Such activities may be assayed by methods known in the art.

This gene is expressed primarily in developing and rapidly growing tissues like placenta fetal heart and endometrial tumor and to a lesser extent in B and T cell lymphoma tissues. Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and disorders of developing tissues and organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic tissues and developing organs and tissues, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types embryonic tissue, endometrium, B-cells, and T-cells, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 33 are useful for treatment and diagnosis of cancer in the hematopoietic system developing organs and tissues. It may also be useful for induction of cell growth in disorders of the hematopoietic system and other tissue and organs.

The homology to fatty acid synthetases indicates that this gene product is useful in the diagnosis and treatment of lipid metabolism disorders such as hyperlipidemia.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 166 as residues : Arg-27 to Glu-34.

FEATURES OF PROTEIN ENCODED BY GENE NO : 34 Gene NO : 34 is expressed primarily in breast and testes tissues and to a lesser extent in hematopoietic tissues including tonsils, T cells and monocytes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the reproductive organs and systems, including cancer, autoimmune diseases and inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the reproductive organs and hematopoietic tissues, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., hematopoietic cells, T-cells and monocytes, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Nucleic acids comprising sequence of this gene are also useful as chromosome markers since this gene maps to Chr. 15,

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 34 are useful for treatment of diseases of the reproductive organs and hematopoietic system including

cancer, autoimmune diseases and inflammatory diseases.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 167 as residues : Phe-81 to Lys-86.

FEATURES OF PROTEIN ENCODED BY GENE NO : 35 The translation product of Gene NO : 35 shares sequence similarity with the mouse cytokine-inducible inhibitor of signaling. See, e. Nature 1997 Jun 26 ; (6636) : Cytokines are secreted proteins that regulate important cellular responses such as proliferation and differentiation. Key events in cytokine signal transduction are well defined : cytokines induce receptor aggregation, leading to activation of members of the JAK family of cytoplasmic tyrosine kinases. In turn, members of the STAT family of transcription factors are phosphorylated, dimerize and increase the transcription of genes with STAT recognition sites in their promoters. Less is known of how cytokine signal transduction is switched off. Expression of the mouse protein inhibited both interleukin-6-induced receptor phosphorylation and STAT activation. We have also cloned two relatives of SOCS-1, named SOCS-2 and SOCS-3, which together with the previously described CIS form a new family of proteins. Transcription of all four SOCS genes is increased rapidly in response to interleukin-6, in vitro and in vivo, suggesting they may act in a classic negative feedback loop to regulate cytokine signal transduction. The translation product of this gene is believed to have similar biological activities as this family of mouse genes. The biological activity of the translation product of this gene may be assayed by methods shown in Nature 1997 Jun 26 ; 387 (6636) : 917-921, which is incorporated herein by reference in its entirety.

Gene NO : 35 is expressed primarily in tissues of hematopoietic origin including activated monocytes, neutrophils, activated T-cells and to a lesser extent in breast, adipose tissue and dendritic cells.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the hematopoietic system including cancer autoimmune diseases and inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., hematopoietic cells and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to cytokine inducible inhibitor of signaling indicates that polypeptides and polynucleotides corresponding to Gene NO : 35 are useful for diagnosis and treatment of diseases of the hematopoietic system including autoimmune diseases, inflammatory diseases, infectious diseases and neoplasia. For example, administration of, or upregulation of this gene could be used to decrease the response of immune-system to lymphokines and cytokines.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 168 as residues : Arg-23 to His-30, Ala-35 to Gly-42.

FEATURES OF PROTEIN ENCODED BY GENE NO : 36 Gene NO : 36 is expressed primarily in infant brain and to a lesser extent in osteoclastoma, placenta, and a wide variety of other tissues.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential

identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., osteoclastoma, placenta, and tissue of the central nervous system, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 36 are useful for diagnosis and treatment of neurologic disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 169 as residues : Gln-31 to Ser-37, to Gly-54, Tyr-57 to Asp-67, Gln-141 to Pro-151, and Val-207 to Thr-219.

FEATURES OF PROTEIN ENCODED BY GENE NO : 37 Gene NO : 37 is expressed primarily in osteoclastoma stromal cells, dendritic cells, liver, and placenta.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, wound, pathological conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues or cell types (e. g., stromal cells, dendritic cells, liver, and placenta and, cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 37 are useful for fundamental role in basic growth and development of human.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 170 as residues : Leu-32 to Thr-37 and Arg-48 to Pro-55.

FEATURES OF PROTEIN ENCODED BY GENE NO : 38 The translation product of Gene NO : 38 shares sequence homology with a yeast protein, which may be involved in processing. (See Accession Nos.

2104457 and 1079682.) It is likely that an upstream signal sequence exists, other than the predicted sequence described in Table Preferred polypeptide fragments comprise the open reading frame upstream from the predicted signal sequence, as well as polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in skin, and to a lesser extent in embryonic tissues, and fetal liver.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential

identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, defects of the skin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., epidermis, liver, and embryonic tissues, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 38 are useful for diagnosis and treatment of defects of the skin.

FEATURES OF PROTEIN ENCODED BY GENE NO : 39 Gene NO : 39 is expressed primarily in Amygdala, activated monocytes, testis, and fetal liver. Moreover, this gene is mapped to chromosome 4. Thus, polynucleotides of the present invention can be used in linkage analysis as markers for chromosome 4.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, defects of the brain, immune system and testis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the brain, immune system and testis, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., Amygdala, monocytes, testes, and liver and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 39 are useful for detecting defects of the brain, immune system and testis because of its abundance in these tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO : 40 The translation product of Gene NO : 40 shares sequence homology with lymphoma 3-encoded protein which is thought to contribute to leukemogenesis when abnormally expressed.

This gene is expressed primarily in Human Neutrophils, and to a lesser extent in Human Osteoclastoma Stromal Cells (unamplified), Hepatocellular Tumor, and Human Neutrophils, (Activated).

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chronic lymphocytic leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., neutrophils, osteoclastoma, and kidney, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial

fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to lymphoma 3-encoded protein indicates that polypeptides and polynucleotides corresponding to Gene NO : 40 are useful for treatment of lymphoma and related cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO : 41 Gene NO : 41 is expressed primarily in ovary tumor, and to a lesser extent in endometrial stromal cells and fetal brain.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, ovarian or endometrial cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system and the developing central nervous system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., ovary, endometrium and brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 41 are useful for development of factors involved in ovarian or endometrial and general reproductive organ disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 174 as residues : Glu-22 to Asn-84 to Asp-90, and Ser-144 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 42 The translation product of Gene 42 has sequence identity with a gene designated PTHrP (B). The PTHrP (B) polypeptide inhibits parathyroid hormone related peptide (PTHrP) activity.

This gene is expressed primarily in adult testis, and to a lesser extent in pituitary.

Therefore polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of male reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., testes, and pituitary, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Furthermore, based in part on sequence identity with PTHrP (B), nucleic acids and polypeptides of the present invention may be used to diagnose or treat such conditions as osteoporosis, and disorders related to calcium metabolism.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 42

are useful for treatment of male reproductive disorders, osteoporosis, and other disorders related to calcium metabolism.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 175 as residues : Tyr-81 to Met-86, Gly-103 to Ser-108, Glu-127 to Pro-128, Pro-175 to Ser-180, Glu-196 to Lys-203, Pro-235 to Ala-249 to Ser-264.

FEATURES OF PROTEIN ENCODED BY GENE NO : 43 The translation product of Gene NO : 43 shares sequence homology with brevican, which is thought to be important as a proteoglycan core protein of the aggrecan/versican family. The translation product of this gene may also contain a hyaluronan (HA)-binding region domain in frame with, but downstream of, the predicted open reading frame (Barta, et al., Biochem. J. 292 : 947-949 (1993)). The HA-binding domain, also termed the link domain, is found in proteins of vertebrates that are involved in the assembly of extracellular matrix, cell adhesion, and migration. It is about 100 amino acids in length. The structure has been shown to consist of two alpha helices and two antiparallel beta sheets arranged around a large hydrophobic core similar to that of C-type lectin. This domain typically contains four conserved cysteines involved in two disulfide bonds.

This gene is expressed primarily in early stage human brain and to a lesser extent in frontal cortex and epileptic tissues.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of disorders associated with, or observed during, neuronal development. Similarly, polypeptides and antibodies directed to these polypeptides are useful as immunological probes for differential identification of neuronal and associated tissues and cell types. For a number of disorders of the above tissues or cells, particularly for those of the nervous system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., brain and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to brevican indicates that polypeptides and polynucleotides corresponding to Gene NO : 43 are useful for neuronal regulation and signaling. The uses include directing or inhibiting axonal growth for the treatment of neuro-fibromatosis and in detection of glioses.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 176 as residues : Asp-28 to Arg-33 and Arg-126 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 44 Gene NO : 44 is the human homolog of Notch-2 (Accession No. 477495) and mouse EGF repeat transmembrane protein (Accession No. 1336628), both genes are important in differentiation and development of an organism. The EGF repeat transmembrane protein is regulated by insulin like growth factor Type I receptor. These proteins are involved in cell-cell signaling and cell fate determination. Based on homology, it is likely that this gene products also involved in cell differentiation and development. Although the predicted signal sequence is indicated in Table 1, it is likely that a second signal sequence is located further upstream. Moreover, further translated coding regions are likely found downstream from the disclosed sequence, which can easily be obtained using standard molecular biology techniques. A occurs somewhere around nucleotide 714, causing a frame shift in amino acid sequence from frame +2 to frame +3. However, using the

homology of Notch-2 and EGF repeat transmembrane protein, the complete open reading frame can be elucidated. Preferred polynucleotide fragments comprise nucleotides 146-715, 281-715, and 714-965. Other preferred polypeptide fragments comprise the following EGF-like motifs : CRCASGFTGEDC (SEQ ID NO : 260), (SEQ ID NO : 261), CLNLPGSYQCQC (SEQ ID NO : 262), CKCLTGFTGQKC (SEQ ID NO : 263), and (SEQ ID NO : 264).

Gene NO : 44 is expressed primarily in placenta and to a lesser extent in stromal and immune cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hemophilia and other blood disorders, central nervous system disorders, muscle disorders, and any other disorder resulting from abnormal development.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoietic and vascular systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., placenta, stromal and immune cells and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to Notch-2 indicates that polypeptides and polynucleotides corresponding to Gene NO : 44 are useful for diagnosing and treating disorders relating to abnormal regulation of cell fate, induction, and differentiation of cells (e. g., cancer), epidermal growth factors, axonal pathfinding, and hematopoiesis.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 177 as residues : Gln-27 to Tyr-32, His-45 to Glu-55, Tyr-61 to Gly-77, Glu-99 to Ser- 106, Ser-125 to and to Trp-144.

FEATURES OF PROTEIN ENCODED BY GENE NO : 45 The translation product of this gene shares sequence homology with Laminin A which is thought to be important in the binding of epithelial cells to basement membrane and is associated with tumor invasion. Moreover, the translated protein is homologous to the Drosophila LAMA gene (Accession No. 1314864), a gene expressed in the first optic ganglion Drosophila. Thus, is likely likely that gene product product this gene gene involved in the development of the eye. Nucleotide fragments comprising nucleotides 822-1223, 212-475, and 1677-1754 are preferred. Also preferred are the polypeptide fragments encoded by these polynucleotide fragments. It is likely that a frame shift occurs somewhere between nucleotides 475 to shifting the open reading frame from +2 to +3. However, the open reading frame can be clarified using known molecular biology techniques.

This gene is expressed primarily in human testes tumor and to a lesser extent in placenta and activated monocytes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, invasive cancers or tumors of the epithelium, as well as disorders relating to eye development. Similarly, polypeptides and antibodies directed to these polypeptides are useful as immunological probes for differential identification of the tissue (s) or cell

type (s). For a number of disorders of the above tissues or cells, particularly of neoplastic conditions, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., testes, placenta, and monocytes and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to Laminin A indicates that polypeptides and polynucleotides corresponding to Gene NO : 45 are useful for study and diagnosis of malignant or benign tumors, fibrotic disorders, and eye disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 178 as residues : to Gly-8, Glu-32 to Ala-37, Met-113 to Asn-119, and Glu-139 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 46 The translation product of Gene NO : novel and shares sequence homology with the product of the Drosophila tissue polarity gene frizzled. In vertebrates, it appears that there is a family of proteins that represent frizzled gene homologs. (See, e. g., Accession Nos. 1946343 and AF017989.) The Drosophila frizzled protein is thought to transmit polarity signals across the plasma membrane of epidermal cells. The structure of frizzled proteins suggest that they may function as a G-protein-coupled receptor. The frizzled proteins are thought to represent receptors for Wnt gene products -secreted proteins that control tissue differentiation and the development of embryonic and adult structures. Inappropriate expression of Wnts has also been demonstrated to contribute to tumor formation. Moreover, mammalian secreted frizzled related proteins are thought to regulate apoptosis. (See Accession No. The human homolog has also been recently cloned by other groups. (See Accession No.

H2415415.) Thus, the protein encoded by this gene plays a role in mediating tissue differentiation, proliferation, tumorigenesis and apoptosis. Preferred polypeptide fragments lack the signal sequence as described in Table 1, as well as N-terminal and C-terminal deletions. Preferred polynucleotide fragments encode these polypeptide fragments.

Gene NO : expressed primarily in fetal tissues-particularly fetal lung-and adult cancers, most notably pancreas tumor and Hodgkin's lymphoma. Together, this distribution is consistent with expression in tissues undergoing active proliferation. The gene is also expressed to a lesser extent in other organs, including stomach, prostate, and thymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer (particularly pancreatic cancer and/or Hodgkin's lymphoma), as well as other forms of aberrant cell proliferation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system and hyperproliferative disorders, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., fetal tissue, pancreas, and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to frizzled indicates that polypeptides and polynucleotides

corresponding to Gene NO : 46 are useful for influencing cell proliferation, differentiation, and apoptosis. The full-length protein or a truncated domain could potentially bind to and regulate the function of specific factors, such as Wnt proteins or other apoptotic genes, and thereby inhibit uncontrolled cellular proliferation. Expression of this protein within a cancer-such as via gene therapy or systemic administration-could effect a switch from proliferation to differentiation, thereby arresting the progression of the cancer.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 179 as residues : Pro-31 to Arg-37.

FEATURES OF PROTEIN ENCODED BY GENE NO : 47 The translation product of Gene NO : 47 shares sequence homology with members of the family of ribonuclease-encoding genes. These ribonuclease proteins are found predominantly in fungi, plants, and bacteria and have been implicated in a number of functions, including phosphate-starvation response, self-incompatibility, and responses to wounding. A second group has recently cloned this same gene, calling it a ribonuclease 6 precursor. (See Accession No. 2209029.) This group also mapped the gene to chromosome 6, thus, the polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 6.

Gene NO : 47 is expressed primarily in hematopoietic cells and tissues, including macrophages, eosinophils, CD34 positive cells, T-cells, and spleen. It is also expressed to a lesser extent in brain and spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors of a hematopoietic origin, graft rejection, wounding, inflammation, and allergy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., hematopoietic cells, and tissues and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the family of ribonuclease-encoding genes indicates that polypeptides and polynucleotides corresponding to Gene NO : 47 are useful as a cytotoxin that could be directed against specific cell types (e. g. cancer cells ; HIV-infected cells), and that would be well tolerated by the human immune system.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 180 as residues : Ala-24 to Asp-30, to Tyr-61, Pro-69 to Ser-78, Pro-105 to Phe- 110, Asn-129 to Phe-135, Pro-187 to Glu-192, Lys-205 to Gln-224, and Pro-250 to His-256.

FEATURES OF PROTEIN ENCODED BY GENE NO : 48 The translation product of Gene NO : 48 shares sequence homology with dolichyl-phosphate glucosyltransferase, a transmembrane-bound enzyme of the reticulum which is thought to be important in N-linked glycosylation, by catalyzing the transfer of glucose from UDP-glucose to dolichyl phosphate. (See Accession No. 535141.) Based on homology, it is likely that this gene product also play a role similar in humans. Preferred polynucleotide fragments comprise nucleotides 132-959. Also preferred are the polypeptide fragments encoded by this

nucleotide fragment.

Gene NO : 48 is expressed primarily in endothelial cells and to a lesser extent in hematopoietic cells and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, defects in proper N-linked glycosylation of proteins, such as Wiskott- Aldrich syndrome ; tumors of an endothelial cell origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the vascular and hematopoietic systems, as well as brain, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., endothelial cells, hematopoietic cells, and brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to dolichyl-phosphate glucosyltransferase indicates that polypeptides and polynucleotides corresponding to Gene NO : 48 are useful in diagnosing and treating defects in N-linked glycosylation pathways that contribute to disease conditions and/or pathologies.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 181 as residues : Lys-50 to Thr-55, Ser-73 to Arg-79, Glu-92 to Pro-99, to to Lys-131, Gly-179 to Asn-188, to Cys-236, and Glu-318 to Asn-324.

FEATURES OF PROTEIN ENCODED BY GENE NO : 49 Gene NO : 49 is expressed primarily in brain, most notably in the hypothalamus and amygdala. This gene is also mapped to chromosome X, and therefore, can be used in linkage analysis as a marker for chromosome X.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors of a brain origin ; neurodegenerative disorders, and sex-linked disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., brain and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 49 are useful for the diagnosis of tumors of a brain origin, and the treatment of neurodegenerative disorders, such as Parkinson's disease, and sex- linked disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO : 50 The translation product Gene NO : 50 shares sequence homology with canine phospholemman, a major plasma membrane substrate for cAMP-dependent protein kinases A and C. (See Accession No. M63934 ; see also Accession No. A40533.) In fact, a group also recently cloned the human phospholemman gene, and mapped this gene to

chromosome 19. (See Accession No. Phospholemman is a type I integral membrane protein that gets phosphorylated in response to specific extracellular stimuli such as insulin and adrenalin. forms ion channels in the cell membrane and appears to regulate taurine transport, suggesting an involvement in cell volume regulation. It has been proposed that phospholemman is a member of a superfamily of membrane proteins, characterized by single transmembrane domains, which function in transmembrane ion flux. They are capable of linking signal transduction to the regulation of such cellular processes as the control of cell volume.

Gene No 50 is expressed primarily in fetal liver and to a lesser extent in adult brain and kidney, as well as other organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, insulin and/or adrenalin defects ; diabetes ; aberrant ion channel signaling ; defective taurine transport ; and defects in cell volume regulation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the brain and/or immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., liver, brain, and kidney, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to phospholemman indicates that polypeptides and polynucleotides corresponding to Gene NO : 50 are useful for treatment of disorders involving the transport of ions and small molecules, in particular taurine. It could also be beneficial for control of pathologies or diseases wherein aberrancies in the control of cell volume are a distinguishing feature, due to the predicted role for phospholemman in the normal control of cell volume. It also may play a role in disorders involving abnormal circulating levels of insulin and/or adrenalin- along with other active secreted molecules-as revealed by its phosphorylation upon stimulation with insulin or adrenalin.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 183 as residues : Ala-20 to Gln-34, Arg-58 to Thr-79, and Leu-87 to Arg-92.

FEATURES OF PROTEIN ENCODED BY GENE NO : 52 Gene NO : 52 is expressed primarily in metastatic melanoma and to a lesser extent in infant brain.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and cancer metastasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., epidermis, and brain, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 52

are useful for diagnosis and treatment of melanoma.

FEATURES OF PROTEIN ENCODED BY GENE NO : 53 The translation product of Gene NO : 53 shares sequence homology with mucin which is thought to be important cell surface molecule. It also exhibits sequence identity with a calcium channel blocker of *Agelenopsis aperta*. In particular, with those calcium channel blockers which affect neuronal and muscle cells.

Gene NO : 53 is expressed primarily in prostate, endothelial cells, smooth muscle and fetal tissues and to a lesser extent in T cells and placenta.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancer, immune disorders, angina, hypertension, cardiomyopathies, supraventricular arrhythmia, oesophageal achalasia, premature labour, and Raynaud's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues or cell types (e. g., prostate, and tissue and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to mucin indicates that polypeptides and polynucleotides corresponding to Gene NO : 53 are useful as a surface antigen for diagnosis of diseases such as prostate cancer and as tumor vaccine.

FEATURES OF PROTEIN ENCODED BY GENE NO : 54 Gene NO : 54 encodes a polypeptide which exhibits sequence identity with the rab receptor and VAMP-2 receptor proteins. (Martincic, et al., J. Biol. Chem. 272 (1997).) Gene NO : 54 is expressed primarily in placenta, fetal liver, osteoclastoma and smooth muscle and to a lesser extent in T cell, fetal lung and colon cancer.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, osteoporosis and immuno-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, hematopoiesis system and bone system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., placenta, liver, osteoclastoma, smooth muscle, T-cells, and lung, and colon, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 54 are useful for treating cancer, osteoporosis and immuno-disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 187 as residues : Pro-16

to Phe-21, Pro-24 to Arg-35, Arg-92 to Pro-98, Asn-143 to and Leu-169 to

FEATURES OF PROTEIN ENCODED BY GENE NO : 55 Gene NO : 55 encodes a protein having sequence identity to the rat galanin receptor GALR2.

Gene NO : 55 is expressed primarily in ovarian cancer.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of ovarian cancer. Similarly, polypeptides and antibodies directed to those polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system and reproductive system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., ovary, and tissues and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. GALR2 antagonists can be used to treat obesity, or disease, while GALR2 agonists can be used to treat anorexia or pain, or to decrease nociception (claimed). Agonists and antagonists can also be used to treat numerous other disorders, including cognitive disorders, sensory disorders, motion sickness, convulsion/epilepsy, hypertension, diabetes, glaucoma, reproductive disorders, gastric and intestinal ulcers, inflammation, immune disorders, and anxiety.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 55 are useful for diagnosis and treatment of ovarian cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO : 56 As indicated in Table 1, the predicted signal sequence of Gene NO : 56 relates to an open reading frame that is homologous to the mouse major histocompatibility locus class III. (See Accession No. 2564953.) Any frame shift mutations that alter the correct open reading frame can easily be clarified using known molecular biology techniques.

Moreover, in the opposite orientation, a second translated product is disclosed. This second translation product of this contig is identical in sequence to intracellular protein lysophosphatidic acid acyltransferase. The nucleotide and amino acid sequences of this translated product have since been published by Stamps and colleagues (Biochem. J.

326 (Pt 2), 455-461 (1997)), West and coworkers (DNA Cell Biol. 6, 691-701 (1997)), Rowan (GenBank Accession No. U89336), and Soyombo and Hofmann (GenBank Accession No. AF020544). This gene is thought to enhance cytokine signaling response in cells. It is likely that a signal peptide is located upstream from this translated product. Preferred polypeptide fragments comprise the amino acid sequence : TPDVPALADRVRHSMHLHCF (SEQ ID NO : 265) ; RVEVRGAHHFPPSQPYVVVSNHQSSDLLGMMEVLPGRVCVPIAKR (SEQ ID NO : 266) ; TVFREISTD (SEQ ID NO : 267) ; or (SEQ ID NO : 268).

Also provided are polynucleotide fragments encoding these polypeptide fragments.

Gene NO : 56 is expressed primarily in infant adrenal gland, hypothalamus, 7 week old embryonic tissue, fetal lung, osteoclastoma stromal cells, and to a lesser extent in a large number of additional tissues.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of developmental disorders and osteoclastoma.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s) in which it is highly expressed. For a number of disorders of the above tissues or cells, particularly during development or of the nervous or bone systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., adrenal, embryonic tissue, lung, and osteoclastomal stromal cells, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Further, expression of this protein can be used to alter the fatty acid composition of a given cell or membrane type.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 56 are useful for diagnosis and treatment of osteoclastoma and other bone and non-bone-related cancers, as well as for the diagnosis and treatment of developmental disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 189 as residues : Gly-29 to Gly-36 and Tyr-49 to Tyr-58.

FEATURES OF PROTEIN ENCODED BY GENE NO : 57 The translation product of Gene NO : 57 shares sequence homology with longevity-assurance protein-1. (See Accession No. 123105.) Preferred polynucleotide fragments comprise nucleotides 6-125 and 118-432, as well as the polypeptides encoded by these polynucleotides. It is likely that a second signal sequence exists upstream from the predicted signal sequence in Table Moreover, a frame shift likely occurs between nucleotides 118-125, which can be elucidated using standard molecular biology techniques.

Gene NO : 57 is expressed primarily in fetal liver, kidney, brain, thymus, and bone marrow.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunological diseases and hyperproliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the fetal liver, kidney, brain, thymus, and bone marrow expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., liver, kidney, brain, thymus, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to longevity-assurance protein suggest that Gene NO : 57 encodes a protein useful in increasing life span and in replacement therapy for those suffering from immune system disorders or hyperproliferative disorders caused by underexpression or overexpression of this gene.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 190 as residues : Val-29 to Arg-46 and Gly-50 to Gly-56.

FEATURES OF PROTEIN ENCODED BY GENE NO : 58 Domains of the Gene NO : 58 product are homologous to porcine surfactant protein-A receptor. (See Accession No. B48516.) The bovine gene binds surfactant protein-A receptor, modulating the secretion of alveolar surfactant. Based on this homology, the gene product encoded by this gene will likely have activity similar to the porcine gene. Preferred polynucleotide fragments comprise nucleotides 887-1039, as well as the polypeptide fragments encoded by this nucleotide fragment.

Gene NO : 58 is expressed primarily in brain and to a lesser extent in endothelial cells.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the central nervous system including dementia, stroke, neurological disorders, respiratory distress, and diseases affecting the endothelium including inflammatory diseases, restenosis, and vascular diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the placenta, liver, endothelial cells, prostate, thymus, and lung, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., brain, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology indicates that polypeptides and polynucleotides corresponding to Gene NO : 58 are useful for the diagnosis and/or treatment of diseases on the central nervous system, such as a factor that promote neuronal survival or protection, in the treatment of inflammatory disorders of the endothelium, or in disorders of the lung. In addition this protein may inhibit or promote angiogenesis and therefore is useful in the treatment of vascular disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 191 as residues : His-66 to Pro-80, Gly-139 to Ser-146 and Ser-262 to Pro-267.

FEATURES OF PROTEIN ENCODED BY GENE NO : 59 The translation product of Gene NO : 59 is homologous to the rat hypertension- induced protein which is thought to be important in hypertension, and found expressed mainly in kidneys. (See Accession No. B61209.) Thus, it is likely that this gene product is involved in hypertension in humans. Preferred polypeptide fragments comprise the short chain dehydrogenase/reductase motif SILGIISVPLSIGYCASKHALRGFFNGLR (SEQ ID NO : 269), as well as polynucleotides encoding this polypeptide fragment. Also preferred are polynucleotide fragments of 337-639, as well as the polypeptide fragments encoded by this polynucleotide fragment.

Gene NO : 59 is expressed primarily in liver, spleen, lung, brain, and prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular, immunological, and renal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of

disorders of the above tissues or cells, particularly of the cardiovascular, renal, and immune, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., liver, spleen, lung, brain, and prostate, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to hypertension-induced protein indicates that polypeptides and polynucleotides corresponding to Gene NO : 59 are useful for treating hypertension.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 192 as residues : Gln-40 to Glu-45, Glu-96 to Glu-102, Asn-256 to Thr-266, and Asp- 308 to Asp-317.

FEATURES OF PROTEIN ENCODED BY GENE NO : 60 Gene NO : 60 is expressed primarily in activated T-cell and Jurkat cell and to a lesser extent in apoptotic T-cell and CD34+ cell. It is likely that alternative open reading frames provide the full length amino acid sequence, which can be verified using standard molecular biology techniques.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T lymphocyte related diseases or hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., T-cells and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 60 are useful for diagnosis or treatment of immune system disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO : 61 The translation product of Gene NO : a vacuolar proton-ATPase, shares sequence homology with a *Caenorhabditis elegans* protein which is thought to be important in development. This protein may be a human secretory homologue that may also influence embryo development. Ludwig, J., also recently cloned this gene from chromaffin granules. (See, Accession No. 2584788.) Although Table 1 indicates the predicted signal peptide sequence, the translated product of this gene may in fact start with the upstream methionine, beginning with the amino acid sequence MAYHGLTV (SEQ ID : 270). Thus, polypeptides comprising this upstream sequence, as well as N-terminus deletions, are also contemplated in the present invention.

Gene NO : 61 is expressed primarily in human placenta, liver, and Hodgkin's Lymphoma and to a lesser extent in bone marrow. Modest levels of expression were also observed in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hyperproliferative disorders, defects in embryonic development, and diseases or disorders caused by defects in chromaffin granules. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly cancer, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., placenta, liver, lymph tissue, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to *Caenorhabditis elegans* indicates that polypeptides and polynucleotides corresponding to Gene NO : 61 are useful for diagnostic or therapeutic modalities for hyperproliferative disorders, embryonic development disorders, and chromaffin granules disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO : 62 The translation product of Gene NO : 62 shares sequence homology with the murine gene which is thought to be important in the mediation of natural killer cell (NK cell) activity as previously determined by experiments in mice containing null mutations of The similarity of this gene to the CD4 receptor may imply that the gene product may be a secreted, soluble receptor and immune mediator.

Gene NO : 62 is expressed primarily in human fetal heart, meningima, and to a lesser extent in tonsils. This gene also is expressed in the breast cancer cell line MDA 36.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, lymphomas, leukemias, breast cancer and any immune system dysfunction, including those dysfunctions which involve natural killer cell activities.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system or breast cancer, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., heart, meningima, and tonsils and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the gene (murine) indicates that the polynucleotides and polypeptides corresponding to Gene NO : 62 are useful for diagnostic and/or therapeutic modalities directed at abnormalities or disease states involving defective immune systems, preferably involving natural killer cell activity, as well as breast cancer.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 195 as residues : Pro-10 to Trp-17, Cys-58 to Pro-67, Thr-76 to Glu-85, and Arg-93 to Asn-101.

FEATURES OF PROTEIN ENCODED BY GENE NO : 63 The translation product of Gene NO : 63 shares sequence homology with a *Caenorhabditis elegans* alpha-collagen gene (Clg), which is thought to be important in organism development, as well as other collagen genes. Thus, based on sequence homology, polypeptides of this gene are expected to have activity similar to collagen, including involvement in organ development.

Gene NO : 63 is expressed primarily in human B-Cell Lymphoma, and to a lesser extent in human pituitary tissue. This gene has also demonstrated expression in keratinocytes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, B-Cell Lymphoma, other lymphomas, leukemias, and other cancers, as well as disorders related to development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., tissue and/or cells of the immune system, and pituitary, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to Caenorhabditis alpha-collagen gene indicates that polypeptides and polynucleotides corresponding to Gene NO : 63 are useful for development of diagnostic and/or therapeutic modalities directed at the detection treatment of cancer, specifically B-Cell Lymphomas, leukemias, or diseases related to development.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 196 as residues : Thr-22 to Arg-27 and Ser-29 to Thr-39.

FEATURES OF PROTEIN ENCODED BY GENE NO : 64 The translation product of Gene NO : 64 shares sequence homology with human extracellular molecule olfactomedin, which is thought to be important in the maintenance, growth, or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons. Based on this sequence homology, it is likely that polypeptides of this gene have activity similar to the olfactomedin, particularly the differentiation or proliferation of neurons.

Gene NO : 64 is expressed primarily in fetal lung tissue.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the lung as well as neural development, particularly of the lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., lungs and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the olfactomedin family indicates that polypeptides and polynucleotides corresponding to Gene NO : 64 are useful for the development of diagnostic and/or therapeutic modalities directed at detection and/or treatment of pulmonary disease states, e. g., cystic fibrosis.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 197 as residues : Gly-17

to Gln-23, Gln-45 to Arg-50, Arg-56 to Lys-61, Glu-70 to Leu-76, Asp-88 to Glu-93, Pro-117 to Asp-161 to Glu-167, Arg-224 to Asn- 237, Asp-302 to Trp-312, Pro-315 to Asn-320, and Thr-337 to Ser-341.

FEATURES OF PROTEIN ENCODED BY GENE NO : 65 The translation product of Gene NO : 65 shares sequence homology with hypothetical protein YKL166 (Accession No. gi/687880) which is thought to be important in secretory vesicular transport mechanisms.

Based on this homology, it is likely that the gene product would have similar activity to YKL166, particularly secretory or transport mechanisms. Preferred polypeptide fragments of this gene include those fragments starting with the amino acid sequence ISAARV (SEQ ID : Other polypeptide fragments include the former fragment, which ends with the amino acid sequence PDVSEFMTRLF (SEQ ID : 272). Further preferred fragments include those polypeptide fragments comprising the amino acid sequence FDPVRVDITSKGKMRAR (SEQ ID : 273). Also preferred are polypeptide fragments having exogenous signal sequences fused to the polypeptide.

Gene No 65 is expressed primarily in placenta, testis, osteoclastoma and to a lesser extent in adrenal gland.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and/or diseases involving defects in protein secretion. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, cartilage and bone, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., placenta, testis, adrenal gland, and osteoclastoma, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the yeast protein indicates that polypeptides and polynucleotides corresponding to Gene NO : 65 are useful for the development of therapeutic diagnostic modalities targeted at cancer or secretory anomalies, such as genetically caused secretory diseases.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 198 as residues : Ser-18 to Ser-29 and Lys-53 to Arg-74.

FEATURES OF PROTEIN ENCODED BY GENE NO : 66 The translation product of Gene NO : 66 shares sequence homology with the human papilloma virus (HPV) E5 ORF region which is thought to be important as a secreted growth factor. Although this is described as a viral gene product, it is believed to have several cellular secretory homologues. Therefore, based on the sequence similarity between the HPV E5 ORF and the translated product of this gene, this gene product is likely to have activity similar to HPV E5 ORF.

Gene NO : 66 is expressed primarily in activated T-Cells, monocytes, cerebellum and to a lesser extent in infant brain.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential

identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and/or human papilloma virus infection. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., brain, lymph tissue, monocytes, and T-cells and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Moreover, polynucleotides of this gene have been mapped to chromosome 1. Therefore, polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 1.

The tissue distribution and homology to human papilloma virus E5 region indicates that polypeptides and polynucleotides corresponding to Gene NO : 66 are useful for development of diagnostic and/or therapeutic modalities directed at the diagnosis and/or treatment of cancer and/or human papilloma virus infection (HPV).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 199 as residues : to Arg-36 and Leu-102 to Ser-112.

FEATURES OF PROTEIN ENCODED BY GENE NO : 67 The translation product of Gene NO : 67 shares sequence homology with the protein precursor [Mus musculus] which is thought to be important in B-Cell mu chain assembly. (See, Accession No. ; Shiraswa, T., EMBO. J.

12 (5) : 1827-1834 (1993).) A polypeptide fragment starting at amino acid 53 is preferred, as well as 1-20 amino acid N-terminus and/or C-terminus deletions. Based on the sequence similarity between 8hs20 protein and the translation product of this gene, the two polypeptides are expected to share certain biological activities, particularly immunologic activities.

Gene NO : 67 is expressed primarily in human B-cells and to a lesser extent in Hodgkin's Lymphoma. It is also likely that the polypeptide will be expressed in B-cell specific cells, bone marrow, and spleen, as is observed with

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, Hodgkin's Lymphoma, Common Variable Immunodeficiency, and/or other B-cell lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., bone marrow, spleen, lymph tissue, and B-cells, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to protein precursor [Mus indicates that polypeptides and polynucleotides corresponding to Gene NO : 67 are useful for therapeutic and/or diagnostic purposes, targeting Hodgkin's Lymphoma, B-cell lymphomas, Common Variable Immunodeficiency, or other

immune disorders.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 200 as residues : Asp-51 to Trp-56, Arg-72 to Asp-85, and Gln-106 to Asp-112.

FEATURES OF PROTEIN ENCODED BY GENE NO : 68 Gene NO : 68 is expressed primarily in fetal liver/spleen, rhabdomyosarcoma, and to a lesser extent in 9 week-old early stage human embryo and bone marrow.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, rhabdomyosarcoma and other cancers, hematopoietic disorders, and immune dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues (e. g., embryonic tissue, striated muscle, liver, spleen, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of Gene NO : 68 is useful for diagnostic and/or therapeutic purposes directed to cancer, preferably rhabdomyosarcoma. Enhanced expression of this gene in fetal liver, spleen, and bone marrow indicates that this gene plays an active role in hematopoiesis. Polypeptides or polynucleotides of the present invention may therefore help modulate survival, proliferation, differentiation of various hematopoietic lineages, including the hematopoietic stem cell. Thus, polynucleotides or polypeptides can be used to treat various hematopoietic disorders and influence the development and differentiation of blood cell lineages, including hematopoietic stem cell expansion. The polypeptide does contain a thioredoxin family active site at amino acids 64-82. Polypeptides comprising this thioredoxin active site are contemplated.

FEATURES OF PROTEIN ENCODED BY GENE NO : 69 Gene NO : 69 is expressed primarily in liver and kidney and to a lesser extent in macrophages, uterus, placenta, and testes.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal disorders, neoplasms (e. g., soft tissue cancer, hepatocellular tumors), immune disorders, endocrine imbalances, and reproductive disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the hepatic, urogenital, immune, and reproductive systems, expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e. g., liver, kidney, uterus, placenta, testes, and macrophages and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 69 are useful for diagnosis and treatment of disorders in the hepatic, urogenital, immune, and reproductive systems.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 202 as residues : Arg-41 to Ser-50, Glu-138 to Asn-148, Ser-155 to Arg-172, Pro-219 to Glu-228.

FEATURES OF PROTEIN ENCODED BY GENE NO : 70 Gene NO : 70 is expressed primarily in the immune system, including macrophages, T-cells, and dendritic cells and to a lesser extent in fetal tissue.

Therefore, polynucleotides or polypeptides of the invention are useful as reagents for differential identification of the tissue (s) or cell type (s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, inflammatory diseases, lymph node disorders, fetal development, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue (s) or cell type (s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems expression of this gene at significantly higher or lower levels may routinely be detected in certain tissues and certain cell types (e. g., macrophages, T-cells, dendritic cells, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e. g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i. e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. There is some evidence that the polynucleotide is mapped to chromosome 19. Thus, the polynucleotide can be a marker for genetic analysis for chromosome 19.

The tissue distribution indicates that polypeptides and polynucleotides corresponding to Gene NO : 70 are useful for treatment, prophylaxis, and diagnosis of immune and autoimmune diseases, such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS. The polypeptides or polynucleotides of the present invention are also useful in the treatment, prophylaxis, and detection of thymus disorders, such as Graves Disease, lymphocytic thyroiditis, hyperthyroidism, and hypothyroidism. The expression observed predominantly in hematopoietic cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e. g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immunodeficiency diseases, leukemia, and septicemia.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO : 203 as residues : Thr-21 to Ser-27, Pro-33 to Ser-38, and Arg-73 to Lys-84. 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 1 HGCM20 97901 pSport1 11 1739 26 1658 54 54 134 1 28 29 466 02/26/97 209047 05/15/97 2 HLDBG33 97898 pCMVSPORT 12 844 1 844 39 39 135 1 8 29 221 02/26/97 3.0 209044 05/15/97 2 HLDBG33 97898 pCMVSPORT 81 795 1 434 10 10 204 1 29 30 34 02/26/97 3.0 209044 05/15/97 3 HTGEW86 97899 Uni-ZAP XR 13 776 134 676 173 173 136 1 35 36 155 02/26/97 209045 05/15/97 4 HKCSR70 97900 pBluescript 14 1376 727 1343 202 202 137 1 20 21 232 02/26/97 209046 05/15/97 4 HKCSR70 97900 pBluescript 82 1342 741 1309 861 205 1 31 32 42 02/26/97 209046 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of

5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 4 HETB187 209010 Uni-ZAP XR 83 1494 1 1484 51 51 206 1 34 35 84 04/28/97 209085 05/29/97 5 HTEAU17 97897 Uni-ZAP XR 15 502 1 502 143 143 138 1 3 34 60 02/26/97 209043 05/15/97 6 HBMCY91 97897 pBluescript 16 425 1 425 56 56 139 1 17 18 72 02/26/97 209043 05/15/97 7 HSSGE07 97897 Uni-ZAP XR 17 1316 1 1298 45 45 140 1 26 27 376 02/26/97 209043 05/15/97 7 HSSGE07 97897 Uni-ZAP XR 84 1285 1 1271 15 15 207 1 28 29 207 02/26/97 209043 05/15/97 8 HBMEY59 97897 pBluescript 18 436 87 384 157 157 141 1 21 22 42 02/26/97 209043 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 9 HNGIT22 97897 Uni-ZAP XR 19 503 1 503 23 23 142 1 19 20 40 02/26/97 209043 05/15/97 10 HERAD57 97897 Uni-ZAP XR 20 358 1 358 147 147 143 1 31 32 69 02/26/97 209043 05/15/97 11 HCENJ40 97898 Uni-ZAP XR 21 1926 573 1926 157 157 144 1 30 31 482 02/26/97 209044 05/15/97 11 HCENJ40 97898 Uni-ZAP XR 85 394 1 94 166 166 208 1 20 21 23 02/26/97 209044 05/15/97 11 HCENJ40 97898 Uni-ZAP XR 86 1925 573 1925 157 157 209 1 30 31 482 02/26/97 209044 05/15/97 11 HCENJ40 97898 Uni-ZAP XR 87 1818 30 1298 1137 210 1 12 02/26/97 209044 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 12 HCSRA90 97898 Uni-ZAP XR 22 1224 64 557 80 80 145 1 30 31 225 02/26/97 209044 05/15/97 13 HBJFC03 97898 Uni-ZAP XR 23 694 1 181 181 146 1 39 40 44 02/26/97 209044 05/15/97 13 HBJFC03 97898 Uni-ZAP XR 88 539 1 539 215 215 211 1 18 19 19 02/26/97 209044 05/15/97 14 HSNBL85 97899 Uni-ZAP XR 24 796 405 796 1 1 147 1 30 31 131 02/26/97 209045 05/15/97 14 HSNBL85 97899 Uni-ZAP XR 89 855 300 85 513 513 212 1 37 38 54 02/26/97 209045 05/15/97 15 HTEBY70 97899 Uni-ZAP XR 25 662 205 653 77 77 148 1 30 31 91 02/26/97 209045 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 15 HTEBY26 97899 Uni-ZAP XR 90 628 198 625 275 213 1 31 32 34 02/26/97 209045 05/15/97 16 HMABH07 97899 Uni-ZAP XR 26 1105 40 1105 88 88 149 1 18 19 164 02/26/97 209045 05/15/97 16 HMABH07 97899 Uni-AZP XR 91 1053 61 1009 79 79 214 1 22 23 229 02/26/97 209045 05/15/97 17 HSKNY94 97899 pBluescript 27 1017 1 1017 97 97 150 1 30 31 138 02/26/97 209045 05/15/97 17 HSKNY94 97899 pBluescript 93 2492 1 943 100 100 216 1 27 28 126 02/26/97 209045 05/15/97 18 HMCDA67 97899 Uni-ZAP XR 28 391 1 391 169 169 151 1 29 30 57 02/26/97 209045 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 19 HOSFF45 97899 Uni-ZAP XR 29 1139 6 1139 109 109 152 1 44 45 47 02/26/97 209045 05/15/97 19 HOSFF45 97899 Uni-ZAP XR 94 3058 1795 2847 1868 1868 217 1 46 47 46 02/26/97 209045 05/15/97 20 HMJAA51 97899 pSport1t 30 465 1 370 47 47 153 1 28 29 41 02/26/97 209045 05/15/97 20 HMJAA51 97899 pSport1 95 1099 664 1000 669 669 218 1 33 34 40 02/26/97 209045 05/15/97 21 HTEBF05 97899 Uni-ZAP XR 31 702 1 702 40 403 154 1 24 25 71 02/26/97 209045 05/15/97 22 HTEAL31 97899 Uni-ZAP XR 32 1142 1 518 49 49 155 1 47 48 105 02/26/97 209045 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 22 HTEAL31 97899 Uni-ZAP XR 96 1580 23 422 32 32 219 1 47 48 104 02/26/97 209045 05/15/97 23 HBMCT32 97899 pBluescript 33 928 1 928 48 48 156 1 27 28 28 02/26/97 209045 05/15/97 23 HBMCT32 97899 pBluescript 97 678 72 593 89 89 220 1 27 28 28 02/26/97 209045 05/15/97 24 HSKXE91 97899 pBluescript 34 773 1 773 39 39 157 1 22 23 52 02/26/97 209045

05/15/97 24 HSKXE91 97899 pBluescript 98 1253 507 1253 507 507 221 1 16 02/26/97 209045
05/15/97 25 HPWTB38 97899 Uni-ZAP XR 35 453 1 453 40 40 158 1 25 26 74 02/26/97 209045
05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ of of 5' NT First SEQ AA AA
First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO: NT Seq.
Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep
Portion OR F 26 HTLEV12 97899 Uni-ZAP XR 36 459 1 459 25 25 159 1 24 25 80 02/26/97 209045
05/15/97 27 HSPAF93 97900 pSport1 37 509 1 509 1 1 160 1 19 20 138 02/26/97 209046 05/15/97 27
HSPAF93 97900 pSport1 99 447 1 447 7 7 222 1 23 24 137 02/26/97 209046 05/15/97 28 HHFGL62
97900 Uni-ZAP XR 38 598 1 598 1 1 161 1 21 22 177 02/26/97 209046 05/15/97 28 HHFGL62 97900
Uni-ZAP XR 100 611 37 611 17 17 223 1 26 27 49 02/26/97 209046 05/15/97 29 HCEIU14 97900 Uni-
ZAP XR 39 454 1 454 1 1 162 1 21 22 71 02/26/97 209046 05/15/97 5' NT NT 5'NT 3'NT of AA First
last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of
AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No.
Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 29 HCEIU14 97900 Uni-ZAP
XR 101 609 176 609 237 237 224 1 14 02/26/97 209046 05/15/97 30 HEBDA39 97900 Uni-ZAP XR
40 425 1 376 223 223 163 1 18 19 66 02/26/97 209046 05/15/97 31 HTHBA79 97900 Uni-ZAP XR 41
2471 141 2471 213 213 164 1 30 31 154 02/26/97 209046 05/15/97 31 HTHBA79 97900 Uni-ZAP XR
102 170 47 1721 119 119 225 1 31 32 154 02/26/97 209046 05/15/97 31 HTHBA79 97900 Uni-ZAP
XR 103 1832 96 1777 138 138 26 1 9 02/26/97 209046 05/15/97 31 HAGBB70 97900 Uni-ZAP XR 42
2659 1172 2659 119 119 165 1 18 19 103 02/26/97 209046 05/15/97 5' NT NT 5'NT 3'NT of AA First
last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of
AA of ID of of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No.
Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 32 HAGBB70 97900 Uni-ZAP
XR 104 2237 878 2237 1134 1134 227 1 19 02/26/97 209046 05/15/97 33 HETDG84 97900 Uni-ZAP
XR 43 1635 100 1580 299 299 166 1 20 21 80 02/26/97 209046 05/15/97 34 HTEGA81 97900 Uni-
ZAP XR 44 780 19 717 10 10 167 1 23 24 92 02/26/97 209046 05/15/97 34 HKGAJ40 209236 pSport1
05 1822 1 1023 272 272 228 1 23 24 93 09/04/97 34 HKMLK44 209084 pBluescript 106 1712 1 1669
168 168 229 1 21 22 93 05/29/97 35 HTXAK60 97900 Uni-ZAP XR 45 2378 1337 2378 1437 1437 168
1 30 31 57 02/26/97 209046 05/15/97 35 HTXAK60 97900 Uni-ZAP XR 107 1969 1068 1892 989 989
230 1 23 24 36 02/26/97 209046 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted ATCC SEQ
of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA
Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and
Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 36 HMHBN40 97901 Uni-ZAP XR 46 172 69 1772
129 129 169 1 30 31 231 02/26/97 209047 05/15/97 36 HMHBN40 97901 Uni-ZAP XR 108 1734 65
1734 100 100 231 1 29 30 80 02/26/97 209047 05/15/97 37 HFVGS85 97901 pBluescript 47 1107 70
1107 83 83 170 1 30 31 71 02/26/97 209047 05/15/97 38 HERAH81 97901 Uni-ZAP XR 48 805 167
764 167 167 171 B1 23 24 64 02/26/97 209047 05/15/97 39 HMSEU04 97901 Uni-ZAP XR 49 1408
131 1258 364 364 172 1 22 23 74 02/26/97 209047 05/15/97 40 HNEDJ57 97901 Uni-ZAP XR 50 1813
1 1184 2 2 173 1 1 2 333 02/26/97 209047 05/15/97 5' NT NT 5'NT 3'NT of AA First last Predicted
ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of
of of AA Gene cDNA No: Z NO: NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and
Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 41 HNTME13 97901 pSport1 51 2070 74 2070
142 142 174 1 20 21 195 02/26/97 209047 05/15/97 41 HNTME13 97901 pSport1 109 2003 15 1957 68
68 232 1 22 23 300 02/26/97 209047 05/15/97 42 HSXBI25 97901 Uni-ZAP XR 52 1426 1 142 158 158
175 1 25 26 264 02/26/97 209047 05/15/97 42 HSXBI25 97901 Uni-ZAP XR 110 1320 80 1311 41 41
233 1 29 30 312 02/26/97 209047 05/15/97 43 HSXCK41 97901 Uni-ZAP XR 53 1720 1 1720 161 161
176 1 22 23 137 02/26/97 209047 05/15/97 43 HSXCK41 97901 Uni-ZAP XR 111 1962 299 1962 566
234 1 33 34 47 02/26/97 209047 05/15/97 5' NT NT 5' NT 3' NT of AA First Last Predicted ATCC SEQ
of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA
Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date
Vector X Seq. Codon Pep Y Pep Pep Portion OR F 44 HE8CJ26 97902 Uni-ZAP XR 54 1117 1 1107

218 218 177 1 25 26 178 02/26/97 209048 05/15/97 44 HE8CJ26 97902 Uni-ZAP XR 112 1785 30
1087 225 235 1 23 24 33 02/26/97 209048 05/15/97 45 HTTDS54 97902 Uni-ZAP XR 55 1903 1 1903
119 119 178 1 31 32 154 02/26/97 209048 05/15/97 45 HTTDS54 97902 Uni-ZAP XR 113 1842 1 1832
80 80 236 1 36 37 312 02/26/97 209048 05/15/97 46 HLHDY31 97902 Uni-ZAP XR 56 1869 133 1838
124 124 179 1 24 25 294 02/26/97 209048 05/15/97 46 HLHDY31 97902 Uni-ZAP XR 114 1960 90
1960 165 165 237 1 24 25 295 02/26/97 209048 05/15/97 5' NT NT 5' NT 3' NT of AA First Last
Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA
of ID of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone
ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 47 HMCBP63 97902 Uni-ZAP XR 57
1259 320 1010 352 352 180 1 26 27 255 02/26/97 209048 05/15/97 48 HEMGE83 97902 Uni-ZAP XR
58 1186 33 557 12 12 181 1 18 19 232 02/26/97 209048 05/15/97 49 HHSDC22 97902 Uni-ZAP XR 59
428 1 304 172 172 182 1 34 35 46 02/26/97 209048 05/15/97 50 HHSDZ57 97902 Uni-ZAP XR 60 501
1 501 40 40 183 1 62 63 92 02/26/97 209048 05/15/97 50 HHSDZ57 97902 Uni-ZAP XR 115 536 73
536 73 73 238 1 22 23 91 02/26/97 209048 05/15/97 52 HMMAB12 97903 pSport1 62 595 1 595 308
308 185 1 29 30 42 02/26/97 209049 05/15/97 5' NT NT 5' NT 3' NT of AA First Last Predicted ATCC
SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of
AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date
Vector X Seq. Codon Pep Y Pep Pep Portion OR F 52 HMMAB12 97903 pSport1 118 453 1 453 198
198 241 1 26 27 27 02/26/97 209049 05/15/97 53 HSKDW02 97903 Uni-ZAP XR 63 1478 40 1436 176
176 186 1 39 40 58 02/26/97 209049 05/15/97 53 HSKDW02 97903 Uni-ZAP XR 119 2016 211 1957
317 317 242 1 25 26 57 02/26/97 209049 05/15/97 54 HETGL41 97903 Uni-ZAP XR 64 2033 1 2033
30 30 187 1 30 31 187 02/26/97 209049 05/15/97 54 HETGL41 97903 Uni-ZAP XR 120 2136 110
2134 296 296 243 1 23 24 122 02/26/97 209049 05/15/97 55 HODAZ50 97903 Uni-ZAP XR 65 440 1
440 1 1 188 1 26 27 145 02/26/97 209049 05/15/97 5' NT NT 5' NT 3' NT of AA First Last Predicted
ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of
of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and
Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 55 HODAZ50 97903 Uni-ZAP XR 121 219 1 1
219 1 244 1 10 11 72 02/26/97 209049 05/15/97 56 HSDGE59 97903 Uni-ZAP XR 66 3301 349 1478
341 341 189 1 30 31 83 02/26/97 209049 05/15/97 57 HE6ES13 97903 Uni-ZAP XR 67 1535 1 1535
331 331 190 1 26 27 57 02/26/97 209049 05/15/97 57 HE6ES13 97903 Uni-ZAP XR 122 1686 239
1678 367 245 1 27 28 48 02/26/97 209049 05/15/97 58 HSSEP68 97903 Uni-ZAP XR 68 1244 402
1244 57 57 191 1 30 31 310 02/26/97 209049 05/15/97 58 HSSEP68 97903 Uni-ZAP XR 123 1211 1
1211 80 80 246 1 30 31 338 02/26/97 209049 05/15/97 5' NT NT 5' NT 3' NT of AA First Last
Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA
of ID of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone
ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 58 HSSEP68 97903 Uni-ZAP XR 124
1804 402 1526 501 501 247 1 17 02/26/97 209049 05/15/97 59 HRDEV41 97903 Uni-ZAP XR 69 1291
1 1278 70 70 192 1 28 29 317 02/26/97 209049 05/15/97 59 HRDEV41 97903 Uni-ZAP XR 125 1282
31 1088 70 70 248 1 21 22 338 02/26/97 209049 05/15/97 60 HILCJ01 97903 pBluescript 70 1031 498
1031 536 536 193 1 30 31 52 02/26/97 SK- 209049 05/15/97 61 HSATP28 97904 Uni-ZAP XR 71 855
178 855 187 187 194 1 28 29 41 02/26/97 209050 05/15/97 62 HHFGL41 97904 Uni-ZAP XR 72 1274
58 1274 118 118 195 1 42 43 101 02/26/97 209050 05/15/97 5' NT NT 5' NT 3' NT of AA First Last
Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA
of ID of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone
ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 62 HHFGL41 97904 Uni-ZAP XR 126
1296 88 1237 133 133 249 1 39 40 95 02/26/97 209050 05/15/97 63 HBJEM49 97904 Uni-ZAP XR 73
688 1 688 173 173 196 1 18 19 44 02/26/97 209050 05/15/97 63 HBJEM49 97904 Uni-ZAP XR 127
737 1 737 174 174 250 1 20 21 78 02/26/97 209050 05/15/97 64 HSLDJ95 97904 Uni-ZAP XR 74 1890
1 1890 112 112 197 1 21 22 354 02/26/97 209050 05/15/97 64 HSLDJ95 97904 Uni-ZAP XR 128 1925
1 1829 87 87 251 1 23 24 353 02/26/97 209050 05/15/97 65 HSREG44 97904 Uni-ZAP XR 75 1133
408 1133 531 531 198 1 18 19 73 02/26/97 209050 05/15/97 5' NT NT 5' NT 3' NT of AA First Last

Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 66 HTXCT40 97904 Uni-ZAP XR 76 585 1 1 199 1 69 70 112 02/26/97 209050 05/15/97 66 HTXCT40 97904 Uni-ZAP XR 129 2713 2023 2713 2133 2133 252 1 39 40 108 02/26/97 209050 05/15/97 67 HRGDF73 97904 Uni-ZAP XR 77 577 1 577 51 51 200 1 23 24 122 02/26/97 209050 05/15/97 68 HRDBF52 97904 Uni-ZAP XR 78 2278 1458 1935 25 25 201 1 23 24 314 02/26/97 209050 05/15/97 68 HRDBF52 97904 Uni-ZAP XR 130 1011 479 1011 701 701 253 1 20 21 44 02/26/97 209050 05/15/97 68 HKMND45 97976 pBluescript 131 2278 1 1929 25 25 254 1 27 28 314 04/04/97 69 HPEBD70 97904 Uni-ZAP XR 79 1143 601 1097 95 95 202 1 6 7 235 02/26/97 209050 05/15/97 5' NT NT 5' NT 3' NT of AA First Last Predicted ATCC SEQ of of 5' NT First SEQ AA AA First AA Last Deposit ID Total Clone Clone of AA of ID of of of AA Gene cDNA No: Z NO; NT Seq. Seq. Start Signal NO: Sig Sig Secreted of No. Clone ID and Date Vector X Seq. Codon Pep Y Pep Pep Portion OR F 69 HPEBD70 97904 Uni-ZAP XR 132 1088 535 1043 588 588 255 1 27 28 52 02/26/97 209050 05/15/97 70 HMCAB89 97904 Uni-ZAP XR 80 557 1 557 132 132 203 1 25 26 92 02/26/97 209050 05/15/97 Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO : X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO : X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No : Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO : X. The nucleotide position of SEQ ID NO : X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO : X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep." The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO : Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO : Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO : Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO : Y of the last amino acid in the open reading frame is identified as "Last AA of SEQ ID NO : X" and the translated SEQ ID NO : Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO : X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO : X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO : Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated

DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99. 9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO : X and the predicted translated amino acid sequence identified as SEQ ID NO : Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO : X, SEQ ID NO : Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein.

Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67 : 31-40 (1988).

Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3 : 271-286 (1985), uses the information from a short N-terminal charged region and a subsequent

uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14 : 4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point (s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et Protein Engineering 10 : 1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO : Y which have an N-terminus beginning within 5 residues (i. e., + or -5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence.

However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

"Identity" per se has an art-recognized meaning and can be calculated using published techniques. (See, e. g. : (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A. M., ed., Oxford University Press, New York, (1988) ; BIOCOMPUTING : INFORMATICS AND GENOME PROJECTS, Smith, D. W., ed., Academic Press, New York, (1993) ; COMPUTER ANALYSIS OF SEQUENCE DATA, PART Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, (1994) ; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, (1987) ; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, (1991).) While there exists a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans. (Carillo, H., and Lipton, D., *SIAM J Applied Math* 48 : 1073 (1988).) Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in "Guide to Huge Computers," Martin J. Bishop, Academic Press, San Diego, (1994), and Carillo, H., and Lipton, D., *SIAM J Applied Math* 48 : 1073 (1988).

Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux, J., et Nucleic Acids Research (1984) 12 : 387 (1984)), BLASTP, BLASTN, (Atschul, S. F. et al., J. Molec. Biol. 215 : 403 (1990)), Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711 (using the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2 : 482-489 When using any of the sequence alignment programs to determine whether a particular sequence is, for instance, 95% identical to a reference sequence, the parameters are set so that the percentage of identity is calculated over the full length of the reference polynucleotide and that gaps in identity of up to of the total number of nucleotides in the reference polynucleotide are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6 : 237-245 (1990).) The term "sequence" includes nucleotide and amino acid sequences. In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB search of a DNA sequence to calculate percent identity are : Matrix=Unitary, Mismatch Penalty=1, Joining Penalty=30, Randomization Group and Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, and Window Size=500 or query sequence length in nucleotide bases, whichever is shorter. Preferred parameters employed to calculate percent identity and similarity of an amino acid alignment are : Matrix=PAM 150, Mismatch Joining Penalty=20, Randomization Group Cutoff Gap Penalty=5, Gap Size Penalty=0.05, and Window Size=500 or query sequence length in amino acid residues, whichever is shorter.

As an illustration, a polynucleotide having a nucleotide sequence of at least 95% "identity" to a sequence contained in SEQ ID NO : X or the cDNA contained in the deposited clone, means that the polynucleotide is identical to a sequence contained in SEQ ID NO : X or the cDNA except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the total length (not just within a given 100 nucleotide stretch). In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to SEQ ID NO : X or the deposited clone, up to 5% of the nucleotides in the sequence contained in SEQ ID NO : X or the cDNA can be deleted, inserted, or substituted with other nucleotides. These changes may occur anywhere throughout the polynucleotide.

Further embodiments of the present invention include polynucleotides having at least 85% identity, more preferably at least 90% identity, and most preferably at least 95%, 96%, 97%, 98% or 99% identity to a sequence contained in SEQ ID NO : X or the cDNA contained in the deposited clone. Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the polynucleotides having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity will encode a polypeptide identical to an amino acid sequence contained in SEQ ID NO : Y or the expressed protein produced by the deposited clone.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference polypeptide, is intended that the amino acid sequence of the polypeptide is identical to the reference polypeptide except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the total length of the reference polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere

between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

Further embodiments of the present invention include polypeptides having at least identity, more preferably at least 85% identity, more preferably at least 90% identity, and most preferably at least 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence contained in SEQ ID NO : Y or the expressed protein produced by the deposited clone. Preferably, the above polypeptides should exhibit at least one biological activity of the protein.

In a preferred embodiment, polypeptides of the present invention include polypeptides having at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98%, or 99% similarity to an amino acid sequence contained in SEQ ID NO : Y or the expressed protein produced by the deposited clone.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e. g., to optimize codon expression for a particular host (change codons in the human to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268 : 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7 : 199-216 (1988).) Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268 : 22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3, 500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3, 500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies

which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N-or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art. _ Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247 : 1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244 : 1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile ; replacement of the hydroxyl residues Ser and Thr ; replacement of the acidic residues Asp and Glu ; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His ; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2 : 331-340 (1967) ; Robbins et al., Diabetes 36 : 838-845 (1987) ; Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10 : 307-377 (1993).) and Polypeptide Fragments In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited

clone or shown in SEQ ID NO : X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO : X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e. g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401- 450, 451-500, 501-550, 551-600, 651-700, and 701 to the end of SEQ ID NO : X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO : Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, and 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred.

Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha- helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn- forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface- forming regions, substrate binding region, and high antigenic index regions.

Polypeptide fragments of SEQ ID NO : Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81 : 3998-4002 (1983).) Fragments which function as epitopes may be produced by any conventional means. (See, e. g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82 : 5131-5135 (1985) further described in U. S. Patent No. 4, 631, 211.) In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37 : 767-778 (1984) ; Sutcliffe, J. G. et Science 219 : 660-666 (1983).) Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra ; Wilson et al., supra ; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82 : 910-914 ; and Bittle, F. J. et al., J. Gen. Virol. 66 : 2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e. g., in Western blotting.) As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F (ab')₂ fragments) which are capable of specifically binding to protein. Fab and F (ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody.

(Wahl et al., J. Nucl. Med. 24 : 316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library.

Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be

combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394, 827 ; Traunecker et al., Nature 331 : 84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J.

Biochem. 270 : 3958-3964 (1995).) Similarly, 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D.

Bennett et al., J. Molecular Recognition 8 : 52-58 (1995) ; K. Johanson et al., J. Biol.

Chem. 270 : 9459-9471 (1995).) Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.

As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86 : 821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein.

Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37 : 767 (1984).) Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the claimed invention.

Vectors Host Cells. and Protein Production The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts

expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells ; fungal cells, such as yeast cells ; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells ; animal cells such as CHO, COS, 293, and Bowes melanoma cells ; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc. ; pBluescript vectors, Phagescript vectors, pNH46A, available from Stratagene Cloning Systems, Inc. ; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pSV2CAT, pOG44, and pSG available from Stratagene ; and pSVK3, and available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from : products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured ; products of chemical synthetic procedures ; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

Uses of the Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO : X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO : X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow- sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases ; however, polynucleotides 2, 000-4, 000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes : a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to

unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix-see Lee et al., Nucl. Acids Res. 6 : 3073 (1979) ; Cooney et Science 241 : 456 (1988) ; and Dervan et Science 251 : 1360 (1991)) or to the itself (antisense-Okano, J. Neurochem. 56 : 560 (1991) ; Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e. g., hair or skin, or body fluids, e. g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by

organ type.

In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101 : 976-985 (1985) ; Jalkanen, M., et al., J. Cell. Biol. 105 : 3087- 3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X- radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S. W. Burchiel et of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging : The Radiochemical Detection of Cancer, S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).) Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual ; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease.

For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e. g., insulin), to supplement absent or decreased levels of

a different polypeptide (e. g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e. g., an oncogene), to activate the activity of a polypeptide (e. g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e. g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e. g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention could be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e. g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to : blood protein disorders (e. g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e. g., afibrinogenemia, factor deficiencies), blood platelet disorders (e. g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important

in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to : Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves'Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T- cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e. g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e. g., TNF or IL-1.) Disorders A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the : abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to : disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families : Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e. g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e. g., Influenza), Papovaviridae, Parvoviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e. g., Rotavirus), Retroviridae (Lentivirus), and Togaviridae (e. g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to : arthritis, bronchiolitis, encephalitis, eye infections (e. g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e. g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e. g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi : Actinomycetales (e. g., Corynebacterium, Mycobacterium, Nocardia), Aspergillosis, (e. g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e. g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e. g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to : bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e. g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic

Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e. g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families : Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas.

These parasites can cause a variety of diseases or symptoms, including, but not limited to : Scabies, Trombiculiasis, eye infections, intestinal disease (e. g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e. g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276 : 59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e. g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e. g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e. g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e. g., resulting

from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e. g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy- Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e. g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body.

For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e. g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e. g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1 (2) : Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e. g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*.

Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a

solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e. g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e. g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of : (a) incubating a candidate binding compound with a polypeptide of the invention ; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e. g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO : X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO : X in the range of positions beginning with the nucleotide at

about the position of the 5'Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO : X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO : X in the range of positions beginning with the nucleotide at about the position of the 5'Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'Nucleotide of the Clone Sequence as defined for SEQ ID NO : X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO : X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3'Nucleotide of the Clone Sequence as defined for SEQ ID NO : X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO : X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO : X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO : X beginning with the nucleotide at about the position of the 5'Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3'Nucleotide of the Clone Sequence as defined for SEQ ID NO : X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO : X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of : a nucleotide sequence of SEQ ID NO : X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1 ; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of : a nucleotide sequence of SEQ ID NO : X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting a nucleotide sequence of SEQ ID NO : X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of : a nucleotide sequence of SEQ ID NO : X wherein X is any integer as defined in Table 1 ; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO : Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO : Y in Table

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO : Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO : Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least identical to the complete amino acid sequence of SEQ ID NO : Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table

1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1 ; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above

group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y wherein Y is any integer as defined in Table 1 ; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of : an amino acid sequence of SEQ ID NO : Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO : Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO : Y is defined in Table 1 ; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical

composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples Example 1 : Isolation of a Selected cDNA Clone From the Deposited Sample Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript." Vector Used to Construct Library Corresponding Deposited Plasmid Lambda Zap pBluescript (pBS) Uni-Zap XR pBluescript (pBS) Zap Express pBK lafmid BA BA pSport pSport pCMVSPORT 2.0 pCMVSPORT 2.0 pCMVSPORT 3.0 pCMVSPORT 3.0 1 1 Vectors Lambda Zap (U. S. Patent Nos. 5, 128, 256 and 5, 286, 636), Uni-Zap XR (U. S. Patent Nos. 5, 128, 256 and 5, 286, 636), Zap Express (U. S. Patent Nos.

5, 128, 256 and 5, 286, 636), pBluescript (pBS) (Short, J. M. et Nucleic Acids Res.

16 : 7583-7600 (1988) ; Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res.

17 : 9494 (1989)) and pBK (Alting-Mees, M. A. et Strategies 5 : 58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS.

The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl ori origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain also available from Life Technologies. (See, for instance, Gruber, C. E., et Focus 15 : 59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector 1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16 : 9677-9686 (1988) and Mead, D. et al., Bio/Technology 9 : Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table

1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid each containing a different cDNA clone ; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO : X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.

The oligonucleotide is labeled, for instance, with using T4 polynucleotide kinase and purified according to routine methods. (E. g., Maniatis et al., *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above.

The transformants are plated on 1. 5% agar plates (containing the appropriate selection agent, e. g., ampicillin) to a density of about 150 transformants (colonies) per plate.

These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e. g., Sambrook et al., *Molecular Cloning : A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1. 93 to 1. 104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO : X (i. e., within the region of SEQ ID NO : X bounded by the 5'NT and the 3'NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 reaction mixture with 0. 5 ug of the above cDNA template. A convenient reaction mixture is 1. 5-5 mM (w/v) gelatin, 20 each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0. 25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at for 1 min ; annealing at for 1 min ; elongation at for 1 min) are performed with a Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5'or 3'non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5'and 3'"RACE"protocols which are well known in the art. For instance, a method similar to 5'RACE is available for generating the missing 5'end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21 (7) : 1683-1684 (1993).) Briefly, a specific RNA oligonucleotide is ligated to the 5'ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5'portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5'phosphate groups

on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5'ends of messenger. This reaction leaves a 5'phosphate group at the 5'end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5'end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5'end sequence belongs to the desired gene.

Example 2 : Isolation of Genomic Clones Corresponding to a A human genomic PI library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO : X., according to the method described in Example (See also, Sambrook.) **Example 3 : Tissue Distribution of Polypeptide** Tissue distribution of expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with the DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA column (Clontech Laboratories, Inc.), according to manufacturer's protocol number. The purified labeled probe is then used to examine various human tissues for expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using hybridization solution (Clontech) according to manufacturer's protocol number. Following hybridization and washing, the blots are mounted and exposed to film overnight, and the films developed according to standard procedures.

Example 4 : Chromosomal Mapping of the A An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO : X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, ; 1 minute, ; 1 minute, This cycle is repeated 32 times followed by one 5 minute cycle at Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3. 5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5 : Expression of a Polypeptide A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5'and 3'ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5'end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance a bacterial origin of replication (ori), an promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance. Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected.

DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 and Kan (25

The culture is used to inoculate a large culture at a ratio of 1 : 100 to 1 : 250. The cells are grown to an optical density 600 of between 0. 4 and 0. 6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM IPTG induces by inactivating the lacI clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at The cell debris removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the resin with high affinity and can be purified in a simple one-step procedure (for details see : The (1995) QIAGEN, Inc., supra).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M pH 8, then washed with 10 volumes pH 6, and finally the polypeptide is eluted with 6 M pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the column. The recommended conditions are as follows : renature using a linear urea gradient in 500 mM NaCl, 20% glycerol, 20 mM pH 7. 4, containing protease inhibitors.

The renaturation should be performed over a period of 1. 5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at or frozen

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number XXXXXX.) This vector contains : 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication is derived from (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5'primer) and XbaI, BamHI, XhoI, or (3'primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6 : Purification of a Polypeptide from an Inclusion Body The following alternative method can

be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at

Upon completion of the production phase of the E. coli fermentation, the cell culture is cooled to and the cells harvested by continuous centrifugation at 15, 000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7. 4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with solution to a final concentration of 0. 5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 5M 100 mM Tris, 50 mM EDTA, pH 7. 4.

The resulting washed inclusion bodies are solubilized with 1. 5 M guanidine hydrochloride for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at overnight to allow further extraction.

Following high speed centrifugation (30, 000 xg) to remove insoluble particles, the solubilized protein is refolded by quickly mixing the extract with 20 volumes of buffer containing 50 mM sodium, pH 4. 5, 150 mM 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0. membrane filter with appropriate surface area (e. g., Filtron), equilibrated with 40 mM sodium acetate, pH 6. 0 is employed. The filtered sample is loaded onto a cation exchange resin (e. g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6. 0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored.

Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6. 0. Both columns are washed with 40 mM sodium acetate, pH 6. 0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0. 2 M NaCl, 50 mM sodium acetate, pH 6. 0 to 1. 0 M NaCl, 50 mM sodium acetate, pH 6. 5. Fractions are collected under constant monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when of purified protein is loaded.

The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0. 1 ng/ml according to LAL assays.

Example 7 : Cloning and Expression of a Polypeptide in a Baculovirus Expression System In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a

polypeptide. This expression vector contains the strong polyhedrin promoter of the Autographa nuclear polyhedrosis virus followed by convenient restriction sites such as BamHI, Xba I and The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM 1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170 : 39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1 % agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1 % agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. E. coli Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five of a plasmid containing the polynucleotide is co-transfected with 1.0 Rg of a commercially available linearized baculovirus DNA baculovirus DNA", San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84 : 7413-7417 (1987). One of virus DNA and 5 of the plasmid are mixed in a sterile well of a microtiter plate containing serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, Lipofectin plus 90 RI Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at The transfection solution is then removed from the plate and 1 of Grace's insect medium supplemented with 10% fetal calf serum is added.

Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e. g., The agar containing the recombinant viruses is then resuspended in a tube containing 200 of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the of these culture dishes are harvested and then they are stored at C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 of methionine and 5 (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8 : Expression of a Polypeptide in Mammalian Cells The polypeptide of the present invention can be expressed in a mammalian cell.

A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e. g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e. g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as and (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), (ATCC 67109), pCMVSPORT 2. 0, and pCMVSPORT 3. 0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and Cos Cos 7 and quail cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e. g., Alt, F. W., et al., J. Biol. Chem. 253 : 1357-1370 (1978) ; Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097 : 107-143 (1990) ; Page, M. J. and Sydenham, M. A., Biotechnology 9 : 64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227 : 277-279 ; Bebbington et al., Bio/Technology 10 : 169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the

cells with the highest resistance are selected. These cell lines contain the amplified gene (s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41 : 521-530 (1985).) Multiple cloning sites, e. g., with the restriction enzyme cleavage sites BamHI, and facilitate the cloning of the gene of interest. The vectors also contain the 3'intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e. g., WO 96/34891.) The amplified fragment is isolated from a gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1 % agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1 % agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. of the expression plasmid pC6 is cotransfected with 0. of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418.

After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate RM, 2 RM, 5 RM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100- 200 Expression of the desired gene product is analyzed, for instance, by SDS- PAGE and Western blot or by reversed phase HPLC analysis.

Example 9 : Protein Fusions The polypeptides of the present invention are preferably fused to other proteins.

These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates

purification. (See Example 5 ; see also EP A 394, 827 ; Traunecker, et al., Nature 331 : 84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e. g., WO Human IgG Fc region :

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTCTTCCCCCAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAGGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO : 1) Example 10 : Production of an from a
Polypeptide The antibodies of the present invention can be prepared by a variety of methods.
```

(See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants.

Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma

technology. et Nature 256 : 495 (1975) ; et al., Eur. J. Immunol. 6 : 511 (1976) ; et al., Eur. J.

Immunol. 6 : 292 (1976) ; Hammerling et al., in : Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N. Y., pp. 563-681 In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium ; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about and supplemented with about 10 of nonessential amino acids, about 1, 000 U/ml of penicillin, and about 100 of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention ; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80 : 225-232 The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide.

Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F (ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F (ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art.

(See, for review, Morrison, Science 229 : 1202 (1985) ; Oi et al., BioTechniques 4 : 214 (1986) ; Cabilly et al., U. S. Patent No. 4, 816, 567 ; Taniguchi et al., EP 171496 ; Morrison et al., EP 173494 ; Neuberger et al., WO 8601533 ; Robinson et al., WO ; Boulianne et al., Nature 312 : 643 (1984) ; Neuberger et Nature 314 : 268 (1985).) Example 11 : Production Of Secreted Protein For Screening Assays The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution in PBS) 1 : 20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each

well (note : a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10⁵ in 5ml DMEM (Dulbecco's Modified Eagle Medium) (with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS (14-503F Penstrep (17-602E Biowhittaker)). Let the cells grow overnight.

The next day, mix together in a sterile solution basin : 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem (31985070 Gibco/BRL)/96-well plate.

With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add of the Lipofectamine/Optimem I mixture to each well.

Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at for 6 hours.

While cells are incubating, prepare appropriate media, either in DMEM with 1x penstrep, or CHO-5 media (see below) with 2mm glutamine and 1x penstrep.

(BSA (81-068-3 Bayer) dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1. appropriate media to each well. Incubate at for 45 or 72 hours depending on the media used : 45 hours or CHO-5 for 72 hours.

On day four, using a multichannel pipetter, aliquot in one 1 ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e. g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

medium formulation : Inorganic Salts CaCl₂ (anhyd) 116.6 mg/L CuSO₄·5H₂O 0.00130 Fe(NO₃)₃·9H₂O 0.050 FeSO₄·7H₂O 0.417 KCl 311.80 MgCl₂ 28.64 MgSO₄ 48.84 NaCl 6995.50 NaHCO₃

2400. 0 NaH₂PO₄-H₂O 62.50 Na₂HPO₄ 71.02 ZnSO₄-7H₂O 4320 Lipids Arachidonic Acid. 002 mg/L Cholesterol 1. 022 DL-alpha-. 070 Tocopherol-Acetate Linoleic Acid 0. 0520 Linolenic Acid 0. 010 Myristic Acid 0. 010 Oleic Acid 0. 010 Palmitic Acid 0. 010 Palmitic Acid 0. 010 Pluronic F-68 100 Stearic Acid 0. 010 Tween 80 2. 20 Carbon Source D-Glucose 4551 mg/L Amino Acids L-Alanine 130. 85 mg/ml L-Arginine-HCL 147. 50 L-Asparagine-H₂O 7.50 L-Aspartic Acid 6. 65 L-Cystine-2HCL-29. 56 HO L-Cystine-2HCL 31. 29 L-Glutamic Acid 7. 35 L-Glutamine 365. 0 Glycine 18. 75 L-Histidine-HCL-52. 48 HO L-Isoleucine 106. 97 L-Leucine 111. 45 L-Lysine HCL 163. 75 L-Methionine 32. 34 L-Phenylalanine 68. 48 L-Proline 40. 0 L-Serine 26. 25 L-Threonine 101. 05 L-Tryptophan 19. 22 L-Tyrosine-2Na-91. 79 2H₇0 L-Valine 99. 65 Vitamins Biotin 0. 0035 mg/L D-Ca Pantothenate 3. 24 Choline Chloride 11. 78 Folic Acid 4. 65 i-Inositol 15. 60 Niacinamide 3. 02 Pyridoxal HCL 3. 00 Pyridoxine HCL 0. 031 Riboflavin 0. 319 Thiamine HCL 3. 17 Thymidine 0. 365 Vitamin B12 0.680 Other Components HEPES Buffer 25 Na Hypoxanthine 2. 39 mg/L Lipoic Acid 0. 105 Sodium Putrescine-2HCL 0. 081 Sodium Pyruvate 55. 0 Sodium Selenite 0. 0067 Ethanolamine 20uM Ferric Citrate 0. 122 Methyl-B-Cyclodextrin complexed with 41. 70 Linoleic Acid Methyl-B-Cyclodextrin complexed with 33. 33 Oleic Acid Methyl-B-Cyclodextrin complexed with 10 Retinal Acetate osmolarity to Example 12 : Construction of GAS Reporter Construct One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site"GAS"elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or"STATs."There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64 : 621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups : (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL- 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin ; and (b) Class 2 includes and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO : 2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

JAKs STATs ISRE Ligand tyk2 Jak2 Jak3 IFN family IFN- α /B + 2, 3 ISRE + + -1 GAS IL-10 + ? ? -1, 3 gp130 family IL-6 (Pleiotrohic) + + + ? 1, 3 GAS (IRF1>Lys6>IFP) IL-11 (Pleiotrohic) ? + ? ? 1, 3 OnM (Pleiotrohic) ? + + ? 1, 3 LIF (Pleiotrohic) ? + + ? 1, 3 CNTF (Pleiotrohic) -/+ + + ? 1, 3 G-CSF (Pleiotrohic) ? + ? ? 1, 3 IL-12 (Pleiotrohic) + 1, 3 g-C family IL-2 (lymphocytes) -/+ + 1, 3, 5 GAS IL-4 6 GAS (IRF1 (IgH) IL-7 (lymphocytes) -/+ + 5 GAS IL-9 (lymphocytes) -/+ + 5 GAS (lymphocyte) -/+ ? ? 6 GAS IL-15 ? + ? + 5 GAS IL-3 (myeloid) -/+ -5 GAS IL-5 GAS GM-CSF (myeloid) -/+ -5 GAS Growth hormone family GH PRL ? 3, 5 EPO GAS Tyrosine Kinases EGF ? + 3 GAS PDGF ? + + -1, 3 ? + + -1, 3 GAS To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1 : 457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an site. The sequence of the 5' primer is : AAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG : 3' (SEQ ID NO : 3) The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site : 5' : GCGGCAAGCTTTTGGCAAAGCCTAGGC : 3' (SEQ ID NO : 4) PCR amplification is performed using the SV40 promoter template present in the B-gal : promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence : 5' : ATTTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC CTAATCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT TGCAAAAAGCTT : 3' (SEQ ID NO : With this GAS promoter element linked to the SV40 promoter, a GAS : SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS : SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS- SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and and inserted into a backbone vector containing the neomycin resistance gene, such as (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16.

However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e. g., GAS/NF-KB/EGR, GAS/NF-KB, 2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to

test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example for

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12.

Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. cells can also be used.

Jurkat T-cells are CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS- SEAP/neo vector using DMRIE-C (Life Technologies) (transfection procedure described below). The transfected cells are seeded to a density of approximately 20, 000 cells per well and transfectants resistant to 1 gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with Combine 2. 5 ml of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2. 5 ml OPTI-MEM containing 50 ul and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (transfection), and resuspend in OPTI-MEM to a final concentration of 1×10^6 cells/ml. Then add of 1×10^6 cells in OPTI-MEM to T25 flask and incubate at for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat : GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 Gentamicin, and These cells are treated with containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500, 000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0. 1. 0, 10 ng) is added to wells H9, and to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs

(note : this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at- 200C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14 : High-Throughput Screening Assay The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.

Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5 : 259-265) is used. First, harvest U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat- inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 of 20 mM (pH 7. 4) buffer containing 0. 5 DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM 5 mM KCl, 375 uM mM MgCl₂, and 675 uM CaCl₂. Incubate at for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The stable cells are obtained by growing the cells in 400 ug/ml G418. The medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1x10⁶ cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of cells/ml. Plate 200 ul cells per well in the 96- well plate (or cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example

Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15 : Screening Assay Identifying Neuronal

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction.

Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in cell lines. cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting cells with a construct containing an EGR promoter linked to SEAP reporter, activation of cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol.

The EGR-1 promoter sequence (-633 to (Sakamoto K et al., Oncogene 6 : 867-871 (1991))) can be PCR amplified from human genomic DNA using the following primers :

5'GCGCTCGAGGGATGACAGCGATAGAACCCCGG-3' (SEQ ID NO : 6)

5'GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO : 7) Using the GAS : SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS : SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a solution (1 : 30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 per well of the 96-well plate, and allowed to air dry for 2 hr.

cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat- inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC 12 stable cells are obtained by growing the cells in 300 G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing horse serum and 0. 5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16 : Screening Assay for NF-KB (Nuclear Factor is a transcription factor activated by a wide variety of agents including the inflammatory cytokines and TNF, CD30 and CD40, and by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, is retained in the cytoplasm with (Inhibitor However, upon stimulation, is phosphorylated and degraded, causing NF-KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF-KB include IL-2, IL-6, GM-CSF, and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the produced in Example Activators or inhibitors of would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID : 8), 18 bp of sequence complementary to the 5'end of the SV40 early promoter sequence, and is flanked with an site : 5' :

GCGGCCTCGAGGGGACTTTCCCCGGGGACTTTCCGGGGACTTTCCGGGAC : 3' (SEQ ID NO : 9)

The downstream primer is complementary to the 3'end of the SV40 promoter and is flanked with a Hind III site : GCGGCAAGCTTTTTGCAAAGCCTAGGC : 3' (SEQ ID NO : 4) PCR amplification is performed using the SV40 promoter template present in the pB-gal : promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with and Hind III and subcloned into BLSK2-.

(Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence : CTCGAGGGGACTTTCCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC

ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCA

AATTTTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC

CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT : 3' (SEQ ID NO : 10) Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this fragment using and

However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the cassette is removed from the above vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the cassette was inserted into (Clontech), replacing the GFP gene, after restricting with SalI and NotI.

Once vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0. 1, 1, 10 ng) is added to wells H9, and with a 5-10 fold activation typically observed.

Example 17 : Assay for SEAP As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2. 5x Dilution Buffer and dispense 15 of 2. 5x dilution buffer into Optiplates containing of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set as blank, and print the results. An increase in indicates reporter activity.

10 60 3 11 65 3. 25 5 13 75 3. 75 15 85 4. 25 5 17 95 4. 75 19 105 5. 25 20 110 5. 5 21 115 5. 75 22 120 6 23 125 6. 25 24 130 6. 5 25 135 6. 75 26 140 7 27 145 7. 25 28 150 7. 5 29 7. 75 30 160 8 31 165 8. 25 32 170 8. 5 33 175 8. 75 34 180 9 35 185 9. 25 36 190 9. 5 37 195 9. 75 38 200 10 39 205 10. 25 40 210 10. 5 41 215 10. 75 42 220 43 225 11. 25 44 230 11. 5 45 235 11. 75 46 240 12 47 245 48 250 12. 5 49 255 12. 75 Example 18 : Screening Assay Changes in Concentration and Membrane Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10, 000-20, 000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours.

The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at in a incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-Sx10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.

The tube is then placed in a water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters : (1) System gain is 300-800 mW ; (2) Exposure time is 0.4 second ; (3) Camera F/stop is F/2 ; (4) Excitation is 488 nm ; (5) Emission is 530 nm ; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular concentration.

Example 19 : High-Throughput Screening Assay Tyrosine Kinase The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e. g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e. g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e. g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 of cell culture grade type I collagen (50 gelatin or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20, and cultured overnight in complete medium.

Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer (20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum.

Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after

detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at at 16, 000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add of SuM Biotinylated Peptide, then (SmM then of Assay Buffer (40mM imidazole hydrochloride, pH7. 3, 40 mM beta-glycerophosphate, 1mM EGTA, 5 mM MnCl₂ 0. 5 BSA), then of Sodium Vanadate (1mM), and then Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide.

Wash the MTP module with of PBS four times. Next add 75 ul of anti- phosphotyrosine antibody conjugated to horse radish peroxidase (anti-P-Tyr- POD to each well and incubate at 37°C for one hour. Wash the well as above.

Next add of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20 : Screening Assay Phosphorylation As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with of protein G for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies against and Erk-2 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at until use.

A431 cells are seeded at 20, 000/well in a 96-well Loprodyne filterplate and cultured overnight in

growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody which specifically recognizes the phosphorylated epitope of the and Erk-2 kinases hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21 : Method of Alterations in a Gene to a RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO : X. Suggested PCR conditions consist of 35 cycles at for 30 seconds ; 60-120 seconds at ; and 60-120 seconds at using buffer solutions described in Sidransky, D., et al., Science 252 : 706 (1991).

PCR products is then sequenced using primers labeled at their 5'end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies).

The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T. A. and Graham, M. W., Nucleic Acids Research, 19 : 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals is identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'- triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et Methods Cell Biol. 35 : 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4, 6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8 : 75 Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22 : Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the

following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect soluble polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 μ l of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.

The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 μ l of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).

Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23 : a Polypeptide The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 to about 50 either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples

of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules.

Sustained-release matrices include polylactides (U. S. Pat. No. 3, 773, 919, EP 58, 481), copolymers of L-glutamic acid and (Sidman, U. et al., *Biopolymers* 22 : 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15 : 167-277 (1981), and R. Langer, *Chem. Tech.* 12 : 98- 105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133, 988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se : DE 3, 218, 121 ; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82 : 3688-3692 (1985) ; Hwang et al., *Proc. Natl. Acad. Sci. USA* 77 : 4030-4034 (1980) ; EP 52, 322 ; EP 36, 676 ; EP 88, 046 ; EP 143, 949 ; EP 142, 641 ; Japanese Pat. Appl. 83-118008 ; U. S. Pat. Nos. 4, 485, 045 and 4, 544, 545 ; and EP 102, 324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both.

Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts ; antioxidants such as ascorbic acid ; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides ; proteins, such as serum albumin, gelatin, or immunoglobulins ; hydrophilic polymers such as polyvinylpyrrolidone ; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine ; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans ; chelating agents such as EDTA ; sugar alcohols such as mannitol or sorbitol ; counterions such as sodium ; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0. 1 to 100 mg/ml, preferably at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile.

Sterility is readily accomplished by filtration through sterile filtration membranes (e. g., 0. 2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile

access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24 : Method of Decreased Levels of the Polypeptide It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form.

Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0. 1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25 : Method of Treating Increased Levels of the Polypeptide Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0. 5, 1. 0, 1. 5, 2. 0 and 3. 0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26 : Method of Treatment Using Gene One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin, is added. The flasks are then incubated at for approximately one week.

At this time, fresh media is added and subsequently changed every several days.

After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7 : 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example Preferably, the 5' primer contains an site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is being produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference.

(1) GENERAL INFORMATION : (i) APPLICANTS : Human Genome Sciences, Inc. et al.

(ii) TITLE OF INVENTION : 70 Human Secreted Proteins (iii) NUMBER OF SEQUENCES : 273 (iv) CORRESPONDENCE ADDRESS : (A) ADDRESSEE : Human Genome Sciences, Inc.

(B) STREET : 9410 Key West Avenue (C) CITY : Rockville (D) STATE : Maryland (E) COUNTRY : USA (F) ZIP : 20850 (v) COMPUTER READABLE FORM : (A) MEDIUM TYPE : 50 inch, storage (B) COMPUTER : HP Vectra 486/33 (C) OPERATING SYSTEM : MSDOS version 6. 2 (D)

SOFTWARE : ASCII Text (vi) CURRENT APPLICATION DATA : (A) APPLICATION NUMBER : (B) FILING DATE : March 6, 1998 (C) CLASSIFICATION : (vii) PRIOR APPLICATION DATA : (A) APPLICATION NUMBER : (B) FILING DATE : (viii) ATTORNEY/AGENT INFORMATION : (A) NAME : A. Anders Brookes (B) REGISTRATION NUMBER : 36, 373 (C) REFERENCE/DOCKET NUMBER : (vi) TELECOMMUNICATION INFORMATION : (A) TELEPHONE : (301) 309-8504 (B) TELEFAX : (301) 309-8439 (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 733 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 1 : GGGATCCGGA GCCCAAATCT TCTGACAAAA CTCACACATG CCCACCGTGC CCAGCACCTG 60 AATTCGAGGG TGCACCGTCA GTCTTCCTCT TCCCCCAAA ACCCAAGGAC ACCCTCATGA 120 TCTCCCGGAC ACATGCGTGG TGGTGGACGT AAGCCACGAA GACCCTGAGG 180 TCAAGTTCAA CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG 240 AGGAGCAGTA CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG CACCAGGACT 300 GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA AGCCCTCCCA ACCCCCATCG 360 AGAAAACCAT CTCAAAGCC AAAGGGCAGC CCCGAGAACC ACAGGTGTAC ACCCTGCCCC 420 CATCCCGGGA TGAGCTGACC AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT 480 ATCCAAGCGA CATCGCCGTG GAGTGGGAGA GCAATGGGCA GCCGAGAAAC AACTACAAGA 540 CCACGCCTCC CGTGCTGGAC TCCGACGGCT CCTTCTTCCT CTACAGCAAG CTCACCGTGG 600 ACAAGAGCAG GTGGCAGCAG GGGAACGTCT TCTCATGCTC CGTGATGCAT GAGGCTCTGC 660 ACAACCACTA CACGCAGAAG AGCCTCTCCC TGTCTCCGGG TAAATGAGTG CGACGGCCGC 720 GACTCTAGAG GAT 733 (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 5 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 2 : Trp Ser Xaa Trp Ser 1 5 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 86 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 3 : GCGCCTCGAG ATTTCCCCGA AATCTAGATT TCCCCGAAAT GATTTCCCCG AAATGATTTC 60 CCCGAAATAT CTGCCATCTC AATTAG 86 (2) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 27 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 4 : GCGGCAAGCT TTTTGCAAAG CCTAGGC 27 (2) INFORMATION FOR SEQ ID NO : 5 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 271 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 5 : CTCGAGATT TCCCCGAAATC TAGATTTC CGAAATGATT TCCCCGAAAT GATTTCCCCG 60 AAATATCTGC CATCTCAATT AGTCAGCAAC CATAGTCCCG CCCCTAACTC CGCCCATCCC 120 GCCCCTAACT CCGCCAGTT CCGCCATTC TCCGCCCAT GGCTGACTAA TTTTTTTTAT 180 TTATGCAGAG GCCGAGGCCG CCTCGGCCTC TGAGCTATTC CAGAAGTAGT GAGGAGGCTT 240 TTTTGGAGGC CTAGGCTTTT GCAAAAAGCT T 271 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 32 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 6 : GCGCTCGAGG GATGACAGCG ATAGAACCCC GG 32 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 31 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 7 : GCGAAGCTTC GCGACTCCCC GGATCCGCCT C 31 (2) INFORMATION FOR SEQ ID NO : 8 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 8 : GGGGACTTTC CC 12 (2) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 73 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE

DESCRIPTION : SEQ ID NO : 9 : GCGGCCTCGA GGGGACTTTC CCGGGGACTT
TCCGGGGACT TTCCGGGACT TTCCATCCTG 60 CCATCTCAAT TAG 73 (2) INFORMATION
FOR SEQ ID NO : 10 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 256 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 10 : CTCGAGGGGA CTTTCCCGGG GACTTTCCGG
GGACTTTCCG GGACTTTCCA TCTGCCATCT 60 CAATTAGTCA GCAACCATAG
TCCCGCCCCCT AACTCCGCCC ATCCCGCCCC TAACTCCGCC 120 CAGTTCCGCC
CATTCTCCGC TTTATTTATG CAGAGGCCGA 180 GGCCGCCTCG GCCTCTGAGC
TATTCCAGAA GTAGTGAGGA GAGGCCTAGG 240 CTTTTGCAAA AAGCTT 256 (2)
INFORMATION FOR SEQ ID NO : 11 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1739
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 11 : GGCCGCGGGA CCTGCAGAGA GGACAGCCGG
CCTGCGCCGG GACATGCGGC 60 CCCAGGAGCT CCCAGGCTC GCGTTCCCGT
GCTGTTGCTG CTGCTGCCGC 120 CGCCGCCGTG CCCTGCCAC AGCGCCACGC
GTTTCGACCC CACCTGGGAG TCCCTGGACG 180 CCCGCCAGCT GCCCGCGTGG
CCAAGTTCGG CATCTTCATC CACTGGGGAG 240 TGTTTTCCGT GCCCAGCTTC
GGTAGCGAGT GGTTCCTGGT GTATTGGCAA AAGGAAAAGA 300 TACCGAAGTA
TGTGGAATTT ATGAAAGATA ATTACCCTCC TARTTTCAAA TATGAAGATT 360
TTGGACCACT ATTTACAGCA AAATTTTTTA ATGCCAACCA RTGGGCARAT ATTTYCAGG
420 CCTCTGGTGC CAAATACATT GTCTTAAGT CCAAACATCA TGAAGGCTTT
ACCTTGTTGG 480 GGTCAGAATA TCGTGGAAC TGGAATGCCA TAGATGAGGG
GCCCAAGAGG GACATTGTCA 540 AGGAAGTTGA GGTAGCCATT AGGAACAGAA
CTGACCTGCG TACTATTCCC 600 TTTTGAATG GTTTCATCCG CTCTTCCTTG
AGGATGAATC CAGTTCATTC CATAAGCGGC 660 AATTTCCAGT TTCTAAGACA
TTGCCAGAGC TCTATGAGTT AGTGAACAAC TATCAGCCTG 720 AGGTTCTGTG
GTCGGATGGT GACGGAGGAG CACCGGATCA ATACTGGAAC ANCACAGGCT 780
TCTTGGCCTG GTTATATAAT GAAAGCCCAG TTCGGGGCAC AGTAGTCACC 840
GGGAGCTGG TAGCATCTGT AAGCATGGTG GCTTCTATAC CTGCAGTGAT
CGTTATAACC CAGGACATCT TTTGCCACAT AAATGGGAAA ACTGCATGAC
AATAGACAAA CTGTCCTGGG 960 GCTATAGGAG GGAAGCTGGA ATCTCTGACT
ATCTTACAAT TGAAGAATTG GTGAAGCAAC 1020 TTGTAGAGAC AGTTTCATGT
GGAGGAAATC AACTAGATG 1080 GCACCATTC TGTAAGTTTT GAGGAGCGAC
TGAGGCAAAT GGGGTCCTGG CTAAAAGTCA 1140 ATGGAGAAGC TATTTATGAA
ACCCATACCT GCGATCCCA GTCACCCAG 1200 ATGTGTGGTA CACATCCAAG
CCTAAAGAAA AATTAGTCTA CTAAATGGC 1260 ACAGCTGTTT CTTGGCCATC
CCAAAGCTAT TCTGGGGGCA ACAGAGGTGA 1320 AACTACTGGG CCATGGACAG
CCACTTAACT GGATTTCTTT GGAGCAAAAT GGCATTATGG 1380 TAGAACTGCC
ACAGCTAACC ATTCATCAGA TGCCGTGTAA ATGGGGCTGG GCTCTAGCCC 1440
TRACTAATGT GATCTAAAGT GCAGCAGAGT GGCTGATGCT TCTAAGGCTA 1500
GGAAGTATCA GGTGTCTATA ATTGTAGCAC ATGGAGAAAG CAAATGTAAA
ACTGGATAAG 1560 AAAATTATTT GCCCTTTCCC 1620 CCATGTAACC ATTTTAACTC
TCCAGTGCAC TTTGCCATTA AAGTCTCTTC ACATTGAAAA 1680 AAAAAAAAAA
AAAAACCCCG CCGGNACCC CATTTCGCCC NTAAAGGGG 1739 (2) INFORMATION FOR
SEQ ID NO : 12 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 844 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 12 : GGCCCCTGGG CCCGAGGGGC TGGAGCCGGG
CCGGGGCGAT GTGGAGCGCG GGCCGCGGCG 60 GGGCTGCCTG GCCGGTGCTG
TTGGGGCTGC TGCTGGCGCT GTTAGTGCCG GGCGGTGGTG 120 CCGCCAAGAC
CGGTGCGGAG CTCGTGACCT GCGGGTCGGT GCTGAAGCTG CTCAATACGC 180
ACCACGCGT GCGGCTGCAC TCGCACGACA TCAAATACGG ATCCGGCAGC
GGCCAGCAAT 240 CGGTGACCGG CGTAGAGGCG TCGGACGACG CCAATAGCTA

CTGGCGGATC CGCGGCGGCT 300 GTGCCGCCGC GGGTCCCCCGG TGCGCTGCGG
 AGGCTCACGC 360 ATGTGCTTAC GGGCAAGAAC CTGCACACGC ACCACTTCCC
 GTCGCCGCTG TCCAACAACC 420 AGGAGGTGAG TGCCTTTGGG GAAGACGGCG
 AGGGCGACGA CCTGGACCTA TGGACAGTGC 480 GCTGCTCTGG ACAGCACTGG
 GAGCGTGAGG CTGCTGTGCG CTTCCAGCAT GTGGGCACCT 540 CTGTGTTCTT
 GTCAGTCACG ATGGAAGCCC CATCCGTGGG CAGCATGAGG 600 TCCACGGCAT
 GCCCAGTGCC AACACGCACA ATACGTGGAA GGCCATGGAA GGCATCTTCA 660
 TCAAGCCTAG TGTGGAGCCC TCTGCAGGTC ACGATGAACT CTGAGTGTGT
 GGATGGATGG 720 GGGGCGTCTG CAGGGCCACT CTTGGCAGAG ACTTTGGGTT 780
 TGTAGGGGTC CTCAAGTGCC TTTGTGATTA AAGAATGTTG GTCTATGAAA 840 AAAA 844

(2) INFORMATION FOR SEQ ID NO : 13 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
 776 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
 SEQUENCE DESCRIPTION : SEQ ID NO : 13 : TTCGAAATAA GCAGAAAAAG AAGGTGTATG
 TTGGGGGTTT 60 AGAGAGCAGG GTCTTGAAAT ACACAGCCCA GAATATGGAG
 CTTCAGAACA AAGTACAGCT 120 TCTGGAGGAA CAGAATTTGT CCCTTCTAGA
 TCAACTGAGG AACTCCAGG CCATGGTGAT 180 TGAGATATCA AACAAAACCA
 GCAGCAGCAG CACCTGCATC TTGGTCCTAC TAGTCTCCTT 240 CTGCCTCCTC
 CTTGTACCTG CTATGTACTC CTCTGACACA AGGGGGAGCC 300 GCATGGAGTG
 TTGTCCCGCC AGCTTCGTGC CCTCCCCAGT GAGGACCCTT 360 GCTGCCTGCC
 CTGCAGTCAG AGACAGCACA CACCAGTGGT TGGACGGCTC 420 CTCCAGGCCC
 CTGGCAACAC TTCCTGCCTG CTGCATTACA 480 TCCCAGTGCA GAGCCTCCCC
 TGGAGTGGCC ATTCCCTGAC CTCTTCTCAG AGCCTCTCTG 540 CCGAGGTCCC
 ATCTCCCCC TGCAGGCAAA TCTCACAAGG AAGGGAGGAT GGCTTCCTAC 600
 TGGTAGCCCC TCTGTCAATT TGCAGGACAG ATACTCAGGC TAGATATGAG
 GATATGTGGG 660 GGGTCTCAGC AGGAGCCTGG GGGGCTCCCC ATCTGTGTCC
 AAATAAAAAG CGGTGGGCAA 720 GGGCTGGCCG CAGCTCCTGT GCCCTGTCAG
 GACGACTGAG CACCAC 776 (2) INFORMATION FOR SEQ ID NO : 14 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1376 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 14 : GAATTCGGCA CGAGGCGCCT ACCCTGCCTG CAGGTGAGCA GTGGTGTGTG
 AGAGCCAGGC 60 GTCCCTCTGC CTGCCCCACTC AGTGGCAACA CCCGGGAGCT
 TTGTGGAGCC 120 TCAGCAGTTC CCTCTTTCAG AACTCACTGC CAAGAGCCCT
 GAACAGGAGC CACCATGCAG 180 TGCTTCAGCT TCATTAAGAC CATGATGATC
 CTCTTCAATT TCTGTGTGGT 240 GCAGCCCTGT TGGCAGTGGG CATCTGGGTG
 TCAATCGATG TCTGAAGATC 300 TTCGGGGCCAC TGTCGTCCAG TTTGTCAACG
 TGGGCTACTT CCTCATCGCA 360 GCCGGCGTTG TGGTCTTTGC TCTTGGTTTC
 CTGGGCTGCT ATGGTGCTAA GACTGAGAGC 420 AAGTGTGCCC TCGTGACGTT
 CTTCTTCATC CTCCTCCTCA TCTTCATTGC 480 GCTGCTGTGG TCGCCTTGGT
 GTACACCACA ATGGCTGAGC ACTTCCTGAC GTTGCTGGTA 540 GTGCCTGCCA
 TCAAGAAAGA TTATGGTTCC CAGGAAGACT TCACTCAAGT GTGGAACACC 600
 ACCATGAAAG GGCTCAAGTG CTGTGGCTTC ACCAACTATA CGGATTTTGA
 GGAATCACCC 660 TACTTCAAAG AGAACAGTGC CTTTCCCCCA TTCTGTTGCA
 ATGACAACGT 720 GCCAATGAAA CCTGCACCAA GCAAAAGGCT CACGACCAAA
 AAGTAGAGGG TTGCTTCAAT 780 CAGCTTTTGT ATGACATCCG AACTAATGCA
 GTCACCGTGG 840 GGGGGCCTCG AGCTGGCTGC CATGATTGTG TCCATGTATC
 TGTACTGCAA TCTACAATAA 900 GTCCACTTCT GCCTCTGCCA CTAAGTGTGC
 CACATGGGAA CTGTGAAGAG 960 AAGCAGCAGT GATTGGGGGA GGGGACAGGA
 TCTAACAATG TCACTTGGGC CAGAATGGAC 1020 TGCTCCAGAC ATAGGGACCA
 CTCCTTTTAN GCGATGCCTG 1080 ACTTTCCTTC CATTGGTGGG TGGATGGGTG
 GGGGGCATTG CAGAGCCTCT AAGGTAGCCA 1140 GTTCTGTTGC CCATCCCCC
 AGTCTATTAA ACCCTTGATA TGCCCCCTAG GCCTAGTGGT 1200 GATCCCAGTG

CTCTACTGGG GGATGAGAGA AAGGCATTTT ATAGCCTGGG CATAAGTGAA 1260
ATCAGCAGAG CCTCTGGGTG GATGTGTAGA AGGCACTTCA AAATGCATAA
ACCTGTTACA 1320 ATGTTRAAAA AAAAAAAAAA AGGGGGGTCC CGTACC 1376 (2)
INFORMATION FOR SEQ ID NO : 15 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 502
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 15 : TAAAACAGTG CCTGCCTCAA AGGGAGGACT
CAGTCAATAT CTGTTGAATG AATGAATGAA 60 TAATTGCCTG GGTCAACGAA
TGAATGGCTG AATGAATGAT CCTCGGCACT 120 GTCTGGAGTC CCCAGGACAG
GCATGGGCAG TCTGTGGCCT GTCCCACTGG 180 CTCATGCTTG AGATCACCCA
CCAGGCTCCC AGGTCGATCC 240 TCTGCTCATG GGAARCTGCG TCCGGCCCN
GCTGCCAGAA CTCCTGCAS GGTGGAGGGA 300 ARARCAGGRA CGATCTGCGA
GCGCCTGAAC AGCGCACAAG AGCCGAGGAG CCGCTGCTTA 360 AAATGCAGGC
GTTGAGAGGA GTTCGCCTC CTTTTTTGAG TTGAATATGA GATTTCGAG 420
CAGCCATGAC GAGTTGGGTT GGTGGAAGTG GGGAGTCCGT TCCTCAGTCA
GATGGAGGAG 480 GGGGTCCCCT TGGATCTCCT CT 502 (2) INFORMATION FOR SEQ ID
NO : 16 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 425 base pairs (B) TYPE : nucleic
acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 16 : ATCTCTAGTG GTGGCTGCCG TCGCTCCAGA CAATCGGAAT CCTGCCTTCA
CCACCATGGG 60 CTGGCTTTTT CTAAAGGTTT TGTTGGCGGG AGTGAGTTTC
TCAGGATTTC TTTATCCTCT 120 TGTGGATTTT TGCATCAGTG GGAAAACAAG
AGGACAGAAG CCAAACCTTG TGATTATTTT 180 GGCCGATGAC ATGGGGTGGG
GTGACTGGGG AGCAAACCTGG GCAGAAACAA AGGACACTGC 240 CAACCTTGAT
AAGATGGCTT CGGAGGGAAT GARGTGARTC TTGARATGCC ARGCCAGCTT 300
TCTTTGGAWG TCTTACTCCC GTTCTTGAAA GCGTGCAAAG CACTTAARGA 360
WTCATKGATG GACCCATGTG ATTTARTTAA TTTATTAATT AATTTGGTTT GGAARCCAGC
420 ATAGC 425 (2) INFORMATION FOR SEQ ID NO : 17 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 1316 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 17 : GGCACGAGGA
GCTGGGGGAG CCTGAGGTGC GGGAACGAGG 60 CCCTGGGGCG GGAGTTGCTT
CTGCTCCTGA TGCAGTTCCT GTGCCATGAG TTCCTGCGAG 120 GGTGACCCGG
CTGCTCTCTG AGATGCGCAT TCACCTGCTG CCCTCCATGA 180 ACCCTGATGG
CTATGAGATC 240 GCCGCTGGAA ATCGATCTTA ACCATAATTT TGCTGACCTC
AACACACCAC 300 TGTGGGAAGC ACAGGACGAT GGGAAGGTGC CCCACATCGT
CCCCAACCAT 360 TGCCCACTTA CTACACCCTG CCAATGCCA CCGTGGCTCC
GCAGTAATCA 420 AGTGGATGAA GCGGATCCCC TTTGTGCTAA GTGCCAACCT
CCACGGGGGT GAGCTCGTGG 480 TGTCTACCC ACTCGCACCC CGTGGGCTGC
CCGCGAGCTC ACGCCACAC 540 CAGATGATGC TGTGTTTCGC TGGCTCAGCA
CTGTCTATGC TGGCAGTAAT CTGGCCATGC 600 AGGACACCAG CCGCCGACCC
AGGACTTCTC CGTGCACGGC AACATCATCA 660 ACGGGGCTGA GTCCCCGGGA
GCATGAATGA CTACACACCA 720 ACTGCTTTGA GAGCTGTCCT GTGACAAGTT
CCCTCACGAG AATGAATTGC 780 CCCAGGAGTG AAAGACGCCC TCCTCACCTA
CCTGGAGCAG GTGCGCATGG 840 AGTGGTGAGG GACAAGGACA CGGAGCTTGG
GATTGCTGAC GCTGTCATTG 900 CCGTGGATGG GATTAACCAT GACGTGACCA
CGGCGTGGGG CGGGGATTAT TGGCGTCTGC 960 TGACCCAGG GTGACTGCCA
GTGCCGAGGG GTGACACGGA 1020 ACTGTCGGGT CACCTTTGAA TCCCCTGCAA
TTTCGTGCTC ACCAAGACTC 1080 GCTGCGCGAG CTGCTGGCAG CTGGGGCCAA
GGTGCCCCCG GACCTTCGCA 1140 GGCGCCTGGA GCGGCTAAGG GGACAGAAGG
ATTGATACCT GCGGTTTAAG AGCCCTAGGG 1200 CAGGCTGGAC CTGTCAAGAC
GGGAAGGGGA AGAGTAGAGA GGGAGGGACA AAGTGAGGAA 1260 AAGGTGCTCA
CGGGCACCTT AAAAAAAAAA AAAAAAAAAA AAAAAA 1316 (2) INFORMATION FOR SEQ
ID NO : 18 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 436 base pairs (B) TYPE :

nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 18 : AAAAAAATTC AATGGATATT ATGAAAATAA
GAGAGTATTT CCAGAAGTAT GGATATAGTC 60 CACGTGTCAA GAAAAATTCA
AAGAAGCCAT TAACTCTGAC CCAGAGTTGT 120 AAATTTTCAG AAGACTGATG
TGAAAGATGA TCTGTCTGAT CCTCCTGTTG 180 TATTTCTGAG AAGTCTCCAC
ACTTTCAGAT TTTGGACTTG 240 AGCGGTACAT CGTATCCCAA GTTCTACCAA
GGCAGTGAAC AACTATAAGG 300 AAGAGCCCGT AATTGTAACC AGTAAAAGTA
CTAAAAACTC 360 CAAAATGTGC ACTAAAATGG ATGATTTTGA GTGTGTACTC
CTAAATTAGA AACTTTTGGT 420 ATCTCTGAAT ATACTA 436 (2) INFORMATION FOR SEQ
ID NO : 19 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 503 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 19 : TGTGCATATC CTGGGGAAAA TGTTTTAGAA
ATTTTACTGT 60 GCAGGCAGTC AGTTTCCCGT GATAGATACA TGCAACACTC
AAGATCCTGC 120 AGAGAGGCAG CCAGCATCTA TTGTTTAAAA AGGTTTCAAA
AAGAATTCGG ATTGCTCKTT 180 TCTCTTTTGA ATCTGTGTGC CAAATGACAG
GGACCAATAT TCGTCTTCTT TTTCKGTAAA 240 AYTCAAGAAAG AMACATGAAA
GAACCCAGAA TGCATTTCTT AAAGGGATTT AGTGCAGTTA 300 TTTTAAATAA
TACATATATC CCCCAGGTAC 360 CCTTTTTACT TGTGTGCAAT CAGTAGCTAC
AATGACTGAA TTGGGACTGT 420 GACATTTAAG CAAATCTTGT NTCTAGAAAN
CGAAATGCCA CAAAGCTGCT 480 503 (2) INFORMATION FOR SEQ ID NO : 20 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 358 base pairs (B) TYPE : nucleic acid
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
20 : GGGCTGTCTC CCCAGTAGTA CCTGCCCTTG AAGTGGGGAA ACTGTGAAGG 60
GCTCCTTGAT CAAGCTTGTC CTCTTTTCTT ACCTCTTCCT CTCTTCTGTT 120
CTGAACAGGC CCTGCCATGG GGTCCCTGCTC TCCTTCTTCT 180 GGATGACTGG
GCTCCTGGTA TTCATCAGCC TCCTCCTCAG TGAGTGGCAG GGTCCCTGGG 240
GGCTGGGCTA GCTGGGCTCT TGGGCTGTTT 300 AACTTCTGAT AACAACACAG
AAAAACACTC TGTTATGATT TACGAAAN 358 (2) INFORMATION FOR SEQ ID NO : 21 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 1926 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
21 : AGTGAAGGGA GCTGGCCGTG CCACTGGGCT TCGGGCCCTG TGCCAGAGGA
GCANGCCTTC 60 CTGAGCAGGA GGAAGCAGGT GGTGGCCGCG GCCTTGAGGC
AGGCCCTGCA GCTGGATGGA 120 AGGATGAGAT CCCAGTGGTA GCTATTATGG
CCACTGGTGG TGGGATCCGG 180 GCAATGACTT CCCTGTATGG GCAGCTGGCT
GGCCTGAAGG AGCTGGGCCT CTTGGATTGC 240 KTCTCCTACA CTCGGGCTCC
TGGCCAACCT CTCAGAAGGA CCCACTGAGT TGCTGAAGAC CCAGGTGACC 360
TGGGTGTGCT GAGCGTGCCC CCAAGCTGC TTCACCAACC GCGCTGCTGC
ATGATGAGCC AAGCTCTCAG GGCCCTGAGT 540 CATCTACTGT GCCCTCAACA
ACTTTTGAAT TTGGGGAGTG GTGCGAGTTC TCTCCCTACG AGGTCGGCTT TCCCCTCTGA
GCTCTTTGGC AGGCTTCCTG AGTCCCGCAT CTGCTTCTTA GAAGGTATCT GGAGCAACCT
GTATGCAGCC 780 GAGCCCAGCC AGTTCTGGGA CCGCTGGGTC 840 CCAACCTGGA
CAAGGAGCAG GTCCCCCTTC TGAAGATAGA AGAACCACCC 900 TGAGTTTTTC
ACCGATCTTC TGACGTGGCG TCCACTGGCC 960 CAGGCCACAC ATAATTTCTT
AAGACTACTT TCAGCATCCT 1020 CACTTCTCCA CATGGAAAGC CCAACCAGCT
GACACCCTCG 1080 TGTGCCTGCT TACCTCATCA ATACCAGCTG CCTGCCCTC 1140
CTGCAGCCCA CTCGGGACGT CTGTCATTGG ACTACAACCT CCACGGAGCC 1200
TGCAGCTCCT GGGCCGGTTC AGGGGATCCC GTTCCCACCC 1260 ATCTCGCCCA
GCCCCGAAGA GCAGCTCCAG CCTCGGGAGT GCCACACCTT CTCCGACCCC 1320
ACCTGCCCCG GAGCCCCTGC GGTGCTGCAC TTTCTCTGG TCAGCGACTC CTTCCGGGAG
1380 TACTCGGCCC CTGGGGTCCG GCGGACACCC GAGGAGGCGG CAGCTGGGGA
GGTGAACCTG 1440 ACTCTCCCTA AAGGTGACCT ACAGCCAGGA GGACGTGGAC 1500

AAGCTGCTGC AGGAGCAGCT GCTGGAGGCT 1560 GAGGCGGCAG CGCAGGCCCC
ACTGATGGCC GGGGCCCTG 1620 CTCTCATTCA TTCCCTGGCT GCTGAGTTGC
AGGTGGGAAC CAGTGCTTNC AGAGCCTCGG GGTCCAGGC GAGCTCCCTT
AGTTTGCAGT CCCCCCGGCC TGTGCCTGTT CGCTACCTTG AGTAGTTGGA 1860
GCACTTGATA GTGAGGCGCT GAGAAAAAAA AAAAAAAAAA 1920 (2) INFORMATION FOR
SEQ ID NO : 22 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1224 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 22 : CCGCCGAAGC TCCGTCCCGC CCGCGGCCGG
CTCCGCCTCA CCTCCCGGCC GCGGCTGCCC 60 TCTGCCCGGG TGGAGGGCGC
TCCACCGGGG TCGCTCGCCC TCCGGCTCCT 120 GCTGTTCGTG GCGCTACCCG
CCTCCGGCTG GCTGACGACG GCGCCCCCG AGCCGCCGCC 180 GCTGTCCGGA
ACGGCATCAG ACTACACTGA AAGATGATGG 240 GGACATATCT TTGTTCTTAA
GAGAGTGGAC AGGTGTATGT 300 AAATGACTTA CCTGTAAATA GTGGTGTAAAC
CCGAATAAGC TGATAGTGAA 360 GAATGAAAAT CTTGAAAATT TGGAGGAAAA
AGAATATTTT GTGTAAGGAT 420 TTTAGTTCAT CAACTAATTG TCATTCAAGA 480
AGAGGTAGTA GAGATTGATG GAAAACAAGT TCAGCAAAAG GATGTCACTG
AAATTGATAT 540 TTTAGTTAAG AACCGGGGAG TACTCAGACA TTCAAATAT
ACCCTCCCTT TGGAAGAAAG 600 CATGCTCTAC TCTATTTCTC GAGACAGTGA
CATTTTATTT ACCCTTCCTA ACCTCTCCAA 660 AAAAGAAAGT GTTAGTTCAC
TGCAAACCAC TAGCCAGTAT CTTATCAGGA ATGTGGAAAC 720 CACTGTAGAT
GAAGATGTTT TACCTGGGCA AGTTACCTGA AACTCCTCTC AGAGCAGAGC 780
CGCCATCTTC ATATAAGGTA GGATGGAAAA GTTTAGAAAA GATCTGTGTA 840
GGTTCTGGAG CAACGTTTTT TTCAGTTTTT GAACATCATG GTGGTTGGAA 900
TTACAGGAGC AGCTGTGGTA ATAACCATCT TAAAGGTGTT TTTCCAGTT 960
AAGGAATTCT TCAGTTGGAT AAAGTGGACG TCATACCTGT GACAGCTATC AACTTATATC
1020 AGAGAAAAGA GCTGAAAACC TTGAAGATAA AACATGTATT TAAAACGCCA 1080
TCTCATATCA TGGACTCCGA AGTAGCCTGT TTTGCCACTT GAATATAATT 1140
TTCTTTAAAT CGTTAAGAAT CAGTTTATAC ACTAGAGAAA TTGCTAAACT CTAAGACTGC
1200 CTGAAAATTG ACCTTTACAG TGCC 1224 (2) INFORMATION FOR SEQ ID NO : 23 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 694 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
23 : CTGTAGCCTG AATCCCCCAG GGTAATTAAT 60 AAAAGTTGAA TGTTCCAGTC
TAAAAGGCAG TGGGAGAAAT TACATAGCAT GGAAATAATA 120 AAATGAACTC
TTATTAATGA GAACGAGGCT CTTGCAGTGG 180 ATGGGGATGG AGCTTTTTTT 240
GTACTTTTCA GTTCTTCCTT CTGACACTCA 300 GTTGAAGGTC GCTTGCATTG
GCATACGGTC 360 ACTTGTTAGC TTGAAGGAAC TAAGAGTATT CAGGGATAGA
GAGCTGAAAA 420 TAGGATTAAT TCCTTCCTTT TGACTCTCCC CTCAAGATGT
CCTTGCTTTG GTCTGAAAAC 480 CTCTCCTGAC TTCTGAACTC TGAGTGAATA 540
TTCCCTTCTG AGCCCTCGTA CTGCCANGTT TGTTTGTTT TTTGTTTCCA 600
AGAGACTGTG TCTTGCTCTG GTTTGAAACC AGCCTGGCAA 660 CCCTATCTCT
ACAAAAAAA AAAAAAAAAA AAAA 694 (2) INFORMATION FOR SEQ ID NO : 24 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 796 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
24 : ATGAGCGGCG GTTGGATGGC GGGCCTGGCG 60 TGCTCGGCCT CGGACTAGGC
CTGGAGGCGC CGCGAGCCCG CTTTCCACCC 120 CGACCTCTGC CCAGGCCGCA
CCCGAGCTCA GGCTCGTGCC CACCCACCAA GTTCCAGTGC 180 CGCACCAGTG
GCTTATGCGT GCCCCTCACC TGGCGCTGCG ACAGGACTTG GACTGCAGCG 240
TGAGGAGGAG TGCAGGATTG AGCCATGTAC CCAGAAAGGG 300 CGCCCCCTGG
CCTCCCCTGC CCCTGCACCG GCGTCAGTGA CTGCTCTGGG GGAAGTGA 360
AGAACTGCG CGCCTGGCCT GRAGSKCMCG WKGACGCTG 420 AGCGATGACT
CACGTGGCGC TCGGACGGCC TCCCGACTCC 480 AGCGACGAGC TCGGCTGTGG

ATCTCCCCGG AAGGGGATGC 540 GGGCCCCCTG TGACCCTGGA TCTCTCAGGA 600
 CCTGTGACCC TGGAGAGTGT CCCCTCTGTC GGAATGCCA TGCCGGAGAC 660
 CAGTCTGGAA GCCCAACTGC ATTGCAGCTG CTGCGGTGCT 720 CTGGTCACCG
 TGGCTCCGAG CCCAGGAGCG 780 TGGTGG 796 (2) INFORMATION FOR SEQ ID NO : 25 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 662 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 25 : TAATTCGGCA CGAGGCTGTG GTGGAGAAGG ACGTGCCGTG CCGCTGGGT
 CTGAGCCGGA 60 GTGGTCGGTG AGGCGACCTT GGAGCAGCAC TTGGAAGACA 120
 TCCCTCCATT GTTGGAGTCC TTCACAAGGA CTTAATCTGG GTTGCCGCGG 180
 GACCCTGTCA ATCTGTTCTA 240 AACCTCTGAC CCCACTGATA TTCCTGTGGT
 GTGTCTAGAA TCAGATAATG GGAACATTAT 300 CACGATGGCA TCACGGTGGC
 AGTGCACAAA ATGGCCTCTT 360 TCTGTTCTTC AGCAGCCTGT CATAGGAACT
 GGATCCTACC TATGTTAATT ACCTTATAGA 420 ACTACTAAAG TAGGCCATTC
 TTTTCTGTTT 480 ATTTAAGAGT CAATTGCTTT CTAATGCTCT ATGGACCGAC
 TTAGTAAGAA 540 AGGATCATGT TTTGAAGCAG TCACTTTGTA 600 AATAAATCTG
 TTTGGAGGAA AAAAAAAAAA AAAAAAATTA CTGCGGNCCG ACAAGGGAAT 660 TC 662
 (2) INFORMATION FOR SEQ ID NO : 26 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
 1105 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
 SEQUENCE DESCRIPTION : SEQ ID NO : 26 : CCTGATCCTC TCTTTTCTGC AGTTCAAGGG
 AAAGACGAGA TCTTGCACAA 60 TTCTGCCCTT GGCTGGGGAA GAGCCTCTCC
 GGCTGCTCAT CTTACTCTTT 120 TGTCCGGAGC ACAGTGTTC AGGGCGTGGC 180
 CTTGCCCCCTA TGACTCCATG GGAGGCGCAA GGCCTGGTGC 240 GAGAGAAGGG
 CCCATGCCAG CGTGTGGTCA GCACGCACAA CTTGTGGCTG 300 CTGTCCTTCC
 TGAGGAGGTG ACAGCCATCA CCTGGGTGGC 360 ACTCTCACCA TTACGCTGCG
 GAATCTACAA CGGGTCTCTA CCAGTGCCAG 420 480 CCCCTGGATC ACCGGGATGC
 TGGAGATCTC GGGAGTCTGA GAGCTTCGAG 540 TGGAGCACAG AGCTCTTCKT
 AGGAAAGGCC GCAAATTCCC 600 ATTCCTTCCC CCAAGAYCTG CATCTTTCTC
 ATCAAGATTC 660 TAGCAGCCAG CGCCCTCTGG GCTGCAGCCT GGCATGGACA
 GAAGCCAGGG ACACATCCAC 720 GGAAGTGTGGC CATGACCCAG GGTATCAGCT
 CCAAACCTCTG 780 AAGCCCAGGA GAAGTCCAC CAGGGACCAG 840 CCCAGCCTGC
 ATACTTGCCA AGGACTCCTT GTTCTGCTCT GGCAAGAGAC 900 TACTCTGCCT
 TCTCCTGGAC CCTGGAAGCA GAGGGAGTGG 960 GGAGGTGGTA AGAACACCTG
 AATATTGGAC ATTTTAAACA CTTACAAATA 1020 AAARRRRRRC CCCGGTACCC 1080
 AATTCGCCCT ATAGTGAGTC GTATA 1105 (2) INFORMATION FOR SEQ ID NO : 27 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 1017 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 27 : CTGTTTCCCG GCTTCATTC TCCCGACTCA GCTTCCCACC CTGGGCTTTC 60
 CGAGGTGCTT TCGCCGCTGT CCCCACCACT GCAGCCATGA TCTCCTTAAC 120
 AAAATTGGAA TGGGATTAAC AGGATTTGGA TGTTCTTTGG AATGATTCTC 180
 TTTTGTGACA AATGTTTAT TTGTAGCCGG CTGGCTTTT 240 GTAATTGGTT
 TAGAAAGAAC AACATAAAAT 300 GGTTTTTTTC TGGGTGGTGT CTTATTGGTT
 GGCTTTTGAT 360 TTCGAAATTT TCTCTGTTC TTCCTGTCGT TGTTGGCTTT 420
 ATAGAAGAG TGGATCCCTC CTGGAATTAG ATCATTGTGA 480 GATAAAGTTG
 GAGAAAGCAA CAATATGGTA GACTCATTTA 540 AAATATTGTG TTATTTATAA
 AGAATATTCA 600 AAATAGCTTG TACAGGAGTT TAAAACGTAT GTACCAGCAG 660
 AAGAAGCAGT GAAAACAGGC TTCTACTCAA GTGAACTAAG 720 CAAGCAAAC
 GAGAGAGGTG AAATCCATGT TAATGATGCT TAAGAACTC TTGAAGGCTA 780
 TTTGTGTTGT TTTCCACAA TGTGCGAAAC TCAGCCATCC TTAGAGAACT GTGGTGCCTG
 840 TTTCTTTTCT TTTATTTTG 900 GTCCACTGCA ATGGCAAAAA TGCACTGTAT
 GATGCATGAA 960 TTAAAGTATT AAAACCAAGG GAAACCCCAA AAAAAAA 1017 (2)
 INFORMATION FOR SEQ ID NO : 28 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 391

base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 28 : CCCTGGAAAG AGGAACTGAT GTTTGAGGGG ACAGATGTGG GTCACCTTCC CTGGCAGTGC 60 CCTCTAGCCT TGCTGCCTTG GCTTTCTGAC CTTCAAGGGGC CTGGGAGATC 120 TCATGCCTCA CATTTAATAG GACATGTCAT GTCAGCCCCA 180 TTTCTAGAGC ACTTGTCCTG TTGTTCTTG CCCCAGACATT 240 GGCCATGGAA TCCATCCAAT AAACACAGCA ACACCCTATG AGCAAAGCTT 300 GCCCCTGGTA AAATCATGAC CAAAGTGTGA CATGAATGTA ACTGAAATGC 360 GGGTTAGTTG CTCAATGTAT A 391 (2) INFORMATION FOR SEQ ID NO : 29 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1139 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 29 : GGTGATATCT TTTTAACTGG TTTACAAAAT 60 CCCTGTAAAA GGCAGGAGAC ATGTGATTAT 120 CTGCACAAAA TTATTGTTTT CAGCCCCCGT GTTATTGTCC TTTTGAAGTGT TTTTTTTTTT 180 ATTAAAGCCA GTATATATTC TGTTAGATGG 240 GAATAAAAAG AACAGTTGTA GTAAATTATT ATAAAGCCGA 300 TGCCAGGTGA CTGTGCTTGT TTGCTTTTAT 360 ATAGTTACTG AAATGACGAG ACCCTTGTTT AATAAGAACC 420 TTGATAAGAA CCATATTCTG TTGACAGCCA TCTTGCCTGA AGCTTGGTGC 480 ATCTCTCTTT GAGAACAGAG CTGGTGGATT 540 AATTAATAGT CTTGATATC TGGCCATGGG GTAACATCA TCAGAAATGGG 600 CAGAGATGAT CTTGAAGTGT CACTATGTCA 660 AAATCCATTA AAGAACAGGA AAAAATAATT ATAAGATGAT AAGCAAATGT TTCAGCCCCA 720 TGTCAACCCA GTAAAAAAA AAATTAATGC TGTGTAAAAT GGTGAAATTA GTTTGCAAAC 780 TATATAAAGA AAAAAGTCTG 840 CTAACCAATT GCCTTTTCTT GTTATCTGAG CTCTCCTATA TTATCATACT CAGATAACCA 900 AATTAAGA ATTAGAATAT GATTTTAAAT AACTTAACA TAAACTCTT CTAACCTTCT 960 TCTTTCTGTG AGATAGTTAT GGATCTTCAA TCATTGTTAT 1020 AAAAAATCAG TTATCACTAT ACCATGCTAT AGGAGACTGG GCAAACCTG 1080 ACCCTGGAAG TTGCTTTTTT ATAAATTTCT TAAATCAAAA AAAAAAAAAA 1139 (2) INFORMATION FOR SEQ ID NO : 30 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 465 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 30 : GCGGACGCGT TGTGCCAGTA GACATTATGT 60 ATCTTTGGTT CTCTAATTCA TATGAATTTG 120 GGGCTCTTCT GAGTACAATT TTGTTGTGAA GAAACTGTGC 180 AGGGAAATGA AGGTAGAATT ATAATGATGT GAAACATAAA GATTTAATAA 240 TTAAGTGTCCA GTAATTACTA TTTATTGCTC 300 TAAGGAAGAT TAGGGAAAAG CTTTGAAAAA TGAAACATCT 360 TGTCTAATTA TAAATTTTA ATCCTTACTG GTTCCTACAA 420 ATGTATTAAA CATTCAAGTT AACTGGTAAA AAAAAAAAAA AAAAA 465 (2) INFORMATION FOR SEQ ID NO : 31 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 702 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 31 : CTGAAGATCA AGAAGCCACT GTCGTACCGC 60 ACACGGACCT GGTGTACATC GAGAAGTCGC CCAACTACTG CGAGGAGGAC CCGGTGACCG 120 CGCGCCTGCA ACAAGACGGC TCCCAGGCC AGCGGCTGTG 180 CTGTGGGCGT GGCTACAACA CCCACAGTA CGCCGCGTG 240 ACTGTAAGTT TGCTATGTCA AGTGCAACAC GTGCAGCGAG CGCACGGANG 300 ATGTACACGT CCGCTGCAAG TCAGATTGCT 360 GGGAGGACTG GACCGTTTCC AAGCTGCGGG CTCCTGGCA GGATGCTGAG CTGCTGAGGA GGGTACTTTT CTGCAGGCAT AAAAAAATCT 480 CTCAGAGNCC TGTTCACAC CCAATGCTGS TCCACCCTCC 540 GCCCAGGTCC GGAGCGAAGC CTTCTGCAGC AGGAACTCTG 600 GCAATATTTA ACAATTTATT CCTGATAAAA ATAATATTAA TTTATTTAAT 660 TAAAAAGAAT TCTTCCAAAA AAAAAAAAAA AAAAAAACNT CG 702 (2) INFORMATION FOR SEQ ID NO : 32 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1142 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 32 : CGGCACGAGG ATCTCTCTTC 60 AACTTCAGTT

CAGCTCCTTC TCTCCTTATC 120 CTGCTGTGCT TTGAGGGCCT GCTCTTCCTC
GTGCACTCCA TGAGACGGGA TGAAAAAGGA AGAGAGAAGA 240 TGGGCTAAAA
AAAGCCGTTT TTGGCCACCC CTTCTCTCTA 300 GCCCCTTTGC CACGCCAGAC
CAGACCCGTA CCAGTATGTG 360 GTCTGAAGGA CCCCAGCCGG TCCACACCAC
AGCACTACCG 420 TCCCATCCGT ACAACTACTC TAAAACTTT 480 TTTTATGTCT
CAAGTAAAAT GGCTGAGCAT TGCAGAGARA AAAAAAAGTC ATTTTTTAAA
AACCATCCTT TCGATTCTT TTGGTGACCG AAGCTGCTCT CTTTTCCTTT 600
TCTCTGGCCT CTGGTTTCTC TCTGCTGTCT ACTAATGTAG 660 CTCGCGCTGT
CTAACTGAGT GAGACATGAC GCTGTGCTGG 720 GATGGAATAG TCTGGACACC
TGGTGGGGGA TGCATGGGAA AGCCAGGAGG GCCCTGACCT 780 TCCCACTGCC
CAGGAGGCAG TGGCGGGCTC CCCGATGGGA CACCGAAGAT 840 GGATGCTTAC
CCCTTGAGGC CTGAGAAGGG GCACAGCGAC 900 CTCATCCCCC AAGTGGACAC
GGTTTGCCTG CTAACCTCGCA AAGCAATTGC CTGCCTTGTA 960 TAGAATGATT
TTGCGGGGGA GTGGGGGAGA AAGATGAAAG 1020 AGGTCTTATT TGTATTCTGA
TGATTATTTG GAAGAGTGTG 1080 TAGGAAAGAC GTTTTTCCAG TTCAAATGC
CAAGAGGAAA AAAAAAAAAA 1140 AG 1142 (2) INFORMATION FOR SEQ ID NO : 33 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 928 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
33 : GGCACGAGGT CTAATGAGGG CTCTCTTGTT GAGAGAAATG TATACTAATC 60
ATTTTAATTT GACTTAAAA TACATTTTAC GATTTTAAAT ATGACAAATT 120
CTTCTAGTAG ATACTAATCT TTCTTGTTA CTAGAGAAGC CTAGGTAAAA 180
ATGGGTTCCA CCTAGTCTGT TTGTATAACA CCTTCCCCCG TCCCCTCTCC ATCCCTGCCA
240 AAGAAAACCT TAGGTTCTTG TATTTGAATT 300 TCCAAAACAA TAAAAGGTTT
TGACTCAAGA TTTGCATTCA GAAATTTTGT 360 CTTATCTTTT TGAACCTGTG
TGCTTAGAAA ATTTACACAC 420 AAGGAATGTT TGAAAAAGTG AGAATTTTAG 480
AGGTGTTTAG GGAAATAATG TTTTGTACAA 540 TGAATGACTG GGGGATATTT
TGAGAAAAGG GAGGGAGTGG GCAGGTTGGA 600 GTGGGGACCT TTCCATTGAA
AGCAGTGCAG TCAGCTGTTT 660 CATTGTTCTT GTGTCCATAA TTGACTGAAA 720
CAGGTGACCA GAAGTAGAAC CTTGTTGATT AGAATAATGT 780 CAAGGTAGTG
GGGGTAAAAT GACAAATAAG ATTTTACTGG TGCTTAGTAT 840 GTACATTAAC
CTCTTTTAA GTTGCATGTT AATCTGGTAT AACGTATTGT GTCTGGTTTA 900
TGCTTTGAGT AAAAAAAAAA AAAAAAAAAA 928 (2) INFORMATION FOR SEQ ID NO : 34 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 773 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
34 : GGCACGAGTT CTGGCCTCTC ATTTCTTAC ACTCTGACAT GAATGAATTA
TTATTATTTT 60 TCTTTTCTT TTTTTTTTTT TTCATTTAAA CAACTTATT 120
ATTATTATTT TTTACAAAAT ATATATATGG AGATGCTCCC TCCCCTGTG AACCCCCCAG
180 TGCCCCCGTG GGGCTGAGTC TGTGGGCCCA CTGGATTCTG TGTACCTAGT 240
ACACAGGCAT GACTGGGATC CCGTGTACCG AGTACACGAC CCAGGTATGT
ACCAAGTAGG 300 CACCCTTGGG CGCACCCACT GTCGGGGGAT GTTGGGAGCC
TCCTCCCCAC 360 CCCACCTCCC GCATTCCAGA TTGGACATGT TCCATAGCCT
TGCTGGGGAA 420 GGGCCCACTG CCAACTCCCT CTGCCCCAGC CCCACCCTTG
GCCATCTCCC TTTGGGAACT 480 AGGGGGCTGC TGGTGGGAAA GGCAGATGTA
TGCATTCCTT TATGTCCCTG 540 TAAATGTGGG ACTACAAGAA GAGGAGCTGC
CTGAGTGGTA CTTTCTCTTC CTGGTAATCC 600 TCTGGCCCAG CTTATGGCA
GAATAGAGGT TATTTTGTGTA 660 CCCTGTGTAG CTGAATTCCC AAGCCCTGCA
TTGTACAGCC CCCCCTCCC 720 CTCACCACCT AATAAAGGAA TCAAAAAAAAAA
AAAAAAAAAA AAA 773 (2) INFORMATION FOR SEQ ID NO : 35 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 453 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
35 : TAAATGTTA CACGCTTGTC TGTATGCCGT TTATCAACAG 60 TTAGCTCAGC

TAACCCTCAT GGTAACCTTG TTAGCCCCGA TTTTGCCAGA TGAGCAAAGT 120
 GAGGTTTTTG AGGCCTTAAG TAACTTGCCC AAGGTCACGT TAACTCTCCC 180
 AGTTCTGAGA TGCCCGAGCC TGGACGCTTT GTCATTGTAC ACCATCAACT 240
 AGTCATTCCA AGCGTAGTCA AGGTTTCTCC ACCTTAGCAC TGTTGACATT 300
 TAATTCTCTG TGGTGAGGAG CTGTCCTATG CTTGTAGGA TATACAACAG 360
 CATCYTGGCT TTACCCACCA GATGYTGGAA CACCTCCCCA GTCGTGACAG
 CCCAAAATGT 420 CTATAGACGT TGCCACGTAT TCC 453 (2) INFORMATION FOR SEQ ID
 NO : 36 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 459 base pairs (B) TYPE : nucleic
 acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 36 : GTGACTGCCG CCCTGCCCCG AGCCATGTGG CCCCCGCTGT TGCTGCTGCT
 GCTGCTGCTC 60 CCGGCCGCCC CGGTCCCCAC CGCCAAAGCC GCTCCCCACC
 CGGATGCTAA 120 AGGAGTCGGG GCTGGCGGAG ACGGAGAGCT GCGGGCAGAC 180
 CCCCCGGGCTC TGGCTGTATT TGGTGGCCAC GCGACCAGAA 240 GAAGACCTGC
 GGTTCCGTGA GAGGCGTCCA CCACGGCGAC 300 AGGCTCCGGG GAACATGGGG
 CTTTCCCTGT CCACTCCCAA GGAGTGTGGG 360 ACGGCCGTGT GCCCTCTYCA
 CCAGATGCAT TTATTAGAAA 420 TAATAAATTC TTTCTTAGCT AAAAAAAAAA
 AAAAAAAT 459 (2) INFORMATION FOR SEQ ID NO : 37 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 509 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 37 : ATGAAATTTA CTTCTTGGA GCTGTAGCAG GGGCCCTGGT CTATGCTGAA 60
 GATGCCTCCT CTGACTCGAC GGTGCTGAT AAGCTGGGAC CTCTAAGCCT 120
 AATGAAGAGA AGCAGAACCA GCTTCACCCC 180 CAGGAGACTT CGGCGGCAGC
 AGTTCAGGGG ACAGCCAAGG TCACCTCAAG 240 CTAAACCCCC TGAAATCCAT
 AGTGGAGAAA AGTATCTTAC AGCCCTTGCA 300 AAAGCAGGAA AAGGAATGCA
 CGGAGGCGTG CCAGGTGGAA AACAATTCAT 360 AGTGAATTTG CACAAAATT
 ACTGAAGAAA TTCAGTCTAT TAAAACCATG GGCATGAGAA 420 GCTGAAAAGA
 TGGACTTAAA GCCTTAAATA CCCTTGTAGC CCAGAGCTAT 480 TAAAACGAAA
 GCATCCAAAA AAAAAAAAAA 509 (2) INFORMATION FOR SEQ ID NO : 38 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 598 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 38 : AGCGCTGGGC CTGCTCCTGC TGCTGCAGGG CTCGGCAGAC 60 GGAAATGGAA
 TCCAGGGATT CTTCTACCCA TGGAGCTGTG AGGGTGACAT ATGGGACCGG 120
 GAGAGCTGTG GGGGCCAGGC GGCCATCGAT AGCCCCAACC TCTGCCTGCG
 TCTCCGGTGC 180 TGCTACCGCA ATGGGGTCTG CTACCACCAG CGTCCAGACG
 AAAACGTGCG GAGGAAGCAC 240 ATGTGGGCGC TGGTCTGGAC CTCCTCCTCC
 TGAGCTGCAG 300 TTCTGGTGGG GGACGTGCTG GGGTCCGTGT 360 GACATGTCCA
 AGTCCGTCTC GCTGCTCTCC GGACCAAGAA GACGCCGTCC 420 ACGGGCAGCG
 GAGTCCAGGG 480 CGGAGGAGGG TGAGGAGACA GAGGGCGAGG AAGAGGAGGA
 TTAGGGGAGT 540 CTGGTCAATA CAGATACGGT GGACGGAAAA AAAAAAAAAA
 AAAAAAAA 598 (2) INFORMATION FOR SEQ ID NO : 39 : (i) SEQUENCE CHARACTERISTICS
 (A) LENGTH : 454 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 39 : ATGGAGGCTG
 TTTTTTTTTT GTTGTTGTTT TGTTTTTAAA GAATACAGAA 60 GGAGCCAAGC
 TTTTTTGCAC TTTGTATCCA GCTGCAAGCT 120 AACCTGACTC ATAATTGACC
 CTTGCAGCTA CCAATAGCC 180 CTTGGAGCTG AGGCTGCAAG ATTTGACTGC
 CTTAAAAACA 240 TAGGCCTGGC AGGGATGTCC CTGTGCCCAG CACTGGGGGC
 TCGAAGACTG GTTTCTAGCA 300 CGGCCATGTC GTCCTAGAAG GTTCCAGAAG
 ATTATTTTAC 360 TTTTAAATGT ATAAAAGCCG 420 TGACGTTCCG AAAA 454 (2)
 INFORMATION FOR SEQ ID NO : 40 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 425
 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
 SEQUENCE DESCRIPTION : SEQ ID NO : 40 : GCTAAAGGCC ATTCCCTCCG CAGGGCATT

GGCGTCGGGT GGGAGGGGAA AACGCATCTT 60 GTTAATTATT TTTAATCTTA
 TTTATTGTAC 120 GGGGGRAGAA GGGTCCCCTC TCTCTGCCCC TTTCTACGGC
 GATTTGTCTG 180 TGTCTGGCCC MCCATCCCCC ATTGTTGTCT GGATGTGGTT
 CTATTTTTTA 240 TCGGTCTCCT TTCCCCTCCT GCCCCCGMCC CACCCCCTGC
 TCCCACTACC 300 CTTTGTCTCT TGCTCTTTCT TACAACTCAA 360 CCCAACGGCA
 AACACTTTAA AAAAAAAAAA AAAAAACTGG 420 GGGGT 425 (2) INFORMATION FOR SEQ
 ID NO : 41 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2471 base pairs (B) TYPE :
 nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 41 : GGCACGAGTA TGGCTTCCCG 60 TCGCGTCTGT
 GCTGACGTCA TCTGGAGGAG ATTTGCTTTC 120 AAAGGGGAGG TGAGTGGCCC
 ACGATGGGAA GAGGGGAAAG CCCAGGGGTA 180 CAGGAGGCCT CGGAGCGACC
 TTGGCCGTTG 240 GCCTGACCAT CTTTGTGCTG TCTGTCGTCA CTATCATCAT
 CTGCTTCACC TGCTCCTGCT 300 GCTGCCTTTA CAAGACGTGC CGCCGACCAC
 GTCCGGTTGT 360 TGCCCCTTAT CCTGGACCAA 420 GCTACCAGGG CTACCACACC
 ATGCCGCCTC AGCCAGGGAT GCCAGCAGCA CCCTACCCAA 480 TGCAGTACCC
 ACCACCTTAC CCATGGGCCC ACCGGCCTAC CACGAGACCC 540 TGGCTGGAGA
 CCTACCCCGC CTTACAACC CGGCCTACAT 600 GGATGCCCCG AAGGCGGCCC
 CCCTGGCCTC TCTGGCTGCC ACTTGGTTAT 660 GTTGTGTGTG TGC GTGAGTG
 GTGTGCAGGC GCGGTTCTT ACGCCCCATG TGTGCTGTGT 720 GTGTCCAGGC
 ACGGTTCTT TGTGCTGTGT GTGTCCTGCC TGTATATGTG 780 GCTTCCTCTG
 ATGCTGACAA AGAGTGGGCT GGGACCAGAC 840 TCCTCACCTG AAATTATGCT
 TCCTAAAATC TCAAGCCAAA CTCAAAGAAT 900 GGGGCACCCT GTGAGGTGGC
 CCCTGAGAGG TCCAGGGCAC 960 ATCTGGAGTT TTACCCTAGG GTGACCAAGT
 AGGGCCTGTC 1020 GGCGCAGCTT TCTGTGTGAT GCAGATGTGT CCTGGTTTCG
 GCAGCGTACC AGCTGCTGCT 1080 GCTCCGTCCC CGGAGTTGGG GGTACCCGTT
 GCAGAGCCAG GGACATGATG 1140 CAGGCGAAGT TGGGGATCTG GCCAAGTTGG
 ACTTTGATCC TGTCCCATTTG 1200 CTCCCTGGAG CTGTTGGGGA TCAGGCAGCC
 AGAACACCTC 1260 AGGCAGAGCC CTACTCAGCT GTACCTGTCT GCCTGGACTG
 TCCCCTGTCC 1320 CTGCCCCCAG GGAGCTCTGC 1380 TGCCCTTGCT GGCCCTGCCC
 TCCTGTCCAC 1440 AGTTCTCTT CCTGCAGTGT TTTAGCCAA ACATTTTGCC
 TGTTTTCTGT 1500 ATAGTTGATA TGAGACTGAA ACCCCTGGGT TGTGGAGGGA 1560
 GAGATGGACA TGTGAGTCCC TGCTTCCCGA ATGGAATATG 1620 CAACAACCTC
 TGTACCCAG TCCACGGTGT TCTGGCAGCA 1680 CAAAGGTGGG GTGTGGGGCC
 CTGGATGGCA GCTCTGGCCC AGACATGAAT 1740 ACCTCGTGTT CCTCCTCCCT
 CTATTACTGT TTCACCAGAG CTGTCTTAGC TCAAATCTGT 1800 TGTGTTTCTG
 AGTCTAGGGT CTGTACACTT GTTTATAATA AATGCAATCG TTTGGAAAAA 1860
 AAAAAAAAAA AAACCTCGTAG GGGGGGCCCC TACCCAATGG GCYCMMARAT
 AGTAGARWAC 1920 RAAAYAMCA ANTGCAACCA AAGAGGGGCC AGGGGANTTT
 TAAGAGGGCC 1980 TTNTTAAGGG GCGGGGGTTA 2040 KYTWCTTCCA ACCAAGGGTT
 YTYGTGGTTA GGCCGGGTTG GGCCCMATGG 2100 GTAAAGTGGT GGGTMAYTGC
 MATTGGGTAG GGTGCTGCTG GCATTCCTGG CTGAGGCGGC 2160 AGCCCTGGTA
 GCTTGGTCCA GGGTAGCTGG TGGAGGCTGA 2220 GGATAAGGGG CATGCACCCA
 CAGTGGTGGG TGTGGTGGTG GTGACAACCG GACGTGGTCG 2280 TTGTAAAGGC
 AGCAGCAGGA GCAGGTGAAG CAGATGATGA TAGTGACGAC 2340 AAGATGGTCC
 CCGAACCCCA TGTTAGCCTC 2400 CAGAGGCCTC CTGTACCCCT CGTGGGCCAC 2460 C
 2471 (2) INFORMATION FOR SEQ ID NO : 42 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 2659 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 42 : GGCACGAGCT TTTCTCTAGA
 GTCTGAAAGA TGCTAGAAAG AAATAAAATT AAGAGAATTA ATTAATAAAA
 TGATTTGAAC GATAATTCTG GTATTTATAG CTTTTTTTAT TCCCCTGCAG AAAACCATAG
 AACATGCTTG GAATTGCGAA AAGAATTTAA 240 ACTGGAGGAC CTGAAGAAGC

TAGAACCAAT CCTAAAGAAT ATTCTTACAT ATAATAAAGA 300 ATTCCCATT
AAGAAGAATT TTGGCACCTG GTGAAGAAGA 360 GAATTTGGAA TTTGAAGAAG
ATGAAGAAGA GGAGCAGGTC TCCTGATTCT 420 TTCCTGCTAG AGTTCCTGGT
ACTTTATTAC CAAGGTTGCC ATCGGAACCA GGAATGACAT 480 CAGAATTGAG
AAAATTGGTT TGAAAGATGC TGGGCAGTGC ATCGATCCCT 540 TAGTGTAAG
GATCTGAATG GCATAGACTT AACTCCTGTG CAAGATACTC 600 CTGTGGCTTC
AAGAAAAGAA GATACATATG TTCATTTTAA TGTGGACATT AAAATTAACC
AAAGGTGCAG CTATCTTCTT CTAACAAAAAG ACCAAGTGTT TTGCTTTCAT GGAGATGGAT
GAAATTAAC 780 TGTAATAGAA CTATACAAGA AACCCACTGA CTTTAAAAGA
AAGAAATTGC 840 AATTATTGAC CAAGAAACCA CTTTATCTTC ATCTACATCA
AAGGAATGAT 900 CCTGACATGA TGAACCTGGA ACTTCTGTGA ATTTTACCAC
TCAGTAGAAA CCATCATAGC 960 TCTGTGTAGC ATATTCACCC TTCAACAGGC
AGGAAGCAAG CCGTACCCAG ACCAGTAGGC 1020 CGGACGGAGT GCTGTACCAC
GTATAGGACT CCTTGGGATA CAGGTTTATT GTAGATTTTG AAACATGTTT TTACTTTTCT
1140 ATTAATTGTG CAATTAATAG TCTATTTTCT AATTTACCAC TACTCCTACC
GAACAATACT GTTGTGGGTA ATCTTCAGAC TTAATACAGC AATAAGAATG 1260
TGCTAGAGTT TACACATCTG TTCACTTTTG CTCCAATATG CTCTTTTGAC TTAACGTCAA
1320 GCTTTGGGTT GATGTGGGTA GGGTAGTGTC AACTGCTTT GAGAGGAATG
GGACCAGTTC 1380 TGCTGCCTAA GAAGGTCTGT CTGGATGTTT ATAGGCAGCA
CCTCTGAAGT GGCCTAAATT 1440 CACCCTGATC TGATAGTTT CCTGCTTAGA
AAGTGTGCCT TGGCCAGATC AGTATCCAC 1500 ATGGGAGTGT TCCCTAGGTT
GTAGCTGTGA TTGTTTCCAG ATGACCAGAT TGTTTTTCTG 1560 AAAATGAGCA
TATTTTLAGT CATGTCGATT AGCTGTTCTT TTCTGATGAT TTAACATTGG AACCATCTCA
AAATAATTAC AAAGTTTTAG 1680 ATGGGTTTAC AATGTCTTCT AAACAATGTA
ATCTAAAAAT AATTGAGTCA GATGCTAACG 1740 GGCATAACTG CTGTTTTTCT
GACAACCTGAT TGTGAAACCT TAAACCTGC 1800 ATACCTCTTC TTACAGTGAG
GAGTATGCAA AATCTGGAAA GATATTCTAT TTTTTTTATA 1860 TAGGTAGATA
TTATTTCTTA TTAGATATA TCCATATGAA 1920 ACTATAATTT TAAATAAAAC 1980
CACATGAGGT GGATATTTGA ATTTGCGGTG GGCTTTCTGT 2040 GGGTTAGATG
TTAAATGAGC AATGCATGAG 2100 GGGAATGCAG TAAACTAGT TAGTCATACC 2160
ATTCAGTATG TTTGCTTTT AAAATAAGTA ACCACAATTA AGTTGTTGTA GCCCTTGCAC
2220 TTCAAGAGAT CTAGTCTTTA TCTGTTAGGT TACTAGACGG 2280 ATGTTAATAA
AAACTATGCG AGCCTGGAAT GGAATTCTCC TAGTCTTGTC 2340 CTCTCCATCT
TGATTGGATT AATTCCAAAT TCTAAAATGA TTCAGTCCAC AATAGCTCTA 2400
GGGGATGAAG AATTTGCCTT GTTCCTAAGA CTGTGAGTTG TCAAATCCCT 2460
AGACTGTAAG AGCAAGAGGC GCATTTTCTC CGTGTCATGT AATTTTCTA 2520
AGGTGTTTGG TACCCTGTGG ACCTTTTGTT TGATGTTGCT 2580 GACAAGACCT
GAAAAAAAAT CCCTTAAAAA AAAAACCCAT TAAAGTGTAG 2640 AWAAAAAAA
AAAAAAA 2659 (2) INFORMATION FOR SEQ ID NO : 43 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1635 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
43 : CGAGGAGGTC ATGAACAAGG AGGCGGGAGA GGTGGACGTG GTGGCTATGA
CCATGGTGGC 60 GAAGAGGAAA TAAGCATCAA GGAGGCTGGA 120 GGAGGTGGCT
ACCAAGATGG TGTTATCGA GATTCAGGTT 180 GGTGGCCACA GCAGTGGTGG
CTATCAAGGC GGAGGTTATG GTGGCTTCCA AACATCTTCT 240 GAAGTGGATA
AGGACAATAG ATACCAAGAT 300 GGCGGGCACC ATGGTGATCG TGGTGGTGGT
GAGGTGGTCG 360 GGTGGTCGTG CAGGCCAGGG AGGAGGCTGG GGAGGAAGAG
GGAGCCAGAA 420 TTTCCAGCAT GGAGGTTATC AGTATAATCA TTCTGGATTT 480
GGACAGGGAA GACATTACAC TACCGAACCT TACATTTTGC TAGAGCTCAA 540
GTAATAGAAA TTCAGCACCT AATGTGAGAC 600 TAAGCATTTG TTCAATTCTG 660
TTAGATTTT TTATTGGACT TACATAATGC CGTTTATTG AACATCTCTC 720

CTTTCTATGA AAAATTTTTT TAAAATTGCC 780 AAACTTTTTT GAAGAAATTA
 CTTGAATAAG TAGTTTTTCAT 840 GTTTTCAATA TGCAGTTTTG AAAATGAGGA
 TTCACCTAGA CTTTTTTAGA TTTACTACYA 900 GGAAACCTTC CYCATATGAA
 TAACCATTTA TATGTGTTTT GCTTAAAGTA 960 GCGGGGCGGT GCCACGTGTG 1020
 GAACTTTTAG GTCAGTTCCT ATTAAATGAG TCAGTAGCCT 1080 TATTTTGTG
 ATGGAATACT GTATCATATG CTCAACTCTG AAAACCTTGA ACACGGCCAA 1140
 GATTATAAAA ATAGTACATG 1200 GTTAAGTATA ACAAATTCCT CCTTCAACCT 1260
 TATTTTACT TGAAATTTGC TAGAAGAAAT AGCAAACCGA AATTTGTTTT 1320
 GTTTGCTTTA AGCAGGTAAC TTTTTTTGTA 1380 TGCCTACAA AGTTAAGACA
 GATTTTGTGCT GGCCCTTTAT 1440 GAAAACAAAA GCCTGGCTGA GTTGATGTTT
 TACATTCTCC CTTACTGAAA 1500 TAAACATTGT CAAGCTGTGA 1560 CTGGAGGTGT
 GCTTTGTGTG AAAGGTGAGC ACTGAAAGTA TCTGTAAAGT 1620 TCTCCNGAAA AAAAA
 1635 (2) INFORMATION FOR SEQ ID NO : 44 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 780 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 44 : AACATGGTCA TGTCTTTTAG
 TTTCATTATT TTCCTACTCC AGAAATTACA 60 TTTTGCATGT TGCTTCAGTG
 AGTGCTTTTC TAATCTGCAG 120 ACCATTTACA TTTCTGTTT GCAGCATGCT
 AYTACGTAAT TTGGAGTATT 180 CAATTATTTG TCCTATTTCC AAATGTGCTG
 AATTGTCTAT 240 AGCTGGGTGG GGTGCTACG 300 TAGTGAGTAG ACTTTCTCTT
 GGGTATAGTA TTTATCTACT 360 TTTCTGTGG AAATAAAACA TCTGAAAGAA
 TAAGATAGCT TTCTGTAGAG 420 AAGGAATTCC TACCTCTAAA ACTGGCAGTT
 TTCTGAGGTG 480 TTCAGTATTA GGGAGAGTCC GACACAGATT 540 AGCAAATGCA
 AAACATTAT AATGTGGTGT TACACAGGT 600 AGAACAAGTA GACTCTGGCA
 AGAGACCCAA GTTTAGGTTC TCATAGTGTA 660 TTTGAAGTAG TTATACTCCT
 GGCTTAAGTA GTTTAGTGCC TGGGAGAATC 720 CTTAAAAAAA AAAAAAAAAA
 AAAACTGAAA AGGTAGTGAA TACAGAATAG 780 (2) INFORMATION FOR SEQ ID NO : 45 :
 (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2378 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 45 : GCGAAGCAGC TGAAGCCGCC GCTCCGTGCG CCATGGTCAC 60 TTTCCCGCCG
 CCGGGATGAG CCGCCCCCTG GACACCAGCC TGCGCCTCAA 120 GACCTTCAGC
 TCCAAGAGCG AGTACCAGCT GGTGGTGAAC GCAGTGC GCA AGTGACAGGAG 180
 ACTGGAGCGC AGTGACCGGC GGCGAGGCGA ACCTGCTGCT CAGTGCCGAG 240
 CCCGCCGGCA CCTTCTGAT TCGGGACCAG TCACGCTCAG 300 CGTCAAGACC
 CAGTCTGGGA GCAGCTTCTC 360 GATCCCCGGA GCACGCAGCC CGTGSCCCGC
 TTCGACTGCG TGCTCAAGCT 420 GGTGCACCAC TACATGCCGC CCCCTGGAGC
 CCCCTCCTTC CCCTCGCCAC CTACTGAACC 480 CTCCTCCGAG GTGCCCGAGC
 AGCCGTCTGC CCAGCCACTC CCTGGGAGTC CCCCCAGAAG 540 AGCCTATTAC
 ATCTACTCCG GGGGCGAGAA GATCCCCCTG GTGTTGAGCC GGCCCCCTCTC 600
 CTCCAACGTG GCCACTCTTC AGCATCTCTG TCGGAAGACC GTCAACGGCC ACCTGGACTC
 660 CTATGAGAAA CATTGCGGAG TTCCTGGACC AGTACGATGC 720 CCCGCTTTAA
 GGGGTAAAGG GAGAGGGGAC GCAGGCCCCCT 780 CTCCTCCGTG CAAGCACAAG
 AAGCCAACCA GGAGAGAGTC CTGTAGCTCT 840 GGCCCCCTCC TCTGCCCTCT
 TGTGGCAGGC 900 GGACCTGGAA TGTGTTGGAG GGAAGGGGGA GTACCACCTG
 TTCTCCGGAG 960 ACGATAGCAA CCACAAGTGG ATTCTCCTTC AATTCCTCAG 1020
 CTTCCCCTCT TCGGAATGC TGAATAATG GGAATCTTC AAACCTTCCA ACGGAACCTG
 TTTGCTCTTT AAACCTGAGC 1140 TGGTTGTGGA GCCTGGGAAA GGTGGAAGAG
 AGAGAGGTCC TGAGGGCCCC AGGGCTGCGG 1200 GCTGGCGAAG GAAATGGTCA
 CACCCCCCGC CGAGGATCCT GGTGACATGC 1260 TCCTCTCCCT GGCTCCGGGG
 AGAAGGGCTT GGGGTGACCT GAAAGGGAAC CCCCACATCC TCTCCTCCG
 GAAAACACAG GTTCCAAAGT CTACCTGGTG 1380 CCTGAGAGCC CCTCCGTTTT
 AAGGGGGAAG TGGTCTCCTT TTCCTACTCA TACTATACCT TCCTGTACCT GGGTGGATGG

1500 AGCGGGAGGA TGGAGAGACG TCCTGGTAGA GAATACAGGG 1560 GATTCTACTC
 TGTGCCTCCT GACTATGTCT GGCTAAGAGA TTCGCCTTAA ATGCTCCCTG 1620
 TCCCATGGAG AGGGACCCAG CATAGGAAAG AGCCTGGATG GGTGGAGAGG 1680
 CACTGGAGGG GGAGGGGGGG 1740 GGAAACCCAT TGAGCACTGG CCAGTAAGTA
 AGGCGCCTCG TGGTCAGAGC AGAGCCACCA GTCCCACTG CCCCAGAGCCC
 TCCCTCCTGC GAGGCTGGAG GTCATTGGAG AGGCTGGACT GCTGCCACCC 1920
 CGGGTGCTCC CGCTCTGCCA TTACAGGAAT GTAGCAGCGA 1980 TGGAATTACC
 TGGAACAGTT TTTTGTITTT GTTTTTGTTT TTGTTTTTGT GGGGGGGGGG 2040
 AACTAAACAA TTCTGTGTCA AGTTGTGTGT 2100 TTTTCTCTA TTTTTTGT
 TGTTCCTTGT TTTTAATAA CACTCTGTCT TTTATAAGA TTCCACTCCA GTCCTCTCTC
 CTCCCCCTA 2220 CTCAGGCCCT TGAGGCTATT AGGAGATGCT TGAAGAACTC
 AACAAAATCC CAATCCAAGT 2280 CAACTTTGC ATTTATATTC AGAAAAGAAA
 CATTTAGTA ATTTATAATA 2340 AAGAGCACTA TTTTAAATG AAAAAAAAAA (2)
 INFORMATION FOR SEQ ID NO : 46 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1772
 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
 SEQUENCE DESCRIPTION : SEQ ID NO : 46 : CGTCCGGGAG CGGGTCCCAA GAGCCTGAGC
 60 CTGAGCCTGA GCCGAGCCGG GAGCCGGTCG CGGGGGCTCC GGGCTGTGGG
 ACCGCTGGGC 120 CCCCAGCGAT GGCAGCCCTG TGGGGAGGCC TTCTTCGGCT
 TGGCTCCTTG CTCAGCCTGT 180 CGTGCCTGGC GCTTCCGTG CTGCTGCTGG
 CGCACTGTCA GACGCCGCCA AGAATTTCTGA 240 GGATGTCAGA TGTAATGTA
 TCTGCCCTCC CTATAAGAA AAATTCTGGG ATAAGAACAT GATTGTGATT GCCTTCATGT
 TGTGGAGCCC ATGCCTGTGC 360 GGGGGCCTGA TGTAAGCA TACTGTCTAC
 GCTGTGAATG CAAGGTTACC ATTATAATT ATCTCTCCAT TTTGGGCCTT CTAATTCTGT
 480 TCTTACTCTG GTTGAGCCCA TACTGAAGAG GCGCCTCTTT GGACATGCAC 540
 GAGTGATGAT TGCTAGCCCG CGAGCCAACG GGTAGAATAT GGCACAGCAG 660
 CGCTGGAAGC AGAGCAGCGA AAAGTCTGTC TTTGACCGGC CAGCTAATTG
 GGAATTGAA CTAGAAAGAA ACAGGCAGAC AACTGGAAAG 780 GAACTGACTG
 GGTTCATTT TAATACCTTG TTGATTTTAC TGGAAGATTC AAAACTGGAA GKAAAACTT
 GCTTGATTTT TTTTCTTGT TAACGTAATA 900 ATAGAGACAT TTTAAAAGC
 AAGTCAGCCA ATAAGTCTTT TCCTATTTGT 960 GACTTTTACT AATAAAAATA
 AATCTGCCTG TAAATAAAT TAAAAAATCC TCTTTTTCAC CACATAGTTT TAACTTGACT
 TTCCAAGATA ATTTTCAGGG 1080 TTTTGTGTG TGTTGTTTTT TGTTGTTTTG
 GATGCCTGGG 1140 AAGTGGTTAA CAACTTTTTT CAAGTCACTT TACTAAACAA
 ACTTTTGTA ATAGACCTTA 1200 CCTTCTATTT TCGAGTTTCA TTTATATTTT
 GCAGTGTAGC CAGCCTCATC AAAGAGCTGA 1260 TGACTTTTGC ACTGACTGTA
 TTATCTGGGT ATCTGCTGTG TCTGCACTTC 1320 GGATCTAAAA TGCCTGGTGG
 CTTTTACAA AAAGCAGATT TTCTTCATGT 1380 ACTGTGATGT GCATCCTAGA
 ACAACTGGC CATTTGCTAG TTTACTCTAA 1440 AGACTAAACA GTGTGTGGTC
 TTACTCATCT TCTAGTACCT TTAAGGACAA 1500 ATCCTAAGGA TGCAATAAAG
 AAATTTTATT TAAACCCAA ATTGATAATA TATACACATT TCCGGTCGTG GCTGTTTGAG
 1620 CTCCAATGTG TGCAGCTTTG AACTAGGGCT GTGCCTCTTC TGAAAGGTCT 1680
 AACCATTATT GGATAACTGG CTTTTTTTCT TCCTCTTTGG AATGTAACAA TAAAAATAAT
 1740 TTTTGAAACA AAAAAAAAAA AA 1772 (2) INFORMATION FOR SEQ ID NO : 47 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 1107 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 47 : CGGGCGAGAA CTCTCCGCC TGAGCCCCGG AAGTGATGTG 60 CGCGGCCTCG
 TATTGACTGT 120 AATCTTGCTG CTTATATGTA CCTGTGCTTA TATTCGATCC 180
 CAGAAATAAA ACTGGATTGT TGGGTATATT TTGGAAGTGT GCCAGAATTG
 GTGAACGGAA 240 GAGTCCTTAT GTTGCAGTAT GCTGTATAGT AATGGCCTTC
 AGCATCTCT TCATACAGTA 300 GCTGGGGAAA ATGCCAGAAT GTAGTTGCCA
 TCAGATTTGA TTGTGAACAA GGAAGTACTG 360 CAGAAAATAA TGGAAGGAT

GTTTAACTCT TTTATCTCCG AACATTGAAT GAGATAAATT 420 TCCAGATGCT
GTTCTCTATT TTAATGTTAT TGGACCAATG TTCTGTATAA ACAATTAAGA 480
TAATAGTCTG CCTCAGTACT GTCACTACAA TATTACATTC 540 ATTCTGTTGT
ATCAGATACA AAATTTTAGT GAGGTATCTC TAAGGCACAT 600 AGTAGAAAAC
AAAATTGGTT AATTACTCAA GTTCCTTTCA CTGTGATTTG GAAATGATTT 660
AATCTTTATA GAATGAGAAC CTTTTTTGGA TATTAATG 720 TGTTGATAAG
ATATTTAATA GTGCTTGCTT TTCCTCTGGG CACACCATT 780 TGATCATTA
TCTACTCTTA GCAAACCTA GTTTATGACA AGTATTTAAA 840 CAAGCTTATG
CAGTTCTTAA GGACGAAGGT TAACTTAAAA 900 ATAGTATTGG GAAAATGTTG
ATAGTTAACA TTAGTGGATT TAGACTAGCC AAATGACATA 960 GTAGGCTCTG
AAACATCTTG GTATTTTGTG TGCTGGAAAG 1020 CTGTCTTTCT CTGAAAAACA
CAACGTTCTT AGAATGAAAA GAACAATTAT AAAATAAAAA 1080 AAAAATTTAA
AAAAAACTGG 1107 (2) INFORMATION FOR SEQ ID NO : 48 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 805 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
48 : ATGGAGTTGC TGTTGGAAAA CTACTACCGA TTGGCTGACG ATCTCTCCAA 60
TGCAGCTCGT GAGCTTAGGG TGCTGATTGA TGATTCACAA AGTATTATTT TCATTAATCT
120 GGACAGCCAC CGAAACGTGA TGATGAGGTT CTGACCATGG GAACCTTCTC 180
TCTTTCGCTC TTTGGACTAA TGGGAGTTGC TTTTGGAAATG AATTGGAAT CTTCCCTTGA
240 AGAATTTTTT GGCTGATTAC AGGAATTATG TTCATGGGAA GTGGCCTCAT 300
CTGGAGGCGC CTGCTTTCAT TCCTTGACG ACAGCTAGAA GCTCCATTGC 360
ATGAAGGATA TGGTTCACGG CGGTATTGTG GAAGGGTTAT 420 GATTAAGTTG
TATGGCCCTT TTCTCAAAC 480 TCCTTCAGTT TCCCTATCTG CGGTATTACC
GGTTATGGGA 540 AGAATTAAC AATATGTGTA CCTAACACAA TAAGTTAGAA 600
ATATAATTTG TGTAAGACTC GATGTTAGTA ATTCTGGTAT 660 AAGGTTTGTC
ATAACCAAAT GGAAATGTAG TAATGTTCTT AAAAGATAGR 720 AAATTCACCT
TGTAATTGAA GATGGCACCA CTGGAATAAA TACTTAAGAC 780 ACTGAAAAAA
AAAAAAAAAA AACTC 805 (2) INFORMATION FOR SEQ ID NO : 49 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1408 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
49 : TCATTATTTA TGAAAGAGTA TATTAATTAT GTTTAGATTT TTGGAAAAAG 60
AAAAGGACCT ATACAGTGCT TTTTAAAAAT ACTATTTTAT 120 TTTTACTCAC
ATATGAAAAA CTATCATGTT CTAACATTGG 180 AAACAGAATA ACGAATTGTA
TTTAAATTTT ATGAAGAACA AAAACACTGA 240 TTGGTTACAG AAAGCAGAGT
TTGAGGAAAA AACATTAGCT ATAATTTTCA TTTTCATTAA 300 CCTCTGAGAA
TAATCAAACCT GATTAGTAAT ATTCATCTAT ACTGCAAAAT 360 AATATGTACA
AAGGAAAGTT AGTGATTGTA CTGATTTTAT TACTTTTACC AAGCCATTTT 420
ATGTTCTCA CTCAATGCAA AGAAATAAAA AGAAAAATAT GTCCTTATTA 480
TTATTCACAA TAAAAAGTTG GCTTTATTCT GCAAGCCTGG GCATATTGTA 540
CACTTAACGG CTCAAGTGGA AGTTTGATTG TGATCCACTG AATAGAATCT 600
CTCATCCATA TCTGGTGACC AGACTAACTC GTGATAGACT 660 TGTGGTATCC
CTAGATCTCA CTAAATAAGA AAGACCCTAC ACCAGAAAAT ATAGCAACTG 720
ATCTATCTAT TATATGCTAG CTCTTTAGTA TAAGTTGGAA AAAGGGGCCC 780
TTTCTTGAGC AAGTATTATT GTAGTCTAAA GATTGCTGGA 840 TGAAGATAAG
AAACCACTGT 900 ACTTGTCTCA CAATGGAGCA AGTTCCTTTT CTAGGCTGAC
AATTAGTCCT 960 GTATTGGCAC TGCTGCTGGC TATGAAACTC ACCACCAAAG
GTAAACGATT AAATTGAACC 1020 ACCTGGTAGG TGTTATAGTA CTTTATTTT
TGAAAGTCC AAGTTTGCTT 1080 CCTTGGTCTG TTGCAAGGGC AAAAGTGGAT
AAGAAACCAG GTCGCAAAGC ATGCTCTGGA 1140 TTGCCACTTT ACTCCATCTC
TATCTGACAC AACAATGGCA 1200 TGGAGCCCTT CAACACTTGG TAACTTTTAA
TACAAGAATC GCTTTAGGTC 1260 ATGAACCCCC TTCTCTCGCA GGATCAATCT

CCACGCCTGG CTGCCTGGTT 1320 CTCTCCGCTG GACAGCTTTA AAGACAGGTT 1380
ACCTCGTCTG CGCTCCAG 1408 (2) INFORMATION FOR SEQ ID NO : 50 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1813 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
50 : CACGAGATGG CCTCTRACTC TTCWAACACT TCACTGCCAT TCTCAAACAT 60
GGGAAATCCA ATGAACACCA CACAGTTAGG GAAATCACTT TTTCAGTGGC
AGGTGGAGCA 120 GGAAGAAAGC AAATTGGCAA ATATTTCCCA AGACCAGTTT
ATGCAGATGG 180 TGACACGTTT CTGTTGCCCA GCACTTTCCT ATGTTCTTGC 240
AAGAAAGATG AATGCACTTC TATTAAGAG CACAATGGAC AGAGTGCCTT 300
GTGGCTGCCA ATCAGCATCT GATCTGGTGA ACATCGGGG 360 ACCACAGACT
GCTGGGGAAG AACACCTCTG CTGAGAAGGG 420 CGATTCAGAA GGGAGCAGTG
GGAAGTAATC TCTTGAGGCA ACTAACTATG ATGGCCTGAC TCCCCTTCAC TGTGCAGTCA
TAGCCCAACA 540 TGCTGTGGTC CATGAACTCC AGAGAAATCA ACAGCCTCAT
TCACCTGAAG TTCAGGAGCT 600 TTTACTGAAG AATAAGAGTC TGGTTGATAC
GGTGAAGCG AAGGATCGCA AAAGTGGCCG CATTTGGCAG CTGAAGAAGC 720
AAATCTGGAA CTCATTGCGC TTGTGAATGC 780 AATGGCAACA CTGCCCTCCA
ATCGGTTGAC 840 GCTGTCCGCC TGTTGATGAG GACCCAAGTA CTCGGAAGTT 900
GGAGAACGAA CAGCCAGTGC ATTTGGTTCC GTGGGAGAAC AGATCCGACG 960
TATCCTGAAG GGAAAGTCCA TTCAGCAGAG AGCTCCACCG TATTAGCTCC
ATTAGCTTGG 1020 AGCCTGGCTA GCAACACTCA CTGTCAGTTA GGCAGTCCTG
ATGTATCTGT TTTGCCTTAT ATTGGCAAAT GTAAGTTGTT TCTATGAAAC AGTTCACTAT
1140 TATATAGTGG AAGAAAAGAA RAAAAATATC TAATTWCTCT TGGCAGATTT 1200
TACCCAGGTA TCTGGATCTA GACATCTGAA TTTGATCTCA ATGGTAACAT 1260
TTTTGAGTAG GAAAGGACTT TGATTTGTGG CACAAAACAT 1320 TATTAATATA
GCTATTGACA GTTTCAAAGC AGGTAAATTG TAAATGTTTC TTTAAGAAAA 1380
AGCATGTGAA CATTTGGCCT TAGTCCCTGG 1440 GAGTTACTGG GCTTCAGTCA
TTGGACTAGA TGAAAGGTGT AATTGATCT TTGCAAACCTG TATATAATTG TTATTTTGT
CCTTAAAAAT AACATGGTCA TATTTGAAAT GTATAAGTCC ATAAAAATAGA
CTATTTAAAA AAATTTTACA ATTCTTACTA AGGAGTTTTT ATTGTGTAAT 1680
CACTAAGTCT TTGTAGATAA AGCAGATGGG GAGTTACGGA GTTGTTCCCT TACTGGCTGA
1740 AAGATATATT CGAATTGTAA TGAAATTATA CATTATTTGT 1800 AGGGAATTGC (2)
INFORMATION FOR SEQ ID NO : 51 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2070
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 51 : GGAAGAGCGC CTGGCCGCTG GCTCGCTGGC
GGCGGCGGCG CCCGGGGACT CGCATTCCCC GGTCCCCCT 120 CGGCCTGGAC
CATGGACGCC GCTGGCTGCG 180 TTCCCCTCCC CCCGAAGCCC CTCCGGAGTC
ATGGACCCAG 240 CTATGGTTCT TCCGATTTGT GGTGAATGCT GCTGGCTATG
CCAGCTTTAT GGTACCAGGC 300 TACCTCCTGG TGCAGTACTT CAGGCGGAAG
AACTACCTGG AGACCGGTAG TTTCCCCTGG TGAAAGCTTG TGTGTTTGGC
AATGAGCCCA AGGCCTCTGA TGAGGTCCC 420 CTGGCGCCCC GGCAGAGACC
ACCCGATGT GAAGCTGCTC 480 CAGGGCTCCA GGTGTCTTAT GGAAAGAGTG 540
ATGACCCGCA GCTATGGGGC TCACCGGGTG TTCCTGGTGC TAATGAACCG
AGTGCTGGCA CTGATTGTGG CTGTGTTCTC 660 CCCGGCATGG GGCACCCATG
TACCGGTACT CTTTTGCCA GCCTGTCCAA 720 TGTGCTTAGC AGCTGGTGCC
AATACGAAGC TCTTAAGTTC GTCAGTTCC CCACCCAGGT 780 GCCTCTAAGG
TGATCCCTGT GGAAAGCTTG TGTCTCGGCG 840 CAGTAACGAA CACTGGGAGT
TCCATTGGGG TCAGCATGTT 900 TCTGCTATCC AGCGGACCAG CTCCCCAGCC
ACCACACTCT GGTATATTG CTTTGAACA GCTTCACCTC AAAGTGGCAG GATGCCCTGT
1020 TTGCCTATAA GATGTCATCG TGTTTGGGGG TCAATTTCTT CTCCTGCCTC 1080
TTCACAGTGG GCTCACTGCT AGAAACAGGG GGCCCTACTG GAGGGAACCC
GCTTCATGGG 1140 GAGTTTGCTG CCCATGCCCT GCTACTCTCC GCTCTTCATC

TTTTACACCA TGGGGCTGCC TCATCATGAC 1260 CCTCCGCCAG GCCTTTGCCA
 TCCTTCTTTC CTGCCTTCTC CTGTCACTGT 1320 CTGGGGGTGG CTGTGGTCTT
 TGCTGCCCTC CTGCTCAGAG TCTACGCGCG 1380 AAGCAACGGG GAAAGAAGGC
 TGTGCCTGTT GAGTCTCCTG TGCAGAAGGT 1440 TTGAGGGTGG AAAGGGCCTG
 AGGGGTGAAG TGAAATAGGA ATCCCCTTCT 1500 GCTGTAACCT CTGAGGGAGC
 TGGCTGAAAG GGCAAATGC TGCAGCAGGG CCCAGGAGGC AGCCTTCCCT
 TTTGCCTTAA 1620 TTCCAGTAAG CAGTTTATTC TGAGCCCCGG GGGTAGACAG
 TCCTCAGTGA 1680 GGGGTTTTGG GGAGTTTGGG GTCAAGAGAG 1740 CAAGTTCCCT
 TAAGTCTTGC CCTAGCTGTG ACTCCCCTCT 1800 AAAAGCACAA GCGGTGTAGG 1860
 GCTTTCCCAG GAGGGTGAAG ATGGTGCTGT GCTGAGGAAA GGGGATGCAG
 AGCCCTGCCC 1920 CCTCCTATGC TCCTGGATCC CTAGGCTCTG 1980 TTTTGGTACT
 TTAGAAATGT AACTTTTTGC TCTTATAATT TTATTTTATT 2040 ACTGCAAAAA
 AAAAAAAAAA AAAAAAAAAA 2070 (2) INFORMATION FOR SEQ ID NO : 52 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1426 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 52 : AGCTGGAGCT CCACCGCGGT GCGGCCGCT CTAGAACTAG 60 TGGATCCCCC
 AATTCGGCAC GTCCGCAGCG GCGGGCTGCT 120 GAGCTGCCTT GTTGGGGATC
 TCGGACCTGC GGCCTGACTC TCTTACTGCT GCTGACGCTG CTGGCCTTTG CCGGGTACTC
 240 AGGGCTACTG TGGGTCACCC CCCATCCGCA ACGTCACTGT 300 CGGCTTTTCA
 CTGAGAGCTG 360 CAGCATCTCT CCCAAGCTCC GCTCCATCGC TGTCTACTAT
 GACAACCCCC 420 CCCTGATAAG TGCCGATGTG GAAGGTGAGG AATCGCCCTC 480
 CCCTGAGCTC ATCGACCTCT ACCAGAAATT GTGTTCTCCT TCCCGGAACC 540
 CAGCCATGTG GTGACAGCCA CCTTCCCT AACACCACCA TTCTGTCCCA 600
 CTACCCGCCG TGTCCATCCT GCCTTGGA CA CCTACATCAA GGAGCGGAAG 660
 ATCTCGGCT GSGATCTAC CAGGAAGACC AGAATCCATT TCATGTGCCC 720
 TTCTATGTGC CTGAGATGAA GGAGACAGAG TGGAAATGGC 780 GACACCCAGG
 TGGATGGCAC ACAATGAGTG ACACGAGTTC 840 TGTAAGCTTG GAAGTGAGCC
 CTGGCAGCCG GGAGACTTCA GCTGCCACAC TGTCACCTGG 900 CGTGGCTGGG
 ATGACGGTGA GAGCACAGCT AACAGCGAGT 960 CGGCTCCTCT TGGACTTTGG
 AGGGCGAGGG GCCCTTAAGG 1020 GGAGTCACGG CTGGACCCTG GGA CTTGAGC
 CTACCAAGTG GCTCTGGGAG 1080 CCCACTGCCC CTGAGAAGGG CAAGGAGTAA
 CCCATGGCCT GCACCCTCCT 1140 TGCTGAGGAA CTGAGCAGAC TCTCCAGCAG
 CCTCTTCCTC CTTCCTCTGG 1200 GGAHGAGGG GTTCCTGAGG GACCTGACTT
 CCCCTGCTCC CTAAGCCTTC 1260 CCTTTAGGCT CCCAGGGCCA GGA CTATTTT 1320
 GCCGCCCTG TTGTGTCTTT TTTTCAGACT CTTCCAGGAC 1380 GCCAATGATT
 AAAAAAAAAA AAAAAA 1426 (2) INFORMATION FOR SEQ ID NO : 53 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1720 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 53 : GGCACGAGTG CGGCCCCAGC CTCTCCTCAC TCTCCGCCGC AGTCTCAGCT 60
 GCAGCTGCAG TGCACCCGGA GGAGACCCCC ACAAACTTCG 120 CAGTGCCGCG
 ACCCAACCCC 180 CTTGCTGGCA GCCCTGGTCC TGGCCCAGGC TCCTGCAGCT
 TTAGCAGATG TTCTGGAAGG 240 AGACAGCTCA GAGGACCGCG GCGCATCGCG
 GCGACGCGC CACTGCAGGG 300 CGTGCTCGGC CCACGTCCAC TACCTGCGGC
 CACCGCCGAG 360 CCGCCGGGCT GTGCTGGGCT CTCCGCGGGT TTCCTGTCCC
 GGGGCCGGA 420 GGCAGAAGTG CTGGTGGCGC GGGGAGTGCG CGTCAAGGTG
 AACGAGGCCT ACCGGTTCCG 480 CGTGGCACTG TCCCCTGGCG 540 TGCGCCCCAA
 CGACTCAGGT ATCTATCGCT GTGAGGTCCA GCACGGCATC GATGACAGCA 600
 GCGACGCTGT GGAGGTCAAG GTCAAAGGTA TCCCATCCAG ACCCCACGAG
 AGGCCTGTTA 660 CGGAGACATG GATGGCTTCC GAACTATGGT GTGGTGGACC 720
 CTATGATGTG TACTGTTATG CTGAAGACCT AAATGGAGAA CTGTTCTTGG GTGACCCTCC
 780 AGAGAAGCTG GACTGCCAG CAGAGATTGC 840 CACCACGGGC CAACTGTATG 900

GCTAGCTGAT GTGGTGGGGG 960 GTCAAGACTC TCTTCCTCTT 1020 CAGCCGCTTC
AACGTCTACT GCTTCCGAGA CTCGGCCCAG CTTCTGCCAT CCCTGAGGCC 1080
TCCAACCCAG CCTCCAACCC AGCTTTGATG GACTAGAGGC GTGACAGAGA 1140
CCCTGGAGGA ACTGCAGCTG TGAATCCCGT GGGGCCATCT 1200 GACGGAGGAG
GTGGAAGCTC CACTCCAGAA 1260 AGGCCCTAG GACGCTCCTA GAATTTGAAA
GGTACCGCCC 1320 CAGAAGAGGA AGGTAAGGCA TTGGAGGAAG AAGAGAAATA
TGAAGATGAA GAAGAGAAAG 1380 AGGAGGAAGA AGAAGAGGAG GAGGTGGAGG
ATGAGGCTCT CCCAGCGAGC 1440 GCCTCTCTCC CCACTGAGCC GAGGAGTCAC 1500
TCTCCCAGGC AGCCTGGTGC ATCACCCTT CCTGATGGAG 1560 AGTCAGAAGC
TACTGAGACT CTGCCCCTC 1620 GAACCTAGCA TCCCCATCAC CTTCCACTCT
AGAGAGGTGG 1680 GGGAGGCAAC GAGCTATCTG GGTCCCTCGA 1720 (2) INFORMATION
FOR SEQ ID NO : 54 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1117 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 54 : GGCACGAGGC CAACTTCGG GCGGCTGAGG
CGGCGGCCGA ACTCCGGGCG 60 CGGGGAGTCG CGGAGCGTAC AGCCTTTGAA 120
GGGAGGAGAG AGTGGGGCTC CTCTATCGGG ACCCCCTCCC CATGTGGATC 180
GCGGCGGCGG AGGAGGCGAC CGAGAAGATG CCCGCCCTGC GCCCCGCTCT 240
CTGCTGGCGC TCTGGCTGTG CTGCGCGACC CATTGCAGTG 300 TCGAGATGGC
TATGAACCCT GTGTAAATGA AGGAATGTGT GTTACCTACC ACAATGGCAC 360
AGGATACTGC AAAGGTCCAG AAGGCTTCTT GGGGGAATAT TGTCAACATC
GAGACCCCTG 420 TGAGAAGAAC CGCTGCCAGA TTGTGTGGCC CAGGCCATGC
TGGGGAAAGC 480 CACGTGCCGA TGTGCCTCAG GGTTCACAGG AGAGGACTGC
CATCTCATCC 540 ATGCTTTGTG TCTCGACCTT GCCTGAATGG 600 CTATGAGTGC
TCGGGTTTAC AGGTAAGGAG CCGATGCCTG 660 CCTGTCTCAT CCCTGTGCAA
ATGGAAGTAC 720 AATGCCTCAC GTGAGACTGA TGTGACATTC 780 GGCACCTGCC
TGTTTCTAC 840 GCCTTCAGGG CAGTACTGTG ACAGCCTGTA TGTGCCCTGT 900
TGGAGGCACC CTGGTGAATT 960 TTCCAGAAAC AGTGAGAAGA GGAACAGAGC
TCTGGGAAAG GTCTGGAATG 1020 GAAAAGAACA CGATGAGAAT TAGACACTGG
AAAATATGTA TGTGTGGTTA ATAAAGTGCT 1080 TTAACTGAA (2) INFORMATION FOR
SEQ ID NO : 55 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1903 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 55 : GGCACGAGCT CGGAGAGGCG GCGCCCCTGA
AGCCTCTCTT 60 CCACCGCGGG CGCAGAGGAA GGTCGCGGCC 120 GACCCGCGGC
GGCGCCCGGG GCTGCCACAG CCGCCGCCGC TTCTGCTGCT 180 GCTGCTGCTG
CCGCTGTTGT TAGTCACCGC AAACCTGCAG GAGTCTACTA 240 TGCAACTGCA
TACTGGATGC CTGCTGAAAA GACAGTACAA GTCAAAAATG TAATGGACAA 300
GCCTATGGCT TTTACAATAA CTCTGTGAAA ACCACAGGCT 360 GGAGATCAGA
GCTCTCAAAC GAGATCATCA 420 TGGCTTTTGT GAGGGTTACC ACACATGAAT
GACCACTACA CAAACCTCTA 480 CCCACAGCTG ATCACGAAAC CTTCCATCAT
GGATAAAGTG CAGGATTTTA TGGAGAAGCA 540 AGATAAGGTG GACCCGGA
AATATCAAAG AATACAAGAC TGATTCATTT TGGAGACATA 600 CAGGCTATGT
GATGGCACA AATAGATGGCC TCTATGTAGG AGCAAAGAAG 660 AAAGCCAATG
ACCCTGTTCC AGATTCAGTT CCTGAATAGT GTTGGAGATC 720 TATTGGATCT
GATTCCCTCA CTCTCTCCA CAAAAACGG CAGCCTAAAG GTTTTAAAGA 780
GATGGGACAT GGGACATTGC TCCGCTCTTA TCCTGGATTT GAGAACATCC 840
TTTTTGCTCA CTCAAGCTGG AAACACTGGG 900 CATAGATAAA GTAGTCGCCT
CTCTTTCAGC AGTTACCCAG 960 GGTTTTTGA GTCTCTGGAT GATTTTACA 1020
CCACAAACAG TGTGTTTAAT AAAACCCTGC TAAAGCAGGT AATACCCGAG
ACTCTCCTGT 1080 CCTGGCAAAG AGTCCGTGTG GCCAATATGA TGGGCAGACA 1140
TCTTTTCAA GGCACCTATA ACAATCAATA GACCTGAAGA 1200 AAGTAAAGCT
CTTGACAAAG GCACTCTGTA 1260 CATATGTAGA ATATTCTGAA CAACTGATG

TTCTACGGAA 1320 ATGTTTCCTTT ATCTACAACT GGAGTGGCTA TCCACTGTTA 1380
 AATTTTCCGG 1440 GGAAAGTGAC TGATACGGCA TCCATGAAAT ATATCATGCG
 ATACAACAAT TATAAGAAGG 1500 TAGAGGTGAC CCCTGTAATA CCATCTGCTG
 CCGTGAGGAC 1560 CCTAACCCAA GTCCTTGGAG GTTGTTATGA TACCTAGCAT 1620
 CTCAGTACAC ATCCTATGCC ATAAGTGGTC AGGTGGCCTC CCTGTTTTTC 1680
 AGAGGTCTAC AACTTTGATT 1740 TTATTACCAT GAAACCAATT TTGAAACTTG
 ATATAAAATG ATGACGGACT 1800 AGAAGACTGT AAATAAGATA TATTTTAGCT
 ATGTTTTTCC CATCAGAATT 1860 ATGCAATAAA ATATATTAAT TTGTCAAAAA
 AAAAAAAAAA AAA 1903 (2) INFORMATION FOR SEQ ID NO : 56 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1869 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 56 : ACAGCTTTTC TCGCACCCAG CGAAGAGAGC GGGCCCGGGA 60 CTCCGGCCGC
 CTCGCCCTTC CCCGGCTCCG CTCCCTCTGC CCCCTCGGGG TCGCGCGCCC 120
 ACGATGCTGC AGGGCCCTGG CTCGCTGCTG CTGCTCTTCC TCGCCTCGCA CTGCTGCCTG
 180 GGCTCGGCGC GCGGGCTCTT CCTCTTTGGC TCTCTACAA GCGCANCAAT 240
 TGCAAGCCCA TCCCGGTCAA TCGAATACCA GAACATGCGG 300 CGAGACCATG 360
 ATCCCGCTGG TCATGAAGCA GTGCCACCCG GACACCAAGA AGTTCCTGTG
 GCGCCCGTCT GCCTCGATGA CCTAGACGAG GCTCTGCGTG 480 CAGGTGAAGG
 ACCGCTGCGC TCCGCCTTCG GYTTCCCCTG CTTGAGTGCG ACCGTTTCCC TCCCCCTCGC
 CACCTCCTGC CAGCCACCGA GGAAGCTCCA AAGGTATGTG AAGCCTGCAA
 AAATAAAAAT 660 GATGATGACA ACGACATAAT GGAAACGCTT TGTA AAAATG
 GAAAATAAAA 720 TAACCTACAT CAACCGAGAT ACCAAAATCA ACCATTTACA
 AGCTGAACGG TGTGTCCGAA AGGGACCTGA AGAAATCGGT TGCAGTGCAC
 CTGTGAGGAG ATGAACGACA TCAACGCGCC CTATCTGGTC 900 AACAGGGTGG
 GGAGCTGGTG ATCACCTCGG CAGAGAGAGT ATCCGCAAGC GTCCCGGCAT 1020
 CCTGATGGCT CCGACAGGCC TGCTCCAGAG CCGGGATCTC 1080 AGCTCCCGTT
 ACTCCTAGCT GCTCCAGTCT AGCTTCCCCC 1140 ACGTTTGCAT TCCTGAGTTA
 GCTGTTTTCA CCTAAAGGAA AAGCCCACCC GAATCTTGTA GAAATATTCA
 AACTAATAAA 1260 ATCATGAATA TTTTATGAA GTTTAAAAAT AGCTCACTTT
 AAAGCTAGTT TTGAATAGGT 1320 GTTGGTTGTT GTTTGTTGTT TGCTTCAATT
 TTCTCTGTGG CCCAACTTG 1440 TGGGTCACAA ACCCTGTTGA GATAAAGCTG
 GCTGTTATCT CAACATCTTC ATCAGCTCCA 1500 GACTGAGACT CAGTGTCTAA
 GTCTTACAAC AATTCATCAT TTTATACCTT TTAAACTGTT ACATGTATCA CATTCCAGCT
 ACAATACTTC CATTTATTAG AAGCACATTA 1620 ACCATTCTTA TCTTCAAGTA
 AAAGGCAAAA GATATAAATT TTATAATTGA 1680 CTTGAGTACT TTTAAACAT
 TTCTTACTTA ACTTTTGCAA ATTAACCCA 1740 TTGTAGCTTA CCTGTAATAT
 TTACCTTTAA AATATTGCTT 1800 TAACCAACAC TGTAATATT TCAGATAAAC
 ATTATATTCT TGTATATAAA CTTTACATCC 1860 (2) INFORMATION FOR SEQ ID NO : 57 :
 (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1259 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 57 : GCGGCTGCAG CGYGGAGGAG TGTGGGTCGC 60 GAACAGAGCC CGGGACGTGC
 GCGCTTGGTG CACGATCCTG AAGGGGAGCT 120 CGGGTCKCCA GGGCTGCTGC
 GGCCATTCCC GGAGCCCGGC GCGGGGCCCG 180 GTTTAGGCCG TCCCAGGGCT
 CCGGGCGCAC CCGKTGGCCG GGAGGGAGCG 240 CGGCGGCGSG CTCCCGGAAT
 CTTCTCGGG 300 CCGGAGCGGC ACTGGCARCG TTCTCTCCGC ANGTCGGCAC 360
 GCTGGGCTGC CTCTGCCTGG CCTGGGCGGT 420 GCGGACAAGC CAACCATGAG
 TGGA AAAAAC TAATTATGGT TCAGCACTGG 480 CCTGAGACAG TATGCGAGAA
 AATTCAAAAC GACTGTAGAG ACCCTCCGGA 540 ATACATGGAC TATGGCCCGA
 TAAAAGTGAA GGATGTAATA GATCGTGGCC 600 GAAGAGATTA AGGATCTTTT
 GCCAGAAATG AGGGCATACT GGCCTGACGT AATTCACTCG 660 TTTCCCAATC
 CTGGAAGCAT AGCATGGGAC CTGCGCCGCC 720 CAGGTGGATG CCAGAAGAAG

TACTTTGGCA 780 GCTTCTAAAA TTGGGGATAA AACCATCCAT CAATTACTAC 840
CAAGTTGCAG ATTTTAAAGA AGAGTATATG GAGTGATACC CAAAATCCAG 900
TGCCTTCCAC CAAGCCAGGA TGAGGAAGTA GTCAGATAGA ACTGTGCCTC 960
ACTAAGCAAG ACCAGCAGCT GGGAGCAGCC 1020 CAGGAAGTCT GAGAGCCGGG
GTCTGAGAGT CTGTGAAGAT 1080 TCTATCCCCC ACCTAAAAAG TTTTGGAAAT 1140
ATTCTGTTTT AAAAAGCAAG AGAAATTCAC TTTCTNAAAA AAAAANAAAA 1200
AAAAATTGGG GGGTTTTTTT GGGGSGCCCG GGGCCCTTGG TTTTCCCCC 1259 (2)
INFORMATION FOR SEQ ID NO : 58 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1186
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 58 : CGGCATGGAG AATGGCTCCG 60
CCGCAGCCCT CGTACTGATT TCCATCGTTG TGCTACAAAA ATGCCAGCAC 120
TCCATCGACA TGAAGAAGAG AAATTCTTCT TAAATGCCAA AGGCCAGAAA
GAAACTTTAC 180 GGA CTCACCT TTTCTGTCGT TGTGCCTTCA TACAATGAAG 240
AAAAACGGTT GCCTGTGATG ATGGATGAAG CTCTGAGCTA TCTAGAGAAG 300
GAGATCCTGC GAAGTGATAG TAGTTGATGA 360 CAAAGGTAGC TTTTAAATAT
ATGGAAGTGA GTGATAACCC 420 TGGTGAAGAA GGTGGAGCGA TCTCGAGGAG 480
AAAAGATCCT TATGGCAGAT GCTGATGGAG TCCAGATGTT GAGAAATTAG 540
AAAAGGGGCT AAATGATCTA CAGCCTTGGC CTAATCAAAT GGCTATAGCA
TGTGGATCTC 600 GAGCTCATTT AGAAAAAGAA AGCGTTCTTA CTTCCGTACT
CTTCTCATGT 660 ATGGGTTCCA CTTTCTGGTG TGGTTCCTTT 720 ATTTACTCGA
GAAGCAGCTT TTCATCTCTA 780 TGATGTAGAA CTACTGTACA CTTTAAATTT
CCAATAGCAG 840 CAACTGGACA GAAATTGAAG GTTCTAAATT AGTTCCATTC
TGGAGCTGGC 900 TAAAGACCTA CTTTTTATAC GACTTCGATA GCCTGGAGGC 960
TTGAGCAAAC TCGGAAAATG AATTAGGTTG TCAGTTGTGT TCTTATGCTT 1020
TTTGAAACTA AAATTTTAAG TAAAGCTGAA ATAACTTCT 1080 TGTCATTGTC
TAATTTTAAA GAAATAACTT TCCATAAGTA AAAAATTATA 1140 TATCTCTTTG
GATATAAATG ATTTTAAAAA GATGTTTATT TAAAAA 1186 (2) INFORMATION FOR SEQ ID
NO : 59 : (i) SEQUENCE CHARACTERISTICS (A) LENGTH : 428 base pairs (B) TYPE : nucleic
acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 59 : GATCCCCCGG CTGCAGGATT ACTGATTCTT KGTTAGTATA 60 AGCAGAGTTC
CAAGTCTCCC CTAGGGTTGT CTCTACATTT CTTTATCATT CCAGTGGGTA 120
RGGTTTAGCT GGGGGAAGGA CATTTCATAA GGGTTAGTTG GACTGAGCAG
TATGGACATT 180 TGCTTTTTTC ATTACGTA CTGTTGTTTTC CTTGTTAGGT
GGTTTTAATA 240 TTATTGTGCC AGGGATGGGG GGTGTGTGG GAAGAGTACT
TATTATTGTG 300 TTTTCTTCAG TGTAATTGTT CTTGGTAATT GATACCTCTC
TGTTTTATTT NTCTCATTCT 360 TTCAAATAA AACTTTTTGA AATTGAAAA
AAAAAAAAAA NAAAAAACTC GGGGGGGGGC 420 CCGGTACC 428 INFORMATION FOR
SEQ ID NO : 60 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 501 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 60 : GGCACGAGCT TTCAGCAGGG GACAGCCCGA
TTGGGGACAA 60 GTGTGGGTCT GCCAAGGCAG GGAACACGAC 120 CCGTTCACCT
ACGACTACCA GTCCCTGCAG ATCGGAGGCC TCGTCATCGC CGGGATCCTC 180
TTCATCCTGG CGTGCTGAGC AGAAGATGCC GGTGCAAGTT CAACCAGCAG 240
CAGAGGACTG GGGAACCCGA TGAAGAGGAG GGAACCTTCC GCAGCTCCAT
CCGCCGTCTG 300 TCCACCCGCA GCGGGTAGAA CGATGGAATC CGGCCAGGAC
TCCCCTGGCA 360 CCTGACATCT CCCACGCTCC AACTGCGCGC CCACCGCCCC
CTCCGCCGCC CCTTCCCCAG 420 CCCTGCCCCC CCGCCGCCA AGACTTCCAA
TAAAACGTGC GTTCCTCTCG 480 AAAAAAAAAA AAATAAAAAA A 501 (2) INFORMATION
FOR SEQ ID NO : 61 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1197 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 61 : TACCAAAGAA CTCAATATCG 60 AGTGCCTGCG

GGACTTCCTG ACGCCCCCGC TGCTGTCCGT 120 CCCCCCAGGC AAGCTCCCAG
TGACCAKCAA CAGCCCACCG 180 AGATGGCGGC GAGCCTCCCT 240 CGCAGAAAAT
AGTTACTAAG GCCAAGCTTC 300 TGGGGTTTGG CTCTGCTCTC CTGGACAATG
TGGACCCCAA CCCTGAGAAC TTCGTGGGGG 360 CGGGGATCAT TGGGCTGTCT
GCTTCGGCTG GAGCCCAATG 420 CCCAGGCCCA GATGTACCGG CTGACCCTGC
GCACCAGCAA GGAGCCCGTC 480 TGTGTGAGCT GCTGGCACAG CAGTTCTGAG
CCCTGGACTC TGCCCCGGGG GATGTGGCCG 540 GCCCCTTGGA GGGGGACCTC 600
AGAGAAGACA CCAGGGTTTG GGGGATGCCT GGGACTTTCC TCCGGCCTTT 660
TTTTTGTTCA TCTGCTGCTG TTTACATTCT GGGGAGTCCC CCTCCCTCCC 720
TTTCCCCCCC CCAGGGAAGT GGATGTCTCC 780 CCCCACCCTG TTGTAGCCCC
TCCTACCCCC TCCCCATCCA GGGGCTGTGT ATTATTGTGA 840 GCGAATAAAC
AGAGAGACGC ATGTCTGTGT CTGTTAGGTA 900 GTCAAAGAAG 960 GGGACTCTGG
GGAGACAGCA AGGCCACCAG 1020 ACGCACTCCT GTGCCTGGTT CTTYAGTCCC 1080
ACCTCATCTT GGAAGTGCGT 1140 GGAGGTGACC AGGGTATAGA AGTTTCGGAG
CTGATTGGAA GAGGATTAAC TTCCCGC 1197 (2) INFORMATION FOR SEQ ID NO : 62 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 595 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
62 : ATTNANGACK WATACMATCA TTATAGGGAR AAGCTGGTAC 60 AATTCNCGGG
AGCGGGAGTT GGTTCCTGACA 120 TCTGCTCCTG GTTAATGTCA GTGAGGGCTG
GAAGTTGAAT AAATGAGAAC 180 AGGAGTGGTC TAAATGATCC TCCCTTGAAA
GGAGGAACAG CTTTCATCAT 240 ATGCATTATA GATCTGGTGC TAAGCAGTGG
GAAAGATCTC 300 ATAAGTAATG TTTTATGTTT TTTCTGTCTC TCCTCTTCTG
TWGTTCTTGG CTTGTGGGTT 360 GTGTTTGTGT AAGCCAGTTG TCTCTAAGTT
TTAAAAACGA 420 ATTAGAAAAA CCATAAAATC TCTGGCCTAT CCTGTTTTGT
GAAAACATTA 480 AAGGGTAAAT AAAAAGGAAG GAGAACAGTC AATAATGTGC
ATCAAATATA TTCTGAGTTC 540 TAGAGAAATT CATTAGAACT AAAAAAAAAA AAAAA
595 (2) INFORMATION FOR SEQ ID NO : 63 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 1478 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 63 : CGGCGCTGAG GACGCACGGA
TGCCTTCCGT AAGATCTCAA TTTTGTGCGC 60 AAGTTCCTAC AGCCCCTGTT
CTGGCTCCGG AAGAACCCAG 120 CCCCTGAATG CGCATGGTCG AGGACTTCCG
AGCCCTGCAC CAGGCAGCCG AGGACATGAA 180 GCTGTTTGAT GCCAGTCCCA
CCTTCTTTGC TTTCCTACTG 240 GGTGCTGGCC TGGCTCCTTA TCTACCTCCT 300
CCGCCTTCAT TCTCAGGCTC AGTCCTGGTG GACCTGGGCC 360 ATGCTCCATC
TTCAAGAAGW CCTGGTGGAA CCACGTGGCC 420 GCTAAAGGGC TTCTCCGCCC
ACTGGTGGAA CTTCCGCCAC ACGCCAAGCC 480 CAACATCTTC CACAAAGACC
CAGACGTGAC GTCTTCCTCC TGGGGGAGTC 540 ATCCGTCGAG TATGGCAAGA
AGAAACGCAG ATACCTACCC TACAACCAGC AGCACCTGTA 600 CTTCTTCCTG
ATCGGCCCGC CGCTGCTCAC CCTGGTGAAC TTTGAAGTGG 660 GTACATGCTG
GTGTGCATGC AGTGGGCGGA TTTGCTCTGG GCCGCCAGCT TCTATGCCCC 720
CTTCTTCTTA TCCTACCTCC CTTCTACGG CGTCCCTGGG GTGCTGCTCT TCTTTGTTGC
780 TGTCAGGGTC CTGGAAAGCC ACTGGTTCGT CAGATGAACC ACATCCCCAA 840
GGAGATCGGC CACGAGAAGC ACCGGGACTG CAGCTGGCAG CCACCTGCAA 900
CGTGGAGCCC CCAACTGGTT CTCAACTTCC AGATCGAGCA 960 CCACCTCTTC
CCCAGGATGC CGAGACACAA CTACAGCCGG GTGGCCCCGC TGGTCAAGTC 1020
GCTGTGTGCC AAGCACGGCC ATGAAGCCCT TCCTCACC GC GCTGGTGGAC 1080
ATCGTCAGGT CCCTGAAGAA GTCTGGTGAC ATCTGGCTGG ACGCCTACCT
CCATCAGTGA 1140 GAGAAGGGCT 1200 CGGGATCGAT ACCCCCACCC GTGCCCTGCC
TGCCCTCCTG 1260 GACTGTTGT CTTCCCTCG GCCCCCTCAC ATGTGTATTC
TGGCCTTGGC 1320 TCTGGGCCTG GGTAGAGGGA CTAGAGCGA 1380 AAAGCTGTTA
TTTTTATATT CAGATGTAAA AAAAATCTCGA CGGNAACCAA TTCGCCCT 1478 (2)

INFORMATION FOR SEQ ID NO : 64 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2033 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 64 : GGCACGAGGA GCTGAGAACA TGGACGTTAA TATCGCCCCA CTCCGCGCCT 60 GGGACGATTT CTTCCCGGGT TCCGATCGCT TTGCCCCGCC 120 AATGGAACAA CCGCGTAGTG AGCAACCTGC TCTATTACCA CTGGTGGTGG 180 TGAGTCCCTT CTGGGAGGAA 240 GCTGGTGTTC CCACAATAAA GACGTCCTTC 300 GCCGGATGAA GAAGCGCTAC CCCACGACGT TCGTTATGGT GGTCATGTTG GCGAGCTATT 360 TCCTTATCTC GGAGTCATGG TCTTTGTGTT TGGCATTACT TTTCCTTTGC 420 TGTTGATGTT TATCCATGCA TCGTTGAGAC TTCGGAACCT CAAGAACAAA CTGGAGAATA 480 AAATGGAAGG AATAGGTTTG AAGAGGACAC CGATGGGCAT TGTCTGGAT GCCCTAGAAC 540 AGCAGGAAGA AGACTCACTG ACTATATCAG CAAAGTGAAG GAATAAACAT 600 AACTTACCTG AGCTAGGGTT TTGAGTTGCA GCTTGCCCTT 660 ATGTTCTGCT TGCGTTTTTG AACAGGAGG TGCACGTACC ACCCAATTAT 720 ATGCATGTAT AGGCCGAACCT ATTATCAGCT CTGATGTTTC AGAGAGAAGA CCTCAGAAAC 780 CGAAAGAAAA CCTATTGTGT CTGAAGTTTC ATGAAATCTA 840 ATGGGAAATG TTTCTTTAAG GGAATTAAAA AAAATAAAAG AATTACGGCT 900 CAATACGATT ATCTTATAGG AAAAAAAAAAT CATTGTAAAG TATCAAGACA 960 ATACGAGTAA ATGAAAAGGC TGTTAAAGTA GATGACATCA TGTGTTAGCC TGTTCCTAAT 1020 CCCCTAGAAT TGTAATGTGT GGGATATAAA TTAGTTTTTA TTATTCTCTT AAAAAATCAA 1080 GATGATCTCT ATCACTTTGC CACCTGTTTG ATGTGCAGTG GAAACTGGTT AAGCCAGTTG 1140 TTCATACTTC CTTTACAAAT ATAAAGATAG TATTTTGTTA 1200 AATTTTTGAA ATGCTAGTAA TGTGTTTTCA CCAGCAAGTA TTTGTTGCAA ACTTAATGTC 1260 ATTTTCCTTA AGCTATGTAA CCTGTATTAT TCTGGACGGA CTTATTAATA 1320 CAAAAAATAA AACAAACTT GAGTTCTATT TACCTTGCAC ATTTTTTGTT 1380 TTTGCATTGT TTCGTTTTTA 1440 ACTGGAACAT TTAGAAAGAA GGAAATGAAT TTAATTCCTT 1500 CTTTTGAAAT TTGAAAAACG TCTTTAGATG 1560 GAAAATGGAA TGCAGCTACT AAAAATTTTA 1620 GATAGCAATT GTTACAACCA TATGCCTTTA TAGCTAGACA TTAGAATTAT GATAGCATGA 1680 TCTATTATTT TTCCTCCCTT TTATAAATAG GTAATAAAAA 1740 ATGTTTTGCC ATGATTTCTG AGCTGAAGTA GAAACATTTA GGTTCCTGTA 1800 GTGAAGACAA CTGGAGTGGT ACTTACTGAA GAACTCTCT GTATGTCCTA 1860 GAATAAGAAG CAATGATGTG CTGCTTCTGA TTTTCTTGC 1920 CTACAGCCAT GATCTTTAGC 1980 CTGTACCCTT GAAGAATAAA ATTGATTAAA GGTTAAAAAA AAA 2033 (2) INFORMATION FOR SEQ ID NO : 65 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 440 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 65 : ATGTTTCTTA CTAGAATACT GTGTCCAACC TAACTTTCCT 60 GTGGCCCTAG GCTGTGCATG GAGATAGCCA GAGGAAACAT TTTTTTCTT 120 AATGAATTGG TGACCACATT TTGTTGTTCT TGCCTCCTAT CTATTTGCAT 180 CCTGGTTTCT TCTACAGTAG TTTATGTAAA TGTTGTTTTG TCCTTGTCGT TCTCAGTAGA 240 ATTGGTTCTG TAAACGAAAC CTGGTCCTGT AATTTTCTAGTA TCTCATCTTT 300 GGCTCTCCCA TTTTCACAGC AGTGATCCCT AAAAGATGTG CCCTAGAGGA TATCCAGAAC 360 GATGTCTTCT CCGCTGCACT CCAGCCTGGG AGACAGAGGG AGACTCNATC 420 440 (2) INFORMATION FOR SEQ ID NO : 66 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 3301 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 66 : GGTCATAAGG GGAGGGTTGN NGTGTGTCCC GCAGAGGGGA TTAGAAGTAA 60 GTAGGTTAGA GGGGAGGTGG AGGGAGTGTG AGCTTTTATG ATGCTGAAAG 120 GATCATGATA TGCTAAGGAC AGGATAGTGT TGGGTTGTAC AGGCAATCCT 180 GGTGGCTAGT ATGTAAAAGT GAATGTCCTG ACTCCCTTAG AGGGTACCTG 240 CTTGGARGGA CTAGTGCTGG AGAAATTAAT AGGAGAGGGG ACGGGCATCC

ATTAACCTTT 300 TCTTGCCTGC AGCCTGTAGG AAAGCGAATC GGGCTGAGCT 360
GTGCACTCTC TTAGGCGGAT TCTCCTTCCT CCTGCTACTG ATACCAGGCG AGGGGGCCAA
420 GGGTGGATCC CTCAGAGAGA GTCAGGGAGT TGGTCCCGCT 480 GAGTCCTACA
TACCTGACCT 540 GAGCGCATCT TACCGCGTTA TGTGGCGGGA GGTGAGGCGG 600
AGACCCATGC AGTGTGCTGC CCCGGGGGCG 660 CTCACCTGTG AAGCCATCTG
TGCCTGAACG GAGGCGTCTG CGTTAGGCCT 720 GACCAGTGCG AGTGCGCCCC
GGGAAGCACT GTCATGTGGA CGTGGATGAA 780 TGTAGGACCA GCATCACCCT
CTGCTCGCAC CATTGTTTTA ATACGGCARG CAGCTTCAMC 840 TGCGGCTGCC
GTGCTAGGCG TGGACGGGCG CACCTGCATG GAGGGGTCCC 900 CAGAGCCCCC
AGCATACTCA GAAAAAGATG 960 ACGCGCTCTG TTCACGAGCT TGAAGCGGCT
GGAGCAGTGG 1020 NCCGGTCAGC NTCAGACGGT CCGCCTGAAG WGCTGCAGCC 1080
AGAACAGGTG GCTGAGCTGT TGACCGGATC GAATCTCTCA GCGACCAGGT 1140
GCTGCTGCTG TAGGTGCCTG CTCCTGTGAG GACAACAGCC TGGGCCTCGG 1200
CGTCAATCAT CGATAAGAAG CCTCTACAGC ACCCCTGCCC CCTAATTTAT
ACAGAAACCG 1260 TCCTCTGGGA TTGGCCGACT GTGAGCTGCA GATAAGGCTA
TCAGCCACCA 1320 AAGAGCAATG AACAATGGAA ACTTCAGAGA GCTGAAGAAA
TGTGTTCTTG 1380 GCCTGCCCCCT GAGTCTTCTG GCAAGAAGT 1440 TCCTTAACAA
ATCTCTCTCT CTCTTTATTT TGCTGTTATC CAGATAATTA ATAAAAACCA ACTGGGTCCC
ACCTCTCCT 1560 TTTGCTCCCA GCCTACCTCC GGAGTGAGAG GCAGGGAGTG 1620
GCTAATGCCN CCAGGAAGAA ATGAAAAGT AGAAATAAAT TAAAAGCCCT
CCTATCCCCT TCGTTCCCT TCCCCAACTC 1740 AGAAGTGAGT ATGTCTGCTT
CTTCCCCTTG TGTCTGGTGA 1800 GATGGTGCAG CAGGGCTGCA GGGGGCTGGG
TCCACTGAAG AACTGTACTA 1860 TGTGGAGACT GAACTGGTAT CCCAGAGAGT
GCACGACCCT 1920 GGGCATCTGG TCTGAATTAG AAGGGTCCAG CCCCCACTGA 1980
CAGGAGGCTA CACTGGGAGG GAAGGTGAAG AAGCTCCCAT GATGAGCCTG 2040
GGAGTGCTTC TTCCAGCCAG AGGGCGAGAA GTCCTCCTCA CACTGGCCAA
AGGGGTAGAG AAGACCACAT AGGAAGAGAC TCCACTGGGG 2220 ATGGAATGTT
CCCCTCCCTT GTGTAGGCTG GATGAGGGGG AGGCAACTGT 2280 AGGTGGGGGT
GACTGCACCG AGGCAAGAGT 2340 CCATGGATGG GGCCTGTAT CTTCAGAAGT 2400
TGAAGATTCC AAAGAGGAGA AGAGGGGAGA GGTTHKGCCC 2460 TGCTTCAGGG
CCCCTGGGT GGGTAGGTGT GGGGAGGAAG ATGGGAGGAG 2520 CAGGGTTCAC
CCACCGCCCC CCACCACCCC 2580 GGAGATTTC CGGAAAACAG TGAAGCATGG
AGTGCCGGAC TCTGTCAGCC 2640 AGAGCTGGGA TGTCAGCCCT TGACATTGTC
CCGAGGTGAA GCGACGCTCC AGAAGTCTTG ATGACTATGG GGACAATGGG
AACCTGGGCC GATGGAAGGC GCCACGTTTG 2820 TGGAGCCATT GTGGTTTCTC
GTTCCCTCAG GAAACACCCA GACCCTCACG 2880 TCCTGGGTGA GGCGACCTCA
GACATGACAC TGATGGCATC CCCCCTGCGC 2940 TGAAGATGAC TCCTGCCAGC
GCCCCGAGAG GTANTCGCGC GCCTGGCAGT TCCCAAGCAG 3060 ATCGAGAGAG
CTCTGGTGGT AACATAGGGC GGAAGTGGTG 3120 AGCCCCCTCGC ACCTCCACTC
GGATCCCGTA ATGTGGAGCA GCATTAGACG 3180 CAAGATCTTC ATGTTCTCGA
CGTTGCGTCC TCGCACGGCA CATTGTAGAA AAGAAGTACT TGGCACTGGG 3300 G 3301
(2) INFORMATION FOR SEQ ID NO : 67 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
1535 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 67 : GGCACGAGGT CAAGCGAAAG GATTTC AAGG
AACAGATCAT TTCACCATCA 60 CTTTTCCTGG TTTGCCAATT ACATCCGAGC
ATCATGGCTC 120 CTTCCGATTA CTTGCTGGAG TCAGCCAAGA TGTTTAACTA
CGCGGGATGG 180 AAGAACACCT GCAACAACAT CTTTCATCGTC TTCGCCATTG
TTTTTATCAT 240 GTCATCCTGC CTTTCTGGAT ACCCTGGTGT GCTCTATCCT 300
GCCTTCTTTG GCTATTACTT CTTCAATTCC ATGATGGGAG TTCTACAGCT 360
ACCTCATTTT TAACTGGAAA GCTGGTAGAA 420 GATGAACGCA GTACCGGGAA
GAAACAGAGA GGAGGAGGCT 480 GAGGAGCAAA GAGCCGGCCC CTAGCCAATG

GCCACCCCAT CCTCAATAAC AACCATCGTA 540 CCAGCTGCCT CCCAGATTAA 600
CCCCGCTCCC TGCCTATAG GGTCACCTTA AAAAAGGAGA AAGTGAGAGG 660
AGAGTTCTCT TCCTTGCTTG 720 CCCAGGTAGG GGGACGTTGG TTATATTCTG
TTAGAGGGGG ACGGTCGTAT 780 TTTCTCCCT ACCCGCCAAG TCATCCTTTC
CTCAGCTCTC 840 TGTGGGTAGG GGTACAATT CACATTCCTT ATTCTGAGAA
TTTGGCCCCA GCTGTTTGCC 900 TTTGACTCCC TGACCTCCAG AGCCAGGGTT
GTCCCATCTG TGGGCCTCAT 960 TCTGCCAAAG GCTAACCTTT CTAAGCTCCC
CAGAAACCAA 1020 AGCTGAGCTT TTAACCTTCT CCCTCTATGA CACAAATGAA
TTGAGGGTAG GAGGAGGGTG 1080 CACATAACCC TTACCCTACC CTGCTCGGAT 1140
GATCTTTCTT AGTGCTACTT CTTTCAGCTG TCCCTGTAGC GACAGGTCTA AGATCTGACT
1200 GCCTCCTCCT TTCTCTGGCC TCTTCCCCCT TCCCTCTTCT CTTTCAGCTAG
GCTAGCTGGT 1260 ATGGCAACTA ATTCTAATTT TTATTTATTA AATATTTGGG
GTTTTGGTTT 1320 TAAAGCCAGA ATTACGGCTA GGGACCATTT 1380 TGTACTGTTA
TTTTAAAATT AAAAGATTAA ATAAAAAATA TTAAATAAAA 1440 AGTGTCAGAC
TATTAGGAAT TGAGAAGGGG ATAAACGAAG 1500 AGAGTCTTTC TTATGCAAAA
AAAAAAAAAAAA AAAA 1535 (2) INFORMATION FOR SEQ ID NO : 68 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1244 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
68 : GGGCACCCAC GACCTCAGCG CGCACCTATG GGCTCGCTAC 60 TCTCCTGAAC 120
TCTACGCCAA CAACGAGATC AGCCTGCGTG ACGTTGAGGT GACTACGACT 180
CCAGTATGCA GACGCACTGC ACCCGAGAT 240 TCCTGATCGA GCACTACAAG
TACCCAGAAG GGATTCGGAA GTATGACTAC AACCCAGCT 300 TTGCCATCCG
TATGACATTC AGAAGAGCCT TCTGATGAAG ATTGACGCCT 360 TCCACTACGT
GGGGCCTCCA GCCTGTGCCA GACGAGGAGG 420 TGATTGAGCT TCCCACTATA
CCAGATGAGT GGCTTCTATG 480 CAGTTCATGG ACATCTTCTC GCTACCGGAG 540
TGTCCTGTGT GGTGGACTAC TTTCTGGGCC ACAGCCTGGA GTTTGACCAA GCACATCTCT
600 GACGGACGCC ATCCGAGACG TGCATGTGAA 660 CATGGAGAAG TACATCCTGA
GACGTTTGCT GTCCTGAGCC 720 CCATGGGAAA CAGCTGTTCC TCATACCAA
AGCTTCGTAG 780 ACAAGGGGAT GCGGCACATG GTGGGTCCCG ATTGGCGCCA
CTCTTCGATG TGGTCATTGT 840 AAGCCCAGCT TCTTCACTGA CTTTNCAGAA
AACTCGATGA 900 ACCGGATCAC CCGCTTGGA TCTATCGGCA 960 GGGAAACCTG
TTTGAATTCT GGAATGGCGT GGCCCCCGCG TGCTCTACTT 1020 CGGGGACCAC
CTCTATAGTG ATCTGGCGGA GGCGCACAGG 1080 CCCGAGCTGG CCGCATCATC
AACACGGAGC AGTACATGCA 1140 CTCGCTKACG CGCTCACGGG GCTKCTKGAG
CCTATCAGGA 1200 CGCGGAGTTG TGCTTCCTTG ATGAAAGANC GNNT 1244 (2)
INFORMATION FOR SEQ ID NO : 69 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1292
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 69 : GGCACGAGCA GCGACGCGAC TCTGGTGCGG
GCCGTCTTCT TCCCCCGAG CTGGGCGTGC 60 GCGGCCGCAA TGAAGTGGGA
GCTGCTGCTG TGCTGTGCGC GCTGCTCCTG 120 CTCTTGGTGC AGCTGCTGCG
CTTCCTGAGG GCTGACGGCG ACCTGACGCT ACTATGGGCC 180 GACGACGCC
AGAATGGGAG CTGACTGATA GGTGACTGGA 240 GCCTCGAGTG GAATTGGTGA
GGAGCTGGCT TACCAGTTGT CTAAACTAGG AGTTTCTCTT 300 GTGCTGTCAG
CCAGAAGAGT GCATGAGCTG GAAAGGGTGA AAAGAAGATG CCTAGAGAAT 360
GGCAATTTAA AAGAAAAAGA TATACTTGTT TTGCCCCTTG ACCTGACCGA 420
CATGAAGCGG CTACCAAAGC TGTTCTCCAG GAGTTTGGTA GAATCGACAT
TCTGGTCAAC 480 AATGGTGGA TGTCCCAGCG TTCTCTGTGC ATGGATACCA 540
CTAATAGAGC TTAACACTT AGGGACGGTG TCCTTGACAA AATGTGTTCT GCCTCACATG
600 ATCGAGAGGA AGCAAGGAAA GATTGTTACT GTGAATAGCA TCCTGGGTAT
CATATCTGTA 660 CCTCTTTCCA TTGGATACTG TGCTAGCAAG GGGGTTTTTT
TAATGGCCTT 720 CGAACAGAAC CCCAGGTATA ATAGTTTCTA AGGACCTGTG 780

TTCCCTAGCT GGAGAAGTCA 840 CCCACAAGAT GACAACCAGT CGTTGTGTGC
 GGCTGATGTT AATCAGCATG 900 GCCAATGATT TGAAAGAAGT TTGGATCTCA
 TCTTGTTTAG TAACATATTT 960 GTGGCAATAC ATGCCAACCT GGGCCTGGTG
 AAGATGGGGA AGAAAAGGAT 1020 TGAGAACTTT AAGAGTGGTG CTCTTCTTAT
 TTTAAAATCT 1080 ACATGACTGA TGTACTTTTC AAGCCACTGG AGGGAGAAAT
 GGAAAACATG 1140 AAAACAGCAA TCTTCTTATG CTTCTGAATA ATCAAAGACT
 AATTTGTGAT TTTACTTTTT 1200 AATAGATATG ACTTTGCTTC TGAAATAAAA
 AATAAATAAT AAAAGATTGC 1260 CATGAATCTT GCAAAAAAAA (2) INFORMATION FOR
 SEQ ID NO : 70 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1031 base pairs (B) TYPE :
 nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 70 : GGGCTGTTGC TTTTGAACAG AACCTATAT
 TACTCTCCTG GGATCTGAGT 60 CATTTGTATG AGTATCTCCT CCCGTATGTG 120
 TTGAACATCA AGTGGTTATG TTGTATCCCC 180 GCTTCAGTTT TTGCTGTAGC
 CCTAGAGCAC 240 CTCTTGCCTA CCTCCTTGCA TGGACAGGGG GATGAATATT 300
 TTTTCTTTCA CTGATACCAC TGAATGGAAC TGGTGCTGTG ACTCCTGCTG 360
 ATGTCCCGAG GGCTGAGTGG AGCCTGAGAC 420 ATGCATGARA GAGAAGTGGC
 AGAGGGAACA GTAACAGCCC AGGGGCCTTT 480 AGGCTGTCCG GGGCTGTTAC
 TGTCTCTTCT GGTATAAAG CAGACATGTG 540 GCCATCTTTT CCGCAGGTTA
 CTTTCTTTTT GGAATCCTTT TCTTCTCCTT 600 TGGTAGCAGC TCCCTGCCTC
 CAGGGCTTCC GCCACCAGCG TCTCTGCTGT 660 TGTTTCTGCC TGCCTGAAAG 720
 ATGAGAAACA TGTCTCCTG CTGCCATTCT 780 TCATCTCCAC TGAGAGCCAG
 AGCTGGTAGG AGCCGAGTGC 840 CTACTCTTAG CCCTCCCTGT CGCCCACTCC
 TCCCTCCTCT 900 CCCTGTCTGT GGGCTCTTTT ACTACCAGCC TATGCTGTGG
 GACTGTCATG 960 CAGAGTGGAN CTGAAATAAA ATGCAAGTAT 1020 AAAAAAAAAA A
 1031 (2) INFORMATION FOR SEQ ID NO : 71 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 855 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 71 : AGCTATTGAC GGGATCCGAG 60
 GTGCCTCTCA TTGTGATGAG 120 GGCTTCGTCG GTCCTAACCG 180 ATTACCATGT
 TGCTATCTCT 240 GCCCAACTCA ACCCTCTCTT TGGACCGCAA TTGAAAAATG
 AAACCATCTG GTATCTGAAG 300 TATCATTGGC CTTGAGGAAG AAGACATGCT 360
 AGAGAAATGCC TTCTAGATGC AAAATCACCT CCACTTTTCT 420 TTAGCTGCCT
 TAAACGTAA CAGCACATTT GAATGCCTTA 480 CAGCGTGTTT TCCTTTGCCT
 TTGGTGAATT ACGTGCCTCC 540 TCCACAAAAC GATTATGTAC TCTTCTGAGA 600
 AGAGATACGT TACTCTCTCC GATGGCTCCT GCCTTCTCAC 660 TAGAAACTGC
 ACAAGACTCC 720 AGCACGTTCA GAGGGAAGAG AGAATCGCAC 780 TTTCAGGATG
 AATTTCTTCT AATATTTTCC 840 855 (2) INFORMATION FOR SEQ ID NO : 72 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1274 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 72 : GGCAGAGCTT TAAGTGCCTG CTGGAATGCG 60 TGTGCCTCCA CTGATAACCA
 GCCGGCCAGA 120 GAAGGCACTG CCGTCCAGGC GGACACCCGC AGAAATGGAG 180
 TCTCTTGCAC TCTGGCTGCC TCTTGCCCTC TCTGTGTCTC TCTTTCTTGG TCTCTCCCTC
 240 TCTCCTCCTC AGCCTGGTCT GTTATTGTTG TGAGCAATGG 300 AAGTTCAAAG
 GAACTCCCTC TCCAGCTCTT CTGAATCTTG GGACACAGCC 360 AAAAAGTTAG
 AAGACAGCAT AGCAACTCAG TACCAGAGAA AAATAGCAAC 420 GCTTTTTTTT
 TTTTTTTAAT AGAATTAGAA GTGATGTCCT 480 TTTATAAAAT GCCTTCTCCC
 CCTTCCCGCC TCCTCTCCCC TTAGAGGGGG 540 GAAAGTGTAT AAACCTACAG
 CTGAAAAGAG GATCCCCCTC ACCCCACCC 600 660 GATATTTCTT GTCTCTTGTG
 CTATCGCCTC 720 TGGCAGGTGC CACCTTTTGG GGTTGGGTTT 780 TTTTTTTTTT
 CCTTTTGGTC TTTTTTTTTT TCTCCTTTTA AAGAAAAGCT 840 AAAGGCCGCT
 GTAGCATATC GAAGATAATT 900 TCCGTCTGCT 960 AGTGAGGTTG GAGCGCACCG 1020
 GTGGAGGCTG CTGTGCCTCT CCAAGGCTGG 1080 CTCTCTGGGT 1140 AAGAAAGTTA

TTCCCGAAGA AAAAAAGAAT GAAAAGTCAT 1200 TGTACTGAAC TGTTTTTATA
TTTTTAAAAG TTACTATTWA 1260 CCCGGTACCC AATT 1274 (2) INFORMATION FOR SEQ
ID NO : 73 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 688 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 73 : GGCACGAGTG GAGGCAATGC CAGCTCCAGG
ACAGAGGCTC CGGGCAAGGC 60 GCTGTGTCTG TTCAAGTCAG CCCTCGCGCA
CAGCGCTTCC 120 CCCACGCAC TGAAGAGGCC GCCTGGGCTG 180 GACCTTCCTG
CTGGTGCTGC CACGTCTGCA CAGAACTTC 240 AGAGCATCTA CTGGGGGCCC 300
GCAGCCCTCG AGCGCTCGCG CCGGAGACCC 360 CTCTCCCGCC CACGCCGGAC
AAGGCGAGAG CTCGGAGTGA 420 CCTGCCACTG TGGCGTGCGG CTCCTCCCCG
CGCCGCGAGG CCGCGACCTC 480 ACCGCGCGCG 540 TTCTCTCCTT GCTTCTGCCT 600
AACTCCGTTT CTAATTAAAT TATTTTTAGT AGAAAAAAAAA AAAAAAAAAA 660
AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 688 (2) INFORMATION FOR SEQ ID NO : 74 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 1890 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
74 : CCTCCAAAGC TAACCCTCGG 60 CTGTACGTTT CTTCTACTCT GGCACCACTC 120
TCCTCATCTT GTTCCTTTTG 180 CACCACCTTG CTAGCTGCTT TAGAGGAACG
GCTGGCCCAG 240 AGAGTAGTCG ACTTCAAGAA 300 GAACTGAGGC 360 TGGATCGTCT
TGGAGACCCA GAACCCAGCT 420 CTGCCCTGTG TAGAGTTTGA CTGGGACCAA 480
AGAAGTACGA TCAAGTGAGA 540 CCAGCTGGTC 600 AGAAGATCTA CGTGTTAGAT
ATGACACAGC CTTTGTCTTC 660 GTGACTTCAC CCTTGCCATG GCTGCCCCGA
AAGCTTCCCG 720 CCCTTCCCCT AGGGCAGCTG GTATATGGTG 780 AGGCTCCTG
ACACTTTGCA 840 TTCCACCTGG CAAACCGAAC AGCTCAGTAT 900 CCCCCCTACG
GCTTGACAGC ATCGACCTGG CAGCTGATGA 960 TGGGCTGTCT ATGCCACCCG 1020
ACACCATGTC CCAGAGAGAA TGCTGAGGCT 1080 GCCTTTGTCA CCTCTATGTC
GTCTATAACA CCCGTCCTGC 1140 GCTCCTTTGA TGAACGGGCA GCACTCCCTT 1200
ATTTTCCCCG GCCTCCGCTA TAACCCCCGA 1260 GGATGATGGC TCTATAAGCT 1320
AGGAGCTAGC CTTGTTTTTT 1380 ATATCCCCAC TAAATTTCTT GGGCCAGTTG 1440
CCTCTATATT 1500 TCCAGATCCT GAGTAATCCT TTTAGAGCCC GAAGAGTCAA
GTTCCCTCCT 1560 GCTCTCCTGC CCCATGTCAA CCCCAGACCC 1620 CCTTGTATGC 1680
CCTCCCTTCA 1740 TTCTCCACAT TGCAACATTT TGCATTAAAA 1800 GGAAAATCCA
AAAAAACGG 1860 1890 (2) INFORMATION FOR SEQ ID NO : 75 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1133 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
75 : CGGCCGCTCT TTTCCCGTCC 60 TGCTGCTGCT GCTGCTATCG GCTGCTGCTG 120
GTCGGCATAG GAGATCGCTT CAAGATTGAG GGGCGTGCG 180 240 AAGAGCACGT
CGGTTTCCTT AAGACAGATG GGTTCATGAT 300 GATCTTATGT GTATCTCCAG
CTTACAGATT TGATCCCGTT CGAGTGGATA 360 AGAGCAAGAT CATCAAAACA 420
CTATCCTCTC CAAATGAAAT ACCTTCTTAC TTTATTAAAA 480 GACTTTCTAA 540
CTGCCTAAAG TGGTCAACAC AAGTGATCCT GACATGAGAC 600 GCAGTCAATG
AATATGCTGA ATTCCAACCA GATGTTTCTG 660 AAGACTCTTC TCTTCAAAT 720
AAGTGGGGCT CCGTCCAGAG 780 GCAACACTGG AGTCTTGGA AACC GTGTGA 840
ATAAACTTGA GTCATCCCGA 900 ATGTTTTGTA GAGAAAACCC TTTTGTCTGT 960
TATTGATGTC CTATAGAAAA 1020 AACTACTATA CATTATGTAT ATTAATTAAA
ACATCTTAAT CCAGAAAAAA AAAAAAARAA 1080 AACTCGAGGG GTCGTAAAAA ATC
1133 (2) INFORMATION FOR SEQ ID NO : 76 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 585 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 76 : ACTCCTCGCC CTCTACCTGT
CCCCTCCCCC 60 TTTGGTTGTA TGATTTTCTT AGCAGCGCCT 120 CTCTCTCTCT
CCTGTGGTGT 180 CCCTTCCCTC TCGGTGTTCA GTGGTGTATA TTTCTTCTCC
CAGACATGGG 240 GCACACGCC GATCCTCTCC TCTTTATAAG 300 GTAGAGGCAG

CCGAGCTGAA 360 GTGCTCCTGG CCACCCAGCC TCTGCTGAGA 420 TGCCTTTCCC
TGTCGTCTCC CCGACCCTCC 480 GCTGTGTCTG TATATTCTAT TTGTCCTTTC
CCTTTGTAAA CTACATTTGA 540 CATGGATTAA ACCAGTATAA ACAGTTAAAA
AAAAAAAAAAAA 585 (2) INFORMATION FOR SEQ ID NO : 77 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 577 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
77 : GGCACGAGGC CTTGCAGAAC CTGCCTCCCT 60 CTTCTTCTG 120 ACTGCTGGTC
AAGTGGCTCA ACTCTCCTGC ACGCTCAGCC 180 GACTACGGTG 240 CCCCTCGATA
TCTCCTCTAC CCACCGGCCT GCTGACATCC 300 CCGATCGATT CTCGGCAGCC
CCCACAATGC CTGTGTCCTC ACCATTAGTC 360 CCGTGCAGCC TGAAGACGAC
TGGCTACGGC TTAGTCCCT 420 TCTGCCTCCC ATTTCTGCCC CTGACCTTGG 480
GTCCCTTTTA AACTTTCTCT GAGCCTTGCT TCCCCTCTGT AAAATGGGT AATAATATTC
540 CAACAAAAAA NAAAAWAAA AACTCGA 577 (2) INFORMATION FOR SEQ ID NO : 78 :
(i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2278 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
78 : ACGAGGCGCC CAACATGGCG GCGGCCCGCA SCTAACGGCG 60 CTCCTGGCCG
GCGACGGCAG GCCCGAGGA GGCCGCGCTG 120 ACCGCCTCCA ACTGGACGCT 180
GGCGAGTGGA TGCTGAAATT TTACGCCCCA 240 CTTTGTGCAA ATACTTCAGA
TCAGTGTGGG 300 TTCTTTGTCA CCACTCTCCC 360 CCGCCGTTAT CGTGGCCCAG
GAATCTTCGA AGACCTGCAG 420 AATTATATCT TAGAGAAGAA ATGGCAATCA
GTCGAGCCTC GAAATCCCCG 480 GCTTCTCTAA CTTTTAGCA GATATGGCAT 540
CTTCACAACT ATTCACAGT GACTCTTGA ATTCTGCTT GGTGTTCTTA 600
GTCATAGCCA AATATCAGAA 660 TGTTTCTATG TGCCACTTCC TCTGAGCGTT
CTGAGCAGAA 720 ATAGAGCTGA AGGAAAAAGA TGATTCAAAT 780 GAAGAAGAAA
CCTTG TAGAT GATGAAGAAG AGAAAGAAGA TCTTGGCGAT 840 AGAGGAGGAG 900
AGAAGTGAGG CCAATGATCA GTGTGACCCG GGAGGNAAGT 960 GAGGCTGAAG
AAGGCATCTC TGAGCAACCC 1020 AGCGTAAAAG TCAGCATGCT TG TAGATTTA 1080
TTCAAGAATA CACACCAAAA 1140 TCCTTAATTT TTCCTGAATG AGCAAGCTTC
TCTTAAAAGA TGCTCTCTAG 1200 TATACTAAGG 1260 ATCAGGATAT ACGTAGTGTN
GGATGGGAAC 1320 AAGTTCATTT CAGAGAGTCT CGACCAGAGG CAGTCCTAAT 1380
CAGCACCTTC GCTGCAGGCC CTGTGAAATG AAAGCCAAGC 1440 ATCCCCAAAG
TGTAACGTAG AAGCCTTGCA TCCTTTTCTT GTGTAAAGTA 1500 TTTATTTTGT
TCAAATTGCA GGCACCACAG TGCATGAAAA 1560 GCTAGAAATT GAGCAGCTCA
GAAGTCATCC 1620 AATCTCCTGT GCTATGTTTT ATTTCTTACC TTTAATTTTT 1680
TCCACACTCT ATAACAGCCA 1740 AACTGTGTTT TTTAGATAAT CAGTAACCAT 1800
AACCCTGAA GCTGTGACTG CCAAACATCT GTTGTGGCCA TCAGAGACTC 1860
AAGGATTTTA CAAGACAGAT TAAAAA AAAAATATAG 1920 TTTTTTTTTA
AGTTTTCTAA AGTCCTCTAA 1980 GTCTTGCCAG TACAAGGTAG TCTTGTGAAG
AAAAGTTGAA TACTGTTTTG TTTTCATCTC 2040 CTGGGTCTTG AACTACTTTA
ATAATACTA AAAAACCCT 2100 GTGCTTTTGG TGAAAGAATT AATGAACCTC
AGTGAAAGAT 2160 TGTAATCTTC CAAAGAATTA TATCTTTGTA AATCTCTCAA 2220
TACTCAATCT ACTGTAAGTA CTAATTTCTT TAAAAA AAAA 2278 (2)
INFORMATION FOR SEQ ID NO : 79 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1143
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 79 : CCCCTCCAAC GCCCTCCCGC CGCCCGCTCG
60 ACAGCCGACA GTGATGAGAT 120 GGCCCCGGAG CGATGTGCAC AGTCTGCCCT 180
GGCCAAGCTC GCTGCTCTGC GCTGCGGCC CGGGCCACCC 240 GATGCAGATC 300 360
GGGGCTGTGG ACGAGAAACG 420 TGCTGAGGAC TCTGCTAGCG TCTCCACAGC 480
CATCGCTGCC CTCAAATTT GGAATGAAGA TTTCCGATAT ATTACAACAG 540
TGCCTGCCGC ATCTCCAGCT CGAGTGACTG GCCCCCACTC AGAGTCCAGA 600
AGAAGTCAGA TATGTACCTC ATGCTGAAGG 660 AACCTTCAG GCCATGCTCT

GATTCTGCTG CTCTGGCCCC 720 TCTGTGGCTG AAAAGAGACC AGAAGGAAAT 780
GTTGGAAGTG AGTGGAATCT CTCCTGATTA TTAGTGCTG GTGCTTCTGC 840
ACCGGGCGTC CCTGCATCTG GAAGAACCAG 900 CAACAGCCCC AGTTATCCTG
GCCCCATGAC GCCCTGCTCC AGCAGCACTT 960 GCCCATTCCT TACACCCCTT
CTCCGCTTCA TGTCCCCTCC 1020 TGTGATAATA AACTCTCATG 1080 GGGGCCGGTA
CCCATTTGGG CTNNGGGGGN GGTTTAAAAT TAATGGGGGG GGTTTAAAAG 1140 GGN
1143 (2) INFORMATION FOR SEQ ID NO : 80 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 557 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 80 : GGCAGAGAGC AGATGGCCTT
GACACCAGCA CGCTATTGCT ACTTCTCTGC 60 TCCCCACAG TTCCTCTGGA
CTTCTCTGGA CTGCCAGACC CCTGCCAGAC 120 TCCTCTTCCT GCTTTTGCTC 180
CAGCTCAGAC GAGAGATCAT 240 GCTCTTGTTT TCCCTCTCTC TGCCGCTCCT
GGCAGGCCTC GTGGCTGCTG 300 ATCGCTGCTC GTGCGCACGC 360 GCCCCGCCCA
AAAGTCTACA TCAACATGCC TGACCCTCCT 420 CCTTTGACTT 480 CCCCCGCCCC
AACTTTTGGG TTGTAATAAA ACAATTGAAA 557 (2) INFORMATION FOR SEQ ID NO : 81 :
(i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 795 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
81 : TGTGGAGCGC GGGCCGCGGC 60 CTGCTGGCGC TGTTAGTGCC GCCGCCAAGA
CTCGTGACCT 120 GCTGAAGCTG CTCAATACGC ACCACCGCGT GCGCTGCACT
CGCACGACAT 180 CAAATACGGA GCCAGCAATC GGTGACCGGC 240 MAATAGCTAC
TGGCGGATCC GCGGCGGCTC TGCCCGCGCG GGTCCCCGGT 300 CAGGCGGTGA
GGCAAGAACY TGCACACGCA 360 TCGCCGCTGT GCCTTTGGGG AAGACGGCGA 420
CTGGACCTAT CTGCTCTGGA CAGCACTGGG 480 TGCTGTGCCT TCCAGCATGT
GTGTTCCCTGT 540 CCAGTGCCAA 600 CATCTTCATC AAGCCTAGTG TGGAGCCCTC
TGCAGGTCAC 660 GATGAACTCT 720 TGGCAGAGAC TNTGATTAAA 780 GAATGTTGGT
CTATG 795 (2) INFORMATION FOR SEQ ID NO : 82 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 1324 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 82 : NAGGCTTTAA AGCGCCTACC
CTGCCTGCAG GTGAGCAGTG GCCAGGCGTC 60 CCTCTGCCTG 120 CTTTCAGAAC
CATGCAGTGC 180 TTCAGCTTCA TTAAGACCAT GATGATCCTC TTCAATTTGC 240
CAGTGGGCAT CATCCTTTCT GAAGATCTTC 300 CGTCCAGTGC 360 TCTTTGCTCT
GGCTGCTATG GTGCTAAGAC 420 TGTGCCCTCG TGACGTTCTT CTCCTCATCT
TCATTGCTGA GGTTCAGCT 480 TCCTGACGTT 540 CCTGCCATCA AGAAAGATTA
TGGTTCCAG GAAGACTTCA CTCAAGTGTG GAACACNACC 600 AACTATACGG
CTCACCTAC 660 TTCAAAGAGA ACAGTGCCTT TCCCCATTC ACAACGTCAC
CAACACAGCC 720 AATGAAACCT GCACCAAGCA CTTCAATCAG 780 ACATCCGAAC
TAATGCAGTC 840 GGCCTCGAGC TGGCTGCCAT GATTGKTCC ATGTATCTGT
ACTGCAATCT ACAATAAGTC 900 CACTTCTGCC TCTGCCACTA CTGCTGCCAC 960
GACAGGATCT AACAATGTCA 1020 CCCTTTCTGC TCCAGACTTG CTTTATAGCGA 1080
GGTGGGTGGA TAGCCAGTTC 1140 TGTTGCCCAT TCCCCAGTC TATTAAACCC
TTGATATGCC CCCTAGGCCT AGTGGTGATC 1200 CCAGTGCTCT CATTATATAG 1260
TGTAAGAGGC ACTTCAAAT GTTACAATGT 1320 TAAA 1324 (2) INFORMATION FOR SEQ
ID NO : 83 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1494 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 83 : CTCAGGCTTC TGTCTCACTT 60 GTCTCTCCCT
CCCCTGTTCC 120 ATGGTGAGAC 180 240 TTCTGTACCA GCCCTAAAC CTCACCCAGG
CTGAGCACTT 300 CCTGACGTTG CTGCCATCAA GAAAGATTAT AAGACTTCAC 360
AACACCACCA 420 GAGAAAGAAG CCTCCACCCT TGCTGTGGCT 480 GAGGACTCAC
CCTACTTCAA AGAGAACAGT GCCTTTCCCC 540 CATTCTGTTG CCAAGCAAAA 600
GGCTCACSAC CNAANAARTAN 660 GCCTCAGAGT CAACTATAAA TGCTCTTTTC 720
TCTTCCYGAA TGTATGACAT CCGAACTAAT GCAGTCACCG 780 TCGAGGTAAG

GCTGGGACTG 840 ATGAGACCAG GCCTCTCTGG AGGAAACAGA 900 CTTCTAACTG 960
 CCCTCATCTC TCCCTGTTCC TCCCTCTCCA GCTGGCTGCC ATGATTGTGT 1020
 GTACTGCAAT TCCACTTCTG CCTCTGCCAC TACTGCTGCC 1080 CACCCTGGCA
 AGCAGCAGTG CTAACAATGT 1140 TGCCCTTTCT GCTCCAGACT 1200 TCCTTTTAGC
 GATGCCTGAC TTTCTTCCA 1260 GAGCCTCTAA TCTGTTGCCC ATTCCCCCAG
 TCTATTAAAC CCTTGATATG 1320 CTAGTGGTGA TCCCAGTGCT ATGAGAGAAA
 GGCATTTTAT 1380 AGCCTGGGCA TAAGTGAAAT CAGCAGAGCC 1440 ATGCATAAAC
 GTAAAAAAA TGCC 1494 (2) INFORMATION FOR SEQ ID NO : 84 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1285 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 84 : GCTACGTGGC GGGAACGAGG CTGCTCCTGA 60 TGCAGTTCCT TTCCTGCGAG 120
 AGATGCGCAT TCACCTGCTG CCCTCCATGA CTATGAGATC 180 ATCGATCTTA 240
 ACCATAATTT AACACACCAC 300 CACCTGCCAT 360 CCGTGGCTCC TGAAACGCGG
 GCGGATCCCC TTTGTGCTAA 420 ACTCGCACCC 480 CCGCGAGCTC ACGCCCACAC
 CAGATGATGC TGTGTTTCGC 540 CTGTCTATGC CTGGCCATGC AGGACACCAG
 CCGCCGACCC TGCCACAGCC 600 AGGACTTCTC CGTGCACGGC AACATCATCA 660
 CCAACTGCTT 720 GTTCCCTCAC GAGAATGAAT GTGGGAGAAC AACAAAGACG 780
 CCCTCCTCAC CAGGTGCGCA TGGGCATTGC AGGAGTGGTG 840 GACGCTGTCA
 TTGCCGTGGA TGGGATTAAC CATGACGTGA 900 TATTGGCGTC ATGGTGACTG 960
 GGGCTACCAT 1020 CCTTCCCCTG CAATTTCTGT CTCACCAAGA CTCCCAAACA
 GAGCTGCTGG 1080 CCGGACCTTC 1140 AAGAGCCCTA GACCTGTCAA 1200
 GGAAGAGTAG ACAAAGTGAG TCATTAAAGC 1260 CTAAAAAAA (2) INFORMATION FOR
 SEQ ID NO : 85 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 394 base pairs TYPE :
 nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 85 : GCGCGCTCTA GGAAGTAGTG GATCCCCCGG
 GTGGAGTGGG CCATCGTAAA 60 TAGTATCTGT GTTGTGCGAT AAATGAGTTA
 ATGTATGCAA AGCCCTTGGC 120 TGTGTAAGTS CTGGCAGGCG TCATGATGGA
 GATATCATGT 180 CTCCTCTTCT TTCTGATGAG 240 GCCTTGAGGC ACTGCTCCAG
 CCTCCTTTGT ACCCTTGGCT 300 GTARCAAGTC TCCCCTCTCC CACTYTGACG
 CTGCTCACGG 360 CGCCTAACCT CTA 394 (2) INFORMATION FOR SEQ ID NO : 86 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 1925 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 86 : AGTGAAGGGA TCGGGCCCTG GCANGCCTTC 60 GCCTTGAGGC 120 CCCAGTGGTA
 GCTATTATGG CCACTGGTGG 180 GCAATGACTT AGCTGGGCCT CTTGGATTGC 240
 KTCTCCTACA 300 CCACTGAGT 360 AAGAACAAGC TGGGTGTGCT GGCCCCCAGC
 GGAGCTGGCC 420 GAGCGTGCCC CCAAGCTGC TTCACCAACC CATCAACGAG 480
 GCGCTGCTGC AAGCTCTCAG GGCCCTGAGT 540 CATGGCCAGA CATCTACTGT
 GCCCTCAACA GAGCCTGACC 600 TTGGGGAGTG GTGCGAGTTC TCTCCCTACG
 AGGTCGGCTT CCCCAAGTAC 660 GGGGCCTTCA TCCCCTCTGA GCTCTTTGGC
 TCCGAGTTCT GCTGATGAAG 720 GTATGCAGCC 780 CTGGGCCTCA GAGCCCAGCC
 CCGCTGGGTC 840 GTCCCCCTTC TGAAGATAGA AGAACCACCC 900 TGAGTTTTTC
 ACCGATCTTC TGACGTGGCG TCCACTGGCC 960 CAGGCCACAC ATAATTTCT
 AAGACTACTT TCAGCATCCT 1020 CACTTCTCCA CATGGAAAGC CCAACCAGCT
 GACACCCTCG 1080 TGTGCCTGCT TACCTCATCA CCTGCCCTC 1140 CTGCAGCCCA
 ACTACAACCT 1200 TGCAGCTCCT GTTCCCACCC 1260 GCCCCGAAGA GCCACACCTT
 CTCCGACCCC 1320 ACCTGCCCCG GAGCCCCTGC TCAGCGACTC 1380 TACTCGGCCC 1440
 ACTCTCCCTA AAGGTGACCT GGACGTGGAC 1500 AAGCTGCTGC TTACAATGTC
 TGCAACAACC AGGAGCAGCT 1560 CAGTGCAGCG ACTGATGGCC 1620 CTCTCATTCA
 GCTGAGTTGC 1680 CAGTGCTTCA ACTGTCCCAG 1740 CGCCTCAGCA GTTTGCAGTG
 TTTGTGTAAT 1800 CCCCCGGCCT GTGCCTGTTT TCCCTTCTGC GCTACCTTGA 1860
 CACTTGATAC ATCACAGACT CATACAAATG AGAAAAAAA AAAAAAAAAA 1920 CTCGA

1925 (2) INFORMATION FOR SEQ ID NO : 87 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1818 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 87 : CCNCGNGNTT TTTTTTTTTT TTTTTTTTTT TATGAGTCTG 60 AGTGCTCCAA TAGCGCAGAA 120 GGTGATTACA ACCCCACTGC AAAGTCTGA CCTCAGCCTG GCTCTGNAAG 240 CACTGCGTGA TGACAGTTCC TCAGCAGCCA GGAATGAAT GAGAGTTAGG 300 GCCCCGGCCA TCAGTGGGGC CTGCGCTGCC CGCAGAGCCT CTCCTGGTTG CGTCCTCCTG GCTGTAGGTC ACCTTCGTGT AGAGTCCGAT 480 TCCGCCGGAC GAGTACTCCC GTAGTCCAAT GACAGGATGA GGTCCACGTC GCAGGCAGCT CCATCCAGAG TGGTAGCTTT AAGTGAGGAT GCTGAAAGTA ATTATGTGTG 960 ACTCAGCTAT GTTGAGGGTG GTTCTTCTAT CTTGTCCAG GAACTGGCTG CCCAGTATAA GCTCCAGATA CTTCTAAGA AGCAGATGCG AGCCTCTTCA TCAGCTGCCC CATAAAGAAC AGAGCTCAGA GCCCGTACT GACCTCGTAG GGAGAGAACT CGCACCCTC GGCTCTGCCC TTTGGTGTTG AGATGGGCAG TTGATCTGAG AGCGCCTCGT GCTCCTGCCG GTACCGCTGC AGCTGGCTGG GGGCCAGCAC ACCCAGCTTG 1560 CCAGGTCCTT CTGAGACCAC 1620 TCTGGGTCCT YATAAAGGT GGCCAAGGCC GAGACGCAAT TCAGGCCAGC TCATTGCCCC GATCCCACCA TAATAGCTAC CACTGGGATC TCATCCTCCT 1800 (2) INFORMATION FOR SEQ ID NO : 88 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 539 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 88 : ATATGAAGTG CAAAAGTTG AATGTTCCAG 60 ATGGAAATAA TAAATGAAY TCTTATTAAT 120 CGATGGGGAT CAAGCTTTTT 180 ACTCACAGTT TCCAACGTCT TTGTTCTTCC 240 CATCTCAAAG CTGTTGAAGG 300 TTGGCATACG GTCCTGTAGC ATCACTTGTT AGCCCACTGC TGCTTGAAGG AACTAAGAGT 360 AAATAGGATT TTTGACTCT CCCCTCAAGA 420 AACCTCTCCT GACAACCTTT 480 ATATATTAGC ATCTTCCCTT CTGAGCCCTC GTACTGCCA 539 (2) INFORMATION FOR SEQ ID NO : 89 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 855 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 89 : CCTCTGCCCA TCGTGCCAC CCACCAAGTT CCAGTGCCGC 60 ACCAGTGGCT TATGCGTGCC CCTCACCTGG 120 GGCAGCGATG AGAAAGGGCA ATGCCCACCG 180 CCCCTGGCC TCCCCTGCC GTCAGTGAAT 240 CCTGGCCTGC AGTCCGTTG 300 GATGACTGCA GTGGCGCTGC 360 GACGAGCTCG CAATGAGATC CTCCCGGAAG 420 CCCCTGTGA TGTCACCTCT CTCAGGAATG 480 GAGAGTGTCC CCTCTGTCGG TCCTCCTCTG 540 GTCTGGAAGC TGCAGCTGCT 600 GGTACCGCC ACCCTCCTCC TTTGTCTCTG GCTCCGAGCC 660 GTGGCCATGA GCTGCTGTCA 720 CTGAGGACAA TCAGCCCTGG GCGTACNGSA 780 AGCCCTTCAG AGACCTGAGC NCTTCTGGCC 840 ACTGGAAGT CGAAC 855 (2) INFORMATION FOR SEQ ID NO : 90 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 628 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 90 : AAGGACGTGC CGTGCCGCTG GGTTCTGAGC ATGGAGGCGA 60 CTTGGAGCA GACACAATGA AGAATCCCTC 120 AGGACTTAAT GTCAGATGAG 180 TGATATCTGT TCTAGCCAG CAAGCAGCTA AGCTAACCTC TGACCCCACT GATATTCCTG 240 AGAATCAGAT TTATGATCCA GAAACACGAT GGCATCACGG 300 CAAAATGGCC CATATCTGTT CTTACGAGC 360 TACCTATGTT AATTACCTTA TAGAACTACT AAAGTTCCAG TAGTTAGGCC 420 ATTCATTAA TGTGCATTAG GTTTATTTAA GAGTCAATTG 480 CGACTATCAA GATATTAGTA 540 TGTATATAGA ATTTTGCTGT ATTCAATAAA TCTGTTTGGA 600 CCGAAGCT 628 (2) INFORMATION FOR SEQ ID NO : 91 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1053 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 91 : CTCTTTTCTG GAAAGACGAG CTTCTGCCCT 60 AGGGTGGCAT GGARCCTCTC CGGCTGCTCA TCTTACTCTT TGTCACAGAG 120 CCCACAACAC CACAGTGTTT CAGGGCGTGG 180 TCTTGCCCCT ATGACTCCAT

CCGCCAGCTG 240 ACTTGTGGCT GCTGTCCTTC 300 ACAGACGATA 360 ATTACGCTGC
GGAATCTACA GAGCCTCCAT 420 GGCAGTGAGG CTGACACCCT 480 CTGGAGATCT
AGAGCTTCGA 540 GAGCCTCTTG TCCCCTTCCC 600 ATCCTTCTCC CATCTTTCTC
ATCAAGATTC TAGCAGCCAG 660 GCTGCAGCCT ACACATCCAC CCAGTGA ACT 720
CATGACCCAG CCAA ACTCTG 780 ATGGGAGGAA GAAGTCCCAC CCCAGCCTGC
ATACTTGCCA 840 AGGACTCCTT GTTCTGCTCT GGCAAGAGAC 900 TCTCCTGGAC
CCTGGAAGCA GAGGGAGTGG AGAACACCTG 960 ACAACTTCTG CTTACAAATA
AATCCAAGAC TGTCATATTT 1020 (2) INFORMATION FOR SEQ ID NO : 92 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1075 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
92 : GATCCTCTCT GACGAGATCT 60 ACTCTGCTTC TGCCCTTGGC CCTCTCCGGC
TGCTCATCTT 120 ACTCTTTGTC ACAGAGCTGT 180 GCCCCTATGA GGC GCAAGGC 240
CTGGTGCCGC AGAAGGGCCC ATGCCAGCGT CGCACA ACTT 300 GTGGCTGCTG
TCCTTCTGA ACGATACCCT 360 CTCACCATTA TCTACAACCC 420 GTGCCAGAGC
GTGAGGCTGA 480 GGCAGACCCC AGTCTGAGAG 540 CTCTTGGAAG GAGAAATCCC 600
CTTCCCACCC ACTTCCATCC TTCTCCTCCT AGATTCTAGC 660 AGCCAGCGCC
CTCTGGGCTG 720 TGA ACTGGAC TCAGCTCCAA ACTCTGCCAG 780 GAGGAAAAGC 840
GCCTGCATAC TTGCCACTTG CTCCTTGTTT AGAGACTACT 900 ACTGCTTCTC
CTGGACCCTG 960 CACCTGACAA TAAACACTTA 1020 ATATTTAAAA 1075 (2)
INFORMATION FOR SEQ ID NO : 93 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 2492
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 93 : TCCCGACTCA TCGCCGCTGT CCCCACCACT
60 TCTCCTTAAC 120 AATGATTCTC TTTTTTGACA AAGCACTACT 180 AATGTTTTAT
TTGTAGCCGG TAGAAAGAAC 240 TTCTTCCAAA AACATAAAAT GAAAGCTACA
ATTTGTAGTC 300 TTCGAAATTT TCTCTTGTTT 360 TTCCTGTCGT TGTGCTTT
ATTAGAAGAG TGCCAGTCCT TGGATCCCTC 420 CTAAATTTAC CTGGAATTAG
GATAAAGTTG GAGAAAGCAA 480 GACTCATTTA TTATTTATAA AGTCATTTGA 540
AGAATATTCA AAATAGCTTG TACAGGAGTT 600 TAAACGTAT GTACCAGCAG
AAGAAGCAGT 660 TTCTACTCAA AAGAAGTCAG AAATCCATGT 720 TAATGATGCT
TAAGAACTC TTTCCACAA TTAGAGAACT TTTCTTTTCT TTTATTTTG TTTAGAAAT
ATGGCAAAAA GATGCATGAA TTAAAGTATT 960 TTTGATGTAT ATAAACTTC
TGTGGTTCTT CTGAATCTTA AATCTGAACT 1080 AGATATTCTT TGTGGAATA
TGCAAAGGTC ATTCTTTACT AACTTTTAGT TACTAAATTA 1140 TAGCTAAGTT
AAAGTCTCAT ACTTCTTGGG AGTCTGCCCT 1200 CCTAAGTATC TGTCTATATC
TGTAAGTATT GCATTCTTGA 1260 TTCATAGCTT GTCTCATTGA TGAAGATACT 1320
AAATGATGCA TAATTTTCTT TTCTTCTTTC 1380 TTTTTTTTAA TGGCTTATTA
TTTGTTTTTC ATAAATTAAA ATAACCTTTG 1440 ATAATGTTTA CTTTAAGACA
TGTAACATGT TGTTTTTAAA 1500 TTTAATCTGA TTTTCCTAGC ATATAATAGT 1560
CATTAAGCAT GACATATCCT AGTTAATTAG AAAATACCTG 1620 AGTTCACGTG
CTAAAGTCAT TCACTGTAA TAACTGACT RTGGTTTCTT AAGAACATGA 1680
CACTAAAAAA AAAGTGGTTT TTTCCACCG GTTTTCTTTA GTTTTACAAG GATGTAGGGA
AACATTTCAA 1800 CAGCCATAGT ACTATTTGTT TTACCACTGA TTGTTTTTTT
AAGCTTTTTA GTATAATTGA ATTTATTTAC ATTACAGCTT ATTTTATTTT TAGTTAAATC
TCTTAATACA CCCAATCTTG CTCATCTAAA TAAGGAAAGA AGTGTGATGG TTAGTCTTA
2040 AGGATTAAGA CATTTTGGT ACTTGCATTT GACTTACGAT GTATCTGTGA
CTACCTCAAT AGTTAATGGA ATAATAAGAG GCTACTGTTG 2160 TCTTCAAAAA
AGTAATATCC TCACTTGGAG AGTGTCAAAT TTATATAAGG TGCCCTGTAG
AAMTCTGTTA TATTTACAAT TTCTACCTTT TTAGAGCAAG AATAGTATCT GCTAATGTAA
2340 CTTTGTAGAC ATGAATTTCT ATCAAAATGT TCTTTGCACT 2400 TTCCTTTTTT
CAATAATCTT AATTCAAAGC ATTATTAGGM CTTGAAAGGG 2460 TCCCGTCTCT
TGGTAAAGGT 2492 (2) INFORMATION FOR SEQ ID NO : 94 : (i) SEQUENCE

CHARACTERISTICS : (A) LENGTH : 3058 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
94 : ACCCTAAATC AAGAGCAACC 60 TTGGCTTCAG TTAAATCAC AAGTTTATCC 120
AGATAAACAT AAGTTGATCT TCCCAAATA CCATCATTAG GACCTATCAC
ACAATATCAC 180 TAGTTTTTTT TGTGTGTTG TTTTCTTGG 240 GACATAATAA
GGATCTTTGA TTAACCCCA 300 TAAGGCATGT AAATATACTT CTCTTTGGCT 360
TGTTAACCA ATCAGATCTG TGAAATTTCC 420 ACCATGCCTA GGACTCACCC
GATCTGTTTA 480 CCTATAATCA CTTGCTAAAC ACTGGGCTTC ATCACCCAGG
GAGATCATTG 540 CCTGCATCAG CCTATTCAA ATTATCTCTC TCTCTAGCTT
TCCACAAATC 600 CTAAATTTCC TGTCCCAAGC CACCCAAATT CTCAGATCTT 660
TAAAATAAAT TGGCTTGGGC TATGGTCTCC AAAGATCCTT CAAAAATACA 720
TTCATTCACT CACTTTACTT AGAACAGAGA 780 TTATTTTATC AATACCAATT
TGGCAGACAT TGCTAATCAA TCACAGCACT 840 ATTCCTATT AAGCCCACTG
ATTTCTTAC AATCCTTCTC AAATTACAAT TCCAAAGAGC 900 CGCCACTCAA
CAGTCAGATG AACCCAACAG TCAGATGAGA GAAATGAACC CTACTTGCTA 960
TCTCTATCTT AGAAAGCAAA AAGCCAGGGG 1020 GTGCCTTAGT 1080 TCTGCAGTGC
CTGACACATC TCCAGGTGTA CCTCCAACCC 1140 TAGCCTTCTC CCACAGCTGC
CTACAACAGA CTTCTCAGAG AGCTAAAACC 1200 AGAAATTTCC AGACTCATGA
AAGCAACCCC CCAACCCTG 1260 AACACTAGGC TTCTTCTTTC ATGTAGTTCC
TCATAAGCAG GGGCCAGAAT 1320 ATCTCAGCCA CCTGCAGTGA CCCCTGAAAA
CCATTCCATA 1380 TTCCCAGGC GAGACATTGA ACTGTTTTGA CTGCTGGCAG 1440
TCTAAAACAG TTCAGAAGTT 1500 CAAGCCGAGA TGCTGACGTT AATGCACCAT 1560
AGTCATATGC TACAAGATGT TGTATGATGA TTTGAAAAG GCTCAGCAGG ATTTGTTCTT
1680 AAACCGACTC CCCCAGTTAT TTAGAATTAC AGTTAAGAAG GAGAACTTC 1740
TATAAGACTG GTGATATCTT TATTACAGGC TTTAACTGGT CCTGTAAAAG TGCACAAAAT
TATTGTTTTT TTATTGTCCT 1920 TTTGAACTGT TTTTTTTT TAAGCCAA
TATATATTCG TATTCCATGT 1980 AATAAAAAGA ACAGTTGTAG TAAATTATTA 2040
GATATTCAT GGCAGGTTAT TCTACCAAGC TGTGCTTGTT ATGACTGTAT TGCTTTTATA
TAGTTACTGA AATGACGAGA CACAGCATTATAAAGAACCT CATATTCTGT CTCACAGTTT
2220 CCCTCCAGTG TTCGATATCT TAACTATCAT CAGAAATGGGC AGAGATGATC
TTGAAGTGTC ACATACTA AAGTCCAAAC 2400 AATCCATTAA AAAATAATTA
TAAGATGATA 2460 TCAGCCCAAT GTCAACCCAG TTAACCAAAA AATTAATGCT
GTGTAAAATG 2520 TTTGCAAAC ATATAAGAC AAAAGTCTGT TAATGCACAT 2580
CCTGTGGGAA TAACCAATTG TTATCTGAGC TCTCCTATAT 2640 TATCATACTC
AGATAACCAA ATTAAAAGAA TTAGAATATG ATTTTAAATA CACTTAACAT 2700
TAACTCTTC TAACCTTCTT CTTTCTGTGA TAATTCAGAA GCCTCTGAGT CCATGCTATA
GGAGACTGGG 2820 CAAAACCTGT ACAATGACAA TGCTTTTTTT AAAAAAATAA
TAAATTTCTT 2880 TTTTTTCTGG TTGTCTGTTT GTTATAAAGT GCAACGKATT
CAAGTCCTCA 2940 ATATCCTGAT CATAATACCA TGCTATAGGA AACCTGTACA
ATGACAACCC 3000 TGGGAAGTTGC TTTTTTAAAA AAATAATAAT TTNTTAATCC
AAAAAANAA (2) INFORMATION FOR SEQ ID NO : 95 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1099 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
95 : GGCTTTGTAG CTGCTCCGCA GGCGCGCTCG 60 GGCNTCCTGC CTCCTCCCTC
CCTCCGCGGT GCCTGCCTTC 120 ATCGTCATTC 180 CAGTTCTGCT AAAAAATTCC
TATATACCCT 240 CCTTCGTTAG CCTAAGAAAG CAATACAAGA ACAACAAAG 300
GCAGACATGA CCAACAGAAA 360 TCTGTGATAA AAAGAAAGAC TAAAGAAATT
TTCCTAAAGG ACCCATCAT TAAAAAATG 420 GACCTGATAA TATGAAGCAT
ATTGTCTCTG CTGAGACCGG 480 ATATTACCT GATACTAATC 540 ATTTAAATG
TAGTTAGTTA TATTTAATGA AAGTTCCTTT TCGTTAATG 600 TAGCTTTCAT
TAATATGATT TTTGTGCCAG 660 GTTACTAAAT AAATCTTTGG TTCTCTAATT

CATATGAATT 720 TGCTGTTTGC TCTAATTTCT TTGGGCTCTT CTAATTTGAG 780
AAACAGTCCA GTGAAACTGT TTTTGGGAGG 840 AAGATTTAAT AATTACTGTC
GAGCAGCTTG TCCACAAATA 900 TAGTAATTAC TATTTATTGC ATTAAAAAAA 960
TTCTTTGAAA AATGAAACAT AATGTCTAAT TATAAAATTT TAATCCTTAC 1020
TGCATTTCTT CTGTTCTTAC AAATGTATTA 1080 AAAAAAACCC 1099 (2) INFORMATION
FOR SEQ ID NO : 96 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1580 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 96 : GGCAGAGACT GGAATCTCTC TTCATGAAAA
AATGCAGCCC GTGCAGCTCC TTCTCTCCAC GATTCTCCTT ATCCTGCTGT CCTGCTCTTC
AGATGAGACG GGAATAGAAC TTTTGGCCA CCCCTTCTCT CTAGGCTGGG CCAGCCCCTT
300 TGCCACGCCA GTACCAGTAT AAGTCCACAC AATGTTTAAA TCGAAAAAGC
AAAACAATA CTCTTAAAC TTTTTTATG TCTCAAGTAA 480 CATTGCAGAG
GTCCCCACAT TTTATTTTTT CTTTCGATTT CCGAWGCTGC TCTCTTTTCC CTCTCTGCTG
TCTGTCTGGC ATGACTAATG TGTCTCGCGC 660 CTACTAACTG AGTGAGACAT
GACGCTGTGC CTCCCACTGC TCACCGAAGA CCCCTTGAGG 840 GGCACAGCGA
CCTCATCCCC CGGTTTGCCT GCTAACTCGC AAAGCAATTG CCTGCCTTGT AAGATGAAAG
ATCAGCAATT TGATTATTTG TAGGAAAGAC GTTTTTCCAG 1080 TTCAAAATGC
CTTATACAAT CAAGAGGAAA AAAAATTACA TTTCCTTTGT TTCATCTGCT TCCTCTCTCA
TCCCTCTCTT CCCCAGCAAG 1200 AGCAGTGTGA ATTCTGACTG CCCACCATCA
TCCCCTTCTC GATTCACCTT CTGATAGTTA 1320 ACCCCCATAA TATCTATATT
GGTTACCTCA CCTTTCAAAG 1440 TTNGACATAT GGGCCATCCC GGACACACCT
GMAYTGGGGG TTTCCATTTT CTTTCCCTGT TGTTCAAGTTC 1560 (2) INFORMATION FOR
SEQ ID NO : 97 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 678 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 97 : ATATTTTTTT AGGCTAATGT GCATTGAGGA
GGCAGCTATG 60 GCTCTCTTGT TTGCTAGAGA GTATACTAAT TGTACTTAAA 120
ATACATTTTA CTAATCATAT TGATTTTAAA TATGACAAAT TCTTCTAGTA GATACTAATC
180 TTTCTTGTTT ATCATATTGT CCTAGAGAAG AATGGGTTCC ACCTAGTCTG 240
ACCTTCCCCC GTCCCCTCTC AATTGGGCTC TATGCATATT 300 TAAGAAAACC
TTAGGTTTCT TTTCCAAAAC 360 TTTGACTCAA CAAGAAGAGG GTCTTATCTT
TTTATCATTT 420 TGTTTCTCTG TATGCTTAGA AAATTTTACA 480 TAGAGTGCTT 540
ACCTTTTTGA TCATGAATGA 600 TTWAKGTTGT GCTGAGAAAA 660 GGAAAACATG
CATTCNGN 678 (2) INFORMATION FOR SEQ ID NO : 98 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1253 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
98 : ACCTCCCTCC CTCTCAGACT GTCCGAATC 60 CCAGCCACTT CCCTTGCTGTG
TTCCAGCTC 120 CCTTGCTCAG GCCCAGACCC GTTACCCCA 180 GACGCTCGTC
AGTTCTTAGA CTAAAGAGAC CCCCCTCCTG 240 CCTCCTTTCT TTCTCTGTCT
CTTCCTTCTT TTAGTCTTT TTCATCCTCT TCTCTTTCCA 300 CCAACCCTCC
TGCATCCTTG CCTTGACGCG 360 CAGTCTTCTT TTATTTATAA CTACCACCA
CCCTGCTGCA GTCTTGTA 420 CCTCCTTCTT CCCCCTTCT CTCTCCCTC
ATTCTTTCT CTCTCCTTCT 480 TTCCTTACAC TCTGACATGA ATGAATTATT
ATTATTTTTC TTTTCTTTT 540 TTTTTTTACA ATTTAAACAA ACTTATTATT ATTATTTTTT
600 TGCTCCCTCC CCCCAGTGC 660 TGNAGTCTGT ACCTAGTACA 720 TGGGATCCCG
TGTACCGAGT AAGTAGGCAC 780 CTCCCCACCC 840 ATTCCAGATT 900 AACTCCCTCT
GCCCCAGCCC CATCTCCCTT 960 AATGTGGGAC 1020 TACAAGAAGA TTCTCTTCTT
TGGCCCAGCC 1080 TTTTGTAAAT ATGGCTTCTG GTCAAAATCC 1140 CTGTGTAGCT
GAATTCCCAA CCACTCCCCT 1200 TAAAGGAATA GTTAACACTC 1253 (2) INFORMATION
FOR SEQ ID NO : 99 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 447 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 99 : CAAAGAATGA AATTTACCAC TCTCCTCTTC 60

CCTCCTCTGA GCTGATCCTG TGGGACCTCT 120 AAGCCTAATG AAGAGATCTC
GAACCAGCTT 180 AGAYTTCGGC CCAAGGTCAC CTCAAGCAGG 240 GAGAAAAGTA
TCTTACTAAC AGAACAAGCC 300 AATGCACGGA ATTCATCGAA 360 AATGGAAGTG
AATTTGCACA AAAATTACTG AAGAAATTCA GTCTATTAAA ACCATGGGCA 420
TGAGAAGCTG AAAAGAATKG GATCATT 447 (2) INFORMATION FOR SEQ ID NO : 100 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 611 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
100 : GGTCTGGGGA GGTGACATGT TGGGCTGTGG GATCCCAGCG CTGGGCCTGC 60
ATGGAATCCA 120 ATTCGATAGC CCCAACYTCT 180 GCCTGCGTCT CCGGTGCTGC
TACCGCAATG 240 CTGGACGTGC AGCGGCCTCC TCCTCCTGAG 300 GGTGGGCCAA 360
CGTCTCGCTG CTCTCCAAGC 420 AGTCGCCCTG TCCAAAGAGT 480 GCGAGGAAGA 540
GGGAGTCCCC 600 AAAAAAAAAA A 611 (2) INFORMATION FOR SEQ ID NO : 101 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 609 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
101 : GCATTGGTAA AGCTTGCGTC TCTTCTGCCT 60 TCGTGCCCTG 120 AGCACAGCAA
CTGCAGGAGC 180 ACCCTRARAT 240 AGGCTGTTTT TACAGTTTTT TTTTTTTTGT
TGTTTTGTTT TTAAAGAATA 300 CAAGCTTTTT TGCACTTTGT 360 GGAAAAACCT
AATGCATAAT AGTACCCAA 420 GAACCAGGCT ACTGCCTTAA 480 TGTCCCTGTG
CCCAGCACTG GGGGCTCGAA GACTGGTTTC 540 GGTCACGGCC ATGTCGTCTT
AGAAGGGTCC TTACGTTGA GTCCATTTTT 600 AATGTTCTG 609 (2) INFORMATION FOR
SEQ ID NO : 102 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1770 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 102 : ACGGYCCGGA ATCCCGGGTC GACCCACGCG
TCCGGGAAAT TGGCCACGA 60 TGGGAAGAGG GGAAAGCCCA AGGCCTCTGG
GTGAAGGCAG AGGCTAACAT 120 GCGACCTTGG CCGTTGGCCT GTGCTGTCTG
TCGTACTAT 180 CATCATCTGC CCTGCTGCTG ACGTGCCGCC 240 ACCACCACAT
GGTGCATGCC CTTATCCTC AGCCTCCAAG 300 TGTGCCGCC AGCTACCTG
CCAGGGCTAC CACACCATGC 360 AGGGATGCCA GCAGCACCT GTACCCACCA
CCTTACCCAG CCCAGCCCAT 420 GGGCCACCG AGACCCTGGC TGGAGGAGCA
GCCGCGCCCT ACCCCGCCAG 480 TACAACCCGG TGCCCCGAAG SGNCCCTCTG
AGCATTCCCT 540 GGCCTCTYTG GCTGCCACTT GGTTATGTTG TGTGTGTGCG
GCAGGCGCGG 600 TTCCTTACGC CCCATGTGTG CTGTGTGTGT CCTGCCTGTA
TATGTGGCTT CCTCTGATGC 660 TGACAAGGTG GGGAACAATC CTTGCCAGAG
CCAGACTTTG TTCTCTTCCT 720 CACCTGAAAT TATGCTTCCT AAAATCTCAA
GCCAAACTCA AAGAATGGGG TGGTGGGGGG 780 CACCCTGTGA GGTGGCCCCT
GAGAGGTGGG GGCCTCTCCA GGAGTTCTTC 840 TCCAGCTTAC CCTAGGGTGA
CCAAGTAGGG CCTGTCACAC 900 TGTGATGCAG ATGTGTCCTG GTTTCGGCAG
GGCCATGGCT 960 CGTCCCCGGA GTTGGGGGTA CCCGTTGCAG ATGATGCAGG 1020
GATCTGGCCA AGTTGGACTT TGATCCTTTG GGCAGATGTC CCATTGCTCC CTGGAGCCTG
1080 TGGGGATCAG GATGCCAGAA AGAGCCCTAC 1140 TCAGCTGTAC CTGTCTGCCT
GGACTGTCCC CTGTCCCCGC ATCTCCCTG GGACCAGCTG 1200 GCCTAGCTGC
CTCTGCTGCC CTTGCTGGCC 1260 CTGCCCTTCC CACAGGTGAG CAGGGCTCCT
CTCTTCCCTG 1320 CAGTGTTTTT ATTTTATTTT TTTGCCTGTT TTCTGTTTCA
AACATGATAG 1380 TTGATATGAG ACTGAAACCC CTGGGTGTG GGCTCAGAGA
TGGACAACCT 1440 GGCAACTGTG AGTCCCTGCT AGCCTCATGG AATATGCAAC
AACTCCTGTA 1500 CGGTGTTCTG 1560 GGTGGGGTGT GGGGCCCTGG ATGGCAGCTC
TGGCCAGAC ATGAATACCT CGTGTTCTC 1620 CTCCCTCTAT CTTAGCTCAA
ATCTGTTGTG TTTCTGAGTC 1680 TAGGGTCTGT ATAATAAATG 1740 TCGTAGGGGG
GGCCCGTACC CAATSGCCTA 1770 (2) INFORMATION FOR SEQ ID NO : 103 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1832 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :

103 : TGTGGCTGAC GTCATCTGGA GGAGATTTGC TTTCTTTTTC TCCAAAAGGG
GAGGAAATTG 60 AAAGTGCAGT GGCCACGAT GGGAAGAGGG GAAAGCCCAG
GGGTACAGGA GGCCTCTGGG 120 GGGTTCGGAG CGACCTTGGC CGTTGGCTGA
CCATCTTTGT 180 GCTGTCTGTC GTCACATCA TCATCTGCTT TTTACAAGAC 240
GTGCCGCCGA ACCACTGTGG TGCATGCCCC 300 CCTCCAAGTG TGCCGCCAG
CTACCCTGGA CCAAGCTACC 360 CACCATGCCG AGCACCTAC 420 TTACCCAGCC
CAGCCCATGG GCCCACCAGG CTACCACGAG ACCCTGGCTG 480 CGCGCCCTAM
CCCGSCAGCC AGCCTCCTTA TACATGGATG CCCGAAGCGG 540 CCCTCTGAGC
ATTCCCTGGC CTCTYTGGCT GCCACTTGGT TATGTTGTGT GTGTGCGTRA 600
GGCGCGGTTT CTTACGCCCC ATGTGTGCTG GGCACGGTTC 660 CTTACGCCCC
TGTGTGTCCT GCCTGTATAT GTGGCTTCCT CTGATGCTGA 720 ACAATCCTTG
CCAGAGTGGG CTGGGACCAG ACTTTGTTCT 780 TGAAATTATG CTTCTAAAA
AACTCAAAGA ATGGGGTGGT 840 CTGTGAGGTG GCCCCTGAGA GGTGGGGGCC
TCTCCAGGGC 900 GCTTACCCTA GGGTGACCAA GTAGGGCCTG TTCTGTGTGA 960
TGCAGATGTG TCCTGGTTTC GGCAGCGTAG CCAGCTGCTG TGGCTCGTCC 1020
CCGGAGTTGG GGGTACCCGT TGCAGAGCCA GGGACATGAT GCAGGCGAAG
YTTGGGATCT 1080 GGCCAAGTTG GACTTTGATC CTTTGGGCAG 1140 CCTGTTGGGG
CTCCTGATGC 1200 TGTACCTGTC TGCCTGGACT GTCCCCTGTC CCCTGGGACC 1260
GCTGCCCCCA GGGAGCTCTG CTGCCCTTGC TGGCCCTGCC 1320 CTTCCACAG
GTGAGCAGGG CTCCTGTCCA CCCTGCAGTG 1380 TTTTCATTTT GATAGTTGAT 1440
ATGAGACTGA AACCCCTGGG TTGTGGAGGG AAATTGGCTC AGAGATGGAC
AACCTGGCAA 1500 CTGTGAGTCC CTGCTTCCCG GCAACAACCTC 1560 GTCCACGGTG
AGGGACACCT GCCATCTGGA CCAAAGGTGG 1620 GGTGTGGGGC CCTGGATGGC
AGCTCTGGCC TACCTCGTGT TCCTCCTCCC 1680 TCTATTACTG CTCAAATCTG
TTGTGTTTCT GAGTCTAGGG 1740 TCTGTACACT TGTTTATAAT AAATGCAATC
GTTTNGGAAA AAAAANANAA AAAAAAAGG 1800 GSGGCGCTC TAAAAGGATN
CCCCNAAGGG GG 1832 (2) INFORMATION FOR SEQ ID NO : 104 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 2237 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
104 : AGTTCCCGGT ACTTTATTAC CAAGGTTGCC ATCGGAACCA GGAATGACAT
TACTCACTAT 60 CAGAATTGAG AAAATTGGTT TGAAAGATGC ATCGATCCCT 120
TAGTGTAAG GATCTGAATG AACTCCTGTG CTGTGGCTTC 180 AAGAAAAGAA
GATACATATG TTCATTTTAA TGTGGACATT AGCATGTTGA 240 AAAATTAACC
AAAGGTGCAG CTATCTTCTT CACTACAAGC 300 GTTTACCAGC TTGCTTTCAT
GGAGATGGAT GAAATTAAC 360 TGTAATAGAA CTATACAAGA AACCCACTGA
CTTTAAAAGA AAGAAATTGC AATTATTGAC 420 CAAGAAACCA CTTTATCTTC
ATCTACATCA AACTTTGCAC AAGGAATGAT CCTGACATGA 480 ACTTCTGTGA
ATTTTACCAC TCAGTAGAAA CCATCATAGC TCTGTGTAGC 540 ATATTCACCC
TTCAACAGGC AGGAAGCAAG CGGACGGAGT 600 GCTGTACCAC GTATAGGACT 660
CCTTGGGATA CAGGTTTATT TTACTTTTCT ATTAATTGTG 720 CAATTAATAG
AATTTACCAC TACTCCTACC CTGCTTCTTG GTTGTGGGTA GGATGTGCTC AATAAGAATG
TGCTAGAGTT 840 CTCTTTTGAC GCTTTGGGT 900 GATGTGGGTA GGGTAGTGTC
AAACTGCTTT GAGAGGAATG GGACCAGTTC GAAGGTCTGT CTGGATGTTT
CCTCTGAAGT GGCCTAAATT TGATAGTTT CCTGCTTAGA AAGTGTGCCT TGGCCAGATC
AGTATCCCAC ATGGGAGTGT 1080 TCCCTAGGTT GTAGCTGTGA TTGTTTCCAG
TGTTTTTCTG TATTTTGTAGT CATGTCGATT AGCTGTTCTT TTGTTACTCT TTCTGATGAT
1200 GATTCTAGGG TTAACATTGG AAATAATTAC AAAGTTTTAG AATGTCTTCT
ATCTAAAAAT AATTGAGTCA GATGCTAACG AGATACTGCA 1320 GGCATAACTG
CTGTTTTTCT GACAACCTGAT TGTGAAACCT TAAAACCTGC ATACCTCTTC 1380
TTACAGTGAG GAGTATGCAA AATCTGGAAA GATATTCTAT TTTTTTATA TAGGTAGATA
1440 GGATCGCCAT TTATTTCTTA TTAGATATA CTGACATTCA TCCATATGAA

AATATGCAGG 1500 ACTATAATTT TAATGGGGCA TAAATAAAAC CACATGAGGT
 GGATATTTGA TACACAGAAC ATTTGCGGTG GGCTTTCTGT GGGTTAGATG 1620
 TAAAGCCCAC ATATTTTAAT TTAAATGAGC AATGCATGAG GGGGAATGCAG 1680
 TGTCAGTACC TGGCCTATTT TTAAACTAGT GTAATCACCC TAGTCATACC TTTGCTTTTT
 AAAATAAGTA ACCACAATTA GCCCTTGCAC TTCAAGAGAT 1800 CTAGTCTTTA
 CTTTCAGTTG TCTGTTAGGT TACTAGACGG ATGTTAATAA 1860 AACTATGCG
 AGCCTGAATG AATTCTCAGC CAAATTTAGT CTTGTCTCTC GATTAATTCC AAATTCTAAA
 TCTAGGGGAT GAAGAATTTG 1980 CCTTACTTTG CCCAGTTCCT AAGACTGTGA
 GTTGTCAAAT CCCTAGACTG TAAGCTCTTC 2040 AAGGAGCAAG AGGCGCATTT
 TCTCCGTGTC ATGTAATTTT TCTAAGGTGT TTGGCAGCAC 2100 TCTGTACCCT
 GTGGAGTACT CAGTACCTTT TGTGTGATGT ACCTGAAAAA 2160 AAATCCCTTA
 CCATTAAAGT GTAGCAAAAC CGAAAAAAA AAAANAAAAA 2220 ACTCGAGACG
 GGCCCGG 2237 (2) INFORMATION FOR SEQ ID : 105 : (i) SEQUENCE CHARACTERISTICS :
 (A) LENGTH : base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 105 : GGTGACCCA CGCGTCCGGA
 ATTTTCGTAG AGTAATTTGC 60 ATTAGCAAGG TTGTAACCTC TGCCTCTTG
 TTCTCGTGCC CCAGCCTCCC 120 GAGTAGCTGG GACTACAGGC ACGCCAGCT
 AATTTTATA TTTTAGTAG 180 AGACGGGGTT TTGCTGTGTT AGTAATCCAC 240
 CTGGCCTGCT CTTTTCATGT CTTAACATGG TTTTCCTACT 300 CCTTGTATGT
 CAAGAAATTA GTCTTATGGA GATGCTGTTA ATTGCTTCAG 360 TGAGTGCTTT
 TCTAATCTGC AGACCATTTA CTGTGTGCAA 420 ATTTGGAGTA TTCAATTATT
 TGTTAGGGCT CTTCTATTT CCAATGTGC 480 TGAATTGTCT ATTGATGGGA
 TTTTCAGATC TTTTCATGAG GTAGCTGGGT 540 GGCACCTACC TAGGTTGCTA
 CGTAGTGAGT AGACTTTCTC TTGGGTATAG TAAGCCTCAG 600 CTTTATCTA
 CTTTACTTGT GGAAATAAAA CAGTCATTTT GTTCTGAAAG 660 AATAAGATAG
 CTTTCTGTAG AGAAGGAATT CCTACCTCTA AAAGCTGCCT TGAGAACTCA 720
 GAACTGGCAG TTTTCTGAGG TGATTTTAA ATTTCAGTAT TAGGGAGAGT CCAGCATTTG
 780 CTAATGTATG ATAGCAAATG ATAATGTGGT 840 GTATCTTGCG TTAGAACAAG
 TAGACTCTGG CCAGAGACCC 900 AAGTTTAGGT TATTTGAAGT AGTTATACTC
 CTGGCTTAAG 960 CCTGGGAGAA TCCATTACTG AAAAGCATTT AACTTAAAAA
 AAAAAAAAAA AAAAAAAAAA 1020 AAACCTCGTG CCGAATTCGG CACGAGCTAA
 CCCAGAAACA AACTGAAGC 1080 TCGCACTCTC GCCTCCAGCA TGAAAGTCTC
 TGCCGCCCTT CTGTGCCTGC TGCTCATAGC 1140 AGCCACCTTC GGCTCGCTCA
 GCCAGATGCA ATCAATGCCC 1200 CTGYTATAAC TTCACCAATA GGAAGATCTC
 AGTGCAGAGG CTCGCGAGCT ATAGAAGAAT 1260 AAGTGTCCCA AAGAAGCTGT
 ACCATTGTGG CCAAGGAGAT 1320 CTGTGCTGAC AGTGGGTTC ACAAAGCAAAC 1380
 CACTACTCC TAACTTATTT 1440 TCCCCTAGCT TTCCCAGAC ACCCTGTTTT
 ATTTTATTAT AATGAATTTT GTTTGTTGAT 1500 ATGCCTTAAG TAATGTTAAT
 TCTTATTTAA GTTATTGATG TTTTAAGTTT 1560 GTACTAGTGT TTTTAGATA
 GGGAAATTGC TTTTCTCTT 1620 TCTACCCCTG AGGGTCTTTG TAATACAAAG 1680
 AATTTTTTTT AACATTCCAA TGCATTGCTA AAATATTATT GTGGAAATGA ATATTTTGTA
 1740 CAAATAAATA TATTTTGTG CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1800
 AAGSGGCCGC TCGAATTAAG CC 1822 (2) INFORMATION FOR SEQ ID NO : 106 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 1712 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 106 : CGTGCCCCAG CCTCCGAGT ACAGGCACGT SCCACCACGC CCAGCTAATT 60
 TTWATATTTT WAGTAGAGAC GGGGTTTTSC TGTKTTGGCC AGGCTGGTCT 120
 CCTGCTCTTT TCATGTCTTA TCTTTTAGTT 180 TCATTATTTT CCTACTCCTT
 GTATGTCAAG TTGCATGTCT TATGGAGATG 240 CTGTTAATTG CTTCAAGTGA
 TGCTTTTCTA ATCTGCAGAC TCCTGTTTGC 300 AGCATGCTGT GTGCAAACAC
 GGAGTATTCA ATTATTTGTT AGGGCTCTTC 360 CTATTTCCAA ATGTGCTGAA

TTGTCTATTG ATGGGATTTT 420 GGAAATGTAG CTGGGTGGCA CCTACCTAGG
 TTGCTACGTA GTGAGTAGAC TTTCTCTTGG 480 GTATAGTAAG CTTTCACTTT
 TATCTACTTT ACTTGTGGAA 540 CATTITGTTC TGAAAGAATA AGATAGCTTT
 CTGTAGAGAA GGAATTCCTA CCTCTAAAAG 600 AACTCAGAAC CTGAGGTGAT
 TTTTAAATTT CAGTATTAGG 660 GAGAGTCCAG CATTGCTGA CACAGATTCT
 ACATAACTAA 720 ACTATTATAA TGTGGTGTAT AACAAGTAGA 780 AGATCTCCAG
 AGACCCAAGT TTAGGTTCTC ATAGTGTATT TGAAGTAGTT ATACTCCTGG 840
 CTTAAGTAGT TTAGTGCCTG GCATTAACT TAAAAAAAAA 900 TCCAATTCTC 960
 AAACTGAAGC TGAAAGTCTC TGCCGCCCTT CTGTGCCTGC 1020 GGCTCGCTCA
 ATCAATGCCC 1080 CTGYTATAAC TTCACCAATA GGAAGATCTC AGTGCAGAGG
 CTCGCGAGCT 1140 AAGAAGCTGT ACCATTGTGG 1200 CCAAGGAGAT CTGTGCTGAC 1260
 AATCTGCAGC 1320 TCCCCTAGCT ACCCTGTTTT ATTTTATTAT AATGAATTTT 1380
 GTTTGTTGAT ATGCCTTAAG TAATGTAAAT TCTTATTAA GTTATTGATG 1440
 TTTTAAGTTT CAGAGACTTG GGGAAATTGC 1500 TTTTCCTCTT TCTACCCCTG 1560
 TAATACAAAG AATTTTTTTT AACATTCCAA TGCATTGCTA AAATATTATT GTGGAAATGA
 1620 ATATTTTGTG ACTATTACAC CAAATAAATA TATTTTGTG AAAAAAAAAA 1680
 AAAAAAAAAA AAGSGGCCGC TCGAATTAAG CC 1712 (2) INFORMATION FOR SEQ ID NO :
 107 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1969 base pairs (B) TYPE : nucleic acid
 (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID
 NO : 107 : CCCCTCCTTC CCCTYGCCAC CTACTGAACC CTCCTCCGAG GTGCCCCGAGC
 AGCCGTCTGC 60 CCAGCCACTC CCTGGGAGTC CCCCCAGAAG AGCCTATTAC
 ATCTACTCCG GGGGCGAGAA 120 GATCCCCCTG GTGTTGAGCC GGCCCCCTCTC
 GCCACTCTTC AGCATCTCTG 180 TCGGAAGACC GTCAACGGCC ACCTGGACTC
 CTATGAGAAA TGCCGGGGGCC 240 CATTCCGRAG TTCCTGGACC AGTACGATGC
 CCCGTTTTAA GGGGTAAAGG GCGCAAAGGG 300 CATGGGTCGG GAGAGGGGAC
 CTCCTCCGTG 360 GGAGAGAGTC CTGTAGCTCT GGCCCCCTCCC 420 TCTGCCCTCT
 TGTGGCAGGC GGACCTGGAA TGTGTTGGAG GGAAGGGGGA 480 TTCTCCGGAG
 CCTGGTGGGA 540 CACAAGTGGA TTCTCCTTCA CCTCCAAACA 600 CGGGAATGCT
 GAAYTAATGA GGAATCTTCA AACTTTCCAA 660 TTGCTCTTTG AACCTGAGCT
 GGTTGTGGAG CCTGGGAAAG GTGGAAGAGA 720 GAGAGGTCCT GAGGGCCCCA
 GGGSTGCGGG AAATGGTCAC ACCCCCCGCC 780 CACCCCAGGC GAGGATCCTG
 GTGACATGCT CCTCTCCCTG GCTCCGGGGA GAAGGGCTTG 840 GGGTGACCTG
 AAGGGAACCA TCCTGGTGCC TCCTCCGGGN ACAGTCACCG 900 TACCTGGTGC
 CTGAGAGCCC AGGGCCCTTC CTCCGTTTTA 960 AGGGGGAAGC AACATTTGGA
 GGGGACGGAT GGGCTGGTCA GCTGGTCTCC TTTTCCTACT 1020 CATACTATAC
 GGAGCGGGAG GATGGAGGAG 1080 AGAGAAGACA GGGGATTCTA CTCTGTGCCT
 CCTGACTATG 1140 TCTGGCTAAG AGATTCGCCT TAAATGCTCC GAGAGGGACC 1200
 CTCAGCCTGG AGGCTGAGGG 1260 GCCAGGGAAG TGGGGAGGGG GGGCGGAAAC
 CCATGCCTCC 1320 CTGGGAATGT CAGCCCAGTA AGTATTGGCC 1380 ACCAGGTCCC
 ACTGCCCCGA GCCCTCCCTC CTGCCTGGGT GGGGGAGGCT 1440 GGAGAGGCTG
 ACCCCGGGTG CTCCCGCTCT GCCATAGCAC 1500 TGATCAGTGA CAATTTACAG
 GAATGTAGCA GCGATGGAAT TACCTGGAAC ATTTTTTGTG 1560 TTTGTTTTTG
 TTTTTGTTTT TGTGGGGGGG GGCAACTAAA GTATTCTGTG 1620 GGCAGTTGTG
 TGTGTTGGTG GTTTTTTTCT CTATTTTTTT 1680 GTTTGTTTCT TGTTTTTTAA
 TAATGTTTAC AATCTGCCTC TCTTTTATAA 1740 AGATTCCACC TCCAGTCCTC
 TCTCCTCCCC CCCTTGAGGC TATTAGGAGA 1800 TGCTTGAAGA ATCCCAATCC
 AAGTCAAACCT TTGCACATAT TTATATTTAT 1860 GAAACATTTT AGTAATTTAT
 AATAAAGAGC ACTATTTTTT AATGAAAAAA 1920 AAAAAAAAAA AAAAAAAAAA
 CGACGCTGGT GACCGGAATY CGACGTACG 1969 (2) INFORMATION FOR SEQ ID NO : 108 :
 (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1734 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :

108 : CGGGTCCCAA GCCTGTGCCT GAGCCTGAGC CTGAGCCTGA GCCCGAGCCG
GGAGCCGGTC 60 GCGGGGGGCTC CGGGCTGTGG GACCGCTGGG TGGCGACCTT
GTGGGGAGGC 120 TTGGCTCCTT CGCTTTCCGT GCTGCTGCTG 180 GCGCATGTNC
AGACGCCGCC AAGAATTCG ATGTAAATGT ATCTGCCCTC 240 CCTATAAAGA
AAATTCTGGG CATATTTATA ATAAGAACAT GATTGTGATT 300 GCCTTCATGT
TGTGGAGCCC ATGCCTGTGC GGGGGCCTGA TGTAGAAGCA TACTGTCTAC 360
GCTGTGAATG CAAATATGAA GAAAGAAGCT ATTATAATTT 420 ATCTCTCCAT
CTACTTCTGT ACATGGTATA TCTTACTCTG GCGCCTCTTT AGTTGATACA GAGTGATGAT
GATATTGGGG 540 ATCACCAGCC TTTTGCAAAT TGCTAGCCCG CGAGCCAACG 600
TGCTGAACAA GGTAAGATAT GCTGGAAGCT TCAAGTCCAA AGTCTGTCTT
TGACCGGCAT GTTGTCTCA AGAAAGAAAC AGGCAGACAA CTGGGAAAGA
AATACCTTGT AACTGTTGCT GGAAGATTCA AACTGGAAG CTTGATTTTT TTTTCTTGTT
AACGTAATAA TAGAGACATT AGTCAGCCAA TAAGTCTTTT CCTATTTGTG ACTTTTACTA
ATAAAAATAA ATCTGCCTGT 960 AAATTATCTT GAAGTCCTTT ACCTGGAACA
AGCACTCTCT TTTTACCAC ATAGTTTTAA 1020 AAGATAATTT TGTTGTTGTT
GTTTTTTGTT GGTGGGAGAG GGGAGGGATG CCTGGGAAGT TCACTTTACT 1140
AAACAACTT TTGTAAATAG ACCTTACCTT CTATTTTCGA GTTTCATTTA TATTTTGCAG
1200 CTCATCAAAG AGCTGACTTA CTCATTTGAC TTTTGCCTG CTGGGTATCT
GCTGTGTCTG CACTTCATGG TAAACGGGAT CTAAAATGCC CAGATTTTCT TCATGTACTG
TGATGTCTGA TGCAATGCAT CCTAGAACAA 1380 TGCTAGTTTA CTCTAAAGAC
TAAACATAGT CTTGGTGTGT GTGGTCTTAC 1440 GTACCTTTAA GGACAAATCC
TAAGGACTTG GACACTTGCA ATAAAGAAAT 1500 TTTATTTTAA CCCTGGATTG
ATAATATATA CACATTTGTC AGCATTTCCG 1560 GAGGCAGCTG TTTGAGCTCC
AATGTGTGCA GCTTTGAACT AGGGCTGGGG 1620 TTGTGGGTGC CTCTTCTGAA
AGGTCTAACC ATTATTGGAT AACAATAAAA (2) INFORMATION FOR SEQ ID NO : 109 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 2003 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
109 : GCGCGGCCCG GGGACTCGCA TTCCCCGTT CCCCCTCCAC CCCACGCGGC 60
CTGGACCATG GGTGGTGCTG GCTGCGTTCC CCTCCCTAGG 120 GGCAGGTGGG
GAGACTCCCG AAGCCCCCTC GGAGTCATGG GGTTCCTCCG 180 ATTTGTGGTG
AATGCTGCTG GCTATGCCAG NTTTATGGTA CCTGGCTACC 240 GTACTTCAGG
CGGAAGAACT CGGTAGGGGC CTCTGCTTTC 300 AGCTTGTGTG AGCCCAAGGC
CTCTGATGAG GTTCCCCTGG CGCCCCGAAC 360 AGAGGCGGCA GAGACCACCC
CGATGTGGCA GGCCCTGAAG CTGCTCTTCT 420 TCTTATCTGA CTTGGGGTGT
GCTGCAGGAA AGAGTGATGA CCCGCAGCTA 480 GCCACATCAC CGGGTGAGCG
CTTTACGGAC TCGCAGTTCC TGGTGCTAAT 540 GAACCGAGTG CTGGCACTGA
TTGTGGCTGG CCTCTCCTGT GTTCTCTGCA AGCAGCCCCG 600 CCCATGTACC
GGTACTCCTT TCCAATGTGC TTAGCAGCTG 660 GAAGCTCTTA AGTTCGTCAG
CCAAGGCCTC 720 TAAGGTGATC CCTGTCATGC TGATGGGAAA GCTTGTGTCT
CGGCGCANTA ACGAACACTG 780 GGAGTACCTG ATGTTTCTGC TATCCAGCGG 840
ACCAGAGCCC CGCAGCTCCC CAGCCACCAC ACTCTCAGGC CTCATCTTAC 900
TATTGCTTTT GCAGGATGCC TGTTTGCCTA 960 TGATGTTTGG TTCTCCTGCC
GGGSTCACTG 1020 CTAGNAACAG GGGGGMCCTA CTGGAGGGAA CCCGCTTCAT
GGGGCGACAC AGTGAGTTTG 1080 CTGCCCATGC CTGCTACTC CCAGCTCTTC 1140
GTTTGGGGCT GCCGTCTTCA CCATCATCAT GACCCTCCGC CAGGCCTTTG 1200
TTCCTGCCTT CTCTATGGCC AACTGTACAC GGGCTGGGGG 1260 TGGCTGTGGT
CTCCTGCTCA GAGTCTACGC GCGGGGCCGT 1320 GGGGAAAGAA GGCTGTGCCT
GTTGAGTCTC CTGTGCAGAA GTTTGAAGG 1380 CTGAGGGGTG AAGTGAAATA
GGACCCTCCC ACCATCCCCT TCTGCTGTAA CCTCTGAGGG 1440 AGCTGGCTGA
AAGGGCAAAA TGCAGGTGTT 1500 GGGGATTGGG GGCAGCCTTC TAAGTCACCC 1560
TTCTGAGCCC CGGGGGTAGA 1620 GGGGTCAAGA GTTACTCTTC CCTTAAGTCT 1680

TGCCCTAGCT GTGCTCTGCC CTCCTCCCC TCTGCAAATA CCTGCATTTC 1740
TTACCCTGGT GAGAAAAGCA CAAGCGGTGT GCTGCTTTCC 1800 AAGATGGTGC
TGTGCTGAGG AAAGGGGATG CCACCTCCTA 1860 TCCCTAGGCT CTGTTCCATG
AGCCTGTTGC AGGTTTTTGGT ACTTTAGAAA 1920 TGTAACCTTT TGCTCTTATA
ATTTTATTTT ATTAAATTAA ATTACTGCAA AAAAAAATCG GGGGGGGGCC CGN 2003 (2)
INFORMATION FOR SEQ ID NO : 110 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
1320 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 110 : GCTGAGCTGC CTTGAGGTGC AGTGTTGGGG
ATGTCGGACC TGCTACTACT 60 GGGCCTGATT GGGGGCCTGA CTCTCTTACT
GCTGCTGACG CTGCTGGCCT TTGCCGGGTA 120 CTCAGGGCTA CTGGCTGGGG
TGGAAGTGAG TGCTGGGTCA CCCCCATCC GCAACGTAC 180 TGTGGCCTAC
TGGGGCTCTA TCACTGAGAG 240 TCTCCCAAGC TCCGCTCCAT CGCTGTCTAC
TATGACAACC CCCACATGGT 300 GCCCCCTGAT AAGTGCCGAT CAGCATCCTG
AGTGAAGGTG AGGAATCGCC 360 CTCCCCTGAG CTCATCGACC TCTACCAGAA
ATTTGGCTTC AAGGTGTTCT CTTCCCCGGC 420 ACCCAGCCAT GTGGTGACAG
ATTCTGTCCA TCTGGCTGGC 480 TACCCGCCGT GAGCGGAAGC TGTGTGCCTA 540
TCCTCGGCTG GAGATCTACC AGGAAGACCA GATCCATTTC ATGTGCCAC 600
GGGAGACTTC TATGTGCCTG AGATGAAGGA GACAGAGTGG AAATGGCGGG
GGCTTGTGGA 660 GGCCATTGAC ATGAGTGACA CGAGTTCTGT 720 AAGCTTGGA
GTGAGCCCTG GACTTCAGCT GCCACACTGT CACCTGGGGC 780 GAGCAGCCGT
ACGGTGACAC 840 TCCTCTTTTG YTTGGAGGGC GAGGGGCCCT TAGGGGAGTC 900
ACGGCTGGAC CCTGGGACTK AGCCCCTGGG GACTACCAAG AGCCCACTGC 960
CCCTGAGAAG GGCAAGGAGT CCTGCAGTGC 1020 GAACTGAGCA GACTCTCCAG
CAGACTCTCC 1080 GGGGTTCTCTG AGGGACCTGA CTTCCCCTGC TCCAGGCCTC
TTGCTAAGCC TTCTCCTCAC 1140 GCTCCCAGGG TTTCTGCAAC 1200 GGCTGCCNCC
CCTGTTGTGT CTTTTTTTCA GACTCACAGT GGACCCAGAA 1260 TAAAGCCAAT
TTTCAAAAAA AAAA WAAAAA AAAAAAAAAA AAAAAAAAAA 1320 (2) INFORMATION
FOR SEQ ID NO : 111 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1962 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 111 : CGGACCCCTT CCTCCTCCTC NAAGCATGTC
GGGGANACAG 60 TCACCTGATG CGGGGACCAC CCTCGSTGGC GCTGTCAAGT 120
GCTGGGCCTG CACTGAGGTC CCTGCTGGGG AGAATTATCT TCAGAGGGGG 180
CCTGGTACCC GTGTGGCTGG GGGGCACCCT 240 CGGAGCTTCC TGTCTCCTCG
CTCTCTCCTC GAGGGACCCC GGACCACCAG 300 GCCTCAACCA GAGTGAAGG
TGATGGGGAT GCTAGGTTCC 360 TCTCCCTGGG GTGGTCCATG GGCCTGGAAG 420
TCCATCAGGA AGTGGTGATG CTTGCTGGCG 480 CCTGGGAGAG TGACTCCTCC
TGGGCTGCTG GAGAGAGGCC 540 GGCTGCTGAG CTCGCTGGGC TCCTCTTCTT 600
CTTCCTCCTC TTTCTCTTCT ATTTCTCTTC GCCTTACCTT 660 CCTCTTYTGR
AAACCCCGTG GGCGGTACCA TGGATTGTGT TTCAAATTCT AGGAGCGTCC 720
TAGGGGCCTC TCTGGAGTGG TCCTCCGTCC TCCATGATGG 780 GGATGGAGTA
CGGGATTAC TTCTGAGGC AGCTGCAGTT 840 GTGACRATAG CCTCTAGTCC
ATCAAAAGCT GGGTTGGAGG 900 GGCCTCAGGG ATGGCAGAAG GCTGGGCCGA
GTCTCGGAAG 960 TGAAGCGGCT GTGCTTATTG GGGAAGCCAG TCTGGTTGGG
GAAGANGAAG 1020 CACCAGGCAA GCCCCACCA CAGCGCTGGC TGGGTGTGAC
GATGGGGTAG CGCACANTGC 1080 CATCAGCTAG CCACCTGGGC 1140 GCCCGTGGTG
GCAATCTCTG CACCCCGCTC CTGGCAGTAC GCCCGTGCTT CCTCCAATGT 1200
GGAGGGTCAC AGGTCTTCAG 1260 CACATCATAG AGGTCATCCG GTCCACCAC
ACCATAGTTC CGGACCCCGG 1320 CTCGTGGGGT CTGGATGGGA TACCTTTGAC
CTTGAMCTCC 1380 GATGCCGTGC TGGACCTCAC AGCGATAGAT ACCTGAGTCG 1440
GCTCGCTCAG GACGTCGGTG AGCGACGCTG 1500 CGGAACCGGT AGGCCTCGTT
CACCTTGACG CGCACTCCCC GCGCCACCAG 1560 TCCCGGCCCC GGGACAGGAA

AGTCCACTTG ACCCGCGGAG AGCCCAGCAC 1620 AGCCCGGCGG CTCGGCGGTG
SCCGCAGGTA GTGGACGTGG 1680 GCCGAGCAAC GGCGCGTCGC GCGCGKTCCT 1740
CTGAGCTGTC AGCCTGGGCC AGGACCAGGG 1800 CTGCCAGCAG TACCCAGGGC
TGGGGTTGGG 1860 GCGAAGTTTG TCGCCTCCTC CGGGGGTCTC CTCCGGGTKC 1920
GCAGCTGAGA CTGCGGCGGA GACTGCGCGA GC 1962 (2) INFORMATION FOR SEQ ID NO :
112 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1785 base pairs (B) TYPE : nucleic acid
(C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID
NO : 112 : CAAACTTCGG GCGGCTGAGG CGGCGGCCGA GGAGCGGCGG ACTCSGGGCG 60
CGGGGAGTCG GCCTGGGCTT CGGAGCGTAC CGCAGGGCCT 120 AGCAGGAGGA
CCTCTATCGG GACCCCCTCC CCATGTGGAT 180 CTGCCCAGGC GGCGGCGGCG
GCCGAGGAGG CGACCGAGAA GATRCCCGCC CTGCGCCCCG 240 CTCTGCTGTG
GGCGCTGCTG TGTGCTGCGC GACCCCGCGC 300 GTGTCGAGAT GGCTATGAAC
CCTGTGTAAG TGAAGGAATG TGTGTTACCT ACCACAATGG 360 TGCAAATGTC
CAGAAGGCTT CTTGGGGGAA ATCGAGACCC 420 CTGTGAGAAG AACCGCTGCC
AGAATGGTGG GACTTGTGTG GCCCAGGCCA TGCTGGGGAA 480 AGCCACGTGC
CGATGTGCCT CAGGGTTTAC AGGAGAGGAC 540 TCCATGCTTT GTGTCTCGAC
CTTGCTGAA TGGCGGCACA TCAGCCGGGA 600 TACCTATGAG TGCACCTGTC
AAGTCGGGT TACAGGTAAG GGACCGATGC 660 CTGCCTGTCT CATCCCTGTG
CAAATGGAAG TACCTGTACC ACTGTGGCCA ACCAGTTCTC 720 CTGCAAATGC
GAAGTGTGAG ACTGATGTCA ATGAGTGTGA 780 ATGGTGGCAC CCTACCAGTG 840
CAGGGCTTCA CAGGCCAGTA CTGTATGTGC 900 CTCGCCTTGT GTCAATGGAG
GCAGACTGGT GACTTCACTT TTGAGTGCAA 960 CTGCCTTCCA GAAACAGTGA
GAAGAGGAAC AGAGCTCTGG GAAAGAGACA GGAAGTCTG 1020 GAATGGAAAA
AGAATTAGAC ACTGGAAAAT ATGTATGTGT GGTTAATAAA 1080 GTGCTTTAAA
CTGAATTGAC GGTGATCAAC TTMCTATGT GCTTGTGCTT 1140 TTGCTTTTGA
TGGAGTAATT TTATCCACCT AAATGCACCC AGCTGCCCTT 1200 GATTTTCTCT
GGGCTACTGG CCTCTCCCAT GTACCCTCTC TGACTTTGGG 1260 GTAACCCTCC
CCTAACTTAA AGCTAGAGAA TTCTGAAACT GAGGAGGGGA TCCTCTGTTA 1320
ATCAGTGAGC ACTTTTTGAT GAGCTGATAG ATGATATATG AGAGACTATG
CGTGGCACA 1380 TACTTTGTTA CACTCTTCAC TGATACAAGT GTTCTAGAGT
CCCAAAGATA 1440 GAAATAAAAA GAGGAGCAGT GTCGGGGAGC TTGGGGCCTG
GTGTTCCATG GAGAGGGAGA 1500 AAGGAACAAG CCTTATAAAA ATGATGAGGA
GGCTGAAAAC 1560 CAAGAATTTT GATTGGGAAC CAGCTGAAC CTAAGCAACA 1620
AAGATCCTGT TTTTATACAA ATATCCTTAG TACAAAAACA AAARAAGGAA
AACTGTAGGG 1680 GGGAGTAATG TGCTAAGTAA GCAGAATTGC AGTTACTCTT 1740
TTCCGGGTNG TGTGGGTATG GTTCC 1785 (2) INFORMATION FOR SEQ ID NO : 113 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 1842 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
113 : GGAGCCTCTC TGCCACCGCG GCCGCCTGAT CCCGCAGAGG 60 AAGTCGCGGC
CGTGGAGCGA TGACCCGCGG CGGTCCGGGC GGGCGCCCGG GCCGCCGCCG
CTTCTGCTGC TGCTGCTGCT GCMGCTGTTG TTAGTCACCG CGGAGCCGCC 180
GAAACCTGCA GGAGTCTACT ATACTGGATG CCTGCTGAAA AGTCAAAAAT
GTAATGGACA AGAATGGGGA CGCCTATGGC TTTTACAATA ACTCTGTGAA 300
AACCACAGGC TGGGGCATCC TGGAGATCAG AGCTGGCTAT CCCTGAGCAA 360
ATGTTTGTGG CTGGCTTTTT GGAGGGTTAC CTCACTGCCC ACAAACCTCT TGGATAAAGT
480 ATGGAGAAGC AAGATAAGTG GACCCGGA AATATCAAAG AATACAAGAC 540
TGATTCATTT CAGGCTATGT GATGGCACA ATAGATGGCC TCTATGTAGG 600
AGCAAAGAAG AGGGCTATAT TAGAAGGGAC AAAGCCAATG CCTGAATAGT
GTTGGAGATC TATTGGATCT GATTCCCTCA CTCTCTCCA CAGCCTAAAG GATGGGACAT
GGGACATTGC TCCGCTCTTA TCAAGGTTCT 780 TCCTGGATTT GAGAACATCC
TTTTTGCTCA CTCAAGCTGG TACACGTATG CAGGATATAT ACTTCAACRT CATAGATAAA

GATACCAGCA GTAGTCGCCT 900 AGTTACCCAG GGTTTTGGGA GTCTCTGGAT
GATTTTACA TTCTTAGCAG 960 TGGATTGATA TGTGTTTAAT AAAACCCTGC
TAAAGCAGTA 1020 ATACCCGAGA CTCTCCTGTC CTGGCAAAGA GTCCGTGTGG
CCAATATGAT GGCAGATAGT 1080 GGCAAGAGGT GGGCAGACAT CTTTTCAAAA
TACAACTCTG GCACCTATAA CAATCAATAC 1140 ATGGTTCTGG ACCTGAAGAA
AGTAAAGCTG TTGACAAAGG CACTCTGTAC 1200 AAATTCCTAC ATATGTAGAA
TATTCTGAAC AAAGTATGT TCTACGGAAA 1260 GGATATTGGC CCTCCTACAA
TGTTCCTTTC CATGAAAAAA TCTACAACTG GAGTGGCTAT 1320 TTCAGAAGCT
GGGCTTGGAC TACTCTTATG ATTTAGCTCC ATTTTCCGGC GTGACCAAGG GAAAGTGACT
GATACGGCAT CCATGAAATA TATCATGCGA 1440 TACAACAATT ATAAGAAGGA
TCCTTACAGT AGAGGTGACC CCTGTAATAC CGTGAGGACC TGAAGTACC
TAACCCAAGT CCTGGAGGTT GTTATGACAC AAAGGTGGCA 1560 GATATCTACC
GTACACATCC TATGCCATAA GTGGTCCCAC AGTACAAGGT 1620 GGCCTCCCTG
TTTTTCGCTG GGACCGTTTC AACAAAACCTC TACATCAGGG CATGSCAGAG 1680
GTCTACAACT TTGATTTTAT CCAATTTTGA AACTTGATAT AAAATGAAGG 1740
AGGGAGATGA CGGACTAGAA GACTGTAAAT AAGATACCAA TTAGCTATGT 1800
TTTTCCCATC AGAATTATGC AATAAAATAT ATTAATTTGT CA 1842 (2) INFORMATION
FOR SEQ ID NO : 114 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1960 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 114 : GAATTCGGCA CGAGCTTCTC CGCGCCCCAG
CCGCCGGCTG CCAGCTTTTC GGGGCCCGCA 60 GCGAAGAGAG CGGGCCCCGGG
ACAAGCTCGA ACTCCGGCCG CCTCGCCCTT 120 CCCC GGCTCC GCTCCCTCTG
CCCCCTCGGG GTCGCGCGCC CACGATGCTG 180 GCTCGCTGCT GCTGCTCTTC
CTCGCCTCGC ACTGCTGCCT GGGCTCGGCG CGCGGGCTCT 240 TCCTCTTTGG
CCAGCCCCGAC TTCTCCTACA AGCGCAGMAA TTGCAAGCCC ATCCCGGTCA 300
ACCTGCAGCT GTGCCACGGC ATCGAATACC AGAACATGCG GCTGCCAAC
CTGCTGGGCC 360 ACGAGACCAT GAAGGAGGTG CCGGCGCTTG GATCCCGCTG
GTCATGAAGC 420 AGTGCCACCC AAGTTCCTGT GCTCGCTCTT CGCCCCCGTC
TGCCTCGATG 480 ACCTAGACGA GACCATCCAG CGCTCTGCGT GCAGGTGAAG 540
CCCCGGTCAT GTCCGCCTTC GGCCCGACAT GCTTGAGTGC GACCGTTTCC 600
CCCAGGACAA CGACCTTTGC ATCCCCCTCG CTAGCAGCGA CCACCTCCTG
CCAGCCACCG 660 AGGAAGCTCC AAAGGTATGT GAAGCCTGCA AAAATAAAAA
TGATGATGAC AACGACATAA 720 TGGAAACGCT TTGTAAAAAT GATTTTGCAC
TGAAAATAAA AGTGAAGGAG ATAACCTACA 780 ATCCTGGAGA CCAAGAGCAA
GACCATTAC AAGCTGAACG 840 GTGTGTCCGA AAGGGACCTG AAGAAATCGG
TGCTGTGGCT TTGCAGTGCA 900 CCTGTGAGGA GATGAACGAC ATCAACGCGC
CCTATCTGGT CATGGGACAG AAACAGGGTG 960 GGGAGCTGGT GTGAAGCGGT
GGCAGAAGGG GCAGAGAGAG TTCAAGCGCA 1020 TCTCCCGCAG CATCCGCAAG
CTGCAGTGCT AGTCCCGGCA TCCTGATGGC TCCGACAGGC 1080 CTGCTCCAGA
GCACGGCTGA CCATTTCTGC TCCGGGATCT CAGCTCCCGT TCCCCAAGCA 1140
CACTCCTAGC TGCTCCAGTC TCAGCCTGGG CAGCTTCCCC CTGCCTTTTG 1200
TTCCTGAGTT ATAAGGCCAC AGGAGTGGAT AGCTGTTTTT ACCTAAAGGA 1260
CGAATCTTGT AAATAATAA AATCATGAAT 1320 AGTTTAAAAA TAGCTCACTT
TAAAGCTAGT TTTGAATAGG TGCAACTGTG ACTTGGGTCT 1380 GGTGTTGTGT
TGTTTGTGT CTGATTTTCA CTTCCCACTG AGGTTGTCAT 1440 TTGCTTCAAT
AACCCTGTTG 1500 AGATAAAGCT TCAACATCTT AGACTGAGAC TCAGTGTCTA 1560
AGTCTTACAA TTTTATACCT TCAATGGGAA CTTAAACTGT TACATGTATC 1620
TACAATACTT CCATTTATTA GAAGCACATT ATAGCATGAT 1680 TTCTTCAAGT
AAAAGGCAAA AGATATAAAT TTTATAATTG ACTTGAGTAC TTAAAGCCTT 1740
GTTTAAACA TTTCTTACTT AACTTTTGCA AATTAAACCC ATTGTAGCTT ACCTGTAATA
1800 TACATAGTAG TTTACCTTAA AAAGTTGTAA AAATATTGCT CTGTAAATAT 1860

TTCAGATAAA CATTATATTC TTGTATATAA CTGTTTTACC TAAAAAAAAA 1920
AAAAAAAAAA AAAAAGCTCG AGGGGGGCCC 1960 (2) INFORMATION FOR SEQ ID NO :
115 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 536 base pairs (B) TYPE : nucleic acid
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
115 : GTGCTCAGCC CCCGGGGCAC AGYAGGACGT TTGGGGGCCT TCTTTCAGCA
GGGGACAGCC 60 CAATGGCGTC TCTTGGCCAC ATCTTGTTT TCTGTGTGGG 120
ATGGCCAAGG CAGAAAGTCC AAAGGAACAC GACCCGTTCA CTTACGACTA
CCAGTCCCTG 180 CAGATCGGAG GCCTCGTCAT CGCCGGGATC CTCTTCATCC
TGGGCATCCT CATCGTGCTG 240 AGCAGAAGAT GCCGGTGCAA GTTCAACCAG
CAGCAGAGGA CTGGGGAACC CGATGAAGAG 300 GAGGGAACCT TCCGCAGCTC
CATCCGCCGT CTGTCCAMCC GCANGCGGTA GAAACACCTG 360 GAGCGATGGA
ATCCGGCCAG GACTCCCCTG GCACCTGACA TCTCCACGC TCCACCTGCG 420
CCCCTCCGCC GCCCCTTCCC CAGCCCTGCC CCCGCAGACT CCCCTGCCG 480
CAATAAAACG TGC GTTCTC AAAAAATAAA AAAACT 536 (2) INFORMATION FOR SEQ ID
NO : 116 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 790 base pairs (B) TYPE : nucleic
acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 116 : GTGGGGAGGG GCGGAGCAA AGCCGCGCCT CTGGGTGGGC GGGTCGGGCC
60 CTGACTTGAA CCTTCCCGGT CGCAGAAAAT 120 AACCACCCCA AGTTACTAAG
GCCAAGCTTC TGGGGTTTGG CTCTGCTCTC 180 CTGGACAATG TGGACCCCAA
CCCTGAGAAC TTCGTGGGGG CGGGGATCAT CCAGACTAAA 240 TGGGCTGTCT
GCTTCGGCTG GAGCCCAATG CCCAGGCCCA GATGTACCGG 300 CTGACCCTGC
GCACCAGCAA GGAGCCCGTC TCCCGTCACC TGTGTGAGCT GCTGGCACAN 360
AGTTCTGAGC CCTGGACTCT GCCCGGGGG ATGTGGCCGG CACTGGGCAG
CCCCTTGAC 420 TGAGGCAGTT TTGGTGGATG GGGGACCTCC ACTGGTGACA 480
GGGATGCCTG GGA CTTTCT CCGGCCTTT GTATTTTAT TTTTGTTCAT CTGCTGCTGT
540 TTACATTCTG GGGGGTTAGG GGGAGTCCCC CTCCCTCCCT TTCCCCC
AGCACAGAGG 600 GGAGAGGGGC CAGGGAAGTG GATGTCTCCT CCCCTCCCAC
CCCACCCTGT TGTAGCCCCT 660 CCTACCCCCT CCCCATCCAG GGGCTGTGTA
TTATTGTGAG CGAATAAACA GAGAGACGTT 720 AACAGCCCCA TGTCTGTGTC
CATCACCCAN TGNTAGGTAG TCAAAGAAGT GGGGTGAGGG 780 790 (2) INFORMATION
FOR SEQ ID NO : 117 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 776 base pairs (B)
TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 117 : CAGCGCTGGA AGCAGCTGAG CCTGTGAGGG
GTGGGGAGGG GCGGAGCAA AGCCGCGCCT 60 CTGGGTGGGC GGGTCGGGCC
GTCCAGGTCC CTGACTTGAA CCTTCCCGGT CCCAGCCCT 120 CAACAGGAGG
CGCAGAAAAT CTTCAAAGCC TGGACGCAGA AGTTACTAAG 180 GCCAAGCTTC
TGGGGTTTGG CTCTGCTCTC CTGGACAATG TGGACCCCAA CCCTGAGAAC 240
TTCGTGGGGG CGGGGATCAT TGGGCTGTCT GCTTCGGCTG 300 GAGCCCAATG
CCCAGGCCCA GATGTACCGG CTGACCCTGC GCACCAGCAA GGAGCCCGTC 360
TGTGTGAGCT GCTGGCACAG AGTTCTGAGC CCTGGACTCT 420 ATGTGGCCGG
CACTGGGCAG CCCCTTGAC TGAGGCAGTT TTGGTGGATG GGGGACCTCC 480
ACTGGTGACA GAGAAGACAC CAGGGTTTGG GGGATGCCTG GGACTTTCCT
CCGGCCTTTT 540 GTATTTTAT TTTTGTTCAT GGGGGTTAGG GGGAGTCCCC 600
CTCCCTCCCT TTCCCCC AGCACAGAGG GGAGAGGGGC GATGTCTCCT 660
CCCCTCCCAC CCCACCCTGT TGTAGCCCCT CCTACCCCCT 720 TTATTGTGAG
CGAATAAACA GAGAGACGCN TAAAAAAAAA AAAAAAAT TGAGGG 776 (2)
INFORMATION FOR SEQ ID NO : 118 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 453
base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 118 : GGTTCTGACA CCAGATGTTCTCTGCTCCTG
GTTAATGTCA GTGAGGGCTG GAAGTTGAAT 60 AAATGAGAAC AGGAGTGGTC
TAAATGATCC TCCCTTGAAA 120 TAAGCCTTGC GATCTGGTGC TAAGCAGTGG 180

GAAAGATCTC ATAAGTAATG TTTTATGTTT TTTCKGTCTC TCYTCTTCKG TTGTTCTTGG
240 GTGTTTGKGG TTGTAACTG GAAAATTGCT TGTCYCKAAK 300 GAATTAGAAA
TCYTCTGGCC YATGCACATK GTCCCYGTTT 360 TGTGAAAACA TTAAAGGGTA
AATAAAAAGG AAGGAGAACA GTCAATAATG TGCATCAAAT 420 ATATTCTGAG
TTCTAGAGAA ATTAATGACC AAG 453 (2) INFORMATION FOR SEQ ID NO : 119 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 2016 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
119 : CAGGCACCCC GAGACAGCGT CCCCCCTCTG GCGCACTGG ATTTGACGTT 60
CGGCTGGAAC CGCTGCTCAC AGACCGGGAC TCCGCCTCCG 120 GTTCCCGAGG
GCGTGGCGAG GCGCTGCGGG ANCCCAACAG GATGCCTTCC AATTTTGTGC
GCAATTCCTA TGATTGGAGA GCTGGCTCCG 240 GAAGAACCCA GCCAKGATGG
ACCCCTGAAT GAGGACTTCC GAGGACATGA AGCTGTTTGA CTTTCCTACT 360
CTGGCCATGG AGGTGCTGGC CTGGCTCCTT ATCTACCTCC TGGGTCCTGG 420
CTGGGTGCCC AGTGCCCTGG NCCGCCTTCA TCCTGGCCAT CTCTCAGGCT GTCTGCAGCA
TGACCTGGGC CATGCTCCAT TCCTGGTGGG CCAGAAGTTC AGCTAAAGGG CTTCTCCGCC
CACTGGTGGG ACTTCCGCCA 600 CACGCCAAGC CCAGACGTGA CCGTGGCGCC 660
CTGGGGGAGT CATCCGTCGA GAAGAAACGC AGATACCTAC 720 TACTTCTTCC
TGATCGGCCC GCCGCTGCTC ACCCTGGTGA 780 ACTTTGAAGT GGAAAATCTG
GCGTACATGC TGGTGTGCAT GCAGTGGGCG GGGCCGCCAG CGCTTCTTCT TATCCTACCT
CCCCTTCTAC GGCCTCCCTG 900 GGGTGCTGCT CTTCTTTGTT GCTGTCAGGT
ATGGCAGGGA GTGGCGAGGT CGACAGGTGA CCCCCACTGC AGCCCCCAC
CTTTTCCCGT TACTGCCTCC CTGGCTTGCT GGTGGAATCA GCCCAGGGTC GGTGGGTTTA
GGGAGCGTGG CCTGGCTTGT AAGTGGCCCG GTGGGTGTCG 1140 GGA CTCAGCC
TTCAGATTCT TTAAACACTG 1200 GCAAGGGGGC ATCCTATTGT ACAGATAAGG
AAGTCAAGGC CAYTTGGGGA 1260 CAGYTGCTCT TCCAGCCTCC CCTTAAGTGG
TGAGCTGGAC GCCGAGCYTC CCCACAGGGT CCTGGAAAGC TGTGGATCAC
ACAGATGAAC 1380 CACATCCCCA AGGAGATCGG GGGTCAGCTC GCCACCTGCA
ACGTGGAGCC CTCACTTTTC ACCAACTGGT TCAGCGGGCA CAGATCGAGC ACCACCTCTT
ACTACAGCCG GGTGGCCCCG 1560 CTGGTCAAGT CGCTGTGTGC CAAGCACGGC
CTCAGCTACG AATGAAGCCC TTCCTACCG 1620 CGCTGGTGGG TCCCTGAAGA
AGTCTGGTGA GACGCCTACC 1680 TCCATCAGTG AAGGCAACAC AGAGAAGGGC
AGCAACCAAG 1740 GCGGGATCGA CCAGCCTGGG GGTGCCCTGC 1800 CTGCCCTCCT
GGTACTGTTG TCTTCCCCTC GGCCCCCTCA CATGTGTATT CTCTGGGCCT GATGGGACAG
GGGTAGAGGG AAGGTGAGCA TCCTAGAGCG AGAATTGGGG GAAAGCTGTT
ATTTTATAT TAAAATACAT TCAGATGTAA 1980 AAAAAAAAAA CGAGGGGGGG
CCCCGG 2016 (2) INFORMATION FOR SEQ ID NO : 120 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 2136 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 120 : GGGGACGGAG
CCGCTGTCAA CTCTCCAAC GATCGGTTGC CGCCGCCGCC 60 GCCGCCAGAT
TCTGGAGGCG AAGAACGCAA AGCTGAGAAC ATGGACGTTA ATATCGCCCC 120
ACTCCGCGCC TGGGACGATT TCTTCCCGGG TTCCGATCGC TTTGCCCGGC CGGACTTCAG
180 GGACATTTCC AAATGGAACA ACCGCGTAGT GAGCAACCTG CTCTATTACC
AGACCAACTA 240 CCTGGTGGTG TGTGGGGTTT CTGAGTCCCT TCAACATGAT 300
CCTGGGAGGA ATCGTGGTGG TGCTGGTGTG GTGTGGGCAG CCCACAATAA 360
AGACGTCCTT CGCCGATGA AGAAGCGCTA TTCGTTATGG TGGTCATGTT 420
GGCGAGCTAT TTCCTTATCT CCATGTTTGG AGGAGTCATG GTCTTTGTGT TTGGCATTAC
480 CTGTTGATGT TTATCCATGC ATCGTTGAGA CTTCGGAACC TCAAGAACAA 540
ACTGGAGAAT AAAATGGAAG GAATAGGTTT GAAGAGGACA TTGTCCTGGA 600
TGCCCTAGAA AAGGCATCAA GCAAAGTGAA 660 GGAATAAACA TAACTTACCT
GAGCTAGGGT TGCAGCAGAA ATTGAGTTGC AGCTTGCCCT 720 TATKTTCTGC
GAAACAGGAG 780 TCTATGGCAG CATGCATGTA TAGGCCGAAC TCTGATGTTT 840

ACCTCAGAAA CCGAAAGAAA ACCACCACCC TCCTATTGTG TCTGAAGTTT 900
TATGAAATCT AATGGGAAAT ATTTCTTTAA GGGAATTAAA AAAAATAAAA 960
GAATTACGGC TTTTACAGCA TATCTTATAG GAAAAAAAAA ATCATTGTAA 1020
AGTATCAAGA CAATACGAGT AAATGAAAAG GCTGTAAAG TAGATGACAT
CATGTGTTAG 1080 CCTGTTCTTA ATCCCCTAGA ATTGTAATGT GTGGGATATA
AATTAGTTTT TATTATTCTC 1140 TAAAAAATCA AAGATGATCT CTATCACTTT
GCCACCTGTT TGATGTGCAG TGGAACTGG 1200 TGTTCATACT TCSTTTACAA
ATATAAGAT AGCTGTTTAG GATATTTTGT 1260 TACATTTTTG TAAATTTTTG
AAATGCTAGT AATGTGTTTT TATTTGTTGC 1320 AAACCTAATG TAAGATGGTT
ACAGCTATGT AACCTGTATT ATTCTGGACG 1380 GACTTATTAA AATACAAACA
GACAAAAAAT AAAACAAAAC TTGAGTTCTA TTTACCTTGC 1440 TTGTTACAGT
TTTTTGCAAT 1500 GTTTCGTTTT TAACTGGAAC ATTTAGAAAG AAGGAAATGA
ATGTGCATTT TATTAATTCC 1560 TTAGGGGCAC AAGGAGGACA ATAATAGCTG
ATCTTTTGAA ATTTGAAAAA CGTCTTTAGA 1620 AAAAGACTTT AAAAATGGT
AATGAAAATG ACTGCAGCTA 1680 ATAAAAAATT TTAGATAGCA CCATATGCCT
TTATAGCTAG ACATTAGAAT 1740 TATGATAGCA TGAGTTTATA CATTCTATTA
TTTTTATAAA 1800 TAGGTAATAA AAAATGTTTT TGAATGATTT CGTAGCTGAA
GTAGAAACAT 1860 TTAGGTTTCT GTAGCATTA AATTGTGAAGA GGTACTTACT
GAAGAACTC 1920 TCTGTATGTC CTAGAATAAG AAGCAATGAT GTGCTGCTTC
TGATTTTTCT TGCATTTTAA 1980 ATTCTCAGCC AGCACAGTGA 2040 CATGGTCTAG
AATCTGTACC TATGAAGAAT AAAATTGATT AAAGGTAAA 2100 AAAAAAWAA
AAAAAMWAGG GGGGCCCGGT 2136 (2) INFORMATION FOR SEQ ID NO : 121 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 219 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
121 : GCCCTAGTAT GTGCATGGAG ATAGCCAGAG GAAACATTTT TTTTCTTAAT 60
GRATTGGTGA TTGTTCTTGC CTCCTATTAT CCGTGCSCA TTTGCATSCT 120
GGTTTCTTCT ACAGTAGTTT ATGTAAATGT TGTTTTGTCC TTGTCGTTCT 180
GGTCTGTAA ACGAAACCTG GTCCTGTAAT TTCAGTATA 219 (2) INFORMATION FOR SEQ
ID NO : 122 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1686 base pairs (B) TYPE :
nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 122 : GCTGGAGATT CTGATTGCCT TCATTGCCGG
ATTGTGGATA 60 AACCTGGTT AAGAAAGTTT GGGAGGGATA TCCCATACAG
AGCACTATCC 120 CTTCCCAGTA ATGATTGAAC TTTCCTTCTA CTGGTCCCTG
TTGCCTCTGA AAGGATTTCA AGGAACAGAT ATTACATCCG CTAATCATGG 300
CTCTGCATGA CTCTCCGAT TACCTGCTGG GATGTTTAAAC TACGCGGGAT 360
GGAAGAACAC ATCTTCATCG TCTTCGCCAT TGTTTTTATC ATCACCCGAC 420
GCCCTTCTGG GCACCCTGGT GTACCCACTG GAGCTCTATC 480 CCATGATGGG
AGTTCTACAG TCTTCTGGGC CCCACAAGTT CATAACTGGG AAAGCTGGTA 600
GAGAGCTCAG AGGGGGAGGA GGGGGAGGAG CAAAGAGCCG GCCCCTAGCC
CCATCCTCAA TAACAACCAT 720 CGTAAGAATG ACTGAACCAT TATTCCAGCT
AAGCCAAGGA 780 ACTACCCYGC TCCCTGCGCT ATAGGGTCAC TTAAAGCTCT
GGGAAAAAG GAGAAAGTGA 840 GAGGAGAGTT CTCTGCATCC TCCCTCCTTG
CTTGTCACCC AGTTGCCTTT AAACCAAATT 900 CTAACCAGCC TAGGGGGACG
TTGGTTATAT TCTGTTAGAG GGGGACGGTC 960 GTATTTTCCT CCCTACCCGC
CAAGTCATCC TTTCTACTGC TTTTGAGGCC TCTCTGTGGG AATTCACATT CCTTATTCTG
CCCAGCTGTT 1080 TCCCTGACCT GGTGTGCCT TCTGTGGGCC 1140 AAAGCTGGAC
CAAGGCTAAC CTTTCTAAGC TCCCTAACTT GGGCCAGAAA 1200 CCAAAGCTGA
GCTTTTAACT TTCTCCCTCT ATGACACAAA TGAATTGAGG GTAGGAGGAG 1260
ACCCTTACCC AAAAAGTGGG GGCTGTACTG GGGACTGCTC 1320 GGATGATCTT
TCTTAGTGCT ACTTCTTTCA GCTGTCCCTG TAGCGACAGG TCTAAGATCT 1380
GACTGCCTCC TCCTTTCTCT GGCTCTTCC CCCTTCCCTC TTCTCTTCAG CTAGGCTAGC

1440 TGGTTTGGAG TAGAATGGCA ACTAATTCTA ATTTTATTT ATTAATATT
 TGGGGTTTTG 1500 GTTTTAAAGC CAGAATTACG GCTAGCACCT AGCATTTCAG
 ATTTTAGACC 1560 AAAATGTACT GTTAATGGGT TTTTTTTTAA AATTAAGA
 TTAAATAAAA AATATTAAAT 1620 AATAAGTGC AGACTATTAG GAATTGAGAA
 GGGGGATCAA CTAAATAAAC 1680 GAAGAG 1686 (2) INFORMATION FOR SEQ ID NO :
 123 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1211 base pairs (B) TYPE : nucleic acid
 (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID
 NO : 123 : CAGCCTGTGC CAGACGAGGA GGTGATTGAG CTGTATGGGG GTACCCAGCA 60
 TACCAGATGA TGGCAAGGGT CCCTCCATTA AGCAGTTCAT 120 TCGCTACCGG
 AGATGGCTCT GCTGTCCTGT GTGGTGGACT ACTTCTGGG 180 GAGTTTGACC
 AACATCTCT GACGGACGCC ATCCGAGACG TGCATGTGAA 240 TCGAGCAGGA
 TACATCCTGA GAGGGGATGA 300 GACGTTTGCT GTCCTGAGCC GCCTGGTGGC
 CCATGGGAAA 360 AGCTTCGTAG GTGGGTCCCG ATTGGCGCCA 420 CTCTTCGATG
 TGGTCATTGT AAGCCCAGCT TCTTCACTGA CCGGCGCAAC 480 TTTCAGAAAA
 CTCGATGAGA TCAGTGGGAC CGGATCACCC GCTTGGAAAA 540 GGGCAAGATC
 GAAACCTGTT TGA CTCTTA CGCTTGACGG AATGGCGTGG 600 CCCCCGCGTG
 CTCTACTTCG GGGACCACCT CTATAGTGAT CTGGCGGATC TCATGCTGCG 660
 CGCACAGGCG CCATCATCCC CGAGCTGGAG CGTGAGATCC GCATCATCAA 720
 CACGGAGCAG CGCTGACGTG GCAGCAGGCG CTCACGGGGC TGCTGGAGCG 780
 CGGAGTCGAG GCAGGTGCTG GCTGCCTGGA TGAAAGAGCG 840 CAGTTCGGCA
 GCATCTTCCG 900 CACCTTCCAC AACCCACCT GCGCCTCGTG CGCTTCTCTG
 ACCTCTACAT 960 GGCCTCCCTC AGCTGCCTGC CGTGGACTTC ACCTTCTACC
 CACGCCGTAC 1020 GCCGCTGCAG CACGAGGCAC CCCTCTGGAT GGACCAGCTT
 CTGCACCGGC TGCATGAAGA 1080 CCCCTTCTCT TGGTGACATG GCTGAGGGCA
 CCTTTATTGT 1140 CCCTCAGCCC CTCCTGCCCC ATCCACCCAG ACAAGCAATA
 AAAGTGGTCT CCTCCCTGAA 1200 AAAAAAAAAA A 1211 (2) INFORMATION FOR SEQ ID
 NO : 124 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1804 base pairs (B) TYPE : nucleic
 acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 124 : CGCACCTATG GGCTCGCTAC CAGGACATGC GGAGACTGGT GCACGACCTC
 CTGCCCCCG 60 AGGTCTGCAG TCTCCTGAAC TCTACGCCAA CAACGAGATC
 AGCCTGCGTG 120 ACGTTGAGGT CTACGGCTTT GACTACGACT ACACCCTGGC
 GACGCACTGC 180 ACCCGAGAT GCCCGTGACA TCCTGATCGA TACCCAGAAG 240
 GGATTCGGAA GTATGACTAC AACCCAGCT TGGCCTCCAC TATGACATTC 300
 AGAAGAGCCT TCTGATGAAG ATTGACGCCT TCCACTACGT GCAGCTGGGG 360
 GGGGCCTCCA GCCTGTGCCA GACGAGGAGG TGATTGAGCT GTATGGGGGT 420
 TCCCACTATA GGCTTCTATG GCAAGGGTCC 480 GCTACCGGAG TGTCCTGTGT
 GGTGGACTAC TTTCTGGGCC 540 ACAGCCTGGN AGTTTGACCA AGCACATCTC
 TACAAGGACG TGACGGACGC 600 GTGCATGTGA AGGGCCTCAT GTACCAGTGG 660
 AGAGGGGATG AGACGTTTGC TGTCCTGAGC CGCCTGGTGG CCCATGGGAA
 ACAGCTGTTT 720 CTCATACCA GACAAGGGGA GGTGGGTCCC 780 GATTGGCGCC
 GTGGTCATTG TTCTTCACTG 840 ACCGGCGCAA AAACCTCGATG AGAAGGGCTC
 ACTTCAGTGG GACCGGATCA 900 CCCGCTTGA AAAGGGCAAG ATCTATCGGC
 AGGGAAACCT GTTTGACTTC TTACGCTTGA 960 CGGAATGGCG TGGCCCCCGC
 GTGCTCTACT TCGGGGACCA CCTCTATAGT GATCTGGCGG 1020 TGGCGCACAG
 GCGCCATCAT CCCCAGCTG GAGCGTGAGA 1080 CAGTACATGC ACTCGCTGAC
 GTGGCAGCAG GCGCTCACGG 1140 ACGCGGAGTC GAGGCAGGTG CTGGCTGCCT 1200
 GGATGAAAGA GCGGCAGGAG CTGAGGTGCA TCACCAAGGC CCTGTTCAAT
 GCGCAGTTCG 1260 CACAACCCCA CTA CTCTC AAAGGCGCCT CGTGCGCTTC 1320
 TCTGACCTCT ACATGGCCTC CTCAGCTGC CTGCTCAACT ACCGCGTGGA 1380
 TACCCACGCC GTACGCCGCT GCAGCACGAG GCACCCCTCT GGATGGACCA 1440
 GGCTGCATGA AGACCCCTT TCCGCTGAGG GCACCTTTAT 1500 AGGCCCTCAG

CCCCTCCTGC ATAAAAGTGG 1560 TCTCCTCCCT CTGCTTTCAG GTCACCTTGAC
 TGTGAGGATC 1620 CTCTGGGTGT CAGGGAAGTC AGTGAGTCAT CGAAGGGTTC
 ACAAAGGTG 1680 GGGGACAGAG ACCAGGGTGG GGTGTTGCC TTCTTGCCAC 1740
 GGTGAGAACT CGGACGCGTG GGTCGACCCG GGAATTCCGG ACCGGTACCT 1800 GCAG
 1804 (2) INFORMATION FOR SEQ ID NO : 125 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 1282 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 125 : CCGCAGGNCA GCGACGCGAC
 TCTGGTGCGG GCCGTCTTCT TCCCCCGAG CTGGGCGTGC 60 GCGGCCGCAA
 TGAAGTGGGA GCTGCTGCTG TGGCTGCTGG TGCTGTGCGC GCTGCTCCTG 120
 CTCTTGGTGC AGCTGCTGCG CTCCTGAGG GCTGACGGCG ACCTGACGCT ACTATGGGCC
 180 GAGTGGCAGG GACGACGCCC AGAATGGGAG CTGACTGATA GTGACTGGA 240
 GCCTCGAGTG GAATTGGTGA GGAGCTGGCT TACCAGTTGT CTAACTAGG AGTTTCTCTT
 300 GTGCTGTCAG CCAGAAGAGT GCATGAGCTG GAAAGGGTGA AAAGAAGATG
 CCTAGAGAAT 360 GGCAATTAA AAGAAAAAGA TATACTTGTT ACCTGACCGA 420
 CATGAAGCGG CTACCAAAGC TGTCTCCAG GAGTTTGGTA GAATCGACAT 480
 AATGGTGGAA TGTCCAGCG TTCTCTGTGC ATGGATACCA CTACAGAAAG 540
 CTAATAGAGC TTAATACTT AGGGACGGTG TCCTTGACAA AATGTGTTCT GCCTCACATG
 600 ATCGAGAGGA AGCAAGGAAA GTGAATAGCA TCCTGGGTAT 660 CCTCTTTCCA
 TTGGATACTG GGGGTTTTTT TAATGGCCTT 720 CCCAGGTATA ATAGTTTCTA
 ACATTTGCCC AGGACCTGTG 780 TTGTGGAGAA TTCCCTAGCT GGAGAAGTCA
 AGGCAATAAT 840 CCCACAAGAT GACAACCAGT CGTTGTGTGC GGCTGATGTT 900
 GCCAATGATT TGAAAGAAGT GAACAACCTT TCTTGTTAGT AACATATTTG 960
 TGGCAATACA TGCCAACCTG GGCCTGGTGG ATAACCAACA AGATGGGGAA
 GAAAAGGATT 1020 GAGAACTTTA AGAGTGGTGT TCTTCTTATT TTAATATCTT
 TAAGACAAAA 1080 CATGACTGAA AAGAGCAYCT GGGARAAATG GAAAACATGA 1140
 CTTCTTATGC TTCTGAATAA TCAAAGACTA ATTTGTGRTT TTACTTTTAA 1200
 ATAGATATGA AACATGGAAT GAAATAAAAA ATAAATAATA 1260 ATGGAAAAAA
 AAAAGNNGGG AN 1282 (2) INFORMATION FOR SEQ ID NO : 126 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1296 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 126 : GGCAGAGCTT AGAGTGTGGA AAAGGCAACC AGGTTGGCCG TAAGTGCCTG
 CTGGAATGCG 60 TGTGCCTCCA CASGGRTCTG GGCATCCGGA CTGATAACCA
 CTGAGGGATG 120 GAAGGCACTG AGATGGGGGC CCGTCCAGGC AGAAATGGAG
 CTTTCTGTGG 180 TCTCTTGCAC TCTGGCTGCC TCTTGCCCTC TCTGTGTCTC
 TCTTTCTTGG TCTCTCCCTC 240 TCTCCTCCTC AGCCTGGTCT TTCTCTTTGG
 TGCACACTTA GTTATTGTTG TGAGCAATGG 300 AAGTTCAAAG GAACTCCCTC
 TCCAGCTCTT CTGAATCTTG GGACACAGCC TAAAAAGGAC 360 AAAAAGTTAG
 AAGACAGCAT AGCAACTCAG CTCAGGGRGC AAATAGCAAC 420 TGATGTGGGT
 GCTTTTTTTT TTTTTTTAAT TTGAATAAAA AGAATTAGAA GTGATGTCCT 480
 TTTATAAAAT GCCTTCTCCC CTTCCCGCC TACAGTCTCT TCCTCTCCCC TTAGAGGGGG
 540 GAAAGTGTAT AAACCTACAG GGTGTTGAGT CTGAAAAGAG GATCCCCCTC
 ACCCCCACCC 600 TGGGCAGAGC AGTGGGGGTT AGAGGGGGAC ACAGATCCTG
 GCACACTGTG 660 GATATTTCTT GTCTCTTGTG GCCCAAACAG GTTAGGTAGA
 CTATCGCCTC 720 TGGCAGGTGC CACCTTTTGG TTAGGATTTG GGTGGGTTT 780
 TTTTGTGTTG TTTTTTTTTT CCNTTGGTC TTTTTTTTTT TCYCCTTKTA AAGAAAAGCT 840
 AAAGGCCGCT GTGAGTCCTG GTGGCAGGCT CTCCATGGAT GTAGCATATC
 GAAGATAATT 900 TTTATACTGC ATTTTATGG ATTATTTTGT AATGTGTGAT
 TCCGTCTGCT GAGGAGGTGG 960 GAGGGGCTCC AGGGAAAGCC AGTGAGGTTG
 CTCCCAGCT GAGCGACCCG 1020 GGCATGGGAT GTGGAGGCTG GCGACACACC
 CTGTGCCTCT CCAAGGCTGG GCGCGTGGGG 1080 CGTCCAGAGT CTCTCTGGGT
 CTCAGATGTC CTCTTGTTAA GGCTCTAGCC 1140 AGAAGGGAGG GTGAGGGTAG

AAGAAAGTTA TTCCCGAAGA AAAAAAGAAT GAAAAGTCAT 1200 TGTACTGAAC
TGTTTTTATA TTTTAAAG TTACTATTAA AAGCGGACGT CGTGGGTCGA 1260
CCCGGGAATT CCCGGACCGG TCTAAC 1296 (2) INFORMATION FOR SEQ ID NO : 127 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 737 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ NO :
127 : GGCANAGTGG AGGCAATGCC AGCTCCAGGA GGTGCCCAAC 60 GCCCAGGGGG
CTGTGTCTGT CTTCCCCGGC NCAGCGCTTC 120 CCGGGGCCCT CTGAAGAGGC
CGCCTGGGCT GCCATGGCCC 180 TGACCTTCCT GCTGGTGCTG CTCACCCTGG
CCACGCTCTG 240 TCCGACGCGG TACTGGGGGC ACAGTGGGCTG 300 CTGTGCTGAA
CGCGCCGGGT CGCCGGAGAC 360 GCCCAGGCCG GACAGCGGCC CGGAAGGCGA
GAGCTCGGAG TGACGGCCTG 420 GGACCTGCCA CTGTGGCGTG CGGTCTCCCC
GCGCCGCGAG GCCGCGAMCT NTGCCACGTG 480 GACCGCGCGC NGGGCGCTMC
CCTGGTGGCG ATGGCGCGGC ACTGGCGAGC ACTGCGKGGG 540 CTTTCCTCCT
TGTTGGTTGC TGAGTGGGCG GAAAAGGAGC 600 TCCCTTGCCA AAACCTCCGT
TCTAATTAATA TTATTTTATAG TAGAAAAAAA AAAAAAAA 660 AAAAAAAA
AAAAAAAAC TCGAGGGGGG GCCCGGTACC 720 AATAGCGATC
GTATNAA 737 (2) INFORMATION FOR SEQ ID NO : 128 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 1925 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 128 : CCCGCCTCC
AAAGCTAACC CTCGGGCTTG AGGGGAAGAR GCTGACTGTA CGTTCCTTCT 60
CACTCTCCAG GCTGCCATGG GGCCAGCAC CCCTCTCCTC ATCTTGTTCC 120
TTTTGTCATG GTCGGGACCC AGCAGCACCA CCTTGTGGAG TACATGGAAC 180
GCCGACTAGC TGCTTTAGAG GAACGGCTGG CCCAGTGCCA GGACCAGAGT
AGTCGGCATG 240 CTGCTGAGCT GCGGGACTTC AAGAACAAGA GCTGGAGGTG
GCAGAGAAGG 300 AGCGGGAGGC GAGGCCGACA CCATCTCCGG GAGAGTGGAT
CGTCTGGAGC 360 GGGAGGTAGA CTATCTGGAG CTGTGTAGAG TTTGATGAGA 420
AGGTGACTGG AGGCCCTGGG ACCAAAGGCA AGGGAAGAAG GAATGAGAAG
TACGATATGG 480 TGACAGACTG GAAGATTCTG AAGCGATTG 540 GTGGCCCAGC
TGGTCTATGG ACCAAGGATC AACAGAGAAG ATCTACGTGT 600 TAGATGGGAC
ACAGAAATGAC GCTGCGTGAC TTCACCCTTG 660 CCGGAAAGCT TCCCGAGTCC
CCCCTGGGTA GGCACAGGGC 720 AGCTGGTATA CTTTATTTTG CTCGGAGGCC
TCCTGGAAGA TCAAATTCCA CCTGGCAAAC CGAACAGTGG 840 TGGACAGCTC
AGTATTCCCA TGATCCCCCTCTACGGCTTG CCTGGCAGCT GATGAGGAAG GTCTTTGGGC
TGTCTATGCC ACCCGGGAGG 960 CTTGTGTCTG GCCAAGTTAG ATCCACAGAC
GAGAATGCTG AGGCTGCCTT GGGACCCTCT 1080 CCTGCCAGTC GGGCCCGCAT
CCAGTGCTCC GCGGACCCTG ACCCCTGAAC CCCTTATTTT CCCCAGAT TGCCAGCCTC
CGCTATAACC CCCGAGAACG CCAGCTCTAT GCCTGGGATG ATGGCTACCA 1260
GATTGTCTAT AAGCTGGAGA TGAGGAAGAA AGAGGAGGAG GTTTGAGGAG
CTAGCCTTGT 1320 TTTCTCACTC CCATACATTT ATATTATATC CCCACTAAAT
TTCTTGTTCC 1380 TCATTCTTCA AATGTGGGCC AGTTGTGGCT ATATTTTATG
CCAATGGCAA 1440 TGTTTCATAC GGAACCTCAG ATCCTGAGTA ATCCTTTTAG 1500
AGCCGAAGA GTCAAAACCC CTCCTGCTCT CCTGCCCCAT GTCAACAAAT 1560
TTCAGGCTAA GGATGCCCCA GACCCAGGGC TCTAACCTTG TATGCGGGCA
GGCCAGGGA 1620 GCAGGCAGCA GTGTTCTTCC CTCAGAGTG GGAGAAATAG
GAGGAGACGT 1680 CCAGCTCTGT CCTCTCTTCC TCACTCCTCC CTGAGGAACA
CACATTGTTT TGTATTGCAA CATTTTGCAT TAAAAGGAAA AAAAAAAA
AAAAAAA ACTGCGGCCG
CTGTCCCTTC TGTCGTCTTC ACCCTTCTGT CGTCTTCTCG 1920 CAGCC 1925 (2)
INFORMATION FOR SEQ ID NO : 129 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
2713 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 129 : TCCTACCTTC GGCATCCCCA GCACTGATGG

60 GCCAGCCGTG ACTGCTTCCA TCCCTTGTCA GCAGCCACGA CCCTTTGGTG 120
TTCCTTTCAC TATACCTTTG CCTCTATGTA 180 GGTGGGGTGC GATTTCCTCC
CTTCTCTACT 240 TCTAGATTGC GTATGCTGAA 300 TGTGGGGGTT TCCGGCCTTT
GSCTCCACCC GRGGACCGGG 360 GTCAGCTTTA CGCCGGCCAA GCGACTTAAG
ACACAGAGTC TCCCCACTTG 420 CGCNTCTCAG GAANGAATAT GACTTTGGGA
ATCTAGCTCC 480 CCCGGTTCAC TAAAGGTTGA AAGAAGATTT TTGCTGTCTC 540
TCTGATCGGG AAGCCTCATC TAGCCCAGAG GNTCGGNAAT GACAGATGTA
AGAAGAAAGC 600 AGCGGCATTG TTCGACAGCC TTGCCCCATC TGCTGAGGCC 660
CAGTGAGCTG TGGAGCAGGA ACTGGAGCAG 720 CAAGAATTCC CTTCTGAAGG
ATGCCATGGC TCCAGGCACC CCAAAGTCCC TCCTGTTGTC 780 AAGAGGGAAG
GAGAGTCTCC AACGGCATCA CTGCCACCGA 840 TGACCTCCAC CATTGAGACA
GATACCAGAC CTTTCTGCGA GTACGAGCCA ACCGGCAGAC 900 CCGAYTGAAT
GYTCGGATTG GGAAAATGAA ACGGAGGAAG CAAGATGAAG GGCAGGTATG 960
TCCCCTGTGC AACCGCCCCC GGAGCAGGAG ATGAGTAGGC ATGTGGAGCA 1020
TTGCCTTTCT AAGAGGGAAG GCTCCTGCAT GGCTGAGGAT GATGCTGTGG
ACATCGAGCA 1080 TGAGAACAAC AACCGCTTTG AGGAGTATGA GTGGTGTGGA
CAGAAGCGGA TACGGGCCAC 1140 CACTCTCCTG GAAGGTGGCT TCCGAGGCTC
TGGCTTCATC ATGTGCAGCG GCAAAGAGAA 1200 CCCGGACAGT GATGCTGACT
TGGATGTGGA TGGGGATGAC ACTCTGGAGT ATGGGAAGCC 1260 GAGGCTGATG
CACAGGCGAG GAGCCTGGTG AAGCCAAGGA 1320 GAGAGAGGCA CTTGGGGGCG
CAGTCCTAAA TGGCGGCCCT 1380 TGAGTTCTCT AAATGGGCCA GTGATGAGAT
AGCAATGGTG AAAGCAGCAA 1440 GCAGGAGGCC ATGCAGAAGA CCTGCAAGAA
CCGAAGATTC 1500 AGCTGTGACC ACGTTTGAGG CTCTGAAGGC GAACTTGAAC
GGCAGCTATC 1560 TCGTGGGGAC CGTTACAAAT GCCTCATCTG TACTCGATGC
CCCTAACGTC 1620 TGGCACGTGC ACTGCGAGGA GTGCTGGCTG CGGACCCTGG
GTGCCAAGAA 1680 GCTCTGCCCT CAGTGCAACA GCCCGGAGAC CTGCGGAGGA 1740
AGCTATCTGC CCTCGCCTCC GCCTCTGTGA 1800 CAGTGACCGT YTCCCTTTGT 1860
TACACACGCA GGA CTCTGGA GCCAGAGTAG 1920 CCAGGCACTA CCTGCTGGCT
CCCACCTATG 1980 TCCCAGGGTG GTGGGGGTTG GGGGAGTAGT GGGGCACGGC 2040
TCCTAAGATC CAGCCCCCAT GGACAGACAG ACCAGACTGA 2100 ATATAGACCG
TGTATGTTTA ACAACTCCTC 2160 GCCCTCTACC TGTCCCCTCC CTTCTTTTTT
AAGAACCCT 2220 GGAAGCAGCG CCTCCTTCAG GGTTGGCTGG GAGCTCGGCC 2280
TGCTCTCTC TCTCCTGTGG TGTCCCTTCC TCAGTGGTGT 2340 ATATTTCTTC
TCCTTAGTCT 2400 TAGCTCATGG GGCTCTTTAT AAGGAGTTGG GGGGTAGAGG
CAGGAAATGG GAACCGAGCT 2460 CTGAGTTAGG GGGCTAGAGG ACAGTGCTCC
TGGCCACCCA GCCTCTGCTG 2520 AGAACCATTG AGCTGCCTTT CCCAGGGAAA
AAGTGTGCTC TCCCCGACCC 2580 TCCCGTGGGC CCTGTGGTGT GATGCTGTGT
CTGTATATTC TATACAAAGG 2640 TTCCCTTTGT TAAACCAGTA TAAACAGTTA
AAAAAAAAAA 2700 CGA 2713 (2) INFORMATION FOR SEQ ID NO : 130 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 1011 base pairs (B) TYPE : nucleic acid (C)
STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
130 : AGAGGACGGT GTGACCCGGG AGGAAGTAGA GCCTGAGGAG GCTGAAGAAG
GCATCTCTGA 60 GCAACCCTGC 120 AAGGGACTGT AGATTTAATG ATGCGTTTTT
AAGAATACAC ACCAAAACAA 180 TATGTCAGCT TCCCTTTGGC TACCAAATCC
TTAATTTTTY YTGAATGAGC 240 AAGCTTCTCT TAAAAGATGC TCTCTAGTCA 300
ACTAAGGAGA TGTGACAATC AGGATATAGA AAAACAAACG TAGTGTNTGG 360
GATCTGTTTG GAGACTGGGA TAGGGGTCAG AGAGTCTCGA 420 TCCTAATCAG
GCAGGCCCTG 480 TGAAATGAAA AGCCTTGGCT AACGTAGAAG 540 CCTTGCATCC
TTTTCTTGTG TAAAGTATTT ATTTTGTCA AATTGCAGGA AACATCAGGC 600
ATGAAAAATC TTTACAGCT AGAAATTGAA AGGGCCTTGG GTATAGAGAG 660
CAGCTCAGAA GTCATCCAG CCCTCTGAAT CTCCTGTGCT ATGTTTTATT 720

AATTTTCCA CATGGGCATT CTATTATCTC 780 GACTCCAATA TGTGTTTGT
 CATTCTGACC 840 TAAGGGGTTT AGATAATCAG TAACCATAAC CCCTGAAGCT
 AACATCTCAA 900 ATGAAATGTT GTRGCCATCA GAGACTCAAA AGGAAGTAAG
 GATTTTACAA 960 AAAAAAATTG TTTTGTCCAA AAAANAAAAA AAAAAAATC
 GAAGGGGGGG C 1011 (2) INFORMATION FOR SEQ ID NO : 131 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 2278 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 131 : GTAATTCGGC ACGAGGCGCC CAACATGGCG GGTGGGCGCT GCGGCCCGCA
 SCTAACGGCG 60 CTCCTGGCCG CCTGGATCGC GGCTGTGGCG GCGACGGCAG
 GCGCCGAGGA GGCCGCGCTG 120 CCGCCGAGC AGAGCCGGGT ACCGCCTCCA
 ACTGGACGCT GGTGATGGAG 180 GCGAGTGGA TGCTGAAATT TTACGCCCCA
 TGGTGTCCAT CTGCCAGCA 240 GAATGGGAGG CTTTGTCAA GAATGGTGAA
 AACTTTCAGA TCAGTGTGGG GAAGGTAGAT 300 GTCATTCAAG TTCTTTGTCA
 CCACTCTCCC AGCATTTTTT 360 CCGCCGTTAT CGTGGCCCAG GAATCTTCGA
 AGACCTGCAG 420 AATTATATCT TAGAGAAGAA ATGGCAATCA GTCGAGCCTC
 TGACTGGCTG GAAATCCCCG 480 GCTTCTCTAA CGATGTCTGG TCTCTGGCAA
 GATATGGCAT 540 CTTCACTACT GACTCTTGA ATTCCTGCTT GGTGTTCTTA
 TGTCTTTTTT 600 GTCATAGCCA ATGGGTCTGG AATATCAGAA 660 TGTTTCTATG
 AAGGCATTTA TCTGAGCGTT CTGAGCAGAA GAGGAGGCTC ATAGAGCTGA
 GATGCGGAGG AGGAAAAAGA TGATTCAAAT 780 GAAGAAGAAA CCTTGTAGAT
 GATGAAGAAG AGAAGAAGA TCTTGGCGAT 840 GAGGATGAAG CAGAGGAAGA
 AGAGGAGGAG GACAACTTGG CTGCTGGTGT GGATGAGGAG 900 AGAAGTGAGG
 GGGGCCCCA GGAGAGGACG GTGTGACCCG GGAGGNAAGT 960 AGAGCCTGAG
 GAGGCTGAAG AAGGCATCTC GGTGGAAGAC TCCTTGAGGC AGCGTAAAAG
 TCAGCATGCT GNCAAGGGAC ATGATGCGTT TTCAAGAATA CACACCAAAA
 GCTTCCCTTT TCCTTAATTT TTCCTGAATG AGCAAGCTTC TCTTAAAAGA TGCTCTCTAG
 1200 TATACTAAGG AGAGTCTTCC ATCAGGATAT ACGTAGTGTN TTGGAGACTG
 GGATGGGAAC 1320 AAGTTCATTT ACTTAGGGGT CAGAGAGTCT CGACCAGAGG
 AGGCCATTCC CAGTCCTAAT 1380 CAGCACCTTC GCTGCAGGCC TGTGAAATGA
 CTCTGAGGCA TCCCCAAAGT GTAACGTAGA AGCCTTGCAAT CCTTTTCTTG TGTAAGATAT
 1500 TTATTTTTGT CAAATTGCAG GAAACATCAG GCACCACAGT GCATGAAAAA
 TCTTTCACAG 1560 CTAGAAATTG AAAGGGCCTT GGGTATAGAG AGCAGCTCAG
 AAGTCATCCC AGCCCTCTGA 1620 ATCTCCTGTG CTATGTTTTA TTTCTTACCT
 TTAATTTTTT TTCAGGCTCT CACTATTATC TCTTGGTCAG AGGACTCCAA TAACAGCCAG
 1740 GTTTACATGA ACTGTGTTTG TTCATTCTGA CCTAAGGGGT TTAGATAATC
 AGTAACCATA 1800 ACCCCTGAAG CTGTGACTGC CAAACATCTC AAATGAAATG
 TTGTRGCCAT CAGAGACTCA 1860 AAAGGAAGTA AGGATTTTAC AAGACAGATT
 AAAAAAAAAT TGTTTTGTCC NAAAATATAG 1920 TTTTTTTTTA AGTTTTCTAA
 GCAATATTTT AGTCCTCTAA 1980 GTCTTGCCAG TACAAGGTAG TCTTGTGAAG
 AAAAGTTGAA TTTTCATCTC 2040 AAGGGGTTCC AACTACTTTA ATAATACTA
 TCTGATTTTC 2100 CTTCACTGAT GTGCTTTTGG TGAAAGAATT AATGAACTCC
 AGTACCTGAA AGTGAAAGAT 2160 TGTAATCTTC CAAAGAATTA TATCTTTGTA
 AATCTCTCAA 2220 ACTGTAAGTA CCCAGGGRGG STAATTTCTT TAAAAAAA
 AAAAAAAA 2278 (2) INFORMATION FOR SEQ ID NO : 132 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 1088 base pairs (B) TYPE : nucleic acid (C)
 STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO :
 132 : GGCAGGGGCG GCGTGAACCC GTCGGGCACT GTGTCCCTGA 60 GATGAGATGG
 CCGCGAGCC 120 CTGCCCTGGC CAAGCTCCTG CTCACCTGCT GCTCTGCGCT
 GCGGCCCGG 180 CCAGGGGCAG CANCCGGCTG GCAGATCGTG CTGGGGATCT 240
 CCTAGGAGGA TTTTCTACA TCCGCGACTA GTCACCTCGG 300 CTGGACAGGG
 GCTGTGGCTG AGCTGCTGCC TTCATTTAYG 360 AGAAACGGGG TGGTACATAC

TGGGCCCTGC TGAGGACTCT GCTARCGCTG GCAGCTTTCT 420 CGCTGCCCTC
 AAACCTTTGGA ATGAAGATTT CCGATATGGC TACTCTTATT 480 CTGCCGCATC
 TCCAGCTCGA GTGACTGGAA 540 GTCCAGAAGA CTACACCTAT GTACCTCCTT
 CATGGACATG CTGAAGGCCT 600 CCTTCAGGCC ATGCTCTTGG GTGTCTGGAT
 TCTGCTGCTT CTGGCATCTC 660 TGGCCCCTCT GTGGCTGTAC TGCTGGAGAA
 TGTTCCCAAC 720 GGAAGTGAGT GGAATCTAGC CTGATTATTA GTGCCTGGTG 780
 GGGCGTCCCT GCTGGAAGAA GAACCAGACT GAGGAAAAGA 840 GGCTCTTCAA
 TATCCTGGCC CCATGACCGT GGCCACAGCC 900 AGCACTTGCC CATTCTTAC
 ACCCCTTCCC CGCTTCATGT CCCCTCCTGA 960 GTAGTCATGT GATAATAAAC
 TTGTTCCNAA AAAAAAAAAA AAAAAAAAAAT 1020 TGGGGGGGGG CCGGTACCCA
 TTGGGCCTNN TAAAATTAAT GGGGGGGGTT 1080 TAAAAGGG 1088 (2) INFORMATION
 FOR SEQ ID NO : 133 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 553 base pairs (B)
 TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 133 : GGCAGAGAGC AGATGGCCTT GACACCAGCA
 CGCTATTGCT ACTTCTCTGC 60 TCCCCCACAG TTCCTCTGGA CTTCTCTGGA
 CTGCCAGACC CCTGCCAGAC 120 CCCAGTCCAC CATGATCCAT CCAGTGGCTG 180
 CAGCTCAGAC GACTCCAGGA GAGAGATCAT CTTTACCCT GGCACCTCAG 240
 GCTCTTGTTT CGGATGTGGG TCCCTCTCTC GGCAGGCCTC GTGGCTGCTG 300
 ATCGCTGCTC ATCGTGGGGG CGGTGTTCTT GTGCGCACGC 360 GCCCCGCCCA
 AGATGGCAAA GTCTACATCA CAGGGGCTGA 420 GCTTGGACCT TTGACTTCTG
 ACCCTCTCAT ACAGGAACCC 480 TAATAAAACA ATTGAAACAC CAAAAAAAAA
 AAAAAAAAAA 540 AAAAAAAAAA AAA 553 (2) INFORMATION FOR SEQ ID NO : 134 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 467 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 134 : Met Arg Pro Gln Glu Leu
 Pro Arg Leu Ala Phe Pro Leu Leu Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Pro Pro Pro Pro Cys Pro
 Ala His Ser Ala Thr 20 25 30 Arg Phe Asp Pro Thr Trp Glu Ser Leu Asp Ala Arg Gln Leu Pro Ala 35
 40 45 Trp Phe Asp Gln Ala Lys Phe Gly Ile Phe Ile His Trp Gly Val Phe 50 55 60 Ser Val Pro Ser Phe
 Gly Ser Glu Trp Phe Trp Trp Tyr Trp Gln Lys 65 70 75 80 Glu Lys Ile Pro Lys Tyr Val Glu Phe Met
 Lys Asp Asn Tyr Pro Pro 85 90 95 Xaa Phe Lys Tyr Glu Asp Phe Gly Pro Leu Phe Thr Ala Lys Phe Phe
 100 105 110 Asn Ala Asn Gln Trp Ala Xaa Ile Phe Gln Ala Ser Gly Ala Lys Tyr 115 120 125 Ile Val
 Leu Thr Ser Lys His His Glu Gly Phe Thr Leu Trp Gly Ser 130 135 140 Glu Tyr Ser Trp Asn Trp Asn
 Ala Ile Asp Glu Gly Pro Lys Arg Asp 145 150 155 160 Ile Val Lys Glu Leu Glu Val Ala Ile Arg Asn
 Arg Thr Asp Leu Arg 165 170 175 Phe Gly Leu Tyr Tyr Ser Leu Phe Glu Trp Phe His Pro Leu Phe Leu
 180 185 190 Glu Asp Glu Ser Ser Ser Phe His Lys Arg Gln Phe Pro Val Ser Lys 195 200 205 Thr Leu
 Pro Glu Leu Tyr Glu Leu Val Asn Asn Tyr Gln Pro Glu Val 210 215 220 Leu Trp Ser Asp Gly Asp Gly
 Gly Ala Pro Asp Gln Tyr Trp Asn Xaa 225 230 235 240 Thr Gly Phe Leu Ala Trp Leu Tyr Asn Glu Ser
 Pro Val Arg Gly Thr 245 250 255 Val Val Thr Asn Asp Arg Trp Gly Ala Gly Ser Ile Cys Lys His Gly
 260 265 270 Gly Phe Tyr Thr Cys Ser Asp Arg Tyr Asn Pro Gly His Leu Leu Pro 275 280 285 His Lys
 Trp Glu Asn Cys Met Thr Ile Asp Lys Leu Ser Trp Gly Tyr 290 295 300 Arg Arg Glu Ala Gly Ile Ser
 Asp Tyr Leu Thr Ile Glu Glu Leu Val 305 310 315 320 Lys Gln Leu Val Glu Thr Val Ser Cys Gly Gly
 Asn Leu Leu Met Asn 325 330 335 Ile Gly Pro Thr Leu Asp Gly Thr Ile Ser Val Val Phe Glu Glu Arg
 340 345 350 Leu Arg Gln Met Gly Ser Trp Leu Lys Val Asn Gly Glu Ala Ile Tyr 355 360 365 Glu Thr
 His Thr Trp Arg Ser Gln Asn Asp Thr Val Thr Pro Asp Val 370 375 380 Trp Tyr Thr Ser Lys Pro Lys
 Glu Lys Leu Val Tyr Ala Ile Phe Leu 385 390 395 400 Lys Trp Pro Thr Ser Gly Gln Leu Phe Leu Gly
 His Pro Lys Ala Ile 405 410 415 Leu Gly Ala Thr Glu Val Lys Leu Leu Gly His Gly Gln Pro Leu Asn
 420 425 430 Trp Ile Ser Leu Glu Gln Asn Gly Ile Met Val Glu Leu Pro Gln Leu 435 440 445 Thr Ile
 His Gln Met Pro Cys Lys Trp Gly Trp Ala Leu Ala Leu Thr 450 455 460 Asn Val Ile 465 (2)
 INFORMATION FOR SEQ ID NO : 135 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 222
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 135 : Met Trp Ser Ala Gly Arg Gly Gly Ala Ala Trp Pro Val Leu Leu Gly 1 5 10 15 Leu Leu
 Leu Ala Leu Leu Val Pro Gly Gly Gly Ala Ala Lys Thr Gly 20 25 30 Ala Glu Leu Val Thr Cys Gly Ser

Val Leu Lys Leu Leu Asn Thr His 35 40 45 His Arg Val Arg Leu His Ser His Asp Ile Lys Tyr Gly Ser
 Gly Ser 50 55 60 Gly Gln Gln Ser Val Thr Gly Val Glu Ala Ser Asp Asp Ala Asn Ser 65 70 75 80 Tyr
 Trp Arg Ile Arg Gly Gly Ser Glu Gly Gly Cys Arg Arg Gly Ser 85 90 95 Pro Val Arg Cys Gly Gln Ala
 Val Arg Leu Thr His Val Leu Thr Gly 100 105 110 Lys Asn Leu His Thr His His Phe Pro Ser Pro Leu
 Ser Asn Asn Gln 115 120 125 Glu Val Ser Ala Phe Gly Glu Asp Gly Glu Gly Asp Asp Leu Asp Leu
 130 135 140 Trp Thr Val Arg Cys Ser Gly Gln His Trp Glu Arg Glu Ala Ala Val 145 150 155 160 Arg
 Phe Gln His Val Gly Thr Ser Val Phe Leu Ser Val Thr Gly Glu 165 170 175 Gln Tyr Gly Ser Pro Ile
 Arg Gly Gln His Glu Val His Gly Met Pro 180 185 190 Ser Ala Asn Thr His Asn Thr Trp Lys Ala Met
 Glu Gly Ile Phe Ile 195 200 205 Lys Pro Ser Val Glu Pro Ser Ala Gly His Asp Glu Leu Xaa 210 215
 220 (2) INFORMATION FOR SEQ ID NO : 136 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 156 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 136 : Met Val Ile Glu Ile Ser Asn Lys Thr Ser Ser Ser Ser Thr Cys Ile 1
 5 10 15 Leu Val Leu Leu Val Ser Phe Cys Leu Leu Leu Val Pro Ala Met Tyr 20 25 30 Ser Ser Asp Thr
 Arg Gly Ser Leu Pro Ala Glu His Gly Val Leu Ser 35 40 45 Arg Gln Leu Arg Ala Leu Pro Ser Glu Asp
 Pro Tyr Gln Leu Glu Leu 50 55 60 Pro Ala Leu Gln Ser Glu Val Pro Lys Asp Ser Thr His Gln Trp Leu
 65 70 75 80 Asp Gly Ser Asp Cys Val Leu Gln Ala Pro Gly Asn Thr Ser Cys Leu 85 90 95 Leu His Tyr
 Met Pro Gln Ala Pro Ser Ala Glu Pro Pro Leu Glu Trp 100 105 110 Pro Phe Pro Asp Leu Phe Ser Glu
 Pro Leu Cys Arg Gly Pro Ile Leu 115 120 125 Pro Leu Gln Ala Asn Leu Thr Arg Lys Gly Gly Trp Leu
 Pro Thr Gly 130 135 140 Ser Pro Ser Val Ile Leu Gln Asp Arg Tyr Ser Gly 145 150 155 (2)
 INFORMATION FOR SEQ ID NO : 137 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 233
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 137 : Met Met Ile Leu Phe Asn Leu Leu Ile Phe Leu Cys Gly Ala Ala Leu 1 5 10 15 Leu Ala
 Val Gly Ile Trp Val Ser Ile Asp Gly Ala Ser Phe Leu Lys 20 25 30 Ile Phe Gly Pro Leu Ser Ser Ser Ala
 Met Gln Phe Val Asn Val Gly 35 40 45 Tyr Phe Leu Ile Ala Ala Gly Val Val Val Phe Ala Leu Gly Phe
 Leu 50 55 60 Gly Cys Tyr Gly Ala Lys Thr Glu Ser Lys Cys Ala Leu Val Thr Phe 65 70 75 80 Phe Phe
 Ile Leu Leu Leu Ile Phe Ile Ala Glu Val Ala Ala Ala Val 85 90 95 Val Ala Leu Val Tyr Thr Thr Met
 Ala Glu His Phe Leu Thr Leu Leu 100 105 110 Val Val Pro Ala Ile Lys Lys Asp Tyr Gly Ser Gln Glu
 Asp Phe Thr 115 120 125 Gln Val Trp Asn Thr Thr Met Lys Gly Leu Lys Cys Cys Gly Phe Thr 130 135
 140 Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Glu Asn Ser Ala 145 150 155 160 Phe Pro Pro
 Phe Cys Cys Asn Asp Asn Val Thr Asn Thr Ala Asn Glu 165 170 175 Thr Cys Thr Lys Gln Lys Ala His
 Asp Gln Lys Val Glu Gly Cys Phe 180 185 190 Asn Gln Leu Leu Tyr Asp Ile Arg Thr Asn Ala Val Thr
 Val Gly Gly 195 200 205 Val Ala Ala Gly Ile Gly Gly Leu Glu Leu Ala Ala Met Ile Val Ser 210 215
 220 Met Tyr Leu Tyr Cys Asn Leu Gln Xaa 225 230 (2) INFORMATION FOR SEQ ID NO : 138 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 61 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 138 : Met Gly Ser Ser Arg Trp
 Ser Val Ala Cys Pro Thr Gly Leu Gly Val 1 5 10 15 Leu Met Leu Gly Leu Gly Gly Asp His Pro Pro Gly
 Ser Gln Val Asp 20 25 30 Pro Leu Leu Met Gly Xaa Cys Val Arg Pro Xaa Leu Pro Glu Leu Thr 35 40
 45 Ala Xaa Trp Arg Glu Xaa Gln Xaa Arg Ser Ala Ser Ala 50 55 60 (2) INFORMATION FOR SEQ ID
 NO : 139 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 73 amino acids (B) TYPE : amino
 acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 139 : Met Gly Trp Leu
 Phe Leu Lys Val Leu Leu Ala Gly Val Ser Phe Ser 1 5 10 15 Gly Phe Leu Tyr Pro Leu Val Asp Phe Cys
 Ile Ser Gly Lys Thr Arg 20 25 30 Gly Gln Lys Pro Asn Phe Val Ile Ile Leu Ala Asp Asp Met Gly Trp 35
 40 45 Gly Asp Trp Gly Ala Asn Trp Ala Glu Thr Lys Asp Thr Ala Asn Leu 50 55 60 Asp Lys Met Ala
 Ser Glu Gly Met Xaa 65 70 (2) INFORMATION FOR SEQ ID NO : 140 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 377 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID : 140 : Met His Gly Asn Glu Ala Leu Gly Arg Glu
 Leu Leu Leu Leu Met 1 5 10 15 Gln Phe Leu Cys His Glu Phe Leu Arg Gly Asn Pro Arg Val Thr
 Arg 20 25 30 Leu Leu Ser Glu Met Arg Ile His Leu Leu Pro Ser Met Asn Pro Asp 35 40 45 Gly Tyr Glu
 Ile Ala Tyr His Arg Gly Ser Glu Leu Val Gly Trp Ala 50 55 60 Glu Gly Arg Trp Asn Asn Gln Ser Ile
 Asp Leu Asn His Asn Phe Ala 65 70 75 80 Asp Leu Asn Thr Pro Leu Trp Glu Ala Gln Asp Asp Gly
 Lys Val Pro 85 90 95 His Ile Val Pro Asn His His Leu Pro Leu Pro Thr Tyr Tyr Thr Leu 100 105 110

Pro Asn Ala Thr Val Ala Pro Glu Thr Arg Ala Val Ile Lys Trp Met 115 120 125 Lys Arg Ile Pro Phe
Val Leu Ser Ala Asn Leu His Gly Gly Glu Leu 130 135 140 Val Val Ser Tyr Pro Phe Asp Met Thr Arg
Thr Pro Trp Ala Ala Arg 145 150 155 160 Glu Leu Thr Pro Thr Pro Asp Asp Ala Val Phe Arg Trp Leu
Ser Thr 165 170 175 Val Tyr Ala Gly Ser Asn Leu Ala Met Gln Asp Thr Ser Arg Arg Pro 180 185 190
Cys His Ser Gln Asp Phe Ser Val His Gly Asn Ile Ile Asn Gly Ala 195 200 205 Asp Trp His Thr Val
Pro Gly Ser Met Asn Asp Phe Ser Tyr Leu His 210 215 220 Thr Asn Cys Phe Glu Val Thr Val Glu Leu
Ser Cys Asp Lys Phe Pro 225 230 235 240 His Glu Asn Glu Leu Pro Gln Glu Trp Glu Asn Asn Lys Asp
Ala Leu 245 250 255 Leu Thr Tyr Leu Glu Gln Val Arg Met Gly Ile Ala Gly Val Val Arg 260 265 270
Asp Lys Asp Thr Glu Leu Gly Ile Ala Asp Ala Val Ile Ala Val Asp 275 280 285 Gly Ile Asn His Asp
Val Thr Thr Ala Trp Gly Gly Asp Tyr Trp Arg 290 295 300 Leu Leu Thr Pro Gly Asp Tyr Met Val Thr
Ala Ser Ala Glu Gly Tyr 305 310 315 320 His Ser Val Thr Arg Asn Cys Arg Val Thr Phe Glu Glu Gly
Pro Phe 325 330 335 Pro Cys Asn Phe Val Leu Thr Lys Thr Pro Lys Gln Arg Leu Arg Glu 340 345 350
Leu Leu Ala Ala Gly Ala Lys Val Pro Pro Asp Leu Arg Arg Arg Leu 355 360 365 Glu Arg Leu Arg Gly
Gln Lys Asp Xaa 370 375 (2) INFORMATION FOR SEQ ID NO : 141 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 43 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 141 : Met Ile Cys Leu Ile Leu Leu Leu Gln Ala
Val Val Phe Leu Arg Ser 1 5 10 15 Leu His Val Val His Asn Phe Gln Ile Leu Asp Leu Ser Gly Thr Ser
20 25 30 Tyr Pro Lys Phe Tyr Gln Thr Leu His Arg Gln 35 40 (2) INFORMATION FOR SEQ ID NO :
142 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 41 amino acids (B) TYPE : amino acid
(D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 142 : Met Val His Val Leu
Glu Ile Leu Leu Phe Ile Thr Met Gln Ala Val 1 5 10 15 Ser Phe Pro Phe Gln Thr Gln Ile Asp Thr Cys
Asn Thr Gln Asp Pro 20 25 30 Ala Glu Arg Gln Pro Ala Ser Ile Val 35 40 (2) INFORMATION FOR
SEQ ID : 143 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 70 amino acids (B) TYPE :
amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 143 : Met Gly
Ser Cys Ser Lys Asn Arg Ser Phe Phe Trp Met Thr Gly Leu 1 5 10 15 Leu Val Phe Ile Ser Leu Leu Leu
Ser Glu Trp Gln Gly Pro Trp Glu 20 25 30 Gly Arg Ala Ile Gly Glu Gly Trp Ala Ser Trp Ala Leu Thr
Asn Gly 35 40 45 Trp Ala Val Gln Leu Leu Met Ser Leu Gly Asn Asn Thr Glu Lys His 50 55 60 Ser
Val Met Ile Tyr Glu 65 70 (2) INFORMATION FOR SEQ ID NO : 144 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 483 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 144 : Met Ala Thr Gly Gly Gly Ile Arg Ala Met
Thr Ser Leu Tyr Gly Gln 1 5 10 15 Leu Ala Gly Leu Lys Glu Leu Gly Leu Leu Asp Cys Xaa Ser Tyr Ile
20 25 30 Thr Gly Ala Ser Gly Ser Thr Trp Ala Leu Ala Asn Leu Tyr Lys Asp 35 40 45 Pro Glu Trp Ser
Gln Lys Asp Leu Ala Gly Pro Thr Glu Leu Leu Lys 50 55 60 Thr Gln Val Thr Lys Asn Lys Leu Gly
Val Leu Ala Pro Ser Gln Leu 65 70 75 80 Gln Arg Tyr Arg Gln Glu Leu Ala Glu Arg Ala Arg Leu Gly
Tyr Pro 85 90 95 Ser Cys Phe Thr Asn Leu Trp Ala Leu Ile Asn Glu Ala Leu Leu His 100 105 110 Asp
Glu Pro His Asp His Lys Leu Ser Asp Gln Arg Glu Ala Leu Ser 115 120 125 His Gly Gln Asn Pro Leu
Pro Ile Tyr Cys Ala Leu Asn Thr Lys Gly 130 135 140 Gln Ser Leu Thr Thr Phe Glu Phe Gly Glu Trp
Cys Glu Phe Ser Pro 145 150 155 160 Tyr Glu Val Gly Phe Pro Lys Tyr Gly Ala Phe Ile Pro Ser Glu
Leu 165 170 175 Phe Gly Ser Glu Phe Phe Met Gly Gln Leu Met Lys Arg Leu Pro Glu 180 185 190 Ser
Arg Ile Cys Phe Leu Glu Gly Ile Trp Ser Asn Leu Tyr Ala Ala 195 200 205 Asn Leu Gln Asp Ser Leu
Tyr Trp Ala Ser Glu Pro Ser Gln Phe Trp 210 215 220 Asp Arg Trp Val Arg Asn Gln Ala Asn Leu Asp
Lys Glu Gln Val Pro 225 230 235 240 Leu Leu Lys Ile Glu Glu Pro Pro Ser Thr Ala Gly Arg Ile Ala
Glu 245 250 255 Phe Phe Thr Asp Leu Leu Thr Trp Arg Pro Leu Ala Gln Ala Thr His 260 265 270 Asn
Phe Leu Arg Gly Leu His Phe His Lys Asp Tyr Phe Gln His Pro 275 280 285 His Phe Ser Thr Trp Lys
Ala Thr Thr Leu Asp Gly Leu Pro Asn Gln 290 295 300 Leu Thr Pro Ser Glu Pro His Leu Cys Leu Leu
Asp Val Gly Tyr Leu 305 310 315 320 Ile Asn Thr Ser Cys Leu Pro Leu Leu Gln Pro Thr Arg Asp Val
Asp 325 330 335 Leu Ile Leu Ser Leu Asp Tyr Asn Leu His Gly Ala Phe Gln Gln Leu 340 345 350 Gln
Leu Leu Gly Arg Phe Cys Gln Glu Gln Gly Ile Pro Phe Pro Pro 355 360 365 Ile Ser Pro Ser Pro Glu Glu
Gln Leu Gln Pro Arg Glu Cys His Thr 370 375 380 Phe Ser Asp Pro Thr Cys Pro Gly Ala Pro Ala Val
Leu His Phe Pro 385 390 395 400 Leu Val Ser Asp Ser Phe Arg Glu Tyr Ser Ala Pro Gly Val Arg Arg
405 410 415 Thr Pro Glu Glu Ala Ala Ala Gly Glu Val Asn Leu Ser Ser Ser Asp 420 425 430 Ser Pro

Tyr His Tyr Thr Lys Val Thr Tyr Ser Gln Glu Asp Val Asp 435 440 445 Lys Leu Leu His Leu Thr His
 Tyr Asn Val Cys Asn Asn Gln Glu Gln 450 455 460 Leu Leu Glu Ala Leu Arg Gln Ala Val Gln Arg
 Arg Arg Gln Arg Arg 465 470 475 480 Pro His Xaa (2) INFORMATION FOR SEQ ID NO : 145 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 226 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 145 : Met Glu Gly Ala Pro Pro
 Gly Ser Leu Ala Leu Arg Leu Leu Leu Phe 1 5 10 15 Val Ala Leu Pro Ala Ser Gly Trp Leu Thr Thr Gly
 Ala Pro Glu Pro 20 25 30 Pro Pro Leu Ser Gly Ala Pro Gln Asp Gly Ile Arg Ile Asn Val Thr 35 40 45
 Thr Leu Lys Asp Asp Gly Asp Ile Ser Lys Gln Gln Val Val Leu Asn 50 55 60 Ile Thr Tyr Glu Ser Gly
 Gln Val Tyr Val Asn Asp Leu Pro Val Asn 65 70 75 80 Ser Gly Val Thr Arg Ile Ser Cys Gln Thr Leu
 Ile Val Lys Asn Glu 85 90 95 Asn Leu Glu Asn Leu Glu Glu Lys Glu Tyr Phe Gly Ile Val Ser Val 100
 105 110 Arg Ile Leu Val His Glu Trp Pro Met Thr Ser Gly Ser Ser Leu Gln 115 120 125 Leu Ile Val Ile
 Gln Glu Glu Val Val Glu Ile Asp Gly Lys Gln Val 130 135 140 Gln Gln Lys Asp Val Thr Glu Ile Asp
 Ile Leu Val Lys Asn Arg Gly 145 150 155 160 Val Leu Arg His Ser Asn Tyr Thr Leu Pro Leu Glu Glu
 Ser Met Leu 165 170 175 Tyr Ser Ile Ser Arg Asp Ser Asp Ile Leu Phe Thr Leu Pro Asn Leu 180 185
 190 Ser Lys Lys Glu Ser Val Ser Ser Leu Gln Thr Thr Ser Gln Tyr Leu 195 200 205 Ile Arg Asn Val
 Glu Thr Thr Val Asp Glu Asp Val Leu Pro Gly Gln 210 215 220 Val Thr 225 (2) INFORMATION FOR
 SEQ ID NO : 146 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 45 amino acids (B) TYPE :
 amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 146 : Met Gly
 Met Gly Ala Phe Gln Ala Phe Phe Trp Val Ile Leu Thr Val 1 5 10 15 Ser Asn Val Cys Val Leu Phe Lys
 Met Ser Leu Phe Phe Leu Leu Thr 20 25 30 Leu Ile Ser Lys Leu His Gly Asp Ala Glu Val Cys Xaa 35
 40 45 (2) INFORMATION FOR SEQ ID NO : 147 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 132 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 147 : Met Ser Gly Gly Trp Met Ala Gln Val Gly Ala Trp Arg Thr Gly
 Ala 1 5 10 15 Leu Gly Leu Ala Leu Leu Leu Leu Gly Leu Gly Leu Gly Leu Glu 20 25 30 Ala Pro
 Arg Ala Arg Phe Pro Pro Arg Pro Leu Pro Arg Pro His Pro 35 40 45 Ser Ser Gly Ser Cys Pro Pro Thr
 Lys Phe Gln Cys Arg Thr Ser Gly 50 55 60 Leu Cys Val Pro Leu Thr Trp Arg Cys Asp Arg Thr Trp Thr
 Ala Ala 65 70 75 80 Met Ala Ala Met Arg Arg Ser Ala Gly Leu Ser His Val Pro Arg Lys 85 90 95 Gly
 Asn Ala His Arg Pro Leu Ala Ser Pro Ala Pro Ala Pro Ala Ser 100 105 110 Val Thr Ala Leu Gly Glu
 Leu Thr Arg Asn Cys Ala Thr Ala Ala Ala 115 120 125 Trp Pro Ala Xaa 130 (2) INFORMATION FOR
 SEQ ID NO : 148 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 92 amino acids (B) TYPE :
 amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 148 : Met Glu
 Ala Thr Leu Glu Gln His Leu Glu Asp Thr Met Lys Asn Pro 1 5 10 15 Ser Ile Val Gly Val Leu Cys Thr
 Asp Ser Gln Gly Leu Asn Leu Gly 20 25 30 Cys Arg Gly Thr Leu Ser Asp Glu His Ala Gly Val Ile Ser
 Val Leu 35 40 45 Ala Gln Gln Ala Ala Lys Leu Thr Ser Asp Pro Thr Asp Ile Pro Val 50 55 60 Val Cys
 Leu Glu Ser Asp Asn Gly Asn Ile Met Ile Gln Lys His Asp 65 70 75 80 Gly Ile Thr Val Ala Val His Lys
 Met Ala Ser Xaa 85 90 (2) INFORMATION FOR SEQ ID NO : 149 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 165 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 149 : Met Glu Pro Leu Arg Leu Leu Ile Leu
 Leu Phe Val Thr Glu Leu Ser 1 5 10 15 Gly Ala His Asn Thr Thr Val Phe Gln Gly Val Ala Gly Gln Ser
 Leu 20 25 30 Gln Val Ser Cys Pro Tyr Asp Ser Met Lys His Trp Gly Arg Arg Lys 35 40 45 Ala Trp Cys
 Arg Gln Leu Gly Glu Lys Gly Pro Cys Gln Arg Val Val 50 55 60 Ser Thr His Asn Leu Trp Leu Leu Ser
 Phe Leu Arg Arg Trp Asn Gly 65 70 75 80 Ser Thr Ala Ile Thr Asp Asp Thr Leu Gly Gly Thr Leu Thr
 Ile Thr 85 90 95 Leu Arg Asn Leu Gln Pro His Asp Ala Gly Leu Tyr Gln Cys Gln Ser 100 105 110 Leu
 His Gly Ser Glu Ala Asp Thr Leu Arg Lys Val Leu Val Glu Val 115 120 125 Leu Ala Asp Pro Leu Asp
 His Arg Asp Ala Gly Asp Leu Trp Phe Pro 130 135 140 Gly Glu Ser Glu Ser Phe Glu Asp Ala His Val
 Glu His Ser Ile Ser 145 150 155 160 Arg Ser Ser Ser Xaa 165 (2) INFORMATION FOR SEQ ID NO :
 150 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 139 amino acids (B) TYPE : amino acid
 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 150 : Met Ile Ser Leu Thr
 Asp Thr Gln Lys Ile Gly Met Gly Leu Thr Gly 1 5 10 15 Phe Gly Val Phe Phe Leu Phe Phe Gly Met Ile
 Leu Phe Phe Asp Lys 20 25 30 Ala Leu Leu Ala Ile Gly Asn Val Leu Phe Val Ala Gly Leu Ala Phe 35
 40 45 Val Ile Gly Leu Glu Arg Thr Phe Arg Phe Phe Phe Gln Lys His Lys 50 55 60 Met Lys Ala Thr

Gly Phe Phe Leu Gly Gly Val Phe Val Val Leu Ile 65 70 75 80 Gly Trp Pro Leu Ile Gly Met Ile Phe Glu
 Ile Tyr Gly Phe Phe Leu 85 90 95 Leu Phe Arg Gly Phe Phe Pro Val Val Val Gly Phe Ile Arg Arg Val
 100 105 110 Pro Val Leu Gly Ser Leu Leu Asn Leu Pro Gly Ile Arg Ser Phe Val 115 120 125 Asp Lys
 Val Gly Glu Ser Asn Asn Met Val Xaa 130 135 (2) INFORMATION FOR SEQ ID NO : 151 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 58 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 151 : Met Ser Ala Pro Gln Thr
 Arg Ile Ser Arg Ala Leu Val Leu Leu Phe 1 5 10 15 Leu Ala Pro Thr Leu Leu Ser Leu Gly His Gly Ile
 His Pro Ile Asn 20 25 30 Thr Ala Thr Pro Tyr Xaa Thr Asp Gln Ala Lys Leu Ala Pro Gly Thr 35 40 45
 Lys Glu Leu Asn His Asp Gln Ser Val Thr 50 55 (2) INFORMATION FOR SEQ ID NO : 152 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 48 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 152 : Met Ile Arg Lys Leu His
 Lys Ile Ile Val Phe Ser Pro Arg Val Ile 1 5 10 15 Val Leu Leu Asn Cys Phe Phe Phe Ile Lys Ala Lys
 Phe Val Leu Tyr 20 25 30 Ile Phe Val Phe His Val Leu Asp Gly Ser Ile Ser Tyr Pro Val Xaa 35 40 45
 (2) INFORMATION FOR SEQ ID NO : 153 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
 42 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION :
 SEQ ID NO : 153 : Met Leu Leu Asn Gln His Phe Lys Ile Phe Gly Ser Leu Ile His Met 1 5 10 15 Asn
 Leu Leu Phe Ala Leu Ile Ser Leu Gly Ser Ser Asn Leu Ser Gly 20 25 30 Val Gln Phe Cys Cys Glu Thr
 Val Gln Xaa 35 40 (2) INFORMATION FOR SEQ ID NO : 154 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 72 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 154 : Met Leu Ser Leu Ser Phe Leu Leu Arg
 Arg Val Leu Phe Leu Gly Phe 1 5 10 15 Leu Gln Ala Ser Val Gly Glu Lys Lys Ser Leu Arg Xaa Leu
 Asn Tyr 20 25 30 Ser Val Pro His Pro Met Leu Xaa His Pro Pro Pro Asp Thr Ala 35 40 45 Val Pro Pro
 Arg Leu Glu Arg Ser Leu Leu Gln Glu Leu Trp Thr 50 55 60 Pro Gly Pro His His Ser Asn Ile 65 70 (2)
 INFORMATION FOR SEQ ID NO : 155 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 106
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 155 : Met Gln Pro Leu Asn Phe Ser Ser Thr Glu Cys Ser Ser Phe Ser Pro 1 5 10 15 Pro Thr Thr
 Val Ile Leu Leu Ile Leu Leu Cys Phe Glu Gly Leu Leu 20 25 30 Phe Leu Ile Phe Thr Ser Val Met Phe
 Gly Thr Gln Val His Ser Ile 35 40 45 Cys Thr Asp Glu Thr Gly Ile Glu Gln Leu Lys Lys Glu Glu Arg
 Arg 50 55 60 Trp Ala Lys Lys Thr Lys Trp Met Asn Met Lys Ala Val Phe Gly His 65 70 75 80 Pro Phe
 Ser Leu Gly Trp Ala Ser Pro Phe Ala Thr Pro Asp Gln Gly 85 90 95 Lys Ala Asp Pro Tyr Gln Tyr Val
 Val Xaa 100 105 (2) INFORMATION FOR SEQ ID NO : 156 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 29 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 156 : Met Tyr Thr Asn His Phe Asn Leu Tyr
 Leu Lys Tyr Ile Leu Leu Ile 1 5 10 15 Ile Leu Ile Leu Asn Met Thr Asn Ser Ser Ser Arg Tyr 20 25 (2)
 INFORMATION FOR SEQ ID NO : 157 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 53
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 157 : Met Asn Glu Leu Leu Leu Phe Phe Phe Phe Phe Phe Phe Thr Phe 1 5 10 15 Cys Ile
 Glu Thr Asn Ser Phe Lys Gln Thr Tyr Tyr Tyr Tyr Phe Leu 20 25 30 Gln Asn Ile Tyr Met Glu Met Leu
 Pro Pro Pro Val Asn Pro Pro Val 35 40 45 Pro Pro Trp Gly Xaa 50 (2) INFORMATION FOR SEQ ID
 NO : 158 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 75 amino acids (B) TYPE : amino
 acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 158 : Met Tyr Ala Val
 Tyr Gln Gln Leu Ala Gln Leu Thr Leu Met Val Thr 1 5 10 15 Leu Leu Ala Pro Ile Leu Pro Asp Glu Gln
 Ser Glu Val Phe Glu Ala 20 25 30 Leu Ser Asn Leu Pro Lys Val Thr Trp Leu Gly Ser Asn Ser Pro Ser
 35 40 45 Ser Glu Met Pro Glu Pro Gly Arg Phe Val Ile Val His His Gln Leu 50 55 60 Ser Ala Ala Ser
 His Ser Ser Ser Gln Leu Ala 65 70 75 (2) INFORMATION FOR SEQ ID NO : 159 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 81 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 159 : Met Trp Pro Pro Leu Leu Leu Leu Leu
 Leu Leu Leu Pro Ala Ala Pro 1 5 10 15 Val Pro Thr Ala Lys Ala Ala Pro His Pro Asp Ala Asn Thr Gln
 Glu 20 25 30 Gly Leu Gln Asn Leu Leu Gln Gly Val Gly Ala Gly Gly Asp Gly Glu 35 40 45 Leu Arg
 Ala Asp Ser His Leu Ala Pro Gly Ser Gly Cys Ile Asp Gly 50 55 60 Ala Val Val Ala Thr Arg Pro Glu
 Ser Arg Gly Gly Arg Pro Ala Val 65 70 75 80 Pro (2) INFORMATION FOR SEQ ID NO : 160 : (i)

SEQUENCE CHARACTERISTICS : (A) LENGTH : 139 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 160 : Met Lys Phe Thr Thr Leu Leu Phe Leu Ala Ala Val Ala Gly Ala Leu 1 5 10 15 Val Tyr Ala Glu Asp Ala Ser Ser Asp Ser Thr Gly Ala Asp Pro Ala 20 25 30 Gln Glu Ala Gly Thr Ser Lys Pro Asn Glu Glu Ile Ser Gly Pro Ala 35 40 45 Glu Pro Ala Ser Pro Pro Glu Thr Thr Thr Thr Ala Gln Glu Thr Ser 50 55 60 Ala Ala Ala Val Gln Gly Thr Ala Lys Val Thr Ser Ser Arg Gln Glu 65 70 75 80 Leu Asn Pro Leu Lys Ser Ile Val Glu Lys Ser Ile Leu Leu Thr Glu 85 Gln Ala Leu Ala Lys Ala Gly Lys Gly Met His Gly Gly Val Pro Gly 100 105 110 Gly Lys Gln Phe Ile Glu Asn Gly Ser Glu Phe Ala Gln Lys Leu Leu 115 120 125 Lys Lys Phe Ser Leu Leu Lys Pro Trp Ala Xaa 130 135 (2) INFORMATION FOR SEQ ID NO : 161 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 178 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 161 : Met Leu Gly Cys Gly Ile Pro Ala Leu Gly Leu Leu Leu Leu Leu Gln 1 5 10 15 Gly Ser Ala Asp Gly Asn Gly Ile Gln Gly Phe Phe Tyr Pro Trp Ser 20 25 30 Cys Glu Gly Asp Ile Trp Asp Arg Glu Ser Cys Gly Gly Gln Ala Ala 35 40 45 Ile Asp Ser Pro Asn Leu Cys Leu Arg Leu Arg Cys Cys Tyr Arg Asn 50 55 60 Gly Val Cys Tyr His Gln Arg Pro Asp Glu Asn Val Arg Arg Lys His 65 70 75 80 Met Trp Ala Leu Val Trp Thr Cys Ser Gly Leu Leu Leu Leu Ser Cys 85 90 95 Ser Ile Cys Leu Phe Trp Trp Ala Lys Arg Arg Asp Val Leu His Met 100 105 110 Pro Gly Phe Leu Ala Gly Pro Cys Asp Met Ser Lys Ser Val Ser Leu 115 120 125 Leu Ser Lys His Arg Gly Thr Lys Lys Thr Pro Ser Thr Gly Ser Val 130 135 140 Pro Val Ala Leu Ser Lys Glu Ser Arg Asp Val Glu Gly Gly Thr Glu 145 150 155 160 Gly Glu Gly Thr Glu Glu Gly Glu Glu Thr Glu Gly Glu Glu Glu 165 170 175 Asp Xaa (2) INFORMATION FOR SEQ ID NO : 162 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 72 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 162 : Met Glu Ala Val Phe Thr Val Phe Phe Phe Val Val Val Leu Phe Leu 1 5 10 15 Lys Asn Thr Glu Gly Ala Lys Leu Phe Cys Thr Leu Tyr Pro Ala Ala 20 25 30 Ser Ser Gly Gln Ser Gln Gly Pro Gly Leu Glu Lys Pro Asp Ser Gln 35 40 45 Glu Cys Ile Ile Asp Pro Cys Ser Tyr Pro Ile Ala Leu Gly Ala Gly 50 55 60 Thr Glu Pro Gly Cys Lys Ile Xaa 65 70 (2) INFORMATION FOR SEQ ID NO : 163 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 67 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 163 : Met Trp Phe Tyr Phe Leu Ser Val Ser Phe Pro Leu Leu Pro Val Xaa 1 5 10 15 Ala Pro Xaa Pro Pro Pro Ala Pro Thr Thr Leu Cys Leu Leu Leu Phe 20 25 30 Leu Gly Xaa Leu Tyr Asn Ser Thr Cys Ile His Cys Val His Thr Thr 35 40 45 Ser Xaa Thr Gln Asn Pro Thr Ala Asn Thr Leu Lys Lys Lys Lys Lys 50 55 60 Asn Trp Gly 65 (2) INFORMATION FOR SEQ ID NO : 164 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 155 amino acids (B) TYPE : amino acid (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 164 : Met Gly Phe Gly Ala Thr Leu Ala Val Gly Leu Thr Ile Phe Val Leu 1 5 10 15 Ser Val Val Thr Ile Ile Ile Cys Phe Thr Cys Ser Cys Cys Cys Leu 20 25 30 Tyr Lys Thr Cys Arg Arg Pro Arg Pro Val Val Thr Thr Thr Thr Ser 35 40 45 Thr Thr Val Val His Ala Pro Tyr Pro Gln Pro Pro Ser Val Pro Pro 50 55 60 Ser Tyr Pro Gly Pro Ser Tyr Gln Gly Tyr His Thr Met Pro Pro 65 70 75 80 Pro Gly Met Pro Ala Ala Pro Tyr Pro Met Tyr Pro Pro Pro Tyr 85 90 95 Pro Ala Gln Pro Met Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly 100 105 110 Glu Pro Arg Pro Thr Pro Pro Ala Ser Leu Leu Thr Thr Arg Pro 115 120 125 Thr Trp Met Pro Arg Arg Arg Pro Ser Glu His Ser Leu Ala Ser Leu 130 135 140 Ala Ala Thr Trp Leu Cys Cys Val Cys Ala Xaa 145 150 155 (2) INFORMATION FOR SEQ ID NO : 165 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 104 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 165 : Met Ile Ile Leu Val Phe Ile Ala Phe Phe Ile Pro Leu Gln Lys Thr 1 5 10 15 Ile Gly Lys Ile Ala Thr Cys Leu Glu Leu Arg Ser Ala Ala Leu 20 25 30 Ser Thr Gln Ser Gln Glu Glu Phe Lys Leu Glu Asp Leu Lys Lys Leu 35 40 45 Glu Pro Ile Leu Lys Asn Ile Leu Thr Tyr Asn Lys Glu Phe Pro Phe 50 55 60 Asp Val Gln Pro Val Pro Leu Arg Arg Ile Leu Ala Pro Gly Glu Glu 65 70 75 80 Glu Asn Leu Glu Phe Glu Glu Asp Glu Glu Glu Gly Gly Ala Gly Ala 85 90 95 Gly Leu Leu Ile Leu Ser Cys Xaa 100 (2) INFORMATION FOR SEQ ID NO : 166 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 81 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 166 : Met Ala Gly Thr Met Val Ile Val Val Val Val Val Val Gly Glu Val 1 5 10 15 Val Val Glu Ala Glu Val Val Val Gln Ala Arg Glu Glu Ala Gly Glu 20 25 30 Glu Glu Gly Ala Arg Ile Ile Thr Lys

Gly Val Asn Leu Asn Ser Ile 35 40 45 Ser Ser Met Glu Val Ile Ser Ile Ile Ile Leu Asp Leu Asp Arg Glu
 50 55 60 Asp Ile Thr Leu Val Glu Ala Thr Glu Pro Tyr Ile Leu Leu Glu Leu 65 70 75 80 Lys (2)
 INFORMATION FOR SEQ ID NO : 167 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 93
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 167 : Met Ser Phe Ser Phe Ile Ile Phe Leu Leu Leu Val Cys Gln Glu Ile 1 5 10 15 Thr Phe Cys
 Met Ser Tyr Gly Asp Ala Val Asn Cys Phe Ser Glu Cys 20 25 30 Phe Ser Asn Leu Gln Thr Ile Tyr Ile
 Ser Cys Leu Gln His Ala Val 35 40 45 Cys Lys His Ser Val Ile Trp Ser Ile Gln Leu Phe Val Arg Ala
 Leu 50 55 60 Pro Ile Ser Lys Cys Ala Glu Leu Ser Ile Asp Gly Ile Phe Arg Ser 65 70 75 80 Phe His Glu
 Asn Trp Lys Cys Ser Trp Val Ala Pro Thr 85 90 (2) INFORMATION FOR SEQ ID : 168 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 58 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 168 : Met Gly Trp Ser Ala Gly
 Leu Leu Phe Leu Leu Ile Leu Tyr Leu Pro 1 5 10 15 Val Pro Gly Trp Met Glu Arg Glu Asp Gly Glu Thr
 Gly His Leu Ser 20 25 30 Pro Gln Ala Pro Gly Arg Glu Tyr Arg Gly Phe Tyr Ser Val Pro Pro 35 40 45
 Asp Tyr Val Trp Leu Arg Asp Ser Pro Xaa 50 55 (2) INFORMATION FOR SEQ ID NO : 169 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 232 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 169 : Met Ala Thr Leu Trp Gly
 Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser 1 5 10 15 Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu
 Ala His Cys Gln Thr 20 25 30 Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro 35 40
 45 Ile Lys Lys Asn Ser Gly His Ile Tyr Asn Lys Asn Ile Ser Gln Lys 50 55 60 Asp Cys Asp Cys Leu
 His Val Val Glu Pro Met Pro Val Arg Gly Pro 65 70 75 80 Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu
 Cys Lys Tyr Glu Glu Arg 85 90 95 Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile Leu 100
 105 110 Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro Ile 115 120 125 Leu Lys Arg
 Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp Asp 130 135 140 Asp Ile Gly Asp His Gln Pro Phe
 Ala Asn Ala His Asp Val Leu Ala 145 150 155 160 Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val
 Glu Tyr Gly Thr 165 170 175 Ala Ala Leu Glu Ala Ser Ser Pro Arg Ala Ala Lys Ser Leu Ser Leu 180
 185 190 Thr Gly Met Leu Ser Ser Ala Asn Trp Gly Ile Glu Phe Lys Val Thr 195 200 205 Arg Lys Lys
 Gln Ala Asp Asn Trp Lys Gly Thr Asp Trp Val Leu Leu 210 215 220 Gly Phe Ile Leu Ile Pro Cys Xaa
 225 230 (2) INFORMATION FOR SEQ ID NO : 170 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 72 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 170 : Met Ser Ala Ile Phe Asn Phe Gln Ser Leu Leu Thr Val Ile Leu
 Leu 1 5 10 15 Leu Ile Cys Thr Cys Ala Tyr Ile Arg Ser Leu Ala Pro Ser Leu Leu 20 25 30 Asp Arg Asn
 Lys Thr Gly Leu Leu Gly Ile Phe Trp Lys Cys Ala Arg 35 40 45 Ile Gly Glu Arg Lys Ser Pro Tyr Val
 Ala Val Cys Cys Ile Val Met 55 60 Ala Phe Ser Ile Leu Phe Ile Gln 65 70 (2) INFORMATION FOR
 SEQ ID NO : 171 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 65 amino acids (B) TYPE :
 amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 171 : Met Gly
 Thr Phe Ser Leu Ser Leu Phe Gly Leu Met Gly Val Ala Phe 1 5 10 15 Gly Met Asn Leu Glu Ser Ser
 Leu Glu Glu Asp His Arg Ile Phe Trp 20 25 30 Leu Ile Thr Gly Ile Met Phe Met Gly Ser Gly Leu Ile
 Trp Arg Arg 35 40 45 Leu Leu Ser Phe Leu Gly Arg Gln Leu Glu Ala Pro Leu Pro Pro Met 50 55 60
 Val 65 (2) INFORMATION FOR SEQ ID NO : 172 : (i) SEQUENCE CHARACTERISTICS : (A)
 LENGTH : 75 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 172 : Met Tyr Lys Gly Lys Leu Val Ile Val Leu Ile Leu Leu Leu Leu
 Pro 1 5 10 15 Ser His Phe Met Phe Leu Thr Gln Cys Lys Glu Ile Lys His Asn Leu 20 25 30 Lys Lys
 Asn Met Ser Leu Leu Leu Phe Thr Ile Lys Ser Trp Leu Tyr 35 40 45 Ser Ala Ser Leu Gly Ile Leu Tyr
 Asn Trp Gln His Leu Thr Ala Gln 55 60 Val Asp Gln Cys Thr Ser Leu Ile Leu Ile His 65 70 75 (2)
 INFORMATION FOR SEQ ID : 173 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 334
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 173 : Met Val Gly His Glu Met Ala Ser Xaa Ser Ser Asn Thr Ser Leu Pro 1 5 10 15 Phe Ser
 Asn Met Gly Asn Pro Met Asn Thr Thr Gln Leu Gly Lys Ser 20 25 30 Leu Phe Gln Trp Gln Val Glu
 Gln Glu Glu Ser Lys Leu Ala Asn Ile 35 40 45 Ser Gln Asp Gln Phe Leu Ser Lys Asp Ala Asp Gly Asp
 Thr Phe Leu 50 55 60 His Ile Ala Val Ala Gln Gly Arg Arg Ala Leu Ser Tyr Val Leu Ala 65 70 75 80
 Arg Lys Met Asn Ala Leu His Met Leu Asp Ile Lys Glu His Asn Gly 85 90 95 Gln Ser Ala Phe Gln Val

Ala Val Ala Ala Asn Gln His Leu Ile Val 100 105 110 Gln Asp Leu Val Asn Ile Gly Ala Gln Val Asn Thr Thr Asp Cys Trp 115 120 125 Gly Arg Thr Pro Leu His Val Cys Ala Glu Lys Gly His Ser Gln Val 130 135 140 Leu Gln Ala Ile Gln Lys Gly Ala Val Gly Ser Asn Gln Phe Val Asp 145 150 155 160 Leu Glu Ala Thr Asn Tyr Asp Gly Leu Thr Pro Leu His Cys Ala Val 165 170 175 Ile Ala His Asn Ala Val Val His Glu Leu Gln Arg Asn Gln Gln Pro 180 185 190 His Ser Pro Glu Val Gln Glu Leu Leu Leu Lys Asn Lys Ser Leu Val 195 200 205 Asp Thr Ile Lys Cys Leu Ile Gln Met Gly Ala Ala Val Glu Ala Lys 210 215 220 Asp Arg Lys Ser Gly Arg Thr Ala Leu His Leu Ala Ala Glu Glu Ala 225 230 235 240 Asn Leu Glu Leu Ile Arg Leu Phe Leu Glu Leu Pro Ser Cys Leu Ser 245 250 255 Phe Val Asn Ala Lys Ala Tyr Asn Gly Asn Thr Ala Leu His Val Ala 260 265 270 Ala Ser Leu Gln Tyr Arg Leu Thr Gln Leu Asp Ala Val Arg Leu Leu 275 280 285 Met Arg Lys Gly Ala Asp Pro Ser Thr Arg Asn Leu Glu Asn Glu Gln 290 295 300 Pro Val His Leu Val Pro Asp Gly Pro Val Gly Glu Gln Ile Arg Arg 305 310 315 320 Ile Leu Lys Gly Lys Ser Ile Gln Gln Arg Ala Pro Pro Tyr 325 330 (2) INFORMATION FOR SEQ ID NO : 174 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 196 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 174 : Met Asp Ala Arg Trp Trp Ala Val Val Val Leu Ala Ala Phe Pro Ser 1 5 10 15 Leu Gly Ala Gly Gly Glu Thr Pro Glu Ala Pro Pro Glu Ser Trp Thr 20 25 30 Gln Leu Trp Phe Phe Arg Phe Val Val Asn Ala Ala Gly Tyr Ala Ser 35 40 45 Phe Met Val Pro Gly Tyr Leu Leu Val Gln Tyr Phe Arg Arg Lys Asn 50 55 60 Tyr Leu Glu Thr Gly Arg Gly Leu Cys Phe Pro Leu Val Lys Ala Cys 65 70 75 80 Val Phe Gly Asn Glu Pro Lys Ala Ser Asp Glu Val Pro Leu Ala Pro 85 90 95 Arg Thr Glu Ala Ala Glu Thr Thr Pro Met Trp Gln Ala Leu Lys Leu 100 105 110 Leu Phe Cys Ala Thr Gly Leu Gln Val Ser Tyr Leu Thr Trp Gly Val 115 120 125 Leu Gln Glu Arg Val Met Thr Arg Ser Tyr Gly Ala Thr Ala Thr Ser 130 135 140 Pro Gly Glu Arg Phe Thr Asp Ser Gln Phe Leu Val Leu Met Asn Arg 145 150 155 160 Val Leu Ala Leu Ile Val Ala Gly Leu Ser Cys Val Leu Cys Lys Gln 165 170 175 Pro Arg His Gly Ala Pro Met Tyr Arg Tyr Ser Phe Cys Gln Pro Val 180 185 190 Gln Cys Ala Xaa 195 (2) INFORMATION FOR SEQ ID NO : 175 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 265 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 175 : Met Ser Asp Leu Leu Leu Leu Gly Leu Ile Gly Gly Leu Thr Leu Leu 1 5 10 15 Leu Leu Leu Thr Leu Leu Ala Phe Ala Gly Tyr Ser Gly Leu Leu Ala 20 25 30 Gly Val Glu Val Ser Ala Gly Ser Pro Pro Ile Arg Asn Val Thr Val 35 40 45 Ala Tyr Lys Phe His Met Gly Leu Tyr Gly Glu Thr Gly Arg Leu Phe 50 55 60 Thr Glu Ser Cys Ser Ile Ser Pro Lys Leu Arg Ser Ile Ala Val Tyr 65 70 75 80 Tyr Asp Asn Pro His Met Val Pro Pro Asp Lys Cys Arg Cys Ala Val 85 90 95 Gly Ser Ile Leu Ser Glu Gly Glu Glu Ser Pro Ser Pro Glu Leu Ile 100 105 110 Asp Leu Tyr Gln Lys Phe Gly Phe Lys Val Phe Ser Phe Pro Glu Pro 115 120 125 Ser His Val Val Thr Ala Thr Phe Pro Leu Thr Pro Pro Phe Cys Pro 130 135 140 Ile Trp Leu Gly Tyr Pro Pro Cys Pro Ser Cys Leu Gly His Leu His 145 150 155 160 Gln Gly Ala Glu Ala Val Cys Leu Ser Ser Ala Gly Asp Leu Pro Gly 165 170 175 Arg Pro Glu Ser Ile Ser Cys Ala His Trp His Gly Gln Gly Asp Phe 180 185 190 Tyr Val Pro Glu Met Lys Glu Thr Glu Trp Lys Trp Arg Gly Leu Val 195 200 205 Glu Ala Ile Asp Thr Gln Val Asp Gly Thr Gly Ala Asp Thr Met Ser 210 215 220 Asp Thr Ser Ser Val Ser Leu Glu Val Ser Pro Gly Ser Arg Glu Thr 225 230 235 240 Ser Ala Ala Thr Leu Ser Pro Gly Ala Ser Ser Arg Gly Trp Asp Asp 245 250 255 Gly Asp Thr Arg Ser Glu His Ser Xaa 260 265 (2) INFORMATION FOR SEQ ID NO : 176 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 138 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 176 : Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln 1 5 10 15 Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu Asp 20 25 30 Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln Gly Val 35 40 45 Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr Leu Arg Pro 50 55 60 Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg Val Lys Trp Thr 65 70 75 80 Phe Leu Ser Arg Gly Arg Glu Ala Glu Val Leu Val Ala Arg Gly Val 85 90 95 Arg Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala 100 105 110 Tyr Pro Ala Ser Leu Thr Asp Val Ser Pro Gly Ala Glu Arg Ala Ala 115 120 125 Pro Gln Arg Leu Arg Tyr Leu Ser Leu Xaa 130 135 (2) INFORMATION FOR SEQ ID NO : 177 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 179 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 177 : Met Pro Ala Leu Arg Pro Ala Leu Leu Trp Ala Leu Leu Ala Leu Trp 1 5 10 15 Leu Cys Cys Ala Thr Pro Ala His Ala Leu

Gln Cys Arg Asp Gly Tyr 20 25 30 Glu Pro Cys Val Asn Glu Gly Met Cys Val Thr Tyr His Asn Gly
 Thr 35 40 45 Gly Tyr Cys Lys Gly Pro Glu Gly Phe Leu Gly Glu Tyr Cys Gln His 50 55 60 Arg Asp
 Pro Cys Glu Lys Asn Arg Cys Gln Asn Gly Gly Thr Cys Val 65 70 75 80 Ala Gln Ala Met Leu Gly Lys
 Ala Thr Cys Arg Cys Ala Ser Gly Phe 85 90 95 Thr Gly Glu Asp Cys Gln Tyr Ser Thr Ser His Pro Cys
 Phe Val Ser 100 105 110 Arg Pro Cys Leu Asn Gly Gly Thr Cys His Met Leu Ser Arg Asp Thr 115 120
 125 Tyr Glu Cys Thr Cys Gln Val Gly Phe Thr Gly Lys Glu Cys Gln Trp 130 135 140 Thr Asp Ala Cys
 Leu Ser His Pro Cys Ala Asn Gly Ser Thr Cys Thr 145 150 155 160 Thr Val Ala Asn His Phe Leu Gln
 Met Pro His Arg Leu His Arg Ala 165 170 175 Glu Val Xaa (2) INFORMATION FOR SEQ ID NO :
 178 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 155 amino acids (B) TYPE : amino acid
 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 178 : Met Thr Arg Gly Gly
 Pro Gly Gly Arg Pro Gly Leu Pro Gln Pro Pro 1 5 10 15 Pro Leu Leu Leu Leu Leu Leu Pro Leu
 Leu Leu Val Thr Ala Glu 20 25 30 Pro Pro Lys Pro Ala Gly Val Tyr Tyr Ala Thr Ala Tyr Trp Met Pro
 35 40 45 Ala Glu Lys Thr Val Gln Val Lys Asn Val Met Asp Lys Asn Gly Asp 50 55 60 Ala Tyr Gly
 Phe Tyr Asn Asn Ser Val Lys Thr Thr Gly Trp Gly Ile 65 70 75 80 Leu Glu Ile Arg Ala Gly Tyr Gly Ser
 Gln Thr Leu Ser Asn Glu Ile 85 90 95 Ile Met Phe Val Ala Gly Phe Leu Glu Gly Tyr Leu Ile Ala Pro
 His 100 105 110 Met Asn Asp His Tyr Thr Asn Leu Tyr Pro Gln Leu Ile Thr Lys Pro 115 120 125 Ser
 Ile Met Asp Lys Val Gln Asp Phe Met Glu Lys Gln Asp Lys Val 130 135 140 Asp Pro Glu Lys Tyr Gln
 Arg Ile Gln Asp Xaa 145 150 155 (2) INFORMATION FOR SEQ ID NO : 179 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 295 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 179 : Met Leu Gln Gly Pro Gly Ser Leu Leu
 Leu Leu Phe Leu Ala Ser His 1 5 10 15 Cys Cys Leu Gly Ser Ala Arg Gly Leu Phe Leu Phe Gly Gln
 Pro Asp 20 25 30 Phe Ser Tyr Lys Arg Xaa Asn Cys Lys Pro Ile Pro Val Asn Leu Gln 35 40 45 Leu Cys
 His Gly Ile Glu Tyr Gln Asn Met Arg Leu Pro Asn Leu Leu 50 55 60 Gly His Glu Thr Met Lys Glu Val
 Leu Glu Gln Ala Gly Ala Trp Ile 65 70 75 80 Pro Leu Val Met Lys Gln Cys His Pro Asp Thr Lys Lys
 Phe Leu Cys 85 90 95 Ser Leu Phe Ala Pro Val Cys Leu Asp Asp Leu Asp Glu Thr Ile Gln 100 105 110
 Pro Cys His Ser Leu Cys Val Gln Val Lys Asp Arg Cys Ala Pro Val 115 120 125 Met Ser Ala Phe Gly
 Phe Pro Trp Pro Asp Met Leu Glu Cys Asp Arg 130 135 140 Phe Pro Gln Asp Asn Asp Leu Cys Ile Pro
 Leu Ala Ser Ser Asp His 145 150 155 160 Leu Leu Pro Ala Thr Glu Glu Ala Pro Lys Val Cys Glu Ala
 Cys Lys 165 170 175 Asn Lys Asn Asp Asp Asp Asn Asp Ile Met Glu Thr Leu Cys Lys Asn 180 185
 190 Asp Phe Ala Leu Lys Ile Lys Val Lys Glu Ile Thr Tyr Ile Asn Arg 195 200 205 Asp Thr Lys Ile Ile
 Leu Glu Thr Lys Ser Lys Thr Ile Tyr Lys Leu 210 215 220 Asn Gly Val Ser Glu Arg Asp Leu Lys Lys
 Ser Val Leu Trp Leu Lys 225 230 235 240 Asp Ser Leu Gln Cys Thr Cys Glu Glu Met Asn Asp Ile Asn
 Ala Pro 245 250 255 Tyr Leu Val Met Gly Gln Lys Gln Gly Gly Glu Leu Val Ile Thr Ser 260 265 270
 Val Lys Arg Trp Gln Lys Gly Gln Arg Glu Phe Lys Arg Ile Ser Arg 275 280 285 Ser Ile Arg Lys Leu
 Gln Cys 290 295 (2) INFORMATION FOR SEQ ID NO : 180 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 256 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 180 : Met Arg Pro Ala Ala Leu Arg Gly Ala
 Leu Leu Gly Cys Leu Cys Leu 1 5 10 15 Ala Leu Leu Cys Leu Gly Gly Ala Asp Lys Arg Leu Arg Asp
 Asn His 20 25 30 Glu Trp Lys Lys Leu Ile Met Val Gln His Trp Pro Glu Thr Val Cys 35 40 45 Glu Lys
 Ile Gln Asn Asp Cys Arg Asp Pro Pro Asp Tyr Trp Thr Ile 50 55 60 His Gly Leu Trp Pro Asp Lys Ser
 Glu Gly Cys Asn Arg Ser Trp Pro 65 70 75 80 Phe Asn Leu Glu Glu Ile Lys Asp Leu Leu Pro Glu Met
 Arg Ala Tyr 85 90 95 Trp Pro Asp Val Ile His Ser Phe Pro Asn Arg Ser Arg Phe Trp Lys 100 105 110
 His Glu Trp Glu Lys His Gly Thr Cys Ala Ala Gln Val Asp Ala Leu 115 120 125 Asn Ser Gln Lys Lys
 Tyr Phe Gly Arg Ser Leu Glu Leu Tyr Arg Glu 130 135 140 Leu Asp Leu Asn Ser Val Leu Leu Lys Leu
 Gly Ile Lys Pro Ser Ile 145 150 155 160 Asn Tyr Tyr Gln Val Ala Asp Phe Lys Asp Ala Leu Ala Arg
 Val Tyr 165 170 175 Gly Val Ile Pro Lys Ile Gln Cys Leu Pro Pro Ser Gln Asp Glu Glu 180 185 190
 Val Gln Thr Ile Gly Gln Ile Glu Leu Cys Leu Thr Lys Gln Asp Gln 195 200 205 Gln Leu Gln Asn Cys
 Thr Glu Pro Gly Glu Gln Pro Ser Pro Lys Gln 210 215 220 Glu Val Trp Leu Ala Asn Gly Ala Ala Glu
 Ser Arg Gly Leu Arg Val 225 230 235 240 Cys Glu Asp Gly Pro Val Phe Tyr Pro Pro Pro Lys Lys Thr
 Lys His 245 250 255 (2) INFORMATION FOR SEQ ID NO : 181 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 324 amino acids (B) TYPE : amino acid (D) TOPOLOGY :

linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 181 : Met Ala Pro Leu Leu Leu Gln Leu Ala Val Leu Gly Ala Ala Leu Ala 1 5 10 15 Ala Ala Ala Leu Val Leu Ile Ser Ile Val Ala Phe Thr Thr Ala Thr 20 25 30 Lys Met Pro Ala Leu His Arg His Glu Glu Glu Lys Phe Phe Leu Asn 35 40 45 Ala Lys Gly Gln Lys Glu Thr Leu Pro Ser Ile Trp Asp Ser Pro Thr 50 55 60 Lys Gln Leu Ser Val Val Val Pro Ser Tyr Asn Glu Glu Lys Arg Leu 65 70 75 80 Pro Val Met Met Asp Glu Ala Leu Ser Tyr Leu Glu Lys Arg Gln Lys 85 90 95 Arg Asp Pro Ala Phe Thr Tyr Glu Val Ile Val Val Asp Asp Gly Ser 100 105 110 Lys Asp Gln Thr Ser Lys Val Ala Phe Lys Tyr Cys Gln Lys Tyr Gly 115 120 125 Ser Asp Lys Val Arg Val Ile Thr Leu Val Lys Asn Arg Gly Lys Gly 130 135 140 Gly Ala Ile Arg Met Gly Ile Phe Ser Ser Arg Gly Glu Lys Ile Leu 145 150 155 160 Met Ala Asp Ala Asp Gly Ala Thr Lys Phe Pro Asp Val Glu Lys Leu 165 170 175 Glu Lys Gly Leu Asn Asp Leu Gln Pro Trp Pro Asn Gln Met Ala Ile 180 185 190 Ala Cys Gly Ser Arg Ala His Leu Glu Lys Glu Ser Ile Ala Gln Arg 195 200 205 Ser Tyr Phe Arg Thr Leu Leu Met Tyr Gly Phe His Phe Leu Val Trp 210 215 220 Phe Leu Cys Val Lys Gly Ile Arg Asp Thr Gln Cys Gly Phe Lys Leu 225 230 235 240 Phe Thr Arg Glu Ala Ala Ser Arg Thr Phe Ser Ser Leu His Val Glu 245 250 255 Arg Trp Ala Phe Asp Val Glu Leu Leu Tyr Ile Ala Gln Phe Phe Lys 260 265 270 Ile Pro Ile Ala Glu Ile Ala Val Asn Trp Thr Glu Ile Glu Gly Ser 275 280 285 Lys Leu Val Pro Phe Trp Ser Trp Leu Gln Met Gly Lys Asp Leu Leu 290 295 300 Phe Ile Arg Leu Arg Tyr Leu Thr Gly Ala Trp Arg Leu Glu Gln Thr 305 310 315 320 Arg Lys Met Asn (2) INFORMATION FOR SEQ ID NO : 182 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 47 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 182 : Met Asp Ile Cys Phe Phe His Tyr Val Leu Leu Phe Phe Leu Val Arg 1 5 10 15 Cys Ala Leu Val Val Leu Ile Leu Leu Cys Gln Gly Trp Gly Asn Gly 20 25 30 Gly Gly Cys Val Gly Arg Val Leu Ile Ile Val Phe Ser Ser Val 35 40 45 (2) INFORMATION FOR SEQ ID NO : 183 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 93 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 183 : Met Ala Ser Leu Gly His Ile Leu Val Phe Cys Val Gly Leu Leu Thr 1 5 10 15 Met Ala Lys Ala Glu Ser Pro Lys Glu His Asp Pro Phe Thr Tyr Asp 20 25 30 Tyr Gln Ser Leu Gln Ile Gly Gly Leu Val Ile Ala Gly Ile Leu Phe 35 40 45 Ile Leu Gly Ile Leu Ile Val Leu Ser Arg Arg Cys Arg Cys Lys Phe 50 55 60 Asn Gln Gln Gln Arg Thr Gly Glu Pro Asp Glu Glu Glu Gly Thr Phe 65 70 75 80 Arg Ser Ser Ile Arg Arg Leu Ser Thr Arg Arg Arg Xaa 85 90 (2) INFORMATION FOR SEQ ID NO : 184 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 168 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 184 : Met Xaa Thr Lys Glu Phe Gly Xaa Gly Arg Ala Val Gln Gln Val Leu 1 5 10 15 Asn Ile Glu Cys Leu Arg Asp Phe Leu Thr Pro Pro Leu Leu Ser Val 20 25 30 Arg Phe Arg Tyr Val Gly Ala Pro Gln Ala Leu Thr Leu Lys Leu Pro 35 40 45 Val Thr Xaa Asn Lys Phe Phe Gln Pro Thr Glu Met Ala Ala Gln Asp 50 55 60 Phe Phe Gln Arg Trp Lys Gln Leu Ser Leu Pro Gln Gln Glu Ala Gln 65 70 75 80 Lys Ile Phe Lys Ala Asn His Pro Met Asp Ala Glu Val Thr Lys Ala 85 90 95 Lys Leu Leu Gly Phe Gly Ser Ala Leu Leu Asp Asn Val Asp Pro Asn 100 105 110 Pro Glu Asn Phe Val Gly Ala Gly Ile Ile Gln Thr Lys Ala Leu Gln 115 120 125 Val Gly Cys Leu Leu Arg Leu Glu Pro Asn Ala Gln Ala Gln Met Tyr 130 135 140 Arg Leu Thr Leu Arg Thr Ser Lys Glu Pro Val Ser Arg His Leu Cys 145 150 155 160 Glu Leu Leu Ala Gln Gln Phe Xaa 165 (2) INFORMATION FOR SEQ ID NO : 185 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 43 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 185 : Met Phe Tyr Val Leu Ser Val Ser Pro Leu Leu Xaa Phe Leu Ala Cys 1 5 10 15 Gly Leu Cys Leu Cys Val Asn Trp Lys Ile Ala Ile Ser Gln Leu Ser 20 25 30 Leu Ser Phe Lys Asn Glu Leu Glu Lys Pro Xaa 35 40 (2) INFORMATION FOR SEQ ID NO : 186 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 59 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 186 : Met Lys Leu Phe Asp Ala Ser Pro Thr Phe Phe Ala Phe Leu Leu Gly 1 5 10 15 His Ile Leu Ala Met Glu Val Leu Ala Trp Leu Leu Ile Tyr Leu Leu 20 25 30 Gly Pro Gly Trp Val Pro Ser Ala Leu Xaa Arg Leu His Pro Gly His 35 40 45 Leu Ser Gly Ser Val Leu Val Ser Ala Ala Xaa 50 55 (2) INFORMATION FOR SEQ ID NO : 187 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 189 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 187 : Met Asp Val Asn Ile Ala Pro Leu Arg Ala Trp Asp Asp Phe Phe Pro 1 5 10 15 Gly Ser Asp Arg Phe Ala Arg Pro Asp Phe Arg Asp Ile Ser Lys Trp

20 25 30 Asn Asn Arg Val Val Ser Asn Leu Leu Tyr Tyr Gln Thr Asn Tyr Leu 35 40 45 Val Val Ala
 Ala Met Met Ile Ser Ile Val Gly Phe Leu Ser Pro Phe 50 55 60 Asn Met Ile Leu Gly Gly Ile Val Val Val
 Leu Val Phe Thr Gly Phe 65 70 75 80 Val Trp Ala Ala His Asn Lys Asp Val Leu Arg Arg Met Lys Lys
 Arg 85 90 95 Tyr Pro Thr Thr Phe Val Met Val Val Met Leu Ala Ser Tyr Phe Leu 100 105 110 Ile Ser
 Met Phe Gly Gly Val Met Val Phe Val Phe Gly Ile Thr Phe 115 120 125 Pro Leu Leu Leu Met Phe Ile
 His Ala Ser Leu Arg Leu Arg Asn Leu 130 135 140 Lys Asn Lys Leu Glu Asn Lys Met Glu Gly Ile Gly
 Leu Lys Arg Thr 145 150 155 160 Pro Met Gly Ile Val Leu Asp Ala Leu Glu Gln Gln Glu Glu Gly Ile
 165 170 175 Asn Arg Leu Thr Asp Tyr Ile Ser Lys Val Lys Glu Xaa 180 185 (2) INFORMATION FOR
 SEQ ID NO : 188 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 146 amino acids (B)
 TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 188 :
 Met Phe Leu Thr Arg Ile Leu Cys Pro Thr Tyr Ile Ala Leu Thr Phe 1 5 10 15 Leu Val Tyr Ile Val Ala
 Leu Val Ser Gly Gln Leu Cys Met Glu Ile 20 25 30 Ala Arg Gly Asn Ile Phe Phe Leu Asn Glu Leu Val
 Thr Thr Phe Cys 35 40 45 Cys Ser Cys Leu Leu Leu Ser Val Pro Tyr Leu His Pro Gly Phe Phe 50 55 60
 Tyr Ser Ser Leu Cys Lys Cys Cys Phe Val Leu Val Val Leu Ser Arg 65 70 75 80 Ile Gly Ser Val Asn
 Glu Thr Trp Ser Cys Asn Phe Ser Ile Cys Ser 85 90 95 Tyr Leu Ile Phe Gly Ser Pro Ile Phe Thr Ala Val
 Ile Pro Lys Arg 100 105 110 Cys Ala Leu Glu Asp Ile Gln Asn Asn Pro Ile Gly Cys Leu Leu Arg 115
 120 125 Cys Thr Pro Ala Trp Glu Thr Glu Gly Asp Ser Ile Ser Lys Lys Ile 130 135 140 Lys Lys 145 (2)
 INFORMATION FOR SEQ ID NO : 189 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 84
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 189 : Met Gly Ser Arg Ala Glu Leu Cys Thr Leu Leu Gly Gly Phe Ser Phe 1 5 10 15 Leu Leu
 Leu Leu Ile Pro Gly Glu Gly Ala Lys Gly Gly Ser Leu Arg 20 25 30 Glu Ser Gln Gly Val Cys Ser Lys
 Gln Thr Leu Val Val Pro Leu His 35 40 45 Tyr Asn Glu Ser Tyr Ser Gln Pro Val Tyr Lys Pro Tyr Leu
 Thr Leu 50 55 60 Cys Ala Gly Ser Ala Ser Ala Ala Leu Thr Gly Pro Cys Thr Ala Leu 65 70 75 80 Cys
 Gly Gly Arg (2) INFORMATION FOR SEQ ID NO : 190 : (i) SEQUENCE CHARACTERISTICS :
 (A) LENGTH : 58 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 190 : Met Met Gly Val Leu Gln Leu Leu His Ile Phe Trp Ala Tyr Leu
 Ile 1 5 10 15 Leu Arg Met Ala His Lys Phe Ile Thr Gly Lys Leu Val Glu Asp Glu 20 25 30 Arg Ser Thr
 Gly Lys Lys Gln Arg Ala Gln Arg Gly Arg Arg Leu Gln 35 40 45 Leu Gly Glu Glu Gln Arg Ala Gly
 Pro Xaa 50 55 (2) INFORMATION FOR SEQ ID NO : 191 : (i) SEQUENCE CHARACTERISTICS :
 (A) LENGTH : 311 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
 DESCRIPTION : SEQ ID NO : 191 : Met Arg Arg Leu Val His Asp Leu Leu Pro Pro Glu Val Cys Ser
 Leu 1 5 10 15 Leu Asn Pro Ala Ala Ile Tyr Ala Asn Asn Glu Ile Ser Leu Arg Asp 20 25 30 Val Glu Val
 Tyr Gly Phe Asp Tyr Asp Tyr Thr Leu Ala Gln Tyr Ala 35 40 45 Asp Ala Leu His Pro Glu Ile Phe Ser
 Thr Ala Arg Asp Ile Leu Ile 50 55 60 Glu His Tyr Lys Tyr Pro Glu Gly Ile Arg Lys Tyr Asp Tyr Asn
 Pro 65 70 75 80 Ser Phe Ala Ile Arg Gly Leu His Tyr Asp Ile Gln Lys Ser Leu Leu 85 90 95 Met Lys Ile
 Asp Ala Phe His Tyr Val Gln Leu Gly Thr Ala Tyr Arg 100 105 110 Gly Leu Gln Pro Val Pro Asp Glu
 Glu Val Ile Glu Leu Tyr Gly Gly 115 120 125 Thr Gln His Ile Pro Leu Tyr Gln Met Ser Gly Phe Tyr
 Gly Lys Gly 130 135 140 Pro Ser Ile Lys Gln Phe Met Asp Ile Phe Ser Leu Pro Glu Met Ala 145 150
 155 160 Leu Leu Ser Cys Val Val Asp Tyr Phe Leu Gly His Ser Leu Glu Phe 165 170 175 Asp Gln Ala
 His Leu Tyr Lys Asp Val Thr Asp Ala Ile Arg Asp Val 180 185 190 His Val Lys Gly Leu Met Tyr Gln
 Trp Ile Glu Gln Asp Met Glu Lys 195 200 205 Tyr Ile Leu Arg Gly Asp Glu Thr Phe Ala Val Leu Ser
 Arg Leu Val 210 215 220 Ala His Gly Lys Gln Leu Phe Leu Ile Thr Asn Ser Pro Phe Ser Phe 225 230
 235 240 Val Asp Lys Gly Met Arg His Met Val Gly Pro Asp Trp Arg His Ser 245 250 255 Ser Met Trp
 Ser Leu Ser Arg Gln Thr Ser Pro Ala Ser Ser Leu Thr 260 265 270 Gly Ala Ser Phe Xaa Glu Asn Ser
 Met Arg Arg Ala His Phe Ser Gly 275 280 285 Thr Gly Ser Pro Ala Trp Lys Arg Ala Arg Ser Ile Gly
 Arg Glu Thr 290 295 300 Cys Leu Thr Ser Tyr Ala Xaa 305 310 (2) INFORMATION FOR SEQ ID
 NO : 192 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 318 amino acids (B) TYPE : amino
 acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID : 192 : Met Asn Trp Glu Leu
 Leu Leu Trp Leu Leu Val Leu Cys Ala Leu Leu 1 5 10 15 Leu Leu Leu Val Gln Leu Leu Arg Phe Leu
 Arg Ala Asp Gly Asp Leu 20 25 30 Thr Leu Leu Trp Ala Glu Trp Gln Gly Arg Arg Pro Glu Trp Glu
 Leu 35 40 45 Thr Asp Met Val Val Trp Val Thr Gly Ala Ser Ser Gly Ile Gly Glu 50 55 60 Glu Leu Ala

Tyr Gln Leu Ser Lys Leu Gly Val Ser Leu Val Leu Ser 65 70 75 80 Ala Arg Arg Val His Glu Leu Glu
 Arg Val Lys Arg Arg Cys Leu Glu 85 90 95 Asn Gly Asn Leu Lys Glu Lys Asp Ile Leu Val Leu Pro
 Leu Asp Leu 100 105 110 Thr Asp Thr Gly Ser His Glu Ala Ala Thr Lys Ala Val Leu Gln Glu 115 120
 125 Phe Gly Arg Ile Asp Ile Leu Val Asn Asn Gly Gly Met Ser Gln Arg 130 135 140 Ser Leu Cys Met
 Asp Thr Ser Leu Asp Val Tyr Arg Lys Leu Ile Glu 145 150 155 160 Leu Asn Tyr Leu Gly Thr Val Ser
 Leu Thr Lys Cys Val Leu Pro His 165 170 175 Met Ile Glu Arg Lys Gln Gly Lys Ile Val Thr Val Asn
 Ser Ile Leu 180 185 190 Gly Ile Ile Ser Val Pro Leu Ser Ile Gly Tyr Cys Ala Ser Lys His 195 200 205
 Ala Leu Arg Gly Phe Phe Asn Gly Leu Arg Thr Glu Leu Ala Thr Tyr 210 215 220 Pro Gly Ile Ile Val
 Ser Asn Ile Cys Pro Gly Pro Val Gln Ser Asn 225 230 235 240 Ile Val Glu Asn Ser Leu Ala Gly Glu
 Val Thr Lys Thr Ile Gly Asn 245 250 255 Asn Gly Asp Gln Ser His Lys Met Thr Thr Ser Arg Cys Val
 Arg Leu 260 265 270 Met Leu Ile Ser Met Ala Asn Asp Leu Lys Glu Val Trp Ile Ser Glu 275 280 285
 Gln Pro Phe Leu Phe Ser Asn Ile Phe Val Ala Ile His Ala Asn Leu 290 295 300 Gly Leu Val Asp Asn
 Gln Gln Asp Gly Glu Glu Lys Asp Xaa 305 310 315 (2) INFORMATION FOR SEQ ID NO : 193 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 53 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 193 : Met Trp Pro Ser Phe Pro
 Gln Val Arg Val Gly Ser Phe Leu Phe Gly 1 5 10 15 Ile Leu Phe Phe Ser Phe Gly Ser Ser Ser Leu Pro
 Pro Gly Leu Pro 20 25 30 Pro Pro Ala Ser Leu Leu Cys Cys Ala Val Gln Trp Gly Ala Arg Ala 35 40 45
 Leu Phe Leu Pro Ala 50 (2) INFORMATION FOR SEQ ID NO : 194 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 42 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 194 : Met Leu Val Thr Cys Ser Val Cys Cys
 Tyr Leu Phe Trp Leu Ile Ala 10 15 Ile Leu Ala Gln Leu Asn Pro Leu Phe Gly Pro Gln Leu Lys Asn Glu
 20 25 30 Thr Ile Trp Tyr Leu Lys Tyr His Trp Pro 35 40 (2) INFORMATION FOR SEQ ID NO : 195 :
 (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 102 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 195 : Met Glu Gly Thr Glu Met
 Gly Ala Arg Pro Gly Gly His Pro Gln Lys 1 5 10 15 Trp Ser Phe Leu Trp Ser Leu Ala Leu Trp Leu Pro
 Leu Ala Leu Ser 20 25 30 Val Ser Leu Phe Leu Gly Leu Ser Leu Ser Pro Pro Gln Pro Gly Leu 35 40 45
 Ser Leu Trp Cys Thr Leu Ser Tyr Cys Cys Glu Gln Trp Lys Phe Lys 50 55 60 Gly Thr Pro Ser Pro Ala
 Leu Leu Asn Leu Gly Thr Gln Pro Lys Lys 65 70 75 80 Asp Lys Lys Leu Glu Asp Ser Ile Ala Thr Gln
 Leu Arg Glu Leu Pro 85 90 95 Glu Lys Asn Ser Asn Xaa 100 (2) INFORMATION FOR SEQ ID NO :
 196 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 45 amino acids (B) TYPE : amino acid
 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 196 : Met Ala Leu Thr Phe
 Leu Leu Val Leu Leu Thr Leu Ala Thr Ser Ala 1 5 10 15 His Gly Cys Thr Glu Thr Ser Asp Ala Gly Arg
 Ala Ser Thr Gly Gly 20 25 30 Pro Gln Arg Thr Ala Arg Thr Gln Trp Leu Leu Cys Xaa 35 40 45 (2)
 INFORMATION FOR SEQ ID NO : 197 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 355
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 197 : Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser 1 5 10 15 Gly Pro Leu
 Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg 20 25 30 Arg Leu Ala Ala Leu Glu Glu Arg
 Leu Ala Gln Cys Gln Asp Gln Ser 35 40 45 Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys
 Met Leu Pro 50 55 60 Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala 65 70 75 80
 Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr 85 90 95 Leu Glu Thr Gln Asn Pro
 Ala Leu Pro Cys Val Glu Phe Asp Glu Lys 100 105 110 Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly
 Arg Arg Asn Glu Lys 115 120 125 Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser
 130 135 140 Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys 145 150 155 160 Asp
 Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln 165 170 175 Asn Asp Thr Ala Phe Val
 Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala 180 185 190 Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val
 Pro Phe Pro Trp Val 195 200 205 Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg
 210 215 220 Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln 225 230 235 240 Leu
 Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val 245 250 255 Phe Pro Ala Glu Gly Leu
 Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr 260 265 270 Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu
 Trp Ala Val Tyr Ala 275 280 285 Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln
 290 295 300 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn 305 310 315 320 Ala

Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn 325 330 335 Thr Arg Pro Ala Ser Arg
Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser 340 345 350 Gly Pro Xaa 355 (2) INFORMATION FOR SEQ
ID NO : 198 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 74 amino acids (B) TYPE :
amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 198 : Met Val
Leu Pro Leu Leu Ile Phe Val Leu Leu Pro Lys Val Val Asn 1 5 10 15 Thr Ser Asp Pro Asp Met Arg Arg
Glu Met Glu Gln Ser Met Asn Met 20 25 30 Leu Asn Ser Asn His Glu Leu Pro Asp Val Ser Glu Phe
Met Thr Arg 35 40 45 Leu Phe Ser Ser Lys Ser Ser Gly Lys Ser Ser Ser Gly Ser Ser Lys 50 55 60 Thr
Gly Lys Ser Gly Ala Gly Lys Arg Arg 65 70 (2) INFORMATION FOR SEQ ID NO : 199 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 113 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 199 : Met Phe Thr Met Leu Cys
Ile Asn Gly Thr Thr Pro Arg Pro Leu Pro 1 5 10 15 Val Pro Ser Pro Phe Gly Cys Met Ile Phe Phe Phe
Phe Lys Asn Pro 20 25 30 Trp Lys Gln Arg Leu Leu Gln Gly Trp Leu Gly Ala Arg Pro Ile His 35 40 45
Leu Leu Gly Tyr Leu Pro Leu Ser Leu Leu Trp Cys Pro Phe Pro Leu 50 55 60 Pro Cys Ala Arg Cys Ser
Val Val Tyr Ile Ser Ser Pro Arg His Gly 65 70 75 80 Ala His Ala Pro Arg Asp Met Ile Leu Ser Leu Val
Leu Ala His Gly 85 90 95 Ala Leu Tyr Lys Glu Leu Gly Gly Arg Gly Arg Lys Trp Glu Pro Ser 100 105
110 Xaa (2) INFORMATION FOR SEQ ID NO : 200 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 123 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 200 : Met Ala Cys Arg Cys Leu Ser Phe Leu Leu Met Gly Thr Phe Leu
Ser 1 5 10 15 Val Ser Gln Thr Val Leu Ala Gln Leu Asp Ala Leu Leu Val Phe Pro 20 25 30 Gly Gln
Val Ala Gln Leu Ser Cys Thr Leu Ser Pro Gln His Val Thr 35 40 45 Ile Arg Asp Tyr Gly Val Ser Trp
Tyr Gln Gln Arg Ala Gly Ser Ala 50 55 60 Pro Arg Tyr Leu Leu Tyr Tyr Arg Ser Glu Glu Asp His His
Arg Pro 65 70 75 80 Ala Asp Ile Pro Asp Arg Phe Ser Ala Ala Lys Asp Glu Ala His Asn 85 90 95 Ala
Cys Val Leu Thr Ile Ser Pro Val Gln Pro Glu Asp Asp Ala Asp 100 105 110 Tyr Tyr Cys Ser Val Gly
Tyr Gly Phe Ser Pro 115 120 (2) INFORMATION FOR SEQ ID NO : 201 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 315 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 201 : Met Ala Gly Gly Arg Cys Gly Pro Xaa
Leu Thr Ala Leu Leu Ala Ala 1 5 10 15 Trp Ile Ala Ala Val Ala Ala Thr Ala Gly Pro Glu Glu Ala Ala
Leu 20 25 30 Pro Pro Glu Gln Ser Arg Val Gln Pro Met Thr Ala Ser Asn Trp Thr 35 40 45 Leu Val Met
Glu Gly Glu Trp Met Leu Lys Phe Tyr Ala Pro Trp Cys 50 55 60 Pro Ser Cys Gln Gln Thr Asp Ser Glu
Trp Glu Ala Phe Ala Lys Asn 65 70 75 80 Gly Glu Ile Leu Gln Ile Ser Val Gly Lys Val Asp Val Ile Gln
Glu 85 90 95 Pro Gly Leu Ser Gly Arg Phe Phe Val Thr Thr Leu Pro Ala Phe Phe 100 105 110 His Ala
Lys Asp Gly Ile Phe Arg Arg Tyr Arg Gly Pro Gly Ile Phe 115 120 125 Glu Asp Leu Gln Asn Tyr Ile
Leu Glu Lys Lys Trp Gln Ser Val Glu 130 135 140 Pro Leu Thr Gly Trp Lys Ser Pro Ala Ser Leu Thr
Met Ser Gly Met 145 150 155 160 Ala Gly Leu Phe Ser Ile Ser Gly Lys Ile Trp His Leu His Asn Tyr
165 170 175 Phe Thr Val Thr Leu Gly Ile Pro Ala Trp Cys Ser Tyr Val Phe Phe 180 185 190 Val Ile Ala
Thr Leu Val Phe Gly Leu Phe Met Gly Leu Val Leu Val 195 200 205 Val Ile Ser Glu Cys Phe Tyr Val
Pro Leu Pro Arg His Leu Ser Glu 210 215 220 Arg Ser Glu Gln Asn Arg Arg Ser Glu Glu Ala His Arg
Ala Glu Gln 225 230 235 240 Leu Gln Asp Ala Glu Glu Glu Lys Asp Asp Ser Asn Glu Glu Glu Asn
245 250 255 Lys Asp Ser Leu Val Asp Asp Glu Glu Glu Lys Glu Asp Leu Gly Asp 260 265 270 Glu
Asp Glu Ala Glu Glu Glu Glu Glu Asp Asn Leu Ala Ala Gly 275 280 285 Val Asp Glu Glu Arg Ser
Glu Ala Asn Asp Gln Gly Pro Pro Gly Glu 290 295 300 Asp Gly Val Thr Arg Glu Xaa Ser Arg Ala Xaa
305 310 315 (2) INFORMATION FOR SEQ ID NO : 202 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 236 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 202 : Met Gly Thr Ala Asp Ser Asp Glu Met Ala Pro Glu Ala Pro Gln
His 1 5 10 15 Thr His Ile Asp Val His Ile His Gln Glu Ser Ala Leu Ala Lys Leu 20 25 30 Leu Leu Thr
Cys Cys Ser Ala Leu Arg Pro Arg Ala Thr Gln Ala Arg 35 40 45 Gly Ser Ser Arg Leu Leu Val Ala Ser
Trp Val Met Gln Ile Val Leu 50 55 60 Gly Ile Leu Ser Ala Val Leu Gly Gly Phe Phe Tyr Ile Arg Asp
Tyr 65 70 75 80 Thr Leu Leu Val Thr Ser Gly Ala Ala Ile Trp Thr Gly Ala Val Ala 85 90 95 Val Leu
Ala Gly Ala Ala Ala Phe Ile Tyr Glu Lys Arg Gly Gly Thr 100 105 110 Tyr Trp Ala Leu Leu Arg Thr
Leu Leu Ala Leu Ala Ala Phe Ser Thr 115 120 125 Ala Ile Ala Ala Leu Lys Leu Trp Asn Glu Asp Phe
Arg Tyr Gly Tyr 130 135 140 Ser Tyr Tyr Asn Ser Ala Cys Arg Ile Ser Ser Ser Ser Asp Trp Asn 145

150 155 160 Thr Pro Ala Pro Thr Gln Ser Pro Glu Glu Val Arg Arg Leu His Leu 165 170 175 Cys Thr
Ser Phe Met Asp Met Leu Lys Ala Leu Phe Arg Thr Leu Gln 180 185 190 Ala Met Leu Leu Gly Val
Trp Ile Leu Leu Leu Leu Ala Ser Leu Ala 195 200 205 Pro Leu Trp Leu Tyr Cys Trp Arg Met Phe Pro
Thr Lys Gly Lys Arg 210 215 220 Asp Gln Lys Glu Met Leu Glu Val Ser Gly Ile Xaa 225 230 235 (2)
INFORMATION FOR SEQ ID NO : 203 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 93
amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 203 : Met Ile His Leu Gly His Ile Leu Phe Leu Leu Leu Leu Pro Val Ala 1 5 10 15 Ala Ala Gln
Thr Thr Pro Gly Glu Arg Ser Ser Leu Pro Ala Phe Tyr 20 25 30 Pro Gly Thr Ser Gly Ser Cys Ser Gly
Cys Gly Ser Leu Ser Leu Pro 35 40 45 Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala Ser Leu Leu
Ile 50 55 60 Val Gly Ala Val Phe Leu Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln 65 70 75 80 Glu Asp
Gly Lys Val Tyr Ile Asn Met Pro Gly Arg Gly 85 90 (2) INFORMATION FOR SEQ ID NO : 204 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 35 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 204 : Met Trp Ser Ala Gly Arg
Gly Gly Ala Ala Trp Pro Val Leu Leu Gly 1 5 10 15 Leu Leu Leu Ala Leu Leu Val Pro Gly Gly Gly
Ala Ala Lys Thr Gly 20 25 30 Ala Asp Ser 35 (2) INFORMATION FOR SEQ ID NO : 205 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 43 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 205 : Asp Cys Xaa His Val Ser
Val Leu Gln Ser Thr Ile Ser Pro Leu Leu 1 5 10 15 Pro Leu Pro Leu Leu Leu Pro His Gly Asn Cys Glu
Glu Ala Pro Trp 20 25 30 Gln Ala Ala Val Ile Gly Gly Gly Asp Arg Ile 35 40 (2) INFORMATION
FOR SEQ ID NO : 206 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 85 amino acids (B)
TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 206 :
Met Arg Asp Cys Leu Ser Leu Lys Pro Arg Pro Leu Phe Pro Thr Gln 1 5 10 15 Phe Phe Phe Ile Leu Leu
Leu Ile Phe Ile Ala Glu Val Ala Ala Ala 20 25 30 Val Val Ala Leu Val Tyr Thr Thr Met Val Arg His
Trp Asp Gly Gly 35 40 45 Arg Glu Glu Asp Trp Ala Lys Pro Trp Glu Trp Ala Val Ala Cys Glu 50 55
60 Trp Pro Pro Ser Val Pro Ala Pro Lys His Trp Pro Ala Ser Pro Arg 65 70 75 80 Leu Ser Thr Ser Xaa
85 (2) INFORMATION FOR SEQ ID NO : 207 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 208 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 207 : Met His Gly Asn Glu Ala Leu Gly Arg Glu Leu Leu Leu Leu Leu
Met 1 5 10 15 Gln Phe Leu Cys His Glu Phe Leu Arg Xaa Asn Pro Arg Val Thr Arg 20 25 30 Leu Leu
Ser Glu Met Arg Ile His Leu Leu Pro Ser Met Asn Pro Asp 35 40 45 Gly Tyr Glu Ile Ala Tyr His Arg
Gly Ser Glu Leu Val Gly Trp Ala 50 55 60 Glu Gly Arg Trp Asn Asn Gln Ser Ile Asp Leu Asn His Asn
Phe Ala 65 70 75 80 Xaa Leu Asn Thr Pro Leu Trp Glu Ala Gln Asp Asp Gly Lys Val Pro 85 90 95 His
Ile Val Pro Asn His His Leu Pro Leu Pro Thr Tyr Tyr Thr Leu 100 105 110 Pro Asn Ala Thr Val Ala
Pro Glu Thr Arg Ala Val Ile Lys Trp Met 115 120 125 Lys Arg Ile Pro Phe Val Leu Ser Ala Asn Leu
His Gly Gly Glu Leu 130 135 140 Val Val Ser Tyr Pro Phe Asp Met Thr Arg Thr Pro Trp Ala Ala Arg
145 150 155 160 Glu Leu Thr Pro Thr Pro Asp Asp Ala Val Phe Arg Trp Leu Ser Thr 165 170 175 Val
Tyr Ala Gly Ser Asn Leu Ala Met Gln Asp Thr Ser Arg Arg Pro 180 185 190 Cys His Ser Gln Asp Phe
Ser Val His Gly Asn Ile Ile Asn Gly Ala 195 200 205 (2) INFORMATION FOR SEQ ID NO : 208 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 24 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 208 : Met Glu Ile Ser Cys Leu
Leu Leu Leu Ile Gln Asp Ser Asp Glu Met 1 5 10 15 Glu Asp Gly Pro Gly Val Gln Asp 20 (2)
INFORMATION FOR SEQ ID NO : 209 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 483
amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 209 : Met Ala Thr Gly Gly Gly Ile Arg Ala Met Thr Ser Leu Tyr Gly Gln 1 5 10 15 Leu Ala
Gly Leu Lys Glu Leu Gly Leu Leu Asp Cys Xaa Ser Tyr Ile 20 25 30 Thr Gly Ala Ser Gly Ser Thr Trp
Ala Leu Ala Asn Leu Tyr Lys Asp 35 40 45 Pro Glu Trp Ser Lys Asp Leu Ala Gly Pro Thr Glu Leu Leu
Lys 50 55 60 Thr Val Thr Lys Asn Lys Leu Gly Val Leu Ala Pro Ser Gln Leu 65 70 75 80 Gln Arg Tyr
Arg Glu Leu Ala Glu Arg Ala Arg Leu Gly Tyr Pro 85 90 95 Ser Cys Phe Thr Asn Leu Trp Ala Leu Ile
Asn Glu Ala Leu Leu His 100 105 110 Asp Glu Pro His Asp His Lys Leu Ser Asp Gln Arg Glu Ala Leu
Ser 115 120 125 His Gly Asn Pro Leu Pro Ile Tyr Cys Ala Leu Asn Thr Lys Gly 130 135 140 Ser Leu
Thr Thr Phe Glu Phe Gly Glu Trp Cys Glu Phe Ser Pro 145 155 160 Tyr Glu Val Gly Phe Pro Lys Tyr

Gly Ala Phe Ile Pro Ser Glu Leu 165 170 175 Phe Gly Ser Glu Phe Phe Met Gly Gln Leu Met Lys Arg
 Leu Pro Glu 180 185 190 Ser Arg Ile Cys Phe Leu Glu Gly Ile Trp Ser Asn Leu Tyr Ala Ala 195 200
 205 Asn Leu Asp Ser Leu Tyr Trp Ala Ser Glu Pro Ser Gln Phe Trp 210 215 220 Asp Arg Trp Val Arg
 Asn Ala Asn Leu Asp Lys Glu Gln Val Pro 225 230 235 240 Leu Leu Lys Ile Glu Glu Pro Pro Ser Thr
 Ala Gly Arg Ile Ala Glu 245 250 255 Phe Phe Thr Asp Leu Leu Thr Trp Arg Pro Leu Ala Gln Ala Thr
 His 260 265 270 Asn Phe Leu Arg Gly Leu His Phe His Lys Asp Tyr Phe Gln His Pro 275 280 285 His
 Phe Ser Thr Trp Lys Ala Thr Thr Leu Asp Gly Leu Pro Asn Gln 290 295 300 Leu Thr Pro Ser Glu Pro
 His Leu Cys Leu Leu Asp Val Gly Tyr Leu 305 310 315 320 Ile Asn Thr Ser Cys Leu Pro Leu Leu Gln
 Pro Thr Arg Asp Val Asp 325 330 335 Leu Ile Leu Ser Leu Asp Tyr Asn Leu His Gly Ala Phe Gln Gln
 Leu 340 345 350 Gln Leu Leu Gly Arg Phe Cys Gln Glu Gln Gly Ile Pro Phe Pro Pro 355 360 365 Ile
 Ser Pro Ser Pro Glu Glu Gln Leu Gln Pro Arg Glu Cys His Thr 370 375 380 Phe Ser Asp Pro Thr Cys
 Pro Gly Ala Pro Ala Val Leu His Phe Pro 385 390 395 400 Leu Val Ser Asp Ser Phe Arg Glu Tyr Ser
 Ala Pro Gly Val Arg Arg 405 410 415 Thr Pro Glu Glu Ala Ala Ala Gly Glu Val Asn Leu Ser Ser Ser
 Asp 420 425 430 Ser Pro Tyr His Tyr Thr Lys Val Thr Tyr Ser Gln Glu Asp Val Asp 435 440 445 Lys
 Leu Leu His Leu Thr His Tyr Asn Val Cys Asn Asn Gln Glu Gln 450 455 460 Leu Leu Glu Ala Leu
 Arg Gln Ala Val Gln Arg Arg Arg Gln Arg Arg 465 470 475 480 Pro His Xaa (2) INFORMATION
 FOR SEQ ID NO : 210 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 13 amino acids (B)
 TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 210 :
 Leu Glu Val Gly Cys Ile Gln Val Ala Pro Asp Thr Phe 1 5 10 (2) INFORMATION FOR SEQ ID NO :
 211 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 20 amino acids (B) TYPE : amino acid
 (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 211 : Met Ser Leu Phe Phe
 Leu Leu Thr Leu Ile Ser Lys Leu His Gly Asp 1 5 10 15 Ala Glu Val Cys 20 (2) INFORMATION FOR
 SEQ ID : 212 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 55 amino acids (B) TYPE :
 amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 212 : Met Pro
 His Pro Pro Leu Pro Glu Thr Ser Leu Glu Ala Gln Leu Pro 1 5 10 15 Met Gly Leu Leu Gln Leu Leu Arg
 Cys Ser Val Gln Ala Trp Ser Pro 20 25 30 Pro Pro Ser Ser Phe Cys Pro Gly Ser Glu Pro Arg Ser Ala Ser
 Ala 35 40 45 His Trp Gly Tyr Trp Trp Pro 50 55 (2) INFORMATION FOR SEQ ID NO : 213 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 35 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 213 : Asp Pro Glu Thr Arg Trp
 His His Gly Gly Ser Ala Gln Asn Gly Leu 1 5 10 15 Leu Met Leu Ile Ser Val Leu Gln Gln Pro Val Ile
 Gly Thr Gly Ser 20 25 30 Tyr Leu Cys 35 (2) INFORMATION FOR SEQ ID NO : 214 : (i)
 SEQUENCE CHARACTERISTICS : (A) LENGTH : 230 amino acids (B) TYPE : amino acid (D)
 TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 214 : Met Glu Pro Leu Arg Leu
 Leu Ile Leu Leu Phe Val Thr Glu Leu Ser 1 5 10 15 Gly Ala His Asn Thr Thr Val Phe Gln Gly Val Ala
 Gly Gln Ser Leu 20 25 30 Gln Val Ser Cys Pro Tyr Asp Ser Met Lys His Trp Gly Arg Arg Lys 35 40 45
 Ala Trp Cys Arg Gln Leu Gly Glu Lys Gly Pro Cys Gln Arg Val Val 50 55 60 Ser Thr His Asn Leu Trp
 Leu Leu Ser Phe Leu Arg Arg Trp Asn Gly 65 70 75 80 Ser Thr Ala Ile Thr Asp Asp Thr Leu Gly Gly
 Thr Leu Thr Ile Thr 85 90 95 Leu Arg Asn Leu Gln Pro His Asp Ala Gly Leu Tyr Gln Cys Gln Ser 100
 105 110 Leu His Gly Ser Glu Ala Asp Thr Leu Arg Lys Val Leu Val Glu Val 115 120 125 Leu Ala Asp
 Pro Leu Asp His Arg Asp Ala Gly Asp Leu Trp Phe Pro 130 135 140 Gly Glu Ser Glu Ser Phe Glu Asp
 Ala His Val Glu His Ser Ile Ser 145 150 155 160 Arg Ser Leu Leu Glu Gly Glu Ile Pro Phe Pro Pro Thr
 Ser Ile Leu 165 170 175 Leu Leu Leu Ala Cys Ile Phe Leu Ile Lys Ile Leu Ala Ala Ser Xaa 180 185 190
 Leu Trp Ala Ala Ala Trp His Gly Gln Lys Pro Gly Thr His Pro Pro 195 200 205 Ser Glu Leu Asp Cys
 Gly His Asp Pro Gly Tyr Gln Leu Gln Thr Leu 210 215 220 Pro Gly Leu Arg Asp Thr 225 230 (2)
 INFORMATION FOR SEQ ID NO : 215 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 231
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 215 : Met Glu Pro Leu Arg Leu Leu Ile Leu Leu Phe Val Thr Glu Leu Ser 1 5 10 15 Gly Ala
 His Asn Thr Thr Val Phe Gln Gly Val Ala Gly Gln Ser Leu 20 25 30 Gln Val Ser Cys Pro Tyr Asp Ser
 Met Lys His Trp Gly Arg Arg Lys 35 40 45 Ala Trp Cys Arg Gln Leu Gly Glu Lys Gly Pro Cys Gln
 Arg Val Val 50 55 60 Ser Thr His Asn Leu Trp Leu Leu Ser Phe Leu Arg Arg Trp Asn Gly 65 70 75 80
 Ser Thr Ala Ile Thr Asp Asp Thr Leu Gly Gly Thr Leu Thr Ile Thr 85 90 95 Leu Arg Asn Leu Gln Pro

His Asp Ala Gly Leu Tyr Gln Cys Gln Ser 100 105 110 Leu His Gly Ser Glu Ala Asp Thr Leu Arg Lys
Val Leu Val Glu Val 115 120 125 Leu Ala Asp Pro Leu Asp His Arg Asp Ala Gly Asp Leu Trp Phe Pro
130 135 140 Gly Glu Ser Glu Ser Phe Glu Asp Ala His Val Glu His Ser Ile Ser 145 150 155 160 Arg
Ser Leu Leu Glu Gly Glu Ile Pro Phe Pro Pro Thr Ser Ile Leu 165 170 175 Leu Leu Leu Ala Cys Ile Phe
Leu Ile Lys Ile Leu Ala Ala Ser Ala 180 185 190 Leu Trp Ala Ala Ala Trp His Gly Gln Lys Pro Gly Thr
His Pro Pro 195 200 205 Ser Glu Leu Asp Cys Gly His Asp Pro Gly Tyr Gln Leu Gln Thr Leu 210 215
220 Pro Gly Leu Arg Asp Thr Xaa 225 230 (2) INFORMATION FOR SEQ ID NO : 216 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 127 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 216 : Met Gly Leu Thr Gly Phe
Gly Val Phe Phe Leu Phe Phe Gly Met Ile 1 5 10 15 Leu Phe Phe Asp Lys Ala Leu Leu Ala Ile Gly Asn
Val Leu Phe Val 20 25 30 Ala Gly Leu Ala Phe Val Ile Gly Leu Glu Arg Thr Phe Arg Phe Phe 35 40 45
Phe Gln Lys His Lys Met Lys Ala Thr Gly Phe Phe Leu Gly Gly Val 50 55 60 Phe Val Val Leu Ile Gly
Trp Pro Leu Ile Gly Met Ile Phe Glu Ile 65 70 75 80 Tyr Gly Phe Phe Leu Leu Phe Arg Gly Phe Phe Pro
Val Val Val Gly 85 90 95 Phe Ile Arg Arg Val Pro Val Leu Gly Ser Leu Leu Asn Leu Pro Gly 100 105
110 Ile Arg Ser Phe Val Asp Lys Val Gly Glu Ser Asn Asn Met Val 115 120 125 (2) INFORMATION
FOR SEQ ID NO : 217 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 47 amino acids (B)
TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 217 :
Met Ile Arg Lys Leu His Lys Ile Ile Val Phe Ser Pro Arg Val Ile 1 5 10 15 Val Leu Leu Asn Cys Phe
Phe Phe Ile Lys Ala Lys Phe Val Leu Tyr 20 25 30 Ile Phe Val Phe His Val Leu Asp Gly Ser Ile Ser Tyr
Pro Val 35 40 45 (2) INFORMATION FOR SEQ ID NO : 218 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 41 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 218 : Met Leu Leu Asn Gln His Phe Lys Ile Phe
Gly Ser Leu Ile His Met 1 5 10 15 Asn Leu Leu Phe Ala Leu Ile Ser Leu Gly Ser Ser Asn Leu Ser Gly
20 25 30 Val Gln Phe Cys Cys Glu Thr Val Gln 35 40 (2) INFORMATION FOR SEQ ID NO : 219 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 105 amino acids (B) TYPE : amino acid
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 219 : Met Gln Pro Leu Asn Phe
Ser Ser Thr Xaa Cys Ser Ser Phe Ser Pro 1 5 10 15 Pro Thr Thr Val Ile Leu Leu Ile Leu Leu Cys Phe
Glu Gly Leu Leu 20 25 30 Phe Leu Ile Phe Thr Ser Val Met Phe Gly Thr Gln Val His Ser Ile 35 40 45
Cys Thr Asp Glu Thr Gly Ile Glu Gln Leu Lys Lys Glu Glu Arg Arg 50 55 60 Trp Ala Lys Lys Thr Lys
Trp Met Asn Met Lys Ala Val Phe Gly His 65 70 75 80 Pro Phe Ser Leu Gly Trp Ala Ser Pro Phe Ala
Thr Pro Asp Gln Gly 85 90 95 Lys Ala Asp Pro Tyr Gln Tyr Val Val 100 105 (2) INFORMATION
FOR SEQ ID NO : 220 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 29 amino acids (B)
TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 220 :
Met Tyr Thr Asn His Phe Asn Leu Tyr Leu Lys Tyr Ile Leu Leu Ile 1 5 10 15 Ile Leu Ile Leu Asn Met
Thr Asn Ser Ser Ser Arg Tyr 20 25 (2) INFORMATION FOR SEQ ID : 221 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 17 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 221 : Met Asn Glu Leu Leu Leu Phe Phe Phe
Phe Phe Phe Phe Leu His Phe 1 5 10 15 Val (2) INFORMATION FOR SEQ ID NO : 222 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 138 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 222 : Met Lys Phe Thr Thr Leu
Leu Phe Leu Ala Ala Val Ala Gly Ala Leu 1 5 10 15 Val Tyr Ala Glu Asp Ala Ser Ser Asp Ser Thr Gly
Ala Asp Pro Ala 20 25 30 Gln Glu Ala Gly Thr Ser Lys Pro Asn Glu Glu Ile Ser Gly Pro Ala 35 40 45
Glu Pro Ala Ser Pro Pro Glu Thr Thr Thr Thr Ala Gln Glu Xaa Ser 50 55 60 Ala Ala Ala Val Gln Gly
Thr Ala Lys Val Thr Ser Ser Arg Gln Glu 65 70 75 80 Leu Asn Pro Leu Lys Ser Ile Val Glu Lys Ser Ile
Leu Leu Thr Glu 85 90 95 Gln Ala Leu Ala Lys Ala Gly Lys Gly Met His Gly Gly Val Pro Gly 100 105
110 Gly Lys Gln Phe Ile Glu Asn Gly Ser Glu Phe Ala Gln Lys Leu Leu 115 120 125 Lys Lys Phe Ser
Leu Leu Lys Pro Trp Ala 130 135 (2) INFORMATION FOR SEQ ID NO : 223 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 50 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 223 : Met Leu Gly Cys Gly Ile Pro Ala Leu Gly
Leu Leu Leu Leu Leu Gln 1 5 10 15 Xaa Ser Ala Asp Gly Asn Gly Ile Gln Gly Phe Phe Tyr Pro Trp Ser
20 25 30 Cys Glu Gly Asp Ile Trp Asp Arg Glu Ser Cys Gly Gly Gln Ala Ala 35 40 45 Ile Arg 50 (2)

INFORMATION FOR SEQ ID NO : 224 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 15 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 224 : Met Glu Ala Val Phe Thr Val Phe Phe Phe Leu Leu Phe Cys Phe 1 5 10 15 (2)

INFORMATION FOR SEQ ID NO : 225 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 155 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 225 : Met Gly Phe Gly Ala Thr Leu Ala Val Gly Leu Thr Ile Phe Val Leu 1 5 10 15 Ser Val Val Thr Ile Ile Ile Cys Phe Thr Cys Ser Cys Cys Cys Leu 20 25 30 Tyr Lys Thr Cys Arg Arg Pro Arg Pro Val Val Thr Thr Thr Thr Ser 35 40 45 Thr Thr Val Val His Ala Pro Tyr Pro Gln Pro Pro Ser Val Pro Pro 50 55 60 Ser Tyr Pro Gly Pro Ser Tyr Gln Gly Tyr His Thr Met Pro Pro Gln 75 80 Pro Gly Met Pro Ala Ala Pro Tyr Pro Met Gln Tyr Pro Pro Pro Tyr 85 90 95 Pro Ala Gln Pro Met Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly 100 105 110 Gly Ala Ala Ala Pro Tyr Pro Ala Ser Gln Pro Pro Tyr Asn Pro Xaa 115 120 125 Tyr Met Asp Ala Pro Lys Xaa Xaa Ser Glu His Ser Leu Ala Ser Leu 130 135 140 Ala Ala Thr Trp Leu Cys Cys Val Cys Ala Xaa 145 150 155 (2) INFORMATION FOR SEQ ID NO : 226 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 10 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 226 : Met Gly Phe Gly Ala Thr Leu Ala Val Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO : 227 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 20 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 227 : Met Ser Ile Phe Leu Val Met Ser Ile Ser Cys Ser Ser Thr Ser His 1 5 10 15 Cys Tyr Ser Phe 20 (2) INFORMATION FOR SEQ ID NO : 228 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 94 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 228 : Met Ser Phe Ser Phe Ile Ile Phe Leu Leu Leu Val Cys Gln Glu Ile 1 5 10 15 Thr Phe Cys Met Ser Tyr Gly Asp Ala Val Asn Cys Phe Ser Glu Cys 20 25 30 Phe Ser Asn Leu Gln Thr Ile Tyr Ile Ser Cys Leu Gln His Ala Val 35 40 45 Cys Lys His Ser Val Ile Trp Ser Ile Gln Leu Phe Val Arg Ala Leu 55 60 Pro Ile Ser Lys Cys Ala Glu Leu Ser Ile Asp Gly Ile Phe Arg Ser 65 70 75 80 Phe His Glu Asn Trp Lys Cys Ser Trp Val Ala Pro Thr Xaa 85 90 (2) INFORMATION FOR SEQ ID NO : 229 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 94 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 229 : Met Ser Phe Ser Phe Ile Ile Phe Leu Leu Leu Val Cys Gln Glu Ile 1 5 10 15 Thr Phe Cys Met Ser Tyr Gly Asp Ala Val Asn Cys Phe Ser Glu Cys 20 25 30 Phe Ser Asn Leu Gln Thr Ile Tyr Ile Ser Cys Leu Gln His Ala Val 35 40 45 Cys Lys His Ser Val Ile Trp Ser Ile Gln Leu Phe Val Arg Ala Leu 50 55 60 Pro Ile Ser Lys Cys Ala Glu Leu Ser Ile Asp Gly Ile Phe Arg Ser 65 70 75 80 Phe His Glu Asn Trp Lys Cys Ser Trp Val Ala Pro Thr Xaa 85 90 (2) INFORMATION FOR SEQ ID NO : 230 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 37 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 230 : Met Gly Trp Ser Ala Gly Leu Leu Phe Leu Leu Ile Leu Tyr Leu Pro 1 5 10 15 Val Pro Gly Trp Met Glu Arg Glu Asp Gly Gly Asp Gly Thr Ser Phe 20 25 30 Thr Ser Gly Ser Trp 35 (2) INFORMATION FOR SEQ ID NO : 231 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 81 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 231 : Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser 1 5 10 15 Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Val Gln Thr 20 25 30 Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro 35 40 45 Ile Lys Lys Ile Leu Gly Ile Phe Ile Ile Arg Thr Tyr Leu Arg Lys 50 55 60 Ile Val Ile Ala Phe Met Leu Trp Ser Pro Cys Leu Cys Gly Gly Leu 65 70 75 80 Met (2) INFORMATION FOR SEQ ID NO : 232 : SEQUENCE CHARACTERISTICS : (A) LENGTH : 301 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 232 : Met Asp Ala Arg Trp Trp Ala Val Val Val Leu Ala Ala Phe Pro Ser 1 5 10 15 Leu Gly Ala Gly Gly Glu Thr Pro Glu Ala Pro Pro Glu Ser Trp Thr 20 25 30 Gln Leu Trp Phe Phe Arg Phe Val Val Asn Ala Ala Gly Tyr Ala Xaa 35 40 45 Phe Met Val Pro Gly Tyr Leu Leu Val Gln Tyr Phe Arg Arg Lys Asn 50 55 60 Tyr Leu Glu Thr Gly Arg Gly Leu Cys Phe Pro Leu Val Lys Ala Cys 65 70 75 80 Val Phe Gly Asn Glu Pro Lys Ala Ser Asp Glu Val Pro Leu Ala Pro 85 90 95 Arg Thr Glu Ala Ala Glu Thr Thr Pro Met Trp Gln Ala Leu Lys Leu 100 105 110 Leu Phe Cys Ala Thr Gly Leu Gln Val Ser Tyr Leu Thr Trp Gly Val 115 120 125 Leu Gln Glu Arg Val Met Thr Arg Ser Tyr Gly Ala Thr Ala Thr Ser 130 135 140 Pro Gly Glu Arg Phe

Thr Asp Ser Gln Phe Leu Val Leu Met Asn Arg 145 155 160 Val Leu Ala Leu Ile Val Ala Gly Leu Ser
 Cys Val Leu Cys Lys Gln 165 170 175 Pro Arg His Gly Ala Pro Met Tyr Arg Tyr Ser Phe Ala Ser Leu
 Ser 180 185 190 Asn Val Leu Ser Ser Trp Cys Gln Tyr Glu Ala Leu Lys Phe Val Ser 195 200 205 Phe
 Pro Thr Gln Val Leu Ala Lys Ala Ser Lys Val Ile Pro Val Met 210 215 220 Leu Met Gly Lys Leu Val
 Ser Arg Arg Xaa Asn Glu His Trp Glu Tyr 225 230 235 240 Leu Thr Ala Thr Leu Ile Ser Ile Gly Val
 Ser Met Phe Leu Leu Ser 245 250 255 Ser Gly Pro Glu Pro Arg Ser Ser Pro Ala Thr Thr Leu Ser Gly
 Leu 260 265 270 Ile Leu Leu Ala Gly Tyr Ile Ala Phe Asp Ser Phe Thr Ser Asn Trp 275 280 285 Gln
 Asp Ala Cys Leu Pro Ile Arg Cys His Arg Cys Arg 290 295 300 (2) INFORMATION FOR SEQ ID
 NO : 233 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 313 amino acids (B) TYPE : amino
 acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 233 : Met Ser Asp Leu
 Leu Leu Gly Leu Ile Gly Gly Leu Thr Leu Leu 1 5 10 15 Leu Leu Leu Thr Leu Leu Ala Phe Ala
 Gly Tyr Ser Gly Leu Leu Ala 20 25 30 Gly Val Glu Val Ser Ala Gly Ser Pro Pro Ile Arg Asn Val Thr
 Val 35 40 45 Ala Tyr Lys Phe His Met Gly Leu Tyr Gly Glu Thr Gly Arg Leu Phe 50 55 60 Thr Glu Ser
 Cys Ser Ile Ser Pro Lys Leu Arg Ser Ile Ala Val Tyr 65 70 75 80 Tyr Asp Asn Pro His Met Val Pro Pro
 Asp Lys Cys Arg Cys Ala Val 85 90 95 Gly Ser Ile Leu Ser Glu Gly Glu Glu Ser Pro Ser Pro Glu Leu
 Ile 100 105 110 Asp Leu Tyr Gln Lys Phe Gly Phe Lys Val Phe Ser Phe Pro Ala Pro 115 120 125 Ser
 His Val Val Thr Ala Thr Phe Pro Tyr Thr Thr Ile Leu Ser Ile 130 135 140 Trp Leu Ala Thr Arg Arg Val
 His Pro Ala Leu Asp Thr Tyr Ile Lys 145 150 155 160 Glu Arg Lys Leu Cys Ala Tyr Pro Arg Leu Glu
 Ile Tyr Gln Glu Asp 165 170 175 Gln Ile His Phe Met Cys Pro Leu Ala Xaa Gln Gly Asp Phe Tyr Val
 180 185 190 Pro Glu Met Lys Glu Thr Glu Trp Lys Trp Arg Gly Leu Val Glu Ala 195 200 205 Ile Asp
 Thr Gln Val Asp Gly Thr Gly Ala Asp Thr Met Ser Asp Thr 210 215 220 Ser Ser Val Ser Leu Glu Val
 Ser Pro Gly Ser Arg Glu Thr Ser Ala 225 230 235 240 Ala Thr Leu Ser Pro Gly Ala Ser Ser Arg Gly
 Trp Asp Asp Gly Asp 245 250 255 Thr Arg Ser Glu His Ser Tyr Ser Glu Ser Gly Ala Ser Gly Ser Ser
 260 265 270 Phe Glu Glu Leu Asp Leu Glu Gly Glu Gly Pro Leu Gly Glu Ser Arg 275 280 285 Leu Asp
 Pro Gly Thr Xaa Pro Leu Gly Thr Thr Lys Trp Leu Trp Glu 290 295 300 Pro Thr Ala Pro Glu Lys Gly
 Lys Glu 305 310 (2) INFORMATION FOR SEQ ID NO : 234 : (i) SEQUENCE
 CHARACTERISTICS : (A) LENGTH : 48 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
 linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 234 : Pro Gln Ser Leu Ile Leu His Leu Leu Leu
 Phe Phe Phe Leu Leu Phe 1 5 10 15 Leu Phe Phe Ile Phe Ile Phe Leu Phe Phe Leu Gln Cys Leu Thr Phe
 20 25 30 Leu Phe Xaa Lys Pro Arg Gly Arg Tyr His Gly Leu Cys Phe Lys Phe 35 40 45 (2)
 INFORMATION FOR SEQ ID NO : 235 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 34
 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
 ID NO : 235 : Pro Ala Leu Arg Pro Ala Leu Leu Trp Ala Leu Leu Ala Leu Trp Leu 1 5 10 15 Cys Cys
 Ala Thr Pro Arg Met His Cys Ser Val Glu Met Ala Met Asn 20 25 30 Pro Val (2) INFORMATION
 FOR SEQ ID NO : 236 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 313 amino acids (B)
 TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 236 :
 Met Thr Arg Gly Gly Pro Gly Gly Arg Pro Gly Leu Pro Gln Pro Pro 1 5 10 15 Pro Leu Leu Leu Leu
 Leu Leu Leu Xaa Leu Leu Leu Val Thr Ala Glu 20 25 30 Pro Pro Lys Pro Ala Gly Val Tyr Tyr Ala Thr
 Ala Tyr Trp Met Pro 35 40 45 Ala Glu Lys Thr Val Gln Val Lys Asn Val Met Asp Lys Asn Gly Asp 50
 55 60 Ala Tyr Gly Phe Tyr Asn Asn Ser Val Lys Thr Thr Gly Trp Gly Ile 65 70 75 80 Leu Glu Ile Arg
 Ala Gly Tyr Gly Ser Gln Thr Leu Ser Asn Glu Ile 85 90 95 Ile Met Phe Val Ala Gly Phe Leu Glu Gly
 Tyr Leu Thr Ala Pro His 100 105 110 Met Asn Asp His Tyr Thr Asn Leu Tyr Pro Gln Leu Ile Thr Lys
 Pro 115 120 125 Ser Ile Met Asp Lys Val Gln Asp Phe Met Glu Lys Gln Asp Lys Trp 130 135 140 Thr
 Arg Lys Asn Ile Lys Glu Tyr Lys Thr Asp Ser Phe Trp Arg His 145 150 155 160 Thr Gly Tyr Val Met
 Ala Gln Ile Asp Gly Leu Tyr Val Gly Ala Lys 165 170 175 Lys Arg Ala Ile Leu Glu Gly Thr Lys Pro
 Met Thr Leu Phe Gln Ile 180 185 190 Gln Phe Leu Asn Ser Val Gly Asp Leu Leu Asp Leu Ile Pro Ser
 Leu 195 200 205 Ser Pro Thr Lys Asn Gly Ser Leu Lys Val Phe Lys Arg Trp Asp Met 210 215 220 Gly
 His Cys Ser Ala Leu Ile Lys Val Leu Pro Gly Phe Glu Asn Ile 225 230 235 240 Leu Phe Ala His Ser Ser
 Trp Tyr Thr Tyr Ala Ala Met Leu Arg Ile 245 250 255 Tyr Lys His Trp Asp Phe Asn Xaa Ile Asp Lys
 Asp Thr Ser Ser Ser 260 265 270 Arg Leu Ser Phe Ser Ser Tyr Pro Gly Phe Leu Glu Ser Leu Asp Asp
 275 280 285 Phe Tyr Ile Leu Ser Ser Gly Leu Ile Leu Leu Gln Thr Thr Asn Ser 290 295 300 Val Phe

Asn Lys Thr Leu Leu Lys Gln 305 310 (2) INFORMATION FOR SEQ ID NO : 237 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 296 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 237 : Met Leu Gln Gly Pro Gly Ser Leu Leu Leu Leu Phe Leu Ala Ser His 1 5 10 15 Cys Cys Leu Gly Ser Ala Arg Gly Leu Phe Leu Phe Gly Gln Pro Asp 20 25 30 Phe Ser Tyr Lys Arg Xaa Asn Cys Lys Pro Ile Pro Val Asn Leu Gln 35 40 45 Leu Cys His Gly Ile Glu Tyr Gln Asn Met Arg Leu Pro Asn Leu Leu 50 55 60 Gly His Glu Thr Met Lys Glu Val Leu Glu Gln Ala Gly Ala Trp Ile 65 70 75 80 Pro Leu Val Met Lys Gln Cys His Pro Asp Thr Lys Lys Phe Leu Cys 85 90 95 Ser Leu Phe Ala Pro Val Cys Leu Asp Asp Leu Asp Glu Thr Ile Gln 100 105 110 Pro Cys His Ser Leu Cys Val Gln Val Lys Asp Arg Cys Ala Pro Val 115 120 125 Met Ser Ala Phe Gly Phe Pro Trp Pro Asp Met Leu Glu Cys Asp Arg 130 135 140 Phe Pro Gln Asp Asn Asp Leu Cys Ile Pro Leu Ala Ser Ser Asp His 145 150 155 160 Leu Leu Pro Ala Thr Glu Glu Ala Pro Lys Val Cys Glu Ala Cys Lys 165 170 175 Asn Lys Asn Asp Asp Asp Asn Asp Ile Met Glu Thr Leu Cys Lys Asn 180 185 190 Asp Phe Ala Leu Lys Ile Lys Val Lys Glu Ile Thr Tyr Ile Asn Arg 195 200 205 Asp Thr Lys Ile Ile Leu Glu Thr Lys Ser Lys Thr Ile Tyr Lys Leu 210 215 220 Asn Gly Val Ser Glu Arg Asp Leu Lys Lys Ser Val Leu Trp Leu Lys 225 230 235 240 Asp Ser Leu Gln Cys Thr Cys Glu Glu Met Asn Asp Ile Asn Ala Pro 245 250 255 Tyr Leu Val Met Gly Gln Lys Gln Gly Gly Glu Leu Val Ile Thr Ser 260 265 270 Val Lys Arg Trp Gln Lys Gly Gln Arg Glu Phe Lys Arg Ile Ser Arg 275 280 285 Ser Ile Arg Lys Leu Gln Cys Xaa 290 295 (2) INFORMATION FOR SEQ ID NO : 238 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 92 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 238 : Met Ala Ser Leu Gly His Ile Leu Val Phe Cys Val Gly Leu Leu Thr 1 5 10 15 Met Ala Lys Ala Glu Ser Pro Lys Glu His Asp Pro Phe Thr Tyr Asp 20 25 30 Tyr Gln Ser Leu Gln Ile Gly Gly Leu Val Ile Ala Gly Ile Leu Phe 35 40 45 Ile Leu Gly Ile Leu Ile Val Leu Ser Arg Arg Cys Arg Cys Lys Phe 50 55 60 Asn Gln Gln Gln Arg Thr Gly Glu Pro Asp Glu Glu Glu Gly Thr Phe 65 70 75 80 Arg Ser Ser Ile Arg Arg Leu Ser Xaa Arg Xaa Arg 85 90 (2) INFORMATION FOR SEQ ID NO : 239 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 71 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 239 : Met Pro Gly Thr Phe Leu Arg Pro Phe Val Phe Leu Phe Leu Phe Ile 1 5 10 15 Cys Cys Cys Leu His Ser Gly Gly Leu Gly Gly Val Pro Leu Pro Pro 20 25 30 Phe Pro Pro Gln Ala Gln Arg Gly Glu Gly Pro Gly Lys Trp Met Ser 35 40 45 Pro Pro Leu Pro Pro His Pro Val Val Ala Pro Pro Thr Pro Ser Pro 50 55 60 Ser Arg Gly Cys Val Leu Leu 65 70 (2) INFORMATION FOR SEQ ID NO : 240 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 71 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 240 : Met Pro Gly Thr Phe Leu Arg Pro Phe Val Phe Leu Phe Leu Phe Ile 1 5 10 15 Cys Cys Cys Leu His Ser Gly Gly Leu Gly Gly Val Pro Leu Pro Pro 20 25 30 Phe Pro Pro Gln Ala Gln Arg Gly Glu Gly Pro Gly Lys Trp Met Ser 35 40 45 Pro Pro Leu Pro Pro His Pro Val Val Ala Pro Pro Thr Pro Ser Pro 50 55 60 Ser Arg Gly Cys Val Leu Leu 65 70 (2) INFORMATION FOR SEQ ID NO : 241 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 28 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID : 241 : Met Phe Tyr Val Leu Ser Val Ser Xaa Leu Xaa Leu Phe Leu Ala Cys 1 5 10 15 Gly Leu Cys Leu Xaa Leu Leu Thr Gly Lys Leu Leu 20 25 (2) INFORMATION FOR SEQ ID NO : 242 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 58 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 242 : Met Lys Leu Phe Asp Ala Ser Pro Thr Phe Phe Ala Phe Leu Leu Gly 1 5 10 15 His Ile Leu Ala Met Glu Val Leu Ala Trp Leu Leu Ile Tyr Leu Leu 20 25 30 Gly Pro Gly Trp Val Pro Ser Ala Leu Xaa Arg Leu His Pro Gly His 35 40 45 Leu Ser Gly Ser Val Leu Val Ser Ala Ala 50 55 (2) INFORMATION FOR SEQ ID NO : 243 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 123 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 243 : Met Ile Leu Gly Gly Ile Val Val Val Leu Val Phe Thr Gly Phe Val 1 5 10 15 Trp Ala Ala His Asn Lys Asp Val Leu Arg Arg Met Lys Lys Arg Tyr 20 25 30 Pro Thr Thr Phe Val Met Val Val Met Leu Ala Ser Tyr Phe Leu Ile 35 40 45 Ser Met Phe Gly Gly Val Met Val Phe Val Phe Gly Ile Thr Phe Pro 50 55 60 Leu Leu Leu Met Phe Ile His Ala Ser Leu Arg Leu Arg Asn Leu Lys 65 70 75 80 Asn Lys Leu Glu Asn Lys Met Glu Gly Ile Gly Leu Lys Arg Thr Pro 85 90 95 Met Gly Ile Val Leu Asp Ala Leu Glu Gln Gln Glu Glu Gly Ile

Asn 100 105 110 Arg Leu Thr Asp Tyr Ile Ser Lys Val Lys Glu 115 120 (2) INFORMATION FOR SEQ ID NO : 244 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 73 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 244 : Ala Leu Val Ser Gly Gln Leu Cys Met Glu Ile Ala Arg Gly Asn Ile 1 5 10 15 Phe Phe Leu Asn Xaa Leu Val Thr Thr Phe Cys Cys Ser Cys Leu Leu 20 25 30 Leu Ser Val Xaa Tyr Leu His Xaa Gly Phe Phe Tyr Ser Ser Leu Cys 35 40 45 Lys Cys Cys Phe Val Leu Val Val Leu Ser Arg Ile Gly Ser Val Asn 55 60 Glu Thr Trp Ser Cys Asn Phe Ser Ile 65 70 (2) INFORMATION FOR SEQ ID NO : 245 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 49 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 245 : Thr Pro Ala Thr Thr Ser Ser Ser Ser Ser Pro Leu Phe Leu Ser Ser 1 5 10 15 Pro Asp Trp Ser Ser Cys Pro Ser Gly Ser Cys Ile Ala Pro Trp Cys 20 25 30 Thr His Trp Ser Ser Ile Leu Pro Ser Leu Xaa Ile Thr Ser Ser Ile 35 40 45 Pro (2) INFORMATION FOR SEQ ID NO : 246 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 339 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 246 : Met Ala Arg Val Pro Pro Leu Ser Ser Ser Trp Thr Ser Ser Arg Tyr 1 5 10 15 Arg Arg Trp Leu Cys Cys Pro Val Trp Trp Thr Thr Phe Trp Ala Thr 20 25 30 Ala Trp Ser Leu Thr Lys His Leu Tyr Lys Asp Val Thr Asp Ala Ile 35 40 45 Arg Asp Val His Val Lys Gly Leu Met Tyr Gln Trp Ile Glu Gln Asp 50 55 60 Met Glu Lys Tyr Ile Leu Arg Gly Asp Glu Thr Phe Ala Val Leu Ser 65 70 75 80 Arg Leu Val Ala His Gly Lys Gln Leu Phe Leu Ile Thr Asn Ser Pro 85 90 95 Phe Ser Phe Val Asp Lys Gly Met Arg His Met Val Gly Pro Asp Trp 100 105 110 Arg His Ser Ser Met Trp Ser Leu Ser Arg Gln Thr Ser Pro Ala Ser 115 120 125 Ser Leu Thr Gly Ala Thr Phe Arg Lys Leu Asp Glu Lys Gly Ser Leu 130 135 140 Gln Trp Asp Arg Ile Thr Arg Leu Glu Lys Gly Lys Ile Tyr Arg Gln 145 150 155 160 Gly Asn Leu Phe Asp Phe Leu Arg Leu Thr Glu Trp Arg Gly Pro Arg 165 170 175 Val Leu Tyr Phe Gly Asp His Leu Tyr Ser Asp Leu Ala Asp Leu Met 180 185 190 Leu Arg His Gly Trp Arg Thr Gly Ala Ile Ile Pro Glu Leu Glu Arg 195 200 205 Glu Ile Arg Ile Ile Asn Thr Glu Gln Tyr Met His Ser Leu Thr Trp 210 215 220 Gln Gln Ala Leu Thr Gly Leu Leu Glu Arg Met Gln Thr Tyr Gln Asp 225 230 235 240 Ala Glu Ser Arg Gln Val Leu Ala Ala Trp Met Lys Glu Arg Gln Glu 245 250 255 Leu Arg Cys Ile Thr Lys Ala Leu Phe Asn Ala Gln Phe Gly Ser Ile 260 265 270 Phe Arg Thr Phe His Asn Pro Thr Tyr Phe Ser Arg Arg Leu Val Arg 275 280 285 Phe Ser Asp Leu Tyr Met Ala Ser Leu Ser Cys Leu Leu Asn Tyr Arg 290 295 300 Val Asp Phe Thr Phe Tyr Pro Arg Arg Thr Pro Leu Gln His Glu Ala 305 310 315 320 Pro Leu Trp Met Asp Gln Leu Leu His Arg Leu His Glu Asp Pro Leu 325 330 335 Pro Trp Xaa (2) INFORMATION FOR SEQ ID NO : 247 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 18 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 247 : Met Ala Leu Leu Ser Cys Val Val Asp Tyr Phe Leu Gly His Ser Leu 1 5 10 15 Xaa Val (2) INFORMATION FOR SEQ ID NO : 248 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 339 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 248 : Met Asn Trp Glu Leu Leu Leu Trp Leu Leu Val Leu Cys Ala Leu Leu 1 5 10 15 Leu Leu Leu Val Gln Leu Leu Arg Phe Leu Arg Ala Asp Gly Asp Leu 20 25 30 Thr Leu Leu Trp Ala Glu Trp Gln Gly Arg Arg Pro Glu Trp Glu Leu 35 40 45 Thr Asp Met Val Val Trp Val Thr Gly Ala Ser Ser Gly Ile Gly Glu 50 55 60 Glu Leu Ala Tyr Gln Leu Ser Lys Leu Gly Val Ser Leu Val Leu Ser 65 70 75 80 Ala Arg Arg Val His Glu Leu Glu Arg Val Lys Arg Arg Cys Leu Glu 85 90 95 Asn Gly Asn Leu Lys Glu Lys Asp Ile Leu Val Leu Pro Leu Asp Leu 100 105 110 Thr Asp Thr Gly Ser His Glu Ala Ala Thr Lys Ala Val Leu Gln Glu 115 120 125 Phe Gly Arg Ile Asp Ile Leu Val Asn Asn Gly Gly Met Ser Gln Arg 130 135 140 Ser Leu Cys Met Asp Thr Ser Leu Asp Val Tyr Arg Lys Leu Ile Glu 145 150 155 160 Leu Asn Tyr Leu Gly Thr Val Ser Leu Thr Lys Cys Val Leu Pro His 165 170 175 Met Ile Glu Arg Lys Gln Gly Lys Ile Val Thr Val Asn Ser Ile Leu 180 185 190 Gly Ile Ile Ser Val Pro Leu Ser Ile Gly Tyr Cys Ala Ser Lys His 195 200 205 Ala Leu Arg Gly Phe Phe Asn Gly Leu Arg Thr Glu Leu Ala Thr Tyr 210 215 220 Pro Gly Ile Ile Val Ser Asn Ile Cys Pro Gly Pro Val Gln Ser Asn 225 230 235 240 Ile Val Glu Asn Ser Leu Ala Gly Glu Val Thr Lys Thr Ile Gly Asn 245 250 255 Asn Gly Asp Gln Ser His Lys Met Thr Thr Ser Arg Cys Val Arg Leu 260 265 270 Met Leu Ile Ser Met Ala Asn Asp Leu Lys Glu Val Trp Ile Ser Glu 275 280 285 Gln Pro Phe Leu Leu Val Thr Tyr Leu Trp Gln Tyr Met Pro Thr Trp 290 295 300 Ala Trp Trp Ile Thr Asn Lys Met Gly Lys Lys Arg Ile Glu Asn Phe 305 310 315 320 Lys Ser Gly Val Asp Ala Asp

Ser Ser Tyr Phe Lys Ile Phe Lys Thr 325 330 335 Lys His Asp (2) INFORMATION FOR SEQ ID NO : 249 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 96 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 249 : Met Gly Ala Arg Pro Gly Gly His Pro Gln Lys Trp Ser Phe Leu Trp 1 5 10 15 Ser Leu Ala Leu Trp Leu Pro Leu Ala Leu Ser Val Ser Leu Phe Leu 20 25 30 Gly Leu Ser Leu Ser Pro Pro Gln Pro Gly Leu Ser Leu Trp Cys Thr 35 40 45 Leu Ser Tyr Cys Cys Glu Gln Trp Lys Phe Lys Gly Thr Pro Ser Pro 50 55 60 Ala Leu Leu Asn Leu Gly Thr Gln Pro Lys Lys Asp Lys Lys Leu Glu 65 70 75 80 Asp Ser Ile Ala Thr Gln Leu Arg Xaa Leu Pro Glu Lys Asn Ser Asn 85 90 95 (2) INFORMATION FOR SEQ ID NO : 250 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 79 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 250 : Met Ala Leu Thr Phe Leu Leu Val Leu Leu Thr Leu Ala Thr Leu Cys 1 5 10 15 Thr Arg Leu His Arg Asn Phe Arg Arg Gly Glu Ser Ile Tyr Trp Gly 20 25 30 Pro Thr Ala Asp Ser Gln Asp Thr Val Ala Ala Val Leu Lys Arg Arg 35 40 45 Leu Leu Gln Pro Ser Arg Arg Val Lys Arg Ser Arg Arg Arg Pro Xaa 50 55 60 Xaa Pro Pro Thr Pro Asp Ser Gly Pro Glu Gly Glu Ser Ser Glu 65 70 75 (2) INFORMATION FOR SEQ ID NO : 251 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 354 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 251 : Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser 1 5 10 15 Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg 20 25 30 Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser 35 40 45 Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro 50 55 60 Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala 65 70 75 80 Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr 85 90 95 Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys 100 105 110 Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys 115 120 125 Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser 130 135 140 Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys 145 150 155 160 Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln 165 170 175 Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala 180 185 190 Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val 195 200 205 Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg 210 215 220 Pro Pro Gly Arg Pro Gly Gly Gly Glu Met Glu Asn Thr Leu Gln 225 230 235 240 Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val 245 250 255 Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr 260 265 270 Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala 280 285 Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln 290 295 300 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn 305 310 315 320 Ala Glu Ala Ala Phe Xaa Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn 325 330 335 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser 340 345 350 Gly Pro (2) INFORMATION FOR SEQ ID NO : 252 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 109 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 252 : Met Leu Cys Ile Asn Gly Thr Thr Pro Arg Pro Leu Pro Val Pro Ser 1 5 10 15 Pro Phe Gly Cys Met Ile Phe Phe Phe Phe Lys Asn Pro Trp Lys Gln 20 25 30 Arg Leu Leu Gln Gly Trp Leu Gly Ala Arg Pro Ile His Leu Leu Gly 35 40 45 Tyr Leu Pro Leu Ser Leu Leu Trp Cys Pro Phe Pro Leu Pro Cys Ala 50 55 60 Arg Cys Ser Val Val Tyr Ile Ser Ser Pro Arg His Gly Ala His Ala 65 70 75 80 Pro Arg Asp Met Ile Leu Ser Leu Val Leu Ala His Gly Ala Leu Tyr 85 90 95 Lys Glu Leu Gly Gly Arg Gly Arg Lys Trp Glu Pro Ser 100 105 (2) INFORMATION FOR SEQ ID NO : 253 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 45 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 253 : Met Phe Tyr Phe Leu Pro Leu Ile Phe Pro Ala Phe Pro Pro Trp Ala 1 5 10 15 Phe Arg Leu Ser Thr Leu Phe Thr Ile Ile Ser Trp Ser Glu Asp Ser 20 25 30 Asn Asn Ser Gln Val Tyr Met Asn Cys Val Cys Ser Phe 35 40 45 (2) INFORMATION FOR SEQ ID NO : 254 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 315 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 254 : Met Ala Gly Gly Arg Cys Gly Pro Xaa Leu Thr Ala Leu Leu Ala Ala 1 5 10 15 Trp Ile Ala Ala Val Ala Ala Thr Ala Gly Pro Glu Glu Ala Ala Leu 20 25 30 Pro Pro Glu Gln Ser Arg Val Gln Pro Met Thr Ala Ser Asn Trp Thr 35 40 45 Leu Val Met Glu Gly Glu Trp Met Leu Lys Phe Tyr Ala Pro Trp Cys 50 55 60 Pro Ser Cys Gln Gln Thr Asp Ser Glu Trp Glu Ala Phe Ala Lys Asn 65 70 75 80 Gly

Glu Ile Leu Gln Ile Ser Val Gly Lys Val Asp Val Ile Gln Glu 85 90 95 Pro Gly Leu Ser Gly Arg Phe
Phe Val Thr Thr Leu Pro Ala Phe Phe 100 105 110 His Ala Lys Asp Gly Ile Phe Arg Arg Tyr Arg Gly
Pro Gly Ile Phe 115 120 125 Glu Asp Leu Gln Asn Tyr Ile Leu Glu Lys Lys Trp Gln Ser Val Glu 130
135 140 Pro Leu Thr Gly Trp Lys Ser Pro Ala Ser Leu Thr Met Ser Gly Met 145 150 155 160 Ala Gly
Leu Phe Ser Ile Ser Gly Lys Ile Trp His Leu His Asn Tyr 165 170 175 Phe Thr Val Thr Leu Gly Ile Pro
Ala Trp Cys Ser Tyr Val Phe Phe 180 185 190 Val Ile Ala Thr Leu Val Phe Gly Leu Phe Met Gly Leu
Val Leu Val 195 200 205 Val Ile Ser Glu Cys Phe Tyr Val Pro Leu Pro Arg His Leu Ser Glu 210 215
220 Arg Ser Glu Gln Asn Arg Arg Ser Glu Glu Ala His Arg Ala Glu Gln 225 230 235 240 Leu Gln Asp
Ala Glu Glu Glu Lys Asp Asp Ser Asn Glu Glu Glu Asn 245 250 255 Lys Asp Ser Leu Val Asp Asp
Glu Glu Glu Lys Glu Asp Leu Gly Asp 260 265 270 Glu Asp Glu Ala Glu Glu Glu Glu Glu Asp
Asn Leu Ala Ala Gly 275 280 285 Val Asp Glu Glu Arg Ser Glu Ala Asn Asp Gln Gly Pro Pro Gly Glu
290 295 300 Asp Gly Val Thr Arg Glu Xaa Ser Arg Ala Xaa 305 310 315 (2) INFORMATION FOR
SEQ ID NO : 255 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 53 amino acids (B) TYPE :
amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 255 : Met Leu
Lys Ala Leu Phe Arg Thr Leu Gln Ala Met Leu Leu Gly Val 1 5 10 15 Trp Ile Leu Leu Leu Ala Ser
Leu Ala Pro Leu Trp Leu Tyr Cys 20 25 30 Trp Arg Met Phe Pro Thr Lys Gly Lys Arg Asp Gln Lys
Glu Met Leu 35 40 45 Glu Val Ser Gly Ile (2) INFORMATION FOR SEQ ID NO : 256 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 93 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 256 : Met Ile His Leu Gly His
Ile Leu Phe Leu Leu Leu Leu Pro Val Ala 1 5 10 15 Ala Ala Gln Thr Thr Pro Gly Glu Arg Ser Ser Leu
Pro Ala Phe Tyr 20 25 30 Pro Gly Thr Ser Gly Ser Cys Ser Gly Cys Gly Ser Leu Ser Leu Pro 35 40 45
Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala Ser Leu Leu Ile 50 55 60 Val Gly Ala Val Phe Leu
Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln 65 70 75 80 Asp Gly Lys Val Tyr Ile Asn Met Pro Gly Arg
Gly Xaa 85 90 (2) INFORMATION FOR SEQ ID NO : 257 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 257 : Pro Gly His Leu Leu Pro His Lys Trp Glu Asn Cys 1 5 10 (2)
INFORMATION FOR SEQ ID NO : 258 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH :
1852 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY : linear (xi)
SEQUENCE DESCRIPTION : SEQ ID NO : 258 : TGGCATCTGT GAGCAGCTGC CAGGCTCCGG
CCAGGATCCC TTCCTTCTCC TCATTGGCTG 60 CTCCTTGACC TTCGTGCTGT TTCTCTCCCT
GGCTTTTGGG 120 GCAAGCTACG GAACAGGTGG GCGCATGATG AACTGCCCAA
AGATTCTCCG GCAGTTGGGA 180 AGCAAAGTGC TGCTGCCCCCT GACATATGAA
AGGATAAATA AGAGCATGAA CAAAAGCATC 240 CACATTGTCG TCACAATGGC
AAAATCACTG GAGAACAGTG TCGAGAACAA AATAGTGTCT 300 CTTGATCCAT
CCGAAGCAGG CCCTCCACGT TATCTAGGAG ATCGCTACAA GTTTTATCTG 360
GAGAATCTCA CCCTGGGGAT ACGGGAAAGC AGGAAGGAGG ATGAGGGGATG
GTACCTTATG 420 ACCCTGGAGA AAAATGTTTC AGTTCAGCGC TTTTGCCTGC
AGTTGAGGCT TTATGAGCAG 480 GTCTCCACTC CAGAAATTAA AGTTTAAAC
AAGACCCAGG AGAACGGGAC 540 ATACTGGGCT GCACAGTGGA GAAGGGGGAC
CATGTGGCTT ACAGCTGGAG TGAAAAGGCG 600 GGCACCCACC CACTGAACCC
AGCCAACAGC TCCCACCTCC TGTCCCTCAC CCTCGGCCCC 660 CAGCATGCTG
ACAATATCTA CATCTGCACC GTGAGCAACC CTATCAGCAA CAATTCACAG 720
ACCTTCAGCC CGTGGCCCCG ATGCAGGACA GACCCCTCAG ATGGGCAGTG 780
TATGCTGGGC TGTTAGGGGG ATTCTCATCA ACTACAGTTG 840 AGAAGAAGAG
GTAAAACGAA CCATTACCAG ACAACAGTGG AAAAAAAAAAG CTTACGATC 900
TATGCCCAAG TCCAGAAACC CTTCGGACTT ATTCTAATCC 960 AGGATGACCT
TCCTTATCTT GACATCTGTG AAGACCTTTA TTCAAATAAA 1020 GTCACATTTT
GACATTCTGC AGCCGGGCGG GGGCGATGTG GAGCGCGGGC 1080 CGCGGCGGGG
CTGCCTGGCC AGTGCCGGGC 1140 GGTGGTGCCG CCAAGACCGG TGCGGAGCTC
GTGACTGCGG GTCGGTGCTG AAGCTGCTCA 1200 ATACGCACCA CCGGTGCGGC
TGCACCTCGCA CGACATCAAA TACGGATCCG GCAGCGGCCA 1260 GCAATCGGTG

ACCGGCGTAG AGGTCGGAGC GACGAATAGC TACTGGCGGA TCCGCGGCGG 1320
 CTCGGAGGGG GGTGCCCCGCG CGGGTCCCCG GTGCGCTGCG GGCAGGCGGT
 GAGGTCACAC 1380 ATGTGCTTAC GGGCAAGAAC CTGCACACGC ACCACTTCCC
 GTCGCCGCTG TCCAACAACC 1440 AGGAAGTGAG TGCCAAAGGG GAAGACGGCG
 AGGGCGACGA 1500 GCTGCTCTGC TCTGGACAGC ACTGGGAGCG TGAGGCTGCT
 GTGGCGCCTT CCAGCATGTG 1560 GCACCTCTGT GGTTCCTGTC AGTCACGGTA
 AGCCCCATCC GTGGGCAGCA 1620 TGAGGTCCAC GCATGCCCAG TGCCAACACG
 CACAATACGT GGAAGGCCAT GGAAGGCATC 1680 TTCATCAAGC CTAGTGTGGA
 GCCCTCTGCA GTGTGGATGG 1740 ATGGGTGGAT TCTGCAGGGC CACTCTTGGC
 AGAGACTTTG 1800 GGTTTGTAGG GGTCCTCAAG TGCCTTTGTG GTTGGTCTAT GA 1852

(2) INFORMATION FOR SEQ ID NO : 259 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 371 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 259 : Met Glu Leu Glu Leu Asp Ala Gly Asp Gln Asp Leu Leu Ala Phe Leu 1 5 10 15 Leu Glu Glu Ser Gly Asp Leu Gly Thr Ala Pro Asp Glu Ala Val Arg 20 25 30 Ala Pro Leu Asp Trp Ala Leu Pro Leu Ser Glu Val Pro Ser Asp Trp 35 40 45 Glu Val Asp Asp Leu Leu Cys Ser Leu Leu Ser Pro Pro Ala Ser Leu 50 55 60 Asn Ile Leu Ser Ser Ser Asn Pro Cys Leu Val His His Asp His Thr 65 80 Tyr Ser Leu Pro Arg Glu Thr Val Ser Met Asp Leu Glu Ser Glu Ser 85 90 95 Cys Arg Lys Glu Gly Thr Gln Met Thr Pro Gln His Met Glu Glu Leu 100 105 110 Ala Glu Gln Glu Ile Ala Arg Leu Val Leu Thr Asp Glu Glu Lys Ser 115 120 125 Leu Leu Glu Lys Glu Gly Leu Ile Leu Pro Glu Thr Leu Pro Leu Thr 130 135 140 Lys Thr Glu Glu Gln Ile Leu Lys Arg Val Arg Arg Lys Ile Arg Asn 145 150 155 160 Lys Arg Ser Ala Gln Glu Ser Arg Arg Lys Lys Lys Val Tyr Val Gly 165 170 175 Gly Leu Glu Ser Arg Val Leu Lys Tyr Thr Ala Gln Asn Met Glu Leu 180 185 190 Gln Asn Lys Val Gln Leu Leu Glu Glu Gln Asn Leu Ser Leu Leu Asp 195 200 205 Gln Leu Arg Lys Leu Gln Ala Met Val Ile Glu Ile Ser Asn Lys Thr 210 215 220 Ser Ser Ser Ser Thr Cys Ile Leu Val Leu Leu Val Ser Phe Cys Leu 225 230 235 240 Leu Leu Val Pro Ala Met Tyr Ser Ser Asp Thr Arg Gly Ser Leu Pro 245 250 255 Ala Glu His Gly Val Leu Ser Arg Gln Leu Arg Ala Leu Pro Ser Glu 260 265 270 Asp Pro Tyr Gln Leu Glu Leu Pro Ala Leu Gln Ser Glu Val Pro Lys 275 280 285 Asp Ser Thr His Gln Trp Leu Asp Gly Ser Asp Cys Val Leu Gln Ala 290 295 300 Pro Gly Asn Thr Ser Cys Leu Leu His Tyr Met Pro Gln Ala Pro Ser 305 310 315 320 Ala Glu Pro Pro Leu Glu Trp Pro Phe Pro Asp Leu Ser Ser Glu Pro 325 330 335 Leu Cys Arg Gly Pro Ile Leu Pro Leu Gln Ala Asn Leu Thr Arg Lys 340 345 350 Gly Gly Trp Leu Pro Thr Gly Ser Pro Ser Val Ile Leu Gln Asp Arg 355 360 365 Tyr Ser Gly 370 (2) INFORMATION FOR SEQ ID NO : 260 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 260 : Cys Arg Cys Ala Ser Gly Phe Thr Gly Glu Asp Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO : 261 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 261 : Cys Thr Cys Gln Val Gly Phe Thr Gly Lys Glu Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO : 262 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 262 : Cys Leu Asn Leu Pro Gly Ser Tyr Gln Cys Gln Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO : 263 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 263 : Cys Lys Cys Leu Thr Gly Phe Thr Gly Gln Lys Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO : 264 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 12 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 264 : Cys Gln Cys Leu Gln Gly Phe Thr Gly Gln Tyr Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO : 265 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 127 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 265 : Gly Leu Ala Cys Trp Leu Ala Gly Val Ile Phe Ile Asp Arg Lys Arg 1 5 10 15 Thr Gly Asp Ala Ile Ser Val Met Ser Glu Val Ala Gln Thr Leu Leu 20 25 30 Thr Gln Asp Val Xaa Val Trp Val Phe Pro Glu Gly Thr Arg Asn His 35 40 45 Asn Gly Ser Met Leu Pro Phe Lys Arg Gly Ala Phe His Leu Ala Val 50 55 60 Gln Ala Gln Val Pro Ile Val Pro Ile

Val Met Ser Ser Tyr Gln Asp 65 70 75 80 Phe Tyr Cys Lys Lys Glu Arg Arg Phe Thr Ser Gly Gln Cys
Gln Val 85 90 95 Arg Val Leu Pro Pro Val Pro Thr Glu Gly Leu Thr Pro Asp Asp Val 100 105 110 Pro
Ala Leu Ala Asp Arg Val Arg His Ser Met Leu His Cys Phe 115 120 125 (2) INFORMATION FOR
SEQ ID NO : 266 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 98 amino acids (B) TYPE :
amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 266 : Pro Ser
Ala Lys Tyr Phe Phe Lys Met Ala Phe Tyr Asn Gly Trp Ile 1 5 10 15 Leu Phe Leu Ala Val Leu Ala Ile
Pro Val Cys Ala Val Arg Gly Arg 20 25 30 Asn Val Glu Asn Met Lys Ile Leu Arg Leu Met Leu Leu
His Ile Lys 35 40 45 Tyr Leu Tyr Gly Ile Arg Val Glu Val Arg Gly Ala His His Phe Pro 50 55 60 Pro
Ser Gln Pro Tyr Val Val Val Ser Asn His Gln Ser Ser Leu Asp 65 70 75 80 Leu Leu Gly Met Met Glu
Val Leu Pro Gly Arg Cys Val Pro Ile Ala 85 90 95 Lys Arg (2) INFORMATION FOR SEQ ID NO :
267 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 9 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 267 : Thr Val Phe Arg Glu Ile
Ser Thr Asp 1 5 (2) INFORMATION FOR SEQ ID NO : 268 : (i) SEQUENCE CHARACTERISTICS :
(A) LENGTH : 11 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID : 268 : Leu Trp Ala Gly Ser Ala Gly Trp Pro Ala Gly 1 5 10 (2)
INFORMATION FOR SEQ ID NO : 269 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 29
amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ
ID NO : 269 : Ser Ile Leu Gly Ile Ile Ser Val Pro Leu Ser Ile Gly Tyr Cys Ala 1 5 10 15 Ser Lys His Ala
Leu Arg Gly Phe Phe Asn Gly Leu Arg 20 25 (2) INFORMATION FOR SEQ ID NO : 270 : (i)
SEQUENCE CHARACTERISTICS : (A) LENGTH : 8 amino acids (B) TYPE : amino acid (D)
TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 270 : Met Ala Tyr His Gly Leu
Thr Val 1 5 (2) INFORMATION FOR SEQ ID NO : 271 : (i) SEQUENCE CHARACTERISTICS : (A)
LENGTH : 6 amino acids (B) TYPE : amino acid (D) TOPOLOGY : linear (xi) SEQUENCE
DESCRIPTION : SEQ ID NO : 271 : Ile Ser Ala Ala Arg Val 1 5 (2) INFORMATION FOR SEQ ID :
272 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 11 amino acids (B) TYPE : amino acid
(D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 272 : Pro Asp Val Ser Glu
Phe Met Thr Arg Leu Phe 1 5 10 (2) INFORMATION FOR SEQ ID NO : 273 : (i) SEQUENCE
CHARACTERISTICS : (A) LENGTH : 17 amino acids (B) TYPE : amino acid (D) TOPOLOGY :
linear (xi) SEQUENCE DESCRIPTION : SEQ ID 273 : Phe Asp Pro Val Arg Val Asp Ile Thr Ser Lys
Gly Lys Met Arg Ala 1 5 10 15 Arg INDICATIONS RELATING TO A DEPOSITED
MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism
referred to in the description on page 64 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits
are identified on an additional sheet | g Name of depositary institution American Type Culture
Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive
Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession
Number 97901 C. ADDITIONAL INDICATIONS/leave blank if not applicable) This information is
continued on an additional sheet C1 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE
MADE (if the indications are not for all designated states/ E. SEPARATE FURNISHING OF INDICATIONS
leave blank if not applicable) The indications listed below will be submitted to the International Bureau
later (aspect j, the general nature of the indications. e. g., "Accession Number of Deposit") For receiving
Office use only For International Bureau use only is sheet was received with the international application
This sheet was received by the International Bureau on : 1 0 Th. Authorized persons \ Authorized officer '
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The
indications made below relate to the microorganism referred to in the description on page 64. line N/A
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Q Name of
depositary institution American Type Culture Collection Address of depositary institution (including
postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America
Date of deposit February 26, 1997 Accession Number 97898 C. ADDITIONAL INDICATIONS (leave
blank if not applicable) This information is continued on an additional sheet fez D. DESIGNATED
STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) i
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed

below will be submitted to the international Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only--- This sheet was received with the international application ^ This sheet was received by the International Bureau on : FEZ Authorized officer Autho INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 64 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet _ Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209044 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : 1-17 Authorized officer Authorized officer () ; INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 64 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet m Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97899 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet t 21 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only. For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : Lj) t Authorized officer Authorized officer _ _ INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 65 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet iz Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209045 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Li D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : Zizi Authorized officer I Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 64. line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet j-j Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97900 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 2 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications. e.

g., "Accession Number of Deposit For receiving Office use only For International Bureau use only -- 31h. is sheet was received with the international application This sheet was received by the International Bureau on : Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 64 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Q Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209046 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 1 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated states) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only is sheet was received with the international application sheet was received by the International Bureau on : u X Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 65 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Q Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit April 28, 1997 Accession Number 209010 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ! ! D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only is sheet was received with the international application This sheet was received by the International Bureau on : For Authorized officer @ Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 65. line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ! ! Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 29, 1997 Accession Number 209085 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 1 X D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only is sheet was received with the international application This sheet was received by the International Bureau on : Authorized officer I 1 Authorized officer I f INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 65 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97897 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet L z D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications. e. g., "Accession Number of Deposit") For receiving

Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : Ld LJ A Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 65 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ! Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209043 C. ADDITIONAL INDICATIONS (leave blank, if not applicable) This information is continued on an additional sheet ' D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the international Bureau on : u Authorized officer ; Authorized officer ?

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 7 : , line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet)-) Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit September 4, 1997 Accession Number 209236 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Li o D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated states/ i E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : U Authorized officer ?

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 73. line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet i= Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 29, 1997 Accession Number 209084 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet g D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : Tri. Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 76 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209048 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet L'i D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated states) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application

This sheet was received by the International Bureau on : 1 J Authorized officer Authorized officer J

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 76 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97902 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet n D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only

This sheet was received with the international application sheet was received by the International Bureau on 0 Authorized officer Authorized officer i INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 77. line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97903 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [""] D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : Authorized officer IF cer _.. _ INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page T7. line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 5, 1997 Accession Number 209049 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet g D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only- This sheet was received with the international application This sheet was received by the International Bureau on : Authorized officer off" ; INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 80 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Q Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit February 26, 1997 Accession Number 97904 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only is sheet was received with the international application This sheet was received by the international Bureau on : LJ LJ Authorized officer F icer Authorized off

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 80 line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209050 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 12 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only - This sheet was received with the international application This sheet was received by the International Bureau on : I Authorized officer Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page. vine N/A 29 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet g Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit April 4, 1997 Accession Number 97976 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application This sheet was received by the International Bureau on : fi Authorized officer Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13 bis) A. The indications made below relate to the microorganism referred to in the description on page 64, line N/A B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet o Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit May 15, 1997 Accession Number 209047 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet g D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e. g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only 2/ sheet was received with the international application This sheet was received by the international Bureau on : lu !) Authorized officer Authorized officer

What Is Claimed Is : An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting (a) a polynucleotide fragment of SEQ ID NO : X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X ; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO : Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X ; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO : Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X ; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO : Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X ; (e) a polynucleotide encoding a polypeptide of SEQ ID NO : Y or the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X, having biological activity ; a polynucleotide

which is a variant of SEQ ID NO : X ; (g) a polynucleotide which is an allelic variant of SEQ ID NO : X ; (h) a polynucleotide which encodes a species homologue of the SEQ ID NO : Y ; (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO : Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X.
4. The isolated nucleic acid molecule of claim wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO : X or the cDNA sequence included in ATCC Deposit No : Z, which is hybridizable to SEQ ID NO : X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N- terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N- terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of : (a) a polypeptide fragment of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z ; (b) a polypeptide fragment of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z, having biological activity ; (c) a polypeptide domain of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z ; (d) a polypeptide epitope of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z ; (e) a secreted form of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z ; a full length protein of SEQ ID NO : Y or the encoded sequence included in ATCC Deposit No : Z ; (g) : Y ; (h) an allelic variant of SEQ ID NO : Y ; or (i) a species homologue of the SEQ NO : Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising : (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed ; and (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising : (a) determining the presence or absence of a mutation in the polynucleotide of claim 1 ; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising : (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample ; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising : (a) contacting the polypeptide of claim 11 with a binding partner ; and (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO : Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises : (a) expressing SEQ ID NO : X in a cell ; (b) isolating the supernatant ; (c) detecting an activity in a biological assay ; and (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 22.